praziquantel has been researched along with Bilharziasis in 733 studies
azinox: Russian drug
| Excerpt | Relevance | Reference |
|---|---|---|
| "Schistosomiasis control relies on praziquantel for preventive chemotherapy." | 9.69 | SCHISTOACT: a protocol for an open-label, five-arm, non-inferiority, individually randomized controlled trial of the efficacy and safety of praziquantel plus artemisinin-based combinations in the treatment of Schistosoma mansoni infection. ( Muok, EMO; Obonyo, CO; Wamae, P; Were, VO, 2023) |
| "Mass drug administration (MDA) of praziquantel is one of the main control measures against human schistosomiasis." | 9.41 | A cluster randomized controlled trial for assessing POC-CCA test based praziquantel treatment for schistosomiasis control in pregnant women and their young children: study protocol of the freeBILy clinical trial in Madagascar. ( Adegnika, AA; Andrianarivelo, MR; Corstjens, PLAM; Dechenaud, M; Fusco, D; Hoekstra, PT; Jaeger, A; Klein, P; Kreidenweiss, A; Lorenz, E; May, J; Puradiredja, DI; Rakotoarivelo, RA; Rakotozandrindrainy, N; Rakotozandrindrainy, R; Rasamoelina, T; Schwarz, NG; Sicuri, E; Stahlberg, K; van Dam, GJ, 2021) |
| "Control of schistosomiasis presently relies largely on preventive chemotherapy with praziquantel through mass drug administration (MDA) programs." | 9.30 | Persistent Hotspots in Schistosomiasis Consortium for Operational Research and Evaluation Studies for Gaining and Sustaining Control of Schistosomiasis after Four Years of Mass Drug Administration of Praziquantel. ( Binder, S; Campbell, CH; Colley, DG; Gazzinelli-Guimaraes, PH; Karanja, DMS; King, CH; Kinung'hi, S; Kittur, N; Magnussen, P; Montgomery, SP; Mwinzi, PNM; N'Goran, EK; Olsen, A; Phillips, AE; Secor, WE; Utzinger, J; Walker, JW, 2019) |
| "Large scale administration of the anthelminthic drug praziquantel (PZQ) to at-risk populations is the cornerstone of schistosomiasis control, although persisting high prevalence of infections in some areas and growing concerns of PZQ resistance have revealed the limitations of this strategy." | 9.27 | Repeated doses of Praziquantel in Schistosomiasis Treatment (RePST) - single versus multiple praziquantel treatments in school-aged children in Côte d'Ivoire: a study protocol for an open-label, randomised controlled trial. ( Amoah, AS; Assaré, RK; Casacuberta Partal, M; Corstjens, PLAM; Coulibaly, JT; Hoekstra, PT; Knopp, S; Meité, A; N'Gbesso, YK; N'Goran, EK; Roestenberg, M; Silué, KD; Tsonaka, S; Utzinger, J; van Dam, GJ; van Lieshout, L, 2018) |
| "Praziquantel (PZQ) is the drug of choice for the treatment of all forms of schistosomiasis, although its mechanisms of action are not completely understood." | 9.22 | Praziquantel: An update on the mechanism of its action against schistosomiasis and new therapeutic perspectives. ( Carvalho, RC; Dos Santos, VAF; Filho, ACCM; Frazão, GCCG; Licá, ICL; Lira, MGS; Miranda, GS; Nascimento, FRF; Nogueira, RA; Rodrigues, JGM, 2022) |
| "To evaluate the efficacy of repeated application of praziquantel in the treatment of hepatic fibrosis due to schistosomiasis." | 9.22 | [Efficacy of repeated application of praziquantel in treatment of hepatic fibrosis due to schistosomiasis]. ( Hong-Bao, L; Ming, S, 2016) |
| "A double-blind placebo-controlled study of the concurrent administration of albendazole and praziquantel was conducted in>1500 children with high prevalences of geohelminths and schistosomiasis." | 9.09 | Double-blind placebo-controlled study of concurrent administration of albendazole and praziquantel in schoolchildren with schistosomiasis and geohelminths. ( Aligui, G; Gachihi, G; Hewlett, J; Horton, RJ; King, C; Koech, D; Kombe, Y; Liu, CY; McGarvey, S; Odhiambo, O; Olds, GR; Olveda, R; Ouma, J; Parraga, I; Peters, P; Ramirez, B; Reeve, P; Whalen, C; Wu, G, 1999) |
| "Schistosomiasis control is heavily reliant on the drug praziquantel (PZQ), which is used as preventive chemotherapy as part of national helminth control strategies." | 9.05 | Drug metabolism and pharmacokinetics of praziquantel: A review of variable drug exposure during schistosomiasis treatment in human hosts and experimental models. ( Mutapi, F; Zdesenko, G, 2020) |
| "Randomized single-blind comparative trials of the newer antischistosomal drugs praziquantel and oxamniquine were undertaken at Mwanza, Tanzania, an area coendemic for schistosomiasis mansoni and haematobium." | 9.05 | Randomized comparative trials of single doses of the newer antischistosomal drugs at Mwanza, Tanzania. I. Praziquantel and oxamniquine for the treatment of schistosomiasis mansoni. ( Asila, J; Chimbe, A; Rugemalila, JB, 1984) |
| "The efficacy of oltipraz as a schistosomicidal drug was investigated in Gabonese children suffering from urinary schistosomiasis in the dosages of 1 X 25 mg/kg body weight, 1 X 35 mg/kg body weight, and 2 X 20 mg/kg body weight and compared to praziquantel, 2 X 30 mg/kg body weight." | 9.05 | Comparative trial of oltipraz versus praziquantel in the treatment of urinary schistosomiasis in the Gabon. ( Baltes, R; Burchard, GD; Dietrich, M; Kern, P, 1984) |
| "158 school children from Lambarene and its surroundings suffering from intestinal manifestations of schistosomiasis due to Schistosoma intercalatum, Schistosoma haematobium, or mixed infections were randomly allocated to patient groups to be treated with oltipraz and praziquantel respectively." | 9.05 | Comparative study of oltipraz versus praziquantel for treatment of schistosomiasis with intestinal manifestation in the Gabon (Schistosoma intercalatum and S. haematobium). ( Burchard, GD; Dietrich, M; Kern, P, 1984) |
| "Praziquantel was compared to niridazole in schistosomiasis intercalatum in the Gabon." | 9.05 | Praziquantel compared to niridazole in schistosomiasis intercalatum therapy. ( Dietrich, M; Feldmeier, H; Steiner, A; Zwingenberger, K, 1981) |
| "The current approach of morbidity control of schistosomiasis, a helminth disease of poverty with considerable public health and socioeconomic impact, is based on preventive chemotherapy with praziquantel." | 8.95 | Controlling schistosomiasis with praziquantel: How much longer without a viable alternative? ( Bergquist, R; Keiser, J; Utzinger, J, 2017) |
| "Chemotherapy based on repeated doses of praziquantel is still the most effective control strategy against Schistosomiasis, however artemisinin derivatives emerged as a family of compounds with schistomicide activity." | 8.88 | Systematic review and meta-analysis of artemisinin based therapies for the treatment and prevention of schistosomiasis. ( Burguillo, FJ; López-Abán, J; Muro, A; Pérez del Villar, L, 2012) |
| "We performed systematic searches of electronic databases PubMed and EMBASE for relevant data using search terms 'schistosomiasis', 'dosing' and 'praziquantel' and hand searches of personal collections and bibliographies of recovered articles." | 8.87 | Utility of repeated praziquantel dosing in the treatment of schistosomiasis in high-risk communities in Africa: a systematic review. ( Carter, J; Colley, DG; King, CH; Olbrych, SK; Singer, ME; Soon, M, 2011) |
| "Praziquantel has been used as first-line drug for chemotherapy of schistosomiasis since 1984." | 8.87 | Efficacy of praziquantel and artemisinin derivatives for the treatment and prevention of human schistosomiasis: a systematic review and meta-analysis. ( Dong, HF; Guo, Y; Jiang, MS; Liu, R; Zhao, QP, 2011) |
| "Treatment with praziquantel (PZQ) has become virtually the sole basis of schistosomiasis control in sub-Saharan Africa and elsewhere, and the drug is reviewed here in the context of the increasing rate that it is being used for this purpose." | 8.85 | Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs. ( Botros, S; Cioli, D; Coles, G; Doenhoff, MJ; Engels, D; Hagan, P; Mbaye, A; Pica-Mattoccia, L; Southgate, V; Tchuem Tchuenté, LA, 2009) |
| "Praziquantel (PZQ) is the only drug being used to treat human schistosomiasis on a large scale." | 8.84 | Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. ( Cioli, D; Doenhoff, MJ; Utzinger, J, 2008) |
| "Praziquantel became available for the treatment of schistosomiasis and other trematode-inflicted diseases in the 1970s." | 8.83 | Praziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance. ( Doenhoff, MJ; Pica-Mattoccia, L, 2006) |
| "Praziquantel is recommended as the drug of choice for all forms of schistosomiasis." | 8.78 | Exudative polyserositis and acute respiratory failure following praziquantel therapy. ( Azher, M; el-Kassimi, FA; Mofti, A; Wright, SG, 1990) |
| " Additional investigations of the proportion of newborns with FGR should obtain more certainty about the effect of praziquantel and schistosomiasis on fetal growth." | 8.31 | Investigation on birth weight outcomes in schistosomiasis and praziquantel research: a correspondence. ( Davi, SD; Holtfreter, MC; Mischlinger, J; Schleenvoigt, BT, 2023) |
| "Over the past two decades, preventive chemotherapy (PC) with praziquantel (PZQ) is the major strategy for controlling schistosomiasis in Senegal." | 8.31 | Schistosomiasis control in Senegal: results from community data analysis for optimizing preventive chemotherapy intervention with praziquantel. ( Ba, M; Boh, OK; Diop, B; Faye, B; Guèye, B; Kane, NM; Kinvi, B; Mané, M; Monteil, R; Mwinzi, P; Ortega, JC; Sacko, M; Sylla, K; Talla, I; Zoure, HGM, 2023) |
| "Schistosomiasis is a widely distributed parasitic disease and one of the most important neglected tropical diseases globally, for which Praziquantel® (PZQ) is the only available treatment." | 8.12 | The Effect of Different Formulations of Praziquantel in Reducing Worms in the Prepatent Period of Schistosomiasis in Murine Models. ( da Silva, CH; de Moraes Neto, AHA; Leonardi, D; Mello Silva, CC; Paulino, ÉT; Real, DA; Ribeiro de Lima, M; Salomon, CJ; Viçosa, AL, 2022) |
| "School-based preventive chemotherapy (Deworming) with praziquantel and albendazole to control and eliminate schistosomiasis and soil-transmitted helminths as public health problems is recommended by the World Health Organization (WHO)." | 8.12 | Safety of Praziquantel and Albendazole Coadministration for the Control and Elimination of Schistosomiasis and Soil-Transmitted Helminths Among Children in Rwanda: An Active Surveillance Study. ( Aklillu, E; Barry, A; Bergman, U; Bienvenu, E; Kabatende, J; Mugisha, M; Ntirenganya, L, 2022) |
| "This study was to determine the relationship between a praziquantel-related adverse event with the health community perception to chemopreventive of Schistosomiasis in Dodolo village, Napu Valley, Central Sulawesi." | 8.02 | Does the presence of praziquantel-related adverse events affect the health community's perception toward the mass chemopreventive program in the highest prevalence area of Schistosomiasis in Indonesia? Study in Dodolo village, Napu Valley, Central Sulawes ( Afriana, F; Daris, R; Hidayat, SH; Putri, ASD; Vera Diana, T, 2021) |
| "Evaluate the efficacy of a low-dose praziquantel and fenbendazole protocol to manage asymptomatic schistosomiasis in dogs and compare fecal saline sedimentation (FSS) and fecal PCR (FPCR) for therapeutic monitoring." | 8.02 | Efficacy of a low-dose praziquantel and fenbendazole protocol in the treatment of asymptomatic schistosomiasis in dogs. ( Cridge, H; Lupiano, H; Mackin, AJ; Nipper, JD; Steiner, JM, 2021) |
| "Schistosomiasis control programs rely heavily on mass drug administration (MDA) campaigns with praziquantel for preventative chemotherapy." | 7.96 | Environmental Predictors of Schistosomiasis Persistent Hotspots following Mass Treatment with Praziquantel. ( Binder, S; Campbell, CH; Castleman, JD; Colley, DG; Drake, JM; King, CH; Kittur, N; Walker, JW, 2020) |
| "For decades, mass drug treatment with praziquantel (PZQ) has been utilized to treat schistosomiasis, yet reinfection and the risk of drug resistance are among the various factors precluding successful elimination of schistosomiasis." | 7.96 | Elucidation of Cellular Responses in Non-human Primates With Chronic Schistosomiasis Followed by Praziquantel Treatment. ( Lazarus, S; Le, L; Melkus, MW; Molehin, AJ; Siddiqui, AA; Siddiqui, AJ; Zhang, W, 2020) |
| "National Health Information System surveillance data, based on routinely collected direct smear results at health centre level, may be able to monitor the impact of mass drug administration with praziquantel on intestinal schistosomiasis in Burundi." | 7.96 | Can direct smear results that are routinely collected at health centre level be used for monitoring the impact of mass drug administration with praziquantel on schistosomiasis in Burundi? A preliminary assessment. ( Bijabuka, U; Bizimana, P; Krit, M; Nibakire, M; Nkeshimana, A; Nsabiyumva, F; Ortu, G; Polman, K; Van Geertruyden, JP, 2020) |
| "Repeated praziquantel treatment for schistosomiasis is an effective method to reduce disease burden." | 7.96 | Change in schistosomiasis-related liver disease with repeated praziquantel treatment in school children in rural Zambia. ( McAdam, D; Paul, E; Strahan, R, 2020) |
| "In view of the potential immunosuppressive and regenerative properties of mesenchymal stem cells (MSC), we investigated whether transplantation of adipose tissue-derived stem cells (ASC) could be used to control the granulomatous reaction in the liver of mice infected with Schistosoma mansoni after Praziquantel (PZQ) treatment." | 7.96 | Liver damage in schistosomiasis is reduced by adipose tissue-derived stem cell therapy after praziquantel treatment. ( Alves, ÉAR; Bicalho, KA; Birbrair, A; Bozzi, A; Chaves, AT; Corrêa-Oliveira, R; de Goes, AM; Eller, DE; Ferraz, LCN; Gomes, TR; Miranda, VHS; Pascoal Xavier, MA; Silva, CEC, 2020) |
| "Praziquantel is a broad spectrum antihelmintic agent and represents the drug of choice for the treatment of schistosomiasis." | 7.91 | Orphan Formulations in Pediatric Schistosomiasis Treatment: Development and Characterization of Praziquantel Nanoparticle-Loaded Powders for Reconstitution. ( Gonzalez Vidal, NL; Gonzalez, MA; Ramírez Rigo, MV, 2019) |
| "Preventive chemotherapy with praziquantel for schistosomiasis morbidity control is commonly done by mass drug administration (MDA)." | 7.85 | Defining Persistent Hotspots: Areas That Fail to Decrease Meaningfully in Prevalence after Multiple Years of Mass Drug Administration with Praziquantel for Control of Schistosomiasis. ( Binder, S; Campbell, CH; Colley, DG; King, CH; Kinung'hi, S; Kittur, N; Magnussen, P; Olsen, A, 2017) |
| "To investigate the clinical therapeutic effect of biological information infrared liver therapeutic apparatus (BILT) combined with praziquantel in the treatment of patients with chronic schistosomiasis." | 7.85 | [Therapeutic effect of BILT combined with praziquantel in treatment of chronic schistosomiasis]. ( Hong-Bo, W; Li-le, L; Na, Z; Ni-Na, P; Ru-Yi, L; Yan, M; Yu, H, 2017) |
| "Praziquantel is the mainstay of treatment of Schistosomiasis, which affects at least 262 million people worldwide." | 7.83 | Treatment of Schistosomiasis in a Patient Allergic to Praziquantel: A Desensitization and Treatment Protocol. ( Bailey, RL; Lukawska, J; Patel, TA; Rowe, J, 2016) |
| "Taken together, these data suggest that the combined treatment of PZQ and edelfosine promotes a high decrease in granuloma formation, as well as in the cellular immune response that underlies granuloma development, with changes in the cytokine patterns, and may provide a promising and effective strategy for a prophylactic treatment of schistosomiasis." | 7.81 | Inhibition of Granulomatous Inflammation and Prophylactic Treatment of Schistosomiasis with a Combination of Edelfosine and Praziquantel. ( López-Abán, J; Mollinedo, F; Muro, A; Rojas-Caraballo, J; Varela-M, RE; Yepes, E, 2015) |
| "To investigate the expression characteristics of miR-155 and miR-146a in mice with schistosomiasis and praziquantel (PZQ) treatment." | 7.80 | [Expression characteristics of microRNA in mice with schistosomiasis and praziquantel treatment]. ( Chen, L; Hou, M; Ji, MJ; Wang, CY; Yang, BY; Zhang, F, 2014) |
| "Formulations that can be divided into four parts (to give 150 mg increments) are preferred for children weighing less than 11 kg; the same dosing can be applied with 600 mf praziquantel formulations that can be divided into four quarters or two halves from 11 kg body weight." | 7.79 | Practical dosing of praziquantel for schistosomiasis in preschool-aged children. ( Chitsulo, L; Hayes, DJ; Montresor, A; Olliaro, PL; Vaillant, M, 2013) |
| "Regular treatment with praziquantel (PZQ) is the strategy for human schistosomiasis control aiming to prevent morbidity in later life." | 7.79 | A latent Markov modelling approach to the evaluation of circulating cathodic antigen strips for schistosomiasis diagnosis pre- and post-praziquantel treatment in Uganda. ( Deelder, AM; Donnelly, CA; Kabatereine, NB; Koukounari, A; Moustaki, I; Tukahebwa, EM; van Dam, GJ; Vennervald, BJ; Webster, JP; Wilson, S, 2013) |
| "Paradoxical reactions (Jarish Herxheimer-like reactions) have been described in patients treated with praziquantel (PZQ) during acute schistosomiasis (infected≤ 3 mo), while PZQ treatment of chronic schistosomiasis is generally considered to be safe." | 7.78 | Acute febrile respiratory reaction after praziquantel treatment during asymptomatic late form of acute schistosomiasis. ( Blum, JA; Hatz, CF; Neumayr, AL; Tschirky, B; Warren, A, 2012) |
| "Two-arm comparative study in northern Ghana integrated praziquantel distribution into an existing lymphatic filariasis and onchocerciasis control programme using Community Directed Distributors." | 7.77 | Simultaneous administration of praziquantel, ivermectin and albendazole, in a community in rural northern Ghana endemic for schistosomiasis, onchocerciasis and lymphatic filariasis. ( Aborigo, R; Adjuik, M; Akweongo, P; Amankwa, J; Anto, F; Anyorigiya, T; Asoala, V; Bimi, L; Hodgson, A; Oduro, A, 2011) |
| "This paper reported one case of acute kidney injury caused by praziquantel." | 7.77 | [One case of acute kidney injury caused by praziquantel]. ( Chai, ZW; Xu, QC, 2011) |
| "Nineteen cases of acute schistosomiasis patients whose temperatures had fallen to normal automatically were treated with praziquantel, and their temperatures recrudesced after the treatment." | 7.77 | [Temperature recrudescence caused by praziquantel treatment after falling to normal automatically in acute schistosomiasis patients: a report of 19 cases]. ( Zhang, SX; Zhang, TY, 2011) |
| "To observe the compliance of film-coated praziquantel tablets in the schistosomiasis transmission controlled areas, so as to provide the evidence for the establishment of chemotherapy intervention measures in these areas." | 7.77 | [Compliance of film-coated praziquantel tablets in schistosomiasis transmission-controlled areas]. ( Bao, ZP; Cao, CL; Chen, L; Guo, JG; Meng, XH; Wang, DH; Wang, H; Wang, L; Zhang, YY; Zhao, GM; Zhong, B, 2011) |
| "In large-scale interventions for control of schistosomiasis, use of the WHO dose pole is favoured for mass drug administration of praziquantel." | 7.76 | An inclusive dose pole for treatment of schistosomiasis in infants and preschool children with praziquantel. ( Betson, M; Day, M; Kabatereine, NB; Sousa-Figueiredo, JC; Stothard, JR, 2010) |
| "Praziquantel (PZQ) is the drug compound of choice in the control and treatment of schistosomiasis." | 7.75 | Taste, a new incentive to switch to (R)-praziquantel in schistosomiasis treatment. ( Bothe, H; Fuchs, S; Meyer, T; Miculka, C; Schollmeyer, D; Sekljic, H, 2009) |
| "To describe sociocultural factors that influence the distribution process of praziquantel for the mass treatment of schistosomiasis infection." | 7.74 | Sociocultural aspects of mass delivery of praziquantel in schistosomiasis control: the Abeokuta experience. ( Adeneye, AK; Adewale, B; Akande, DO; Akinwale, OP; Appelt, B; Idowu, ET; Mafe, MA; Manafa, OU; Omotola, BD; Sulyman, MA, 2007) |
| "The purpose of this study was to evaluate whether a progressive cycle ergometer test (PCET) can detect minimal functional abnormalities that might indicate compromise of the pulmonary vascular bed in patients treated with praziquantel for chronic schistosomiasis who have no clinical signs of cardiopulmonary impairment." | 7.72 | [Evaluation of exercise tolerance in patients treated with praziquantel for chronic schistosomiasis with no signs of cardiopulmonary impairment]. ( de Noya, B; López, JM; Montes de Oca, M; Sánchez, MA; Tálamo, C, 2003) |
| "Schistosomiasis control programmes are generally based on mass distribution of praziquantel (PZQ)." | 7.72 | Is praziquantel therapy safe during pregnancy? ( Adam, I; Elwasila, el T; Homeida, M, 2004) |
| "This study was conducted to evaluate the efficacy of praziquantel (CAS 55268-74-1, EMBAY 8440, Biltricide) in different grades of Schistosoma mansoni infection." | 7.70 | Correlation between infection intensity, serum immunoglobulin profile, cellular immunity and the efficacy of treatment with praziquantel in murine schistosomiasis mansoni. ( Demerdash, Z; Nessim, NG, 2000) |
| "Humoral and cellular immune response in schistosomiasis was studied pre and post praziquantel therapy." | 7.68 | Humoral and cellular immune response in schistosomiasis pre and post praziquantel therapy. ( el Said, A; Elhayawan, IA; Hamadto, HH; Rashed, SM, 1990) |
| "A retrospective survey involving 25,693 persons was carried out in four provinces and the city of Shanghai, China between December 1981 until May 1982 to document relatively serious side effects of praziquantel used in a mass treatment programme for schistosomiasis japonica." | 7.66 | A retrospective survey on side effects of praziquantel among 25,693 cases of schistosomiasis japonica. ( Chen, MG; Fu, S; Hua, XJ; Wu, HM, 1983) |
| "The authors study the results of a treatment of 700 cases of bilharziasis seen in Paris and in two foci in Togo, by oxamniquine, oltipraz or praziquantel." | 7.66 | [Treatment of 700 cases of bilharziasis with the new drugs oxamniquine, oltipraz, praziquantel]. ( Ancelle, T; Dupouy-Camet, J; Faurant, C; Heyer, F; Keita, A; Lapierre, J; Tourte-Schaefer, C, 1983) |
| "The object of the study was to identify any potential therapeutic advantage in using the two antischistosomal drugs, oxamniquine and praziquantel, in combination rather than separately, in the treatment of schistosomiasis." | 7.66 | The treatment of experimental schistosomiasis with a combination of oxamniquine and praziquantel. ( Brammer, KW; Shaw, JR, 1983) |
| "Fourteen patients with active schistosomiasis mansoni in spite of previous treatment with oxamniquine and/or hycanthone were treated with praziquantel, single oral dose of 45 to 50 mg/kg body-weight." | 7.66 | Use of praziquantel in patients with schistosomiasis mansoni previously treated with oxamniquine and/or hycanthone: resistance of Schistosoma mansoni to schistosomicidal agents. ( de Jesus Pedro, R; de Souza Dias, LC; Deberaldini, ER, 1982) |
| "In the past three months 2-cyclo-hexylcarbonyl-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one (praziquantel, EMBAY 8440, Biltricide) has been used in Kenya in the treatment of schistosomiasis mansoni at a single oral dose of 40 mg/kg." | 7.66 | Preliminary observations on the treatment of Schistosomiasis mansoni with praziquantel in Kenya. ( Highton, RB; Roberts, JM; Smith, DH, 1981) |
| "Treatment with praziquantel did not have a significant effect on birthweight (2·85 kg in both groups, β=-0·002 [95% CI -0·088 to 0·083]; p=0·962)." | 6.82 | Efficacy and safety of praziquantel for the treatment of human schistosomiasis during pregnancy: a phase 2, randomised, double-blind, placebo-controlled trial. ( Acosta, LP; Ayaso, EB; Baltazar, PI; Estanislao, GG; Friedman, JF; Ida, A; Kurtis, JD; Lesiguez, JL; McDonald, EA; Monterde, DB; Olveda, RM; Tallo, V; Watson, N; Wu, HW, 2016) |
| "Praziquantel was efficacious at reducing infection 12 weeks after treatment: cure rate = 94." | 6.82 | Comparative Assessment of Health Benefits of Praziquantel Treatment of Urogenital Schistosomiasis in Preschool and Primary School-Aged Children. ( Gwisai, R; Mduluza, T; Midzi, N; Mutapi, F; Nausch, N; Wami, WM; Woolhouse, ME, 2016) |
| "Nevertheless, treatment of schistosomiasis and de-worming were followed by a partial, but significant, reduction of anaemia in schoolchildren, not explainable by any other obvious intervention." | 6.73 | Controlling schistosomiasis: significant decrease of anaemia prevalence one year after a single dose of praziquantel in Nigerian schoolchildren. ( Boisier, P; Bosqué-Oliva, E; Chanteau, S; Duchemin, JB; Garba, A; Ibrahim, ML; Mahamane, AE; Mainassara, HB; Tohon, ZB, 2008) |
| "Schistosomiasis is a widespread public health concern in the poorest regions of the world." | 6.61 | Differential impact of mass and targeted praziquantel delivery on schistosomiasis control in school-aged children: A systematic review and meta-analysis. ( Clarke, NE; Cribb, DM; Doi, SAR; Vaz Nery, S, 2019) |
| "Schistosomiasis affects more than 260 million people worldwide, mostly in sub-Saharan Africa, where more than 280 000 deaths per year are estimated." | 6.61 | High-dose or multi-day praziquantel for imported schistosomiasis? A systematic review. ( Bisoffi, Z; Bottieau, E; Buonfrate, D; Cucchetto, G; Ferrari, A; Gobbi, F; Marchese, V; Rodari, P; Silva, R; Zanotti, P, 2019) |
| "Schistosomiasis is a serious public health burden in sub-Saharan Africa." | 6.58 | Efficacy of praziquantel treatment regimens in pre-school and school aged children infected with schistosomiasis in sub-Saharan Africa: a systematic review. ( Chimbari, MJ; Kabuyaya, M; Mukaratirwa, S, 2018) |
| "PZQ is the drug of choice for the treatment of schistosomiasis; it is effective against all major forms of schistosomiasis, although it is less active against juvenile than mature parasites." | 6.55 | Praziquantel for Schistosomiasis: Single-Drug Metabolism Revisited, Mode of Action, and Resistance. ( Brindley, PJ; Correia da Costa, JM; Gärtner, F; Gouveia, MJ; Rinaldi, G; Vale, N, 2017) |
| "Human schistosomiasis is a neglected tropical disease caused by Schistosoma mansoni, S." | 5.91 | Oxamniquine derivatives overcome Praziquantel treatment limitations for Schistosomiasis. ( Alwan, SN; LoVerde, PT; McHardy, SF; Rhodes, J; Taylor, AB; Tidwell, M, 2023) |
| "Schistosomiasis is one of the most devastating tropical diseases in the world." | 5.72 | Use of wogonin as a cooperative drug with praziquantel to better combat schistosomiasis. ( Cheng, PC; Hung, MY; Pekkle Lam, HY; Peng, SY, 2022) |
| "Praziquantel treatment of infected mice fed with a standard diet (IN-PZQ) resulted in a significant reduction of worm and egg burdens and a normalization of iron and calcium levels." | 5.72 | Protein undernutrition reduces the efficacy of praziquantel in a murine model of Schistosoma mansoni infection. ( Abou-Bacar, A; Boukeng Jatsa, H; Brunet, J; Cannet, C; Gipwe Feussom, N; Greigert, V; Kadji Fassi, JB; Kamgang, R; Kamtchouing, P; Kenfack, CM; Membe Femoe, U; Pfaff, AW; Tchuem Tchuenté, LA; Tienga Nkondo, E, 2022) |
| "Plumbagin treatment restored hepatic enzymes activity to nearly normal levels and induced an increase in catalase, SOD, GSH, total thiol and GST in liver tissue homogenate." | 5.72 | Anti-inflammatory, antioxidant, anti-fibrotic and schistosomicidal properties of plumbagin in murine schistosomiasis. ( Abdel-Latif, M; Abuelsaad, ASA; Allam, GA; Bakery, HH; Elkenawy, AE; Khalil, RG, 2022) |
| "Arpraziquantel, a first-line orodispersible tablet, showed high efficacy and favourable safety in preschool-aged children with schistosomiasis." | 5.69 | Efficacy, safety, and palatability of arpraziquantel (L-praziquantel) orodispersible tablets in children aged 3 months to 6 years infected with Schistosoma in Côte d'Ivoire and Kenya: an open-label, partly randomised, phase 3 trial. ( Aka, NAD; Assandé Aka, R; Badenhorst, H; Bagchus, WM; Bezuidenhout, D; Bödding, M; Dälken, B; Haj-Ali Saflo, O; Huber, E; Kourany-Lefoll, E; N'Goran, EK; Odiere, MR; Ogutu, B; Ouattara, M; Rawago, F; Tappert, A; Yin, X, 2023) |
| "Schistosomiasis control relies on praziquantel for preventive chemotherapy." | 5.69 | SCHISTOACT: a protocol for an open-label, five-arm, non-inferiority, individually randomized controlled trial of the efficacy and safety of praziquantel plus artemisinin-based combinations in the treatment of Schistosoma mansoni infection. ( Muok, EMO; Obonyo, CO; Wamae, P; Were, VO, 2023) |
| "Annual mass drug administration (MDA) using praziquantel is the cornerstone of schistosomiasis morbidity control but is not sufficient to interrupt transmission." | 5.51 | Effectiveness of Four Different Interventions Against Schistosoma haematobium in a Seasonal Transmission Setting of Côte d'Ivoire: A Cluster Randomized Trial. ( Assaré, RK; Bassa, FK; Coulibaly, JT; Diakité, NR; Guindo-Coulibaly, N; Hattendorf, J; Konan, CK; Koné, N; N'Goran, EK; Ouattara, M; Tian-Bi, YT; Utzinger, J; Yao, PK, 2022) |
| "Schistosomiasis is a parasitic disease caused by blood flukes." | 5.46 | Developing a comprehensive response for treatment of children under 6 years of age with schistosomiasis: research and development of a pediatric formulation of praziquantel. ( Klohe, K; Reinhard-Rupp, J, 2017) |
| "Praziquantel (PZQ), an anthelmintic drug used in developing countries for the treatment of schistosome infections, was processed using the fluid bed wet granulation technology to prepare fast dispersible granules, as an appropriate and flexible dosage form for pre-school-aged children." | 5.42 | Development of flexible and dispersible oral formulations containing praziquantel for potential schistosomiasis treatment of pre-school age children. ( Albertini, B; Dolci, LS; Passerini, N; Trastullo, R, 2015) |
| "Mass drug administration (MDA) of praziquantel is one of the main control measures against human schistosomiasis." | 5.41 | A cluster randomized controlled trial for assessing POC-CCA test based praziquantel treatment for schistosomiasis control in pregnant women and their young children: study protocol of the freeBILy clinical trial in Madagascar. ( Adegnika, AA; Andrianarivelo, MR; Corstjens, PLAM; Dechenaud, M; Fusco, D; Hoekstra, PT; Jaeger, A; Klein, P; Kreidenweiss, A; Lorenz, E; May, J; Puradiredja, DI; Rakotoarivelo, RA; Rakotozandrindrainy, N; Rakotozandrindrainy, R; Rasamoelina, T; Schwarz, NG; Sicuri, E; Stahlberg, K; van Dam, GJ, 2021) |
| "Preventive chemotherapy using praziquantel is the mainstay for schistosomiasis control." | 5.41 | Effectiveness of school-based preventive chemotherapy strategies for sustaining the control of schistosomiasis in Côte d'Ivoire: Results of a 5-year cluster randomized trial. ( Assaré, RK; Bassa, FK; Coulibaly, JT; Diakité, NR; Guindo-Coulibaly, N; Hattendorf, J; Koné, N; N'Goran, EK; Ouattara, M; Saric, J; Utzinger, J; Yao, PK, 2021) |
| " From the obtained results, PZQ-loaded SLN could be a new drug delivery system for the schistosomiasis treatment especially in marginalized communities, improving the therapeutic efficacy and reducing the toxic effects of PZQ." | 5.40 | In vitro evaluation of permeation, toxicity and effect of praziquantel-loaded solid lipid nanoparticles against Schistosoma mansoni as a strategy to improve efficacy of the schistosomiasis treatment. ( Allegretti, SM; Andreani, T; Chaud, MV; de Oliveira, RN; de Souza, AL; dos Santos, FK; Gremião, MP; Kiill, CP; Silva, AM; Souto, EB, 2014) |
| " Proper dosage adjustment of praziquantel by bodyweight can be difficult to achieve if accurate weighing scales are unavailable." | 5.39 | Validating the WHO dose pole in the Philippines for school-based mass drug administration of praziquantel for morbidity control of schistosomiasis. ( Belizario, VY; Chua, PL; Erfe, JM; Naig, JR, 2013) |
| "In the Koome islands of Lake Victoria, Uganda, where baseline schistosomiasis prevalence (by single stool sample, Kato Katz) was 52% overall (all ages) and 67% among school-aged children, we conducted a cluster-randomised trial of community-wide, intensive MDA (quarterly single-dose praziquantel 40mg/kg; triple-dose albendazole 400mg) versus standard, Uganda government intervention (annual single-dose praziquantel 40mg/kg; 6-monthly single-dose albendazole)." | 5.34 | Anthelminthic treatment receipt and its predictors in Lake Victoria fishing communities, Uganda: Intervention coverage results from the LaVIISWA cluster randomised trial. ( Akurut, H; Elliott, AM; Kabatereine, NB; Kaweesa, J; Kizindo, R; Kizza, M; Lubyayi, L; Nampijja, M; Nsubuga, D; Sanya, RE; Sewankambo, M; Tukahebwa, E; Webb, EL, 2020) |
| "Pentoxifylline (PTX) was proved to exert both anti-inflammatory and anti-fibrotic effects, and was used therapeutically in this experimental model to investigate its role alone or with praziquantel (PZQ) in Schistosoma mansoni-infected mice, and to explore its impact on the tissue expression of transforming growth factor-beta1 (TGF-beta1)." | 5.34 | Pharmacodynamics of pentoxifylline and/or praziquantel in murine schistosomiasis mansoni. ( El-Lakkany, N; Nosseir, M, 2007) |
| "Samples from a study designed to examine Praziquantel treatment during pregnancy were used (n = 359)." | 5.30 | Maternal anemia type during pregnancy is associated with anemia risk among offspring during infancy. ( Abioye, AI; Acosta, LP; Amoylen, AJ; Baltazar, PI; Bennett, B; Friedman, JF; Kurtis, JD; McDonald, EA; Olveda, RM; Park, S; Pond-Tor, S; Ripp, K; Sagliba, MJ; Tallo, V; Wu, HW, 2019) |
| "Control of schistosomiasis presently relies largely on preventive chemotherapy with praziquantel through mass drug administration (MDA) programs." | 5.30 | Persistent Hotspots in Schistosomiasis Consortium for Operational Research and Evaluation Studies for Gaining and Sustaining Control of Schistosomiasis after Four Years of Mass Drug Administration of Praziquantel. ( Binder, S; Campbell, CH; Colley, DG; Gazzinelli-Guimaraes, PH; Karanja, DMS; King, CH; Kinung'hi, S; Kittur, N; Magnussen, P; Montgomery, SP; Mwinzi, PNM; N'Goran, EK; Olsen, A; Phillips, AE; Secor, WE; Utzinger, J; Walker, JW, 2019) |
| "Praziquantel was administered to all bilharzial positive cases." | 5.29 | The effect of praziquantel administration on the course of hepatitis B among cases with concomitant schistosome infection. ( Barakat, RM; Farghaly, AG, 1993) |
| "Large scale administration of the anthelminthic drug praziquantel (PZQ) to at-risk populations is the cornerstone of schistosomiasis control, although persisting high prevalence of infections in some areas and growing concerns of PZQ resistance have revealed the limitations of this strategy." | 5.27 | Repeated doses of Praziquantel in Schistosomiasis Treatment (RePST) - single versus multiple praziquantel treatments in school-aged children in Côte d'Ivoire: a study protocol for an open-label, randomised controlled trial. ( Amoah, AS; Assaré, RK; Casacuberta Partal, M; Corstjens, PLAM; Coulibaly, JT; Hoekstra, PT; Knopp, S; Meité, A; N'Gbesso, YK; N'Goran, EK; Roestenberg, M; Silué, KD; Tsonaka, S; Utzinger, J; van Dam, GJ; van Lieshout, L, 2018) |
| "Mice treated with praziquantel showed a prompt decrease in S." | 5.27 | Reversal of hepatic fibrosis after praziquantel therapy of murine schistosomiasis. ( Dunn, MA; Girgis, NI; Ishak, EA; Khayyal, MT; Mansour, MM; Morcos, SH; Saleh, S, 1985) |
| "Praziquantel appears to be an effective, well tolerated and easily administrable schistosomicide and thus a favourable contribution to the control of urinary schistosomiasis." | 5.26 | [Trial of praziquantel in the treatment of urinary schistosomiasis in Senegal]. ( Bah, IB; Diallo, S; Dieng, Y; Diouf, F; Ndir, O; Victorius, A, 1981) |
| "In Eseka and Edea bilharziasis caused by S." | 5.26 | [Epidemiological study of foci of S. intercalatum schistosomiasis in Eseka and Edea (Cameroon). Effects of treatment with praziquantel]. ( Carrié, J; Deniau, M; Pagbe, JJ; Ravinet, L; Ripert, C; Same Ekobo, A, 1981) |
| " The source databases used were Science Direct and PubMed/Medline, in the intervals between 2015 and 2021 with the drugs key-words or diseases, like "schistosomiasis", "praziquantel", "malaria", "artesunate", "Chagas' disease", "benznidazole", "filariasis", diethylcarbamazine", "ivermectin", " albendazole"." | 5.22 | Drug associations as alternative and complementary therapy for neglected tropical diseases. ( Alves, LP; Andrade, MC; Barbosa, IDNG; Ferraz, LRM; Rolim, LA; Rolim-Neto, PJ; Sales, VAW; Santos, WMD; Silva, LCPBB; Souza, ML, 2022) |
| "Praziquantel (PZQ) is the drug of choice for the treatment of all forms of schistosomiasis, although its mechanisms of action are not completely understood." | 5.22 | Praziquantel: An update on the mechanism of its action against schistosomiasis and new therapeutic perspectives. ( Carvalho, RC; Dos Santos, VAF; Filho, ACCM; Frazão, GCCG; Licá, ICL; Lira, MGS; Miranda, GS; Nascimento, FRF; Nogueira, RA; Rodrigues, JGM, 2022) |
| "To evaluate the efficacy of repeated application of praziquantel in the treatment of hepatic fibrosis due to schistosomiasis." | 5.22 | [Efficacy of repeated application of praziquantel in treatment of hepatic fibrosis due to schistosomiasis]. ( Hong-Bao, L; Ming, S, 2016) |
| "Sustaining high uptake of praziquantel is key for long-term control of schistosomiasis." | 5.20 | Reduced uptake of mass treatment for schistosomiasis control in absence of food: beyond a randomized trial. ( Katahoire, A; Muhumuza, S; Nuwaha, F; Olsen, A, 2015) |
| "School-based mass treatment with praziquantel is the cornerstone for schistosomiasis control in school-aged children." | 5.19 | Effectiveness of a pre-treatment snack on the uptake of mass treatment for schistosomiasis in Uganda: a cluster randomized trial. ( Katahoire, A; Kiragga, AN; Muhumuza, S; Nuwaha, F; Olsen, A, 2014) |
| " This study reports on the safety of a combination of albendazole, ivermectin and praziquantel in the treatment of lymphatic filariasis (LF), schistosomiasis and soil-transmitted helminthiasis (STH) in infected children." | 5.15 | A randomised controlled clinical trial on the safety of co-administration of albendazole, ivermectin and praziquantel in infected schoolchildren in Uganda. ( Kabatereine, N; Namwanje, H; Olsen, A, 2011) |
| " We investigated systemic inflammation as measured by plasma levels of soluble tumor necrosis factor-alpha receptor II (sTNF-rII), interleukin-8, (IL-8), and IL-10 during schistosomiasis and HIV co-infection and after schistosomiasis treatment." | 5.13 | Schistosomiasis and infection with human immunodeficiency virus 1 in rural Zimbabwe: systemic inflammation during co-infection and after treatment for schistosomiasis. ( Butterworth, AE; Deelder, AM; Erikstrup, C; Gerstoft, J; Gomo, E; Kallestrup, P; Ostrowski, SR; Pedersen, BK; Ullum, H; van Dam, GJ; Zinyama-Gutsire, RB, 2008) |
| "Despite mass drug administration programmes with praziquantel, the prevalence of schistosomiasis remains high." | 5.12 | Immunological Considerations for ( Cose, S; Driciru, E; Elliott, AM; Koopman, JPR; Roestenberg, M; Siddiqui, AA; Yazdanbakhsh, M, 2021) |
| ": Lipid-based nanosystems (LBNSs) formulations can be used to overcome the shortcomings associated with the use of praziquantel in the schistosomiasis treatment due to their amphipathic nature." | 5.12 | Synthesis and therapeutic delivery approaches for praziquantel: a patent review (2010-present). ( Adekiya, TA; Choonara, YE; Kondiah, PPD; Kumar, P; Pillay, V, 2021) |
| "To determine whether treatment of schistosomiasis has an effect on the course of human immunodeficiency virus type 1 (HIV-1) infection, individuals with schistosomiasis and with or without HIV-1 infection were randomized to receive praziquantel treatment at inclusion or after a delay of 3 months; 287 participants were included in the study, and 227 (79%) were followed up." | 5.11 | Schistosomiasis and HIV-1 infection in rural Zimbabwe: effect of treatment of schistosomiasis on CD4 cell count and plasma HIV-1 RNA load. ( Butterworth, AE; Erikstrup, C; Gerstoft, J; Gomo, E; Kallestrup, P; Mudenge, B; Ullum, H; van Dam, GJ; Zinyama, R, 2005) |
| "A double-blind placebo-controlled study of the concurrent administration of albendazole and praziquantel was conducted in>1500 children with high prevalences of geohelminths and schistosomiasis." | 5.09 | Double-blind placebo-controlled study of concurrent administration of albendazole and praziquantel in schoolchildren with schistosomiasis and geohelminths. ( Aligui, G; Gachihi, G; Hewlett, J; Horton, RJ; King, C; Koech, D; Kombe, Y; Liu, CY; McGarvey, S; Odhiambo, O; Olds, GR; Olveda, R; Ouma, J; Parraga, I; Peters, P; Ramirez, B; Reeve, P; Whalen, C; Wu, G, 1999) |
| "Many actors responded to the London Declaration which reinforced praziquantel's central role in control and elimination of schistosomiasis whereas access to affordable insulin emerged secondary to framing around prevention and management of diabetes." | 5.05 | Spotlight on experiences of medicine unavailability: access to medicines challenges for NCDs and NTDs - the contrasting cases of insulin and praziquantel. ( Beran, D; Chappuis, F; Wells, N, 2020) |
| "Praziquantel is a remarkably effective drug for the treatment of schistosomiasis." | 5.05 | Praziquantel: An Enigmatic, Yet Effective, Drug. ( Timson, DJ, 2020) |
| "Schistosomiasis control is heavily reliant on the drug praziquantel (PZQ), which is used as preventive chemotherapy as part of national helminth control strategies." | 5.05 | Drug metabolism and pharmacokinetics of praziquantel: A review of variable drug exposure during schistosomiasis treatment in human hosts and experimental models. ( Mutapi, F; Zdesenko, G, 2020) |
| "While praziquantel mass drug administration is currently the most widely used method in the control of human schistosomiasis, it does not prevent subsequent reinfection hence persistent transmission." | 5.05 | A systematic review and meta-analysis on the rate of human schistosomiasis reinfection. ( Makene, T; Mushi, V; Zacharia, A, 2020) |
| "Randomized single-blind comparative trials of the newer antischistosomal drugs praziquantel and oxamniquine were undertaken at Mwanza, Tanzania, an area coendemic for schistosomiasis mansoni and haematobium." | 5.05 | Randomized comparative trials of single doses of the newer antischistosomal drugs at Mwanza, Tanzania. I. Praziquantel and oxamniquine for the treatment of schistosomiasis mansoni. ( Asila, J; Chimbe, A; Rugemalila, JB, 1984) |
| "The efficacy of oltipraz as a schistosomicidal drug was investigated in Gabonese children suffering from urinary schistosomiasis in the dosages of 1 X 25 mg/kg body weight, 1 X 35 mg/kg body weight, and 2 X 20 mg/kg body weight and compared to praziquantel, 2 X 30 mg/kg body weight." | 5.05 | Comparative trial of oltipraz versus praziquantel in the treatment of urinary schistosomiasis in the Gabon. ( Baltes, R; Burchard, GD; Dietrich, M; Kern, P, 1984) |
| "158 school children from Lambarene and its surroundings suffering from intestinal manifestations of schistosomiasis due to Schistosoma intercalatum, Schistosoma haematobium, or mixed infections were randomly allocated to patient groups to be treated with oltipraz and praziquantel respectively." | 5.05 | Comparative study of oltipraz versus praziquantel for treatment of schistosomiasis with intestinal manifestation in the Gabon (Schistosoma intercalatum and S. haematobium). ( Burchard, GD; Dietrich, M; Kern, P, 1984) |
| "Praziquantel is a newly developed drug effective in the treatment of schistosomiasis." | 5.05 | Treatment of Schistosoma mekongi with praziquantel: a double-blind study. ( Cheever, AW; Hofstetter, M; Nash, TE; Ottesen, EA, 1982) |
| "A double-blind controlled trial of 2-cyclohexylcarbonyl-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a] isoquinolin-4-one (praziquantel, EMBAY 8440, Biltricide) in the treatment of vesical schistosomiasis has been carried out in 90 Nigerian schoolchildren of both sexes aged 9--16 years." | 5.05 | Clinical experience with praziquantel in the treatment of Nigerian patients infected with S. haematobium. ( Bamgboye, EA; Bammeke, AO; Kofie, BA; Oyediran, AB, 1981) |
| "Praziquantel was compared to niridazole in schistosomiasis intercalatum in the Gabon." | 5.05 | Praziquantel compared to niridazole in schistosomiasis intercalatum therapy. ( Dietrich, M; Feldmeier, H; Steiner, A; Zwingenberger, K, 1981) |
| "Previous studies have reported that chemotherapy of schistosomiasis by praziquantel in humans boosts protective antibody responses against S mansoni and S haematobium." | 5.01 | Population level changes in schistosome-specific antibody levels following chemotherapy. ( Fukushige, M; Mutapi, F; Woolhouse, MEJ, 2019) |
| "Praziquantel has remained the drug of choice for schistosomiasis chemotherapy for almost 40 years." | 4.98 | Antischistosomal agents: state of art and perspectives. ( da Silva Filho, AA; de Moraes, J; Lago, EM; Silva, LM; Teixeira, TR; Xavier, RP, 2018) |
| "The commitment to eliminate schistosomiasis as a public health problem has mobilized the expansion of praziquantel treatment to meet the London Declaration targets." | 4.98 | Acting beyond 2020: better characterization of praziquantel and promising antischistosomal leads. ( Keiser, J; Panic, G, 2018) |
| " We also discuss recent results showing that praziquantel, the current drug of choice against schistosomiasis, selectively targets host TRP channels in addition to its likely primary targets in the parasite." | 4.98 | TRP channels as potential targets for antischistosomals. ( Bais, S; Greenberg, RM, 2018) |
| "The current approach of morbidity control of schistosomiasis, a helminth disease of poverty with considerable public health and socioeconomic impact, is based on preventive chemotherapy with praziquantel." | 4.95 | Controlling schistosomiasis with praziquantel: How much longer without a viable alternative? ( Bergquist, R; Keiser, J; Utzinger, J, 2017) |
| "An action plan for paediatric schistosomiasis and female genital schistosomiasis (FGS) is needed with expanded access to praziquantel (PZQ) treatment required." | 4.95 | Paediatric and maternal schistosomiasis: shifting the paradigms. ( Bustinduy, AL; Friedman, JF; Stothard, JR, 2017) |
| "The mainstay of current schistosomiasis control programs is mass preventive chemotherapy of school-aged children with praziquantel." | 4.95 | Systematic review of community-based, school-based, and combined delivery modes for reaching school-aged children in mass drug administration programs for schistosomiasis. ( Burnim, M; Ivy, JA; King, CH, 2017) |
| "Here, we conducted a meta-analysis of clinical trials of praziquantel for treating children with any form of schistosomiasis." | 4.95 | Efficacy and safety of praziquantel 40 mg/kg in preschool-aged and school-aged children: a meta-analysis. ( Olliaro, P; Zwang, J, 2017) |
| "While there are challenges to implementing therapy for schistosomiasis, and praziquantel therapy is not fully curative, reductions in egg output are significantly correlated with decreased morbidity and can be used to project diminution in disease burden when contemplating more aggressive strategies to minimize infection intensity." | 4.95 | Decline in infection-related morbidities following drug-mediated reductions in the intensity of Schistosoma infection: A systematic review and meta-analysis. ( Andrade, G; Bertsch, DJ; Gazzinelli, A; King, CH, 2017) |
| "The control of schistosomiasis emphasizes preventive chemotherapy with praziquantel, which aims at decreasing infection intensity and thus morbidity in individuals, as well as transmission in communities." | 4.91 | Toward Measuring Schistosoma Response to Praziquantel Treatment with Appropriate Descriptors of Egg Excretion. ( Coulibaly, JT; Diawara, A; Garba, A; Keiser, J; King, CH; Knopp, S; Landouré, A; N'Goran, EK; Olliaro, PL; Raso, G; Scherrer, AU; Sousa-Figueiredo, JC; Stete, K; Utzinger, J; Vaillant, M; Zhou, XN, 2015) |
| "Praziquantel has been the mainstay of schistosomiasis control since 1984 and widely distributed since 2006 through 'preventive chemotherapy' programmes to school-aged children or at-risk populations." | 4.90 | The little we know about the pharmacokinetics and pharmacodynamics of praziquantel (racemate and R-enantiomer). ( Delgado-Romero, P; Keiser, J; Olliaro, P, 2014) |
| "Within the World Health Organization 2012-2020 roadmap for control and elimination of schistosomiasis, the scale-up of mass drug administration with praziquantel is set to change the epidemiological landscape across Africa and Arabia." | 4.90 | Diagnostics for schistosomiasis in Africa and Arabia: a review of present options in control and future needs for elimination. ( Al-Helal, MA; Allan, F; Betson, M; Bustinduy, AL; Hassan, AA; Memish, ZA; Rollinson, D; Sousa-Figueiredo, JC; Stanton, MC; Stothard, JR; Van Dam, GJ; Ward, S; Waterhouse, D, 2014) |
| "Preventive chemotherapy campaigns against schistosomiasis have progressively scaled-up during the last decade, administering single standard dose praziquantel (40 mg/kg) treatments to millions of African children." | 4.89 | Advocacy, policies and practicalities of preventive chemotherapy campaigns for African children with schistosomiasis. ( Navaratnam, AM; Sousa-Figueiredo, JC; Stothard, JR, 2013) |
| "Praziquantel remains the drug of choice for schistosomiasis, but it has the low bioavailability and single dosage form." | 4.89 | [Progress of research on preparation and application of praziquantel]. ( Liu, YF; Ma, Z; Ning, A; Wu, DZ; Zhu, WF, 2013) |
| " Anti-inflammatory drugs can provide symptomatic relief; praziquantel, the mainstay of chronic schistosomiasis treatment, is likely not effective against acute disease; the only reliable prevention remains avoidance of contaminated freshwater in endemic areas, as there is no vaccine." | 4.88 | Acute pulmonary schistosomiasis in travelers: case report and review of the literature. ( Cetron, MS; Kozarsky, P; Pavlin, BI, 2012) |
| "Chemotherapy based on repeated doses of praziquantel is still the most effective control strategy against Schistosomiasis, however artemisinin derivatives emerged as a family of compounds with schistomicide activity." | 4.88 | Systematic review and meta-analysis of artemisinin based therapies for the treatment and prevention of schistosomiasis. ( Burguillo, FJ; López-Abán, J; Muro, A; Pérez del Villar, L, 2012) |
| "Schistosomiasis is a widespread tropical parasitic disease, currently treated with Praziquantel, whose precise molecular target is actually unknown." | 4.87 | Macromolecular bases of antischistosomal therapy. ( Angelucci, F; Bellelli, A; Boumis, G; Brunori, M; Dimastrogiovanni, D; Miele, AE, 2011) |
| "We performed systematic searches of electronic databases PubMed and EMBASE for relevant data using search terms 'schistosomiasis', 'dosing' and 'praziquantel' and hand searches of personal collections and bibliographies of recovered articles." | 4.87 | Utility of repeated praziquantel dosing in the treatment of schistosomiasis in high-risk communities in Africa: a systematic review. ( Carter, J; Colley, DG; King, CH; Olbrych, SK; Singer, ME; Soon, M, 2011) |
| "Praziquantel, due to high efficacy, excellent tolerability, few and transient side effects, simple administration, and competitive cost, is virtually the only drug of choice for treatment of human schistosomiasis." | 4.87 | New insight into praziquantel against various developmental stages of schistosomes. ( Huang, YX; Wang, W; Wu, W, 2011) |
| "Praziquantel has been used as first-line drug for chemotherapy of schistosomiasis since 1984." | 4.87 | Efficacy of praziquantel and artemisinin derivatives for the treatment and prevention of human schistosomiasis: a systematic review and meta-analysis. ( Dong, HF; Guo, Y; Jiang, MS; Liu, R; Zhao, QP, 2011) |
| " Antischistosomal therapy, praziquantel, used for pulmonary hypertension secondary to schistosomiasis usually has no effect, but it is given to prevent further progression of disease." | 4.86 | Pulmonary vascular disease associated with schistosomiasis. ( Butrous, G; Crosby, A; Harhay, MO; Kolosionek, E; Morrell, N, 2010) |
| "Treatment with praziquantel (PZQ) has become virtually the sole basis of schistosomiasis control in sub-Saharan Africa and elsewhere, and the drug is reviewed here in the context of the increasing rate that it is being used for this purpose." | 4.85 | Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs. ( Botros, S; Cioli, D; Coles, G; Doenhoff, MJ; Engels, D; Hagan, P; Mbaye, A; Pica-Mattoccia, L; Southgate, V; Tchuem Tchuenté, LA, 2009) |
| "Praziquantel (PZQ) is the only drug being used to treat human schistosomiasis on a large scale." | 4.84 | Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. ( Cioli, D; Doenhoff, MJ; Utzinger, J, 2008) |
| "Praziquantel became available for the treatment of schistosomiasis and other trematode-inflicted diseases in the 1970s." | 4.83 | Praziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance. ( Doenhoff, MJ; Pica-Mattoccia, L, 2006) |
| "Publications reviewed for this article cover: the development of treatment strategies; the planning, implementation and impact of control programmes; the re-evaluation of the burden of schistosomiasis; improved tools for control; new drugs; the safety of treatment during pregnancy; and the development of resistance against praziquantel." | 4.83 | Schistosomiasis: challenges for control, treatment and drug resistance. ( Fenwick, A; Webster, JP, 2006) |
| "Praziquantel (PZQ) is the safest of all anti-helminthics and now forms the backbone for all national control programs against schistosomiasis (Med." | 4.82 | Administration of praziquantel to pregnant and lactating women. ( Olds, GR, 2003) |
| "Praziquantel is the drug of choice for the treatment of all forms of schistosomiasis." | 4.82 | Praziquantel. ( Cioli, D; Pica-Mattoccia, L, 2003) |
| "Despite the limited reports of praziquantel resistance, the relative success of chemotherapy-based control programmes for schistosomiasis has prompted overdue efforts to expand the use of cheap, generic, praziquantel in sub-Saharan Africa." | 4.82 | Schistosomiasis control: keep taking the tablets. ( Appleton, CC; Coles, GC; Hagan, P; Kusel, JR; Tchuem-Tchuenté, LA, 2004) |
| "Praziquantel is recommended as the drug of choice for all forms of schistosomiasis." | 4.78 | Exudative polyserositis and acute respiratory failure following praziquantel therapy. ( Azher, M; el-Kassimi, FA; Mofti, A; Wright, SG, 1990) |
| " The introduction of oxamniquine and praziquantel constitutes a break through in the treatment of intestinal and urogenital schistosomiasis." | 4.76 | [Present status of the treatment of helminthiasis]. ( Coulaud, JP, 1984) |
| "Mass drug administration of praziquantel becomes a less attractive strategy for elimination of schistosomiasis in low-prevalence areas due to cost implications and low treatment compliance." | 4.31 | Test-Treat-Track-Test-Treat Strategy for Control of Schistosomiasis in Two Low-Prevalence Villages in Northwestern Tanzania. ( Angelo, T; Campbell, CH; Kinung'hi, SM; Maganga, JK; Mosha, J; Mwanga, JR, 2023) |
| "Only praziquantel is available for treating schistosomiasis, a disease affecting more than 200 million people." | 4.31 | Non-covalent inhibitors of thioredoxin glutathione reductase with schistosomicidal activity in vivo. ( Aboagye, SY; Angelucci, F; Ardini, M; Byrne, ME; Dangi, B; Effantin, G; Fata, F; Gabriele, F; Gone, V; Harding, LNM; Ippoliti, R; Johnson, JJ; Lantvit, DD; Ling, WL; Lullo, RP; Martin, LM; Nikolic, D; Petukhov, PA; Petukhova, VZ; Thatcher, GRJ; Williams, DL, 2023) |
| " Additional investigations of the proportion of newborns with FGR should obtain more certainty about the effect of praziquantel and schistosomiasis on fetal growth." | 4.31 | Investigation on birth weight outcomes in schistosomiasis and praziquantel research: a correspondence. ( Davi, SD; Holtfreter, MC; Mischlinger, J; Schleenvoigt, BT, 2023) |
| "Over the past two decades, preventive chemotherapy (PC) with praziquantel (PZQ) is the major strategy for controlling schistosomiasis in Senegal." | 4.31 | Schistosomiasis control in Senegal: results from community data analysis for optimizing preventive chemotherapy intervention with praziquantel. ( Ba, M; Boh, OK; Diop, B; Faye, B; Guèye, B; Kane, NM; Kinvi, B; Mané, M; Monteil, R; Mwinzi, P; Ortega, JC; Sacko, M; Sylla, K; Talla, I; Zoure, HGM, 2023) |
| "Racemic praziquantel (PZQ) is the standard treatment for schistosomiasis and liver fluke infections (opisthorchiasis and clonorchiasis)." | 4.12 | R-praziquantel integrated population pharmacokinetics in preschool- and school-aged African children infected with Schistosoma mansoni and S. haematobium and Lao adults infected with Opisthorchis viverrini. ( Coulibaly, J; Falcoz, C; Guzy, S; Keiser, J; Kovač, J; Lin, YW; Meister, I; Sayasone, S; Wesche, D, 2022) |
| "Schistosomiasis is a widely distributed parasitic disease and one of the most important neglected tropical diseases globally, for which Praziquantel® (PZQ) is the only available treatment." | 4.12 | The Effect of Different Formulations of Praziquantel in Reducing Worms in the Prepatent Period of Schistosomiasis in Murine Models. ( da Silva, CH; de Moraes Neto, AHA; Leonardi, D; Mello Silva, CC; Paulino, ÉT; Real, DA; Ribeiro de Lima, M; Salomon, CJ; Viçosa, AL, 2022) |
| "School-based preventive chemotherapy (Deworming) with praziquantel and albendazole to control and eliminate schistosomiasis and soil-transmitted helminths as public health problems is recommended by the World Health Organization (WHO)." | 4.12 | Safety of Praziquantel and Albendazole Coadministration for the Control and Elimination of Schistosomiasis and Soil-Transmitted Helminths Among Children in Rwanda: An Active Surveillance Study. ( Aklillu, E; Barry, A; Bergman, U; Bienvenu, E; Kabatende, J; Mugisha, M; Ntirenganya, L, 2022) |
| "the study had provided evidence of the distribution of schistosomiasis in South Sudan for policy direction and recommended annual preventive chemotherapy with praziquantel in all endemic areas." | 4.12 | Prevalence and factors associated with transmission of schistosomiasis in school-aged children in South Sudan: a cross-sectional study. ( Abe, A; Ajo, JPH; Berta, KK; Bidali, A; Ndenzako, F; Olu, OO; Onyeze, A; Pascale, JR; Senkwe, MN; Sube, J; Yibi, SM, 2022) |
| "Praziquantel (PZQ) is the only drug available for community-based control programs which aim to reduce the prevalence and morbidity associated with schistosomiasis." | 4.12 | EF24, a schistosomicidal curcumin analog: Insights from its synthesis and phenotypic, biochemical and cytotoxic activities. ( Alegretti, SM; Badoco, FR; Caffrey, CR; El-Sakkary, N; Janku Cabral, F; Katz, N; Loiola, MC; Magalhães, LG; Mendes, TMF; Orenha, RP; Parreira, RLT; Paula, LAL; Sairre, MI; Squarisi, IS; Tavares, DC, 2022) |
| "Schistosomiasis control relies mainly on mass drug administration of Praziquantel (PZQ) to school aged children (SAC)." | 4.12 | Fine-scale mapping of Schistosoma mansoni infections and infection intensities in sub-districts of Makenene in the Centre region of Cameroon. ( Casacuberta-Partal, M; Kamdem, CN; Mbagnia, MCT; Mengoue, LET; Mewamba, EM; Njiokou, F; Simo, G; Tatang, RJA; Tchounkeu, EY; Tiofack, AAZ; Womeni, HM, 2022) |
| " The search targeted journals that described the treatment of schistosomiasis in children 5 years and below using praziquantel." | 4.12 | Patient journey and resources mapping to implement a praziquantel mass drug administration program for children aged 5 years and below in resource-limited settings. ( Chimbari, MJ; Kabuyaya, M; Ncube, MV, 2022) |
| "Schistosomiasis is a major global health problem caused by blood-dwelling parasitic worms, which is currently tackled primarily by mass administration of the drug praziquantel." | 4.12 | Screening of a Library of Recombinant Schistosoma mansoni Proteins With Sera From Murine and Human Controlled Infections Identifies Early Serological Markers. ( Berriman, M; Brandt, C; Clare, S; Crosnier, C; Hokke, CH; Janse, JJ; Langenberg, MCC; Protasio, AV; Rinaldi, G; Roestenberg, M; Wilson, S; Wright, GJ, 2022) |
| "Schistosomiasis is a major neglected parasitic disease that affects more than 265 million people worldwide and for which the control strategy consists of mass treatment with the only available drug, praziquantel." | 4.02 | Synthesis, structure-activity relationships, cocrystallization and cellular characterization of novel smHDAC8 inhibitors for the treatment of schistosomiasis. ( Darwish, S; Erdmann, F; Ghazy, E; Heimburg, T; Jung, M; Lancelot, J; Pierce, R; Robaa, D; Romier, C; Schmidt, M; Schmidtkunz, K; Shaik, TB; Simoben, CV; Sippl, W; Truhn, A; Zeyen, P, 2021) |
| " In the pathway analysis, arachidonic acid metabolism was found to be altered following PZQ treatment, indicating that this pathway may be affected by the drug and potentially considered as a novel target for anti-schistosomiasis drug development." | 4.02 | Metabolomics reveal alterations in arachidonic acid metabolism in Schistosoma mekongi after exposure to praziquantel. ( Adisakwattana, P; Chienwichai, P; Chusongsang, P; Chusongsang, Y; Limpanont, Y; Reamtong, O; Tarning, J; Tipthara, P, 2021) |
| "This study was to determine the relationship between a praziquantel-related adverse event with the health community perception to chemopreventive of Schistosomiasis in Dodolo village, Napu Valley, Central Sulawesi." | 4.02 | Does the presence of praziquantel-related adverse events affect the health community's perception toward the mass chemopreventive program in the highest prevalence area of Schistosomiasis in Indonesia? Study in Dodolo village, Napu Valley, Central Sulawes ( Afriana, F; Daris, R; Hidayat, SH; Putri, ASD; Vera Diana, T, 2021) |
| "The Geshiyaro project aims to break transmission of soil-transmitted helminths and schistosomiasis in the Wolaita Zone of Ethiopia through a combination of two interventions: behavior change communication (BCC) for increased water, sanitation and hygiene (WaSH) infrastructure use alongside preventive chemotherapy (PC) using albendazole (ALB) and praziquantel (PZQ), targeted to reach 90% treatment coverage." | 4.02 | Coverage evaluation surveys following soil-transmitted helminthiasis and schistosomiasis mass drug administration in Wolaita Zone of Ethiopia-The Geshiyaro project. ( Anjulo, U; Belay, H; Chernet, M; Endrias, T; Gidey, B; Kalahasti, S; Landeryou, T; Liyew, EF; Maddren, R; Mehari, Z; Mekete, K; Mengistu, B; Ower, AK; Phillips, AE; Tamiru, A; Tasew, G; Tollera, G, 2021) |
| "Efforts to eliminate schistosomiasis are hindered by incomplete efficacy of the only FDA-approved antischistosomal drug, praziquantel." | 4.02 | Booming Omics in Schistosoma. ( Boissier, J; Gourbal, B; Le Govic, Y, 2021) |
| " These issues in Africa could be addressed by increasing cultural awareness of BCa causes and symptoms via social media, banning smoking in public places, and ensuring that praziquantel is readily available in areas at high risk of schistosomiasis." | 4.02 | Bladder Cancer and Associated Risk Factors: The African Panorama. ( Der Merwe, AV; Mantica, G; Terrone, C, 2021) |
| "The control and elimination of schistosomiasis have over the last two decades involved several strategies, with the current strategy by the World Health Organization (WHO) focusing mainly on treatment with praziquantel during mass drug administration (MDA)." | 4.02 | Rethinking the Top-Down Approach to Schistosomiasis Control and Elimination in Sub-Saharan Africa. ( Bengtson, M; Diehl, JC; Oladepo, O; Onasanya, A; Van Engelen, J, 2021) |
| "Evaluate the efficacy of a low-dose praziquantel and fenbendazole protocol to manage asymptomatic schistosomiasis in dogs and compare fecal saline sedimentation (FSS) and fecal PCR (FPCR) for therapeutic monitoring." | 4.02 | Efficacy of a low-dose praziquantel and fenbendazole protocol in the treatment of asymptomatic schistosomiasis in dogs. ( Cridge, H; Lupiano, H; Mackin, AJ; Nipper, JD; Steiner, JM, 2021) |
| " mansoni in PSAC in Assoni using double-stool smear preparation, (ii) treated the infected PSAC with a standard dose of praziquantel 40 mg/kg, (iii) ran educational campaigns each year in the village, and (iv) built latrines to improve sanitation and reduce schistosomiasis transmission." | 4.02 | A 12-year follow-up of intestinal schistosomiasis in pre-school-aged children in Assoni Village, Eastern Senegal. ( Barbier, D; Bessin, F; Danfakha, F; Dewavrin, P; Diawara, L; Diop, B; Keita, BF; Keita, F; Keita, G; Klotz, F; N'Diaye, M; Senghor, CS; Vernet, C, 2021) |
| "Schistosomiasis control programs rely heavily on mass drug administration (MDA) campaigns with praziquantel for preventative chemotherapy." | 3.96 | Environmental Predictors of Schistosomiasis Persistent Hotspots following Mass Treatment with Praziquantel. ( Binder, S; Campbell, CH; Castleman, JD; Colley, DG; Drake, JM; King, CH; Kittur, N; Walker, JW, 2020) |
| "Hycanthone (HYC) is a retired drug formerly used to treat schistosomiasis caused by infection from Schistosoma mansoni and S." | 3.96 | Molecular basis for hycanthone drug action in schistosome parasites. ( Cao, X; Guzman, M; LoVerde, PT; McHardy, SF; Rugel, A; Tarpley, RS; Taylor, AB, 2020) |
| "For decades, mass drug treatment with praziquantel (PZQ) has been utilized to treat schistosomiasis, yet reinfection and the risk of drug resistance are among the various factors precluding successful elimination of schistosomiasis." | 3.96 | Elucidation of Cellular Responses in Non-human Primates With Chronic Schistosomiasis Followed by Praziquantel Treatment. ( Lazarus, S; Le, L; Melkus, MW; Molehin, AJ; Siddiqui, AA; Siddiqui, AJ; Zhang, W, 2020) |
| "National Health Information System surveillance data, based on routinely collected direct smear results at health centre level, may be able to monitor the impact of mass drug administration with praziquantel on intestinal schistosomiasis in Burundi." | 3.96 | Can direct smear results that are routinely collected at health centre level be used for monitoring the impact of mass drug administration with praziquantel on schistosomiasis in Burundi? A preliminary assessment. ( Bijabuka, U; Bizimana, P; Krit, M; Nibakire, M; Nkeshimana, A; Nsabiyumva, F; Ortu, G; Polman, K; Van Geertruyden, JP, 2020) |
| "Repeated praziquantel treatment for schistosomiasis is an effective method to reduce disease burden." | 3.96 | Change in schistosomiasis-related liver disease with repeated praziquantel treatment in school children in rural Zambia. ( McAdam, D; Paul, E; Strahan, R, 2020) |
| "The Schistosomiasis Consortium for Operational Research and Evaluation (SCORE), a program focusing on schistosomiasis control in sub-Saharan Africa between 2008 and 2019, investigated ways to improve coverage and efficacy of ongoing chemotherapy programs and concluded that because of continued transmission, mass distribution of praziquantel cannot eliminate the disease without complementary control activities." | 3.96 | Schistosomiasis Consortium for Operational Research and Evaluation: Mission Accomplished. ( Bergquist, NR, 2020) |
| " We determined the perception of Zimbabwe's National Helminth Control Program (2012-2017) with a specific focus on schistosomiasis in the school children treated with praziquantel, schoolteachers and village health workers (VHW)." | 3.96 | Positive impact of preventative chemotherapy during a national helminth control program: Perception and KAP. ( Fourier, C; Lim, R; Mangwanda, B; Mduluza, T; Mutapi, F; Tagwireyi, P, 2020) |
| "In view of the potential immunosuppressive and regenerative properties of mesenchymal stem cells (MSC), we investigated whether transplantation of adipose tissue-derived stem cells (ASC) could be used to control the granulomatous reaction in the liver of mice infected with Schistosoma mansoni after Praziquantel (PZQ) treatment." | 3.96 | Liver damage in schistosomiasis is reduced by adipose tissue-derived stem cell therapy after praziquantel treatment. ( Alves, ÉAR; Bicalho, KA; Birbrair, A; Bozzi, A; Chaves, AT; Corrêa-Oliveira, R; de Goes, AM; Eller, DE; Ferraz, LCN; Gomes, TR; Miranda, VHS; Pascoal Xavier, MA; Silva, CEC, 2020) |
| "Praziquantel is a broad spectrum antihelmintic agent and represents the drug of choice for the treatment of schistosomiasis." | 3.91 | Orphan Formulations in Pediatric Schistosomiasis Treatment: Development and Characterization of Praziquantel Nanoparticle-Loaded Powders for Reconstitution. ( Gonzalez Vidal, NL; Gonzalez, MA; Ramírez Rigo, MV, 2019) |
| " This paper describes the learnings and challenges faced by the Pediatric Praziquantel Consortium team during the implementation of an industry-sponsored Phase II clinical study in pre-school-aged children infected with schistosomiasis, conducted in remote rural settings in Côte d'Ivoire." | 3.91 | Challenges and Lessons From Conducting A Paediatric Clinical Trial in Sub-Saharan Africa: The Case of the Praziquantel Oral Dispersible Tablets Phase II Study in Côte d'Ivoire. ( Bezuidenhout, D; David Aka, NA; Huber, E; Kourany-Lefoll, E; N'Goran, E; Ouattara, M, 2019) |
| "Treatment of schistosomiasis has relied on the anthelmintic drug praziquantel (PZQ) for more than a generation." | 3.91 | The antioxidants resveratrol and N-acetylcysteine enhance anthelmintic activity of praziquantel and artesunate against Schistosoma mansoni. ( Azevedo, C; Brindley, PJ; da Costa, JMC; Gärtner, F; Gouveia, MJ; Vale, N, 2019) |
| "A paper published in 1990 by Webbe and El Hag described the progress being made in the control of schistosomiasis with the introduction of a new medicine 'Praziquantel' to treat infected individuals, and the use of a molluscicide 'niclosamide', with which to kill the intermediate host snails." | 3.91 | Egypt's schistosomiasis control programme in the 1980s prepared the ground for the global elimination of schistosomiasis by 2030. ( Fenwick, A, 2019) |
| "The cornerstone of current schistosomiasis control programmes is delivery of praziquantel to at-risk populations." | 3.85 | Optimising cluster survey design for planning schistosomiasis preventive chemotherapy. ( Clements, M; Fenwick, A; Fleming, FM; Gower, CM; Harrison, WE; Jemu, S; Knowles, SCL; Kollie, K; Meite, A; Phillips, AE; Rebollo, MP; Sturrock, HJW; Styles, B; Thomas, B; Thomas, C; Turner, H; Whitton, JM, 2017) |
| "Preventive chemotherapy with praziquantel for schistosomiasis morbidity control is commonly done by mass drug administration (MDA)." | 3.85 | Defining Persistent Hotspots: Areas That Fail to Decrease Meaningfully in Prevalence after Multiple Years of Mass Drug Administration with Praziquantel for Control of Schistosomiasis. ( Binder, S; Campbell, CH; Colley, DG; King, CH; Kinung'hi, S; Kittur, N; Magnussen, P; Olsen, A, 2017) |
| "To investigate the clinical therapeutic effect of biological information infrared liver therapeutic apparatus (BILT) combined with praziquantel in the treatment of patients with chronic schistosomiasis." | 3.85 | [Therapeutic effect of BILT combined with praziquantel in treatment of chronic schistosomiasis]. ( Hong-Bo, W; Li-le, L; Na, Z; Ni-Na, P; Ru-Yi, L; Yan, M; Yu, H, 2017) |
| "This study assessed the impact of annual versus biennial praziquantel treatment regimens on the prevalence, intensity of infection, and liver fibrosis dynamics of Asiatic schistosomiasis (caused by Schistosoma japonicum) among individuals residing in 18 endemic barangays in Northern Samar, Philippines." | 3.85 | Biennial versus annual treatment for schistosomiasis and its impact on liver morbidity. ( Guevarra, JR; Harn, DA; Inobaya, MT; Lam, AK; Li, Y; McManus, DP; Ng, SK; Olveda, DU; Olveda, RM; Ross, AG; Vinluan, ML, 2017) |
| "Mass drug administration utilising a single oral dose of 40mg/kg of praziquantel (PZQ) has been endorsed and advocated by the World Health Organisation (WHO) for the global control and elimination of schistosomiasis." | 3.85 | A new global strategy for the elimination of schistosomiasis. ( Chau, TN; Harn, DA; Inobaya, MT; Li, Y; Olveda, RM; Ross, AG, 2017) |
| "Praziquantel is the drug of first choice for the control and treatment of all forms of schistosomiasis." | 3.85 | A quantification method for determination of racemate praziquantel and R-enantiomer in rat plasma for comparison of their pharmacokinetics. ( Ji, J; Nie, L; Sun, D; Wang, H; Zhang, D, 2017) |
| "Praziquantel (PZQ) is widely used in the treatment of several parasitic infections in both humans and animals, and is the first choice in the treatment of Schistosomiasis in humans." | 3.83 | Polymeric Nanostructured Systems for Liquid Formulation of Praziquan-tel: Development and in vitro Assessment. ( Conti, DS; da Rocha, SR; de Campos, VE; Mansur, CR; Ricci-Júnior, E; Silva, JA, 2016) |
| "Praziquantel is the mainstay of treatment of Schistosomiasis, which affects at least 262 million people worldwide." | 3.83 | Treatment of Schistosomiasis in a Patient Allergic to Praziquantel: A Desensitization and Treatment Protocol. ( Bailey, RL; Lukawska, J; Patel, TA; Rowe, J, 2016) |
| "In the Philippines, the current national control strategy for schistosomiasis is annual mass drug administration (MDA) with 40 mg/kg of praziquantel in all schistosomiasis-endemic villages with a prevalence ≥10%." | 3.81 | Can mass drug administration lead to the sustainable control of schistosomiasis? ( Chau, TN; Chy, D; Gray, DJ; Harn, DA; Li, Y; McManus, DP; Olveda, DU; Olveda, RM; Ross, AG; Tallo, V; Williams, GM, 2015) |
| "Taken together, these data suggest that the combined treatment of PZQ and edelfosine promotes a high decrease in granuloma formation, as well as in the cellular immune response that underlies granuloma development, with changes in the cytokine patterns, and may provide a promising and effective strategy for a prophylactic treatment of schistosomiasis." | 3.81 | Inhibition of Granulomatous Inflammation and Prophylactic Treatment of Schistosomiasis with a Combination of Edelfosine and Praziquantel. ( López-Abán, J; Mollinedo, F; Muro, A; Rojas-Caraballo, J; Varela-M, RE; Yepes, E, 2015) |
| "The cornerstone of schistosomiasis control is mass praziquantel treatment in high prevalence areas." | 3.80 | Dosing of praziquantel by height in sub-Saharan African adults. ( Brigham, T; Chasekwa, B; Humphrey, JH; Mbuya, MN; Palha De Sousa, CA; Prendergast, AJ; Tielsch, JM, 2014) |
| "To complement ongoing schistosomiasis control within national control programmes (NCPs) that administer praziquantel to school-age children, assessing the risk and extent of schistosomiasis in pre-school-age children (PSAC) is important." | 3.80 | Schistosomiasis in pre-school-age children and their mothers in Chikhwawa district, Malawi with notes on characterization of schistosomes and snails. ( Betson, M; Lalloo, DG; Mzembe, K; Naunje, A; Poole, H; Stanton, M; Stothard, JR; Terlouw, DJ, 2014) |
| "To investigate the expression characteristics of miR-155 and miR-146a in mice with schistosomiasis and praziquantel (PZQ) treatment." | 3.80 | [Expression characteristics of microRNA in mice with schistosomiasis and praziquantel treatment]. ( Chen, L; Hou, M; Ji, MJ; Wang, CY; Yang, BY; Zhang, F, 2014) |
| "To assess whether schistosomiasis coinfection with chronic hepatitis C virus (HCV) influences hepatic fibrosis and pegylated-interferon/ribavirin (PEG-IFN/RIB) therapy response." | 3.79 | Coinfection with hepatitis C virus and schistosomiasis: fibrosis and treatment response. ( Abdel-Rahman, M; El Raziky, M; El-Akel, W; El-Sayed, M; Elsharkawy, A; Esmat, G; Ghoneim, H; Khattab, H, 2013) |
| "To explore the value of B-ultrasound on the evaluation of the effects of traditional Chinese medicine compound of Radix astragali, Salvia miltiorrhiza and Angelica sinensis, and TCM + praziquantel on liver fibrosis in rabbits with schistosomiasis." | 3.79 | Effect of Chinese herbal compound on liver fibrosis in rabbits with schistosomiasis by B-ultrasound. ( Liang, XL; Yuan, JY, 2013) |
| "After praziquantel treatment for schistosomiasis, parasitological cure rates of 60%-90% are usual." | 3.79 | Sonographic response in the liver and urinary bladder of children 14 months after treatment for schistosomiasis. ( McAdam, D; Schneider, ME; Strahan, R, 2013) |
| "We showed that for a variation of efficacy between 30-70% of mass praziquantel administration for reducing the enhanced risk of HIV transmission per sexual act due to FGS, annual administration of praziquantel to school-age children in Zimbabwe could result in net savings of US$16-101 million compared with no mass treatment of schistosomiasis over a ten-year period." | 3.79 | Potential cost-effectiveness of schistosomiasis treatment for reducing HIV transmission in Africa--the case of Zimbabwean women. ( Atkins, KE; Galvani, AP; Meyers, LA; Ndeffo Mbah, ML; Orenstein, EW; Poolman, EM; Townsend, JP, 2013) |
| "Formulations that can be divided into four parts (to give 150 mg increments) are preferred for children weighing less than 11 kg; the same dosing can be applied with 600 mf praziquantel formulations that can be divided into four quarters or two halves from 11 kg body weight." | 3.79 | Practical dosing of praziquantel for schistosomiasis in preschool-aged children. ( Chitsulo, L; Hayes, DJ; Montresor, A; Olliaro, PL; Vaillant, M, 2013) |
| "Regular treatment with praziquantel (PZQ) is the strategy for human schistosomiasis control aiming to prevent morbidity in later life." | 3.79 | A latent Markov modelling approach to the evaluation of circulating cathodic antigen strips for schistosomiasis diagnosis pre- and post-praziquantel treatment in Uganda. ( Deelder, AM; Donnelly, CA; Kabatereine, NB; Koukounari, A; Moustaki, I; Tukahebwa, EM; van Dam, GJ; Vennervald, BJ; Webster, JP; Wilson, S, 2013) |
| " She was diagnosed with schistosomiasis and was cured with praziquantel." | 3.79 | An unusual presentation of a common infection. ( Bienemann, K; Germing, U; Häussinger, D; Kandolf, R; Klingel, K; Quintanilla-Martinez, L; Richter, J; Sander, O; Zeus, T, 2013) |
| "Schistosomiasis, a high volume neglected tropical disease affecting more than 200 million people worldwide, can only be effectively treated by the tetrahydroisoquinoline drug praziquantel (PZQ)." | 3.78 | MCR synthesis of praziquantel derivatives. ( Botros, S; Dömling, A; Herdtweck, E; Liu, H; William, S, 2012) |
| "Paradoxical reactions (Jarish Herxheimer-like reactions) have been described in patients treated with praziquantel (PZQ) during acute schistosomiasis (infected≤ 3 mo), while PZQ treatment of chronic schistosomiasis is generally considered to be safe." | 3.78 | Acute febrile respiratory reaction after praziquantel treatment during asymptomatic late form of acute schistosomiasis. ( Blum, JA; Hatz, CF; Neumayr, AL; Tschirky, B; Warren, A, 2012) |
| "The fear that schistosomes will become resistant to praziquantel (PZQ) motivates the search for alternatives to treat schistosomiasis." | 3.77 | Piggy-backing the concept of cancer drugs for schistosomiasis treatment: a tangible perspective? ( Dissous, C; Grevelding, CG, 2011) |
| "Two-arm comparative study in northern Ghana integrated praziquantel distribution into an existing lymphatic filariasis and onchocerciasis control programme using Community Directed Distributors." | 3.77 | Simultaneous administration of praziquantel, ivermectin and albendazole, in a community in rural northern Ghana endemic for schistosomiasis, onchocerciasis and lymphatic filariasis. ( Aborigo, R; Adjuik, M; Akweongo, P; Amankwa, J; Anto, F; Anyorigiya, T; Asoala, V; Bimi, L; Hodgson, A; Oduro, A, 2011) |
| "Praziquantel remains the drug of choice for the worldwide treatment and control of schistosomiasis." | 3.77 | Resolution of praziquantel. ( de Gooijer, J; Olliaro, P; Pouwer, K; Seerden, JP; Todd, MH; Woelfle, M, 2011) |
| "This paper reported one case of acute kidney injury caused by praziquantel." | 3.77 | [One case of acute kidney injury caused by praziquantel]. ( Chai, ZW; Xu, QC, 2011) |
| "Nineteen cases of acute schistosomiasis patients whose temperatures had fallen to normal automatically were treated with praziquantel, and their temperatures recrudesced after the treatment." | 3.77 | [Temperature recrudescence caused by praziquantel treatment after falling to normal automatically in acute schistosomiasis patients: a report of 19 cases]. ( Zhang, SX; Zhang, TY, 2011) |
| "To observe the compliance of film-coated praziquantel tablets in the schistosomiasis transmission controlled areas, so as to provide the evidence for the establishment of chemotherapy intervention measures in these areas." | 3.77 | [Compliance of film-coated praziquantel tablets in schistosomiasis transmission-controlled areas]. ( Bao, ZP; Cao, CL; Chen, L; Guo, JG; Meng, XH; Wang, DH; Wang, H; Wang, L; Zhang, YY; Zhao, GM; Zhong, B, 2011) |
| " The impact of praziquantel (PZQ) treatment on such potential inter-specific schistosome interactions and resulting morbidity using uniquely detailed longitudinal data (pre- and one year post-PZQ treatment) arising from the National Schistosomiasis Control Program in three areas of Mali: Ségou, Koulikoro and Bamako, is also evaluated." | 3.76 | The impact of single versus mixed schistosome species infections on liver, spleen and bladder morbidity within Malian children pre- and post-praziquantel treatment. ( Bosqué-Oliva, E; Dembelé, R; Donnelly, CA; Fenwick, A; Gabrielli, AF; Gouvras, A; Keita, AD; Koukounari, A; Landouré, A; Sacko, M; Traoré, M; Webster, JP, 2010) |
| "In large-scale interventions for control of schistosomiasis, use of the WHO dose pole is favoured for mass drug administration of praziquantel." | 3.76 | An inclusive dose pole for treatment of schistosomiasis in infants and preschool children with praziquantel. ( Betson, M; Day, M; Kabatereine, NB; Sousa-Figueiredo, JC; Stothard, JR, 2010) |
| "Although praziquantel (PZQ) has been used to treat schistosomiasis for over 20 years its mechanism of action remains unknown." | 3.75 | Towards an understanding of the mechanism of action of praziquantel. ( Aragon, AD; Blackburn, VR; Cunningham, C; Cupit, PM; Goronga, T; Imani, RA; Loker, ES; Melman, SD; Webb, T, 2009) |
| "Praziquantel (PZQ) is the drug compound of choice in the control and treatment of schistosomiasis." | 3.75 | Taste, a new incentive to switch to (R)-praziquantel in schistosomiasis treatment. ( Bothe, H; Fuchs, S; Meyer, T; Miculka, C; Schollmeyer, D; Sekljic, H, 2009) |
| "Contemporary control of schistosomiasis is typically reliant upon large-scale administration of praziquantel (PZQ) to school age children." | 3.75 | Improving control of African schistosomiasis: towards effective use of rapid diagnostic tests within an appropriate disease surveillance model. ( Stothard, JR, 2009) |
| "In the year 2000, the Philippines' Department of Health adopted mass chemotherapy using praziquantel to eliminate schistosomiasis." | 3.74 | Is mass treatment the appropriate schistosomiasis elimination strategy? ( Alday, PP; Balolong, E; Carabin, H; McGarvey, ST; Olveda, RM; Tallo, VL, 2008) |
| "To describe sociocultural factors that influence the distribution process of praziquantel for the mass treatment of schistosomiasis infection." | 3.74 | Sociocultural aspects of mass delivery of praziquantel in schistosomiasis control: the Abeokuta experience. ( Adeneye, AK; Adewale, B; Akande, DO; Akinwale, OP; Appelt, B; Idowu, ET; Mafe, MA; Manafa, OU; Omotola, BD; Sulyman, MA, 2007) |
| "We report a case of the Mazzotti reaction in a 13-year-old Liberian refugee after presumptive treatment of schistosomiasis and strongyloidiasis with ivermectin, praziquantel and albendazole." | 3.73 | Mazzotti reaction after presumptive treatment for schistosomiasis and strongyloidiasis in a Liberian refugee. ( Domachowske, JB; Olson, BG, 2006) |
| "There is evidence from experimental models that the praziquantel-induced clearance of schistosomiasis is dependent on the host's immune response." | 3.73 | Schistosomiasis and HIV in rural Zimbabwe: efficacy of treatment of schistosomiasis in individuals with HIV coinfection. ( Butterworth, AE; Erikstrup, C; Gerstoft, J; Gomo, E; Kallestrup, P; Ullum, H; van Dam, GJ; Zinyama, R, 2006) |
| "The purpose of this study was to evaluate whether a progressive cycle ergometer test (PCET) can detect minimal functional abnormalities that might indicate compromise of the pulmonary vascular bed in patients treated with praziquantel for chronic schistosomiasis who have no clinical signs of cardiopulmonary impairment." | 3.72 | [Evaluation of exercise tolerance in patients treated with praziquantel for chronic schistosomiasis with no signs of cardiopulmonary impairment]. ( de Noya, B; López, JM; Montes de Oca, M; Sánchez, MA; Tálamo, C, 2003) |
| "Currently, schistosomiasis control in Mali is mainly based on treatment with praziquantel (PZQ)." | 3.72 | Evaluation of case management in the integrated schistosomiasis-control programme in Mali. ( de Vlas, SJ; Landouré, A; Traoré, M; van der Werf, MJ, 2003) |
| "A prospective cohort study was conducted in two villages in Zambia to compare the efficacy of praziquantel in the treatment of schistosomiasis haematobium in people with and without concomitant infection with human immunodeficiency virus (HIV)." | 3.72 | Interactions between Schistosoma haematobium and human immunodeficiency virus type 1: the effects of coinfection on treatment outcomes in rural Zambia. ( Ernest, A; Mwanakasale, V; Sukwa, TY; Tanner, M; Vounatsou, P; Ziba, M, 2003) |
| "Passive case finding based on adequate diagnosis and treatment of symptomatic individuals with praziquantel by the health care facilities is a minimum requirement for integrated schistosomiasis control." | 3.72 | Quantitative evaluation of integrated schistosomiasis control: the example of passive case finding in Ghana. ( Bosompem, KM; Danso-Appiah, A; de Vlas, SJ; Habbema, JD; van der Werf, MJ, 2004) |
| "Schistosomiasis control programmes are generally based on mass distribution of praziquantel (PZQ)." | 3.72 | Is praziquantel therapy safe during pregnancy? ( Adam, I; Elwasila, el T; Homeida, M, 2004) |
| "This article analyzes policies that affected the availability of praziquantel, the drug of choice for schistosomiasis." | 3.70 | Dilemmas in drug development for tropical diseases. Experiences with praziquantel. ( Govindaraj, R; Reich, MR, 1998) |
| " This paper examines the actual costs of a combination of mass and selective treatment for schistosomiasis using praziquantel and mass treatment for intestinal nematodes using albendazole, as an integral part of school health programmes reaching 80442 pupils in 577 schools in Volta Region, Ghana, and reaching 109099 pupils in 350 schools in Tanga Region, Tanzania." | 3.70 | The cost of large-scale school health programmes which deliver anthelmintics to children in Ghana and Tanzania. The Partnership for Child Development. ( , 1999) |
| "This study was conducted to evaluate the efficacy of praziquantel (CAS 55268-74-1, EMBAY 8440, Biltricide) in different grades of Schistosoma mansoni infection." | 3.70 | Correlation between infection intensity, serum immunoglobulin profile, cellular immunity and the efficacy of treatment with praziquantel in murine schistosomiasis mansoni. ( Demerdash, Z; Nessim, NG, 2000) |
| "The effects of different doses of Interferon alpha 2b (IFN alpha 2b), alone and in combination with praziquantel (PZQ), on hepatic schistosomiasis were tested." | 3.70 | Parasitological, pathological and functional studies on the effects of IFN alpha 2b in murine hepatic schistosomiasis. ( Baddour, NM; Eissa, MM, 2000) |
| "Humoral and cellular immune response in schistosomiasis was studied pre and post praziquantel therapy." | 3.68 | Humoral and cellular immune response in schistosomiasis pre and post praziquantel therapy. ( el Said, A; Elhayawan, IA; Hamadto, HH; Rashed, SM, 1990) |
| "Eighty-four cases of schistosomiasis mekongi among Cambodian refugees in holding centres in Thailand received praziquantel at 30 mg/kg body-weight orally twice in one day." | 3.67 | Treatment of Schistosoma mekongi with praziquantel in Cambodian refugees in holding centres in Prachinburi Province, Thailand. ( D'Agnes, T; Keittivuti, A; Keittivuti, B; O'Rourke, T, 1984) |
| "This study was designed to determine the effects of early active schistosomiasis and treatment with antischistosomal agents on concentrations of the oral contraceptive (OC) steroids, ethinyl estradiol and levonorgestrel." | 3.67 | Contraceptive steroid concentrations in women with early active schistosomiasis: lack of effect of antischistosomal drugs. ( Back, DJ; el-Raghy, I; Fathalla, M; Orme, ML; Osman, F, 1986) |
| "Cattle naturally infected with nasal schistosomiasis were treated with a single oral dose of praziquantel at 20 mg/kg body weight." | 3.67 | Efficacy of praziquantel against Schistosoma nasale infection in cattle. ( D'Souza, PE; Jagannath, MS; Prabhakar, KS; Prem, G; Rahman, SA; Sano, M, 1988) |
| "A retrospective survey involving 25,693 persons was carried out in four provinces and the city of Shanghai, China between December 1981 until May 1982 to document relatively serious side effects of praziquantel used in a mass treatment programme for schistosomiasis japonica." | 3.66 | A retrospective survey on side effects of praziquantel among 25,693 cases of schistosomiasis japonica. ( Chen, MG; Fu, S; Hua, XJ; Wu, HM, 1983) |
| "The authors study the results of a treatment of 700 cases of bilharziasis seen in Paris and in two foci in Togo, by oxamniquine, oltipraz or praziquantel." | 3.66 | [Treatment of 700 cases of bilharziasis with the new drugs oxamniquine, oltipraz, praziquantel]. ( Ancelle, T; Dupouy-Camet, J; Faurant, C; Heyer, F; Keita, A; Lapierre, J; Tourte-Schaefer, C, 1983) |
| "The object of the study was to identify any potential therapeutic advantage in using the two antischistosomal drugs, oxamniquine and praziquantel, in combination rather than separately, in the treatment of schistosomiasis." | 3.66 | The treatment of experimental schistosomiasis with a combination of oxamniquine and praziquantel. ( Brammer, KW; Shaw, JR, 1983) |
| "Fourteen patients with active schistosomiasis mansoni in spite of previous treatment with oxamniquine and/or hycanthone were treated with praziquantel, single oral dose of 45 to 50 mg/kg body-weight." | 3.66 | Use of praziquantel in patients with schistosomiasis mansoni previously treated with oxamniquine and/or hycanthone: resistance of Schistosoma mansoni to schistosomicidal agents. ( de Jesus Pedro, R; de Souza Dias, LC; Deberaldini, ER, 1982) |
| "In the past three months 2-cyclo-hexylcarbonyl-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one (praziquantel, EMBAY 8440, Biltricide) has been used in Kenya in the treatment of schistosomiasis mansoni at a single oral dose of 40 mg/kg." | 3.66 | Preliminary observations on the treatment of Schistosomiasis mansoni with praziquantel in Kenya. ( Highton, RB; Roberts, JM; Smith, DH, 1981) |
| "polyps) are not uncommon presentation of this infection." | 3.01 | Schistosomal (bilharzial) polyps: Travel through the colon and beyond. ( Abdelrazik, O; Elazab, M; Elbatae, H; Emara, MH; Mahros, AM; Mohamed, B; Radwan, MI; Rasheda, AMA, 2023) |
| "Schistosomiasis is a public health issue of concern in Gabon, with the disease being reported from all regions of the country." | 2.82 | Schistosomiasis in Gabon from 2000 to 2021 - A review. ( Adegnika, AA; Dejon-Agobé, JC; Edoa, JR; Grobusch, MP, 2022) |
| "Schistosomiasis is a helminthiasis infecting approximately 250 million people worldwide." | 2.82 | Review of 2022 WHO guidelines on the control and elimination of schistosomiasis. ( Bezerra, FSM; Colley, DG; Danso-Appiah, A; Eusebi, P; Fleming, FM; Garba, A; Hagan, P; Homeida, M; Kabatereine, N; Kabole, FM; King, CH; Liang, S; Lo, NC; Loker, ES; Mafe, MA; Midzi, N; Murad, MH; Mutapi, F; Mwanga, JR; Obonyo, CO; Quansah, R; Ramzy, RMR; Satrija, F; Stothard, JR; Traoré, MS; Utzinger, J; Vaillant, M; Webster, JP; Zhou, XN, 2022) |
| "Schistosomiasis is a poverty-associated tropical disease caused by blood dwelling trematodes that threaten approximately 10% of the world population." | 2.82 | Improving translational power in antischistosomal drug discovery. ( Biendl, S; Keiser, J; Probst, A, 2022) |
| "Praziquantel is an old drug registered for human use in 1982 and has since been administered en masse for chemotherapy, risking the development of resistance, thus the need for new drugs with different mechanisms of action." | 2.82 | Prediction of antischistosomal small molecules using machine learning in the era of big data. ( Agyenkwa-Mawuli, K; Broni, E; Kwofie, SK; Miller Iii, WA; Wilson, MD, 2022) |
| "Schistosomiasis is a debilitating helminthiasis which commonly establishes as a chronic infection in people from endemic areas." | 2.82 | Influence of schistosomiasis on host vaccine responses. ( Brombacher, F; Kamdem, SD; Musaigwa, F; Nnaji, CA; Nono, JK, 2022) |
| "Treatment with praziquantel did not have a significant effect on birthweight (2·85 kg in both groups, β=-0·002 [95% CI -0·088 to 0·083]; p=0·962)." | 2.82 | Efficacy and safety of praziquantel for the treatment of human schistosomiasis during pregnancy: a phase 2, randomised, double-blind, placebo-controlled trial. ( Acosta, LP; Ayaso, EB; Baltazar, PI; Estanislao, GG; Friedman, JF; Ida, A; Kurtis, JD; Lesiguez, JL; McDonald, EA; Monterde, DB; Olveda, RM; Tallo, V; Watson, N; Wu, HW, 2016) |
| "Praziquantel was efficacious at reducing infection 12 weeks after treatment: cure rate = 94." | 2.82 | Comparative Assessment of Health Benefits of Praziquantel Treatment of Urogenital Schistosomiasis in Preschool and Primary School-Aged Children. ( Gwisai, R; Mduluza, T; Midzi, N; Mutapi, F; Nausch, N; Wami, WM; Woolhouse, ME, 2016) |
| "Schistosomiasis and opisthorchiasis are of public health importance in Southeast Asia." | 2.77 | Efficacy of praziquantel against Schistosoma mekongi and Opisthorchis viverrini: a randomized, single-blinded dose-comparison trial. ( Akkhavong, K; Ayé Soukhathammavong, P; Hatz, C; Keiser, J; Lovis, L; Mak, TK; Odermatt, P; Phongluxa, K; Tanner, M; Utzinger, J; Vonghachack, Y; Vounatsou, P, 2012) |
| "Nevertheless, treatment of schistosomiasis and de-worming were followed by a partial, but significant, reduction of anaemia in schoolchildren, not explainable by any other obvious intervention." | 2.73 | Controlling schistosomiasis: significant decrease of anaemia prevalence one year after a single dose of praziquantel in Nigerian schoolchildren. ( Boisier, P; Bosqué-Oliva, E; Chanteau, S; Duchemin, JB; Garba, A; Ibrahim, ML; Mahamane, AE; Mainassara, HB; Tohon, ZB, 2008) |
| "Schistosomiasis affects nearly 220 million people worldwide, mainly in Sub-Saharan Africa (SSA)." | 2.72 | Factors affecting the uptake of preventive chemotherapy treatment for schistosomiasis in Sub-Saharan Africa: A systematic review. ( Dhanani, N; Fleming, FM; Torres-Vitolas, CA, 2021) |
| "Schistosomiasis is a parasitic infection that commonly affects the gastrointestinal and genitourinary tracts." | 2.72 | Surgical management outcome of cerebral schistosomiasis: a case report and review of the literature. ( Ahmed, MMZ; Ginawi, A; Mohamed, AHA; Osman, HHM, 2021) |
| "Human schistosomiasis is a debilitating, life-threatening disease affecting more than 229 million people in as many as 78 countries." | 2.72 | Rational approach to drug discovery for human schistosomiasis. ( Alwan, SN; Anderson, TJ; Chevalier, FD; LoVerde, PT; McHardy, SF; Rhodes, J; Taylor, AB, 2021) |
| "Treatment of schistosomiasis has relied on a single drug - praziquantel (PZQ) - for decades." | 2.66 | The Journey to Discovering a Flatworm Target of Praziquantel: A Long TRP. ( Marchant, JS; Park, SK, 2020) |
| "Left untreated, schistosomiasis can lead to severe health problems and even death." | 2.66 | Cost of interventions to control schistosomiasis: A systematic review of the literature. ( Fürst, T; Knopp, S; Salari, P; Tediosi, F; Utzinger, J, 2020) |
| " Two dosage regimes were compared, a single dose of 40 mg/kg bodyweight, and a divided dose 2 X 20 mg/kg given 4-6 h apart." | 2.66 | Treatment with praziquantel of schoolchildren with concurrent Schistosoma mansoni and S. haematobium infections in Gezira, Sudan. ( Daffalla, AA; Dixon, HG; el Igail, AB; el Tayeb, M; Fenwick, A; Kardaman, MW, 1985) |
| " mansoni, or both, were treated with praziquantel (Biltricide; Bayer-Miles) at a dosage of 40 mg/kg body weight." | 2.65 | Effectiveness of praziquantel against the South African strains of Schistosoma haematobium and S. mansoni. ( Mosese, G; Osman, Y; Schutte, CH; Van Deventer, JM, 1983) |
| " Up to now safe and successful treatment of over 25,000 patients has been documented in Africa, Asia and South America with single dose or single day dosage schemes against all five schistosome species pathogenic to man." | 2.65 | The profile of the trematodicidal compound praziquantel. ( Wegner, DH, 1984) |
| "Praziquantel 40 mg/kg was the most effective drug giving a greater than 97% reduction in egg output six months after treatment; combined treatment with niridazole 25 mg/kg and metrifonate 10 mg/kg gave a reduction of greater than 92% and metrifonate 10 mg/kg alone a reduction of greater than 86%." | 2.65 | Single dose oral treatment in urinary schistosomiasis: a double blind trial. ( Pugh, RN; Teesdale, CH, 1983) |
| " In the investigational phase III already under way we hope to fill those gaps and also to find the optimum dosage for large scale use under field conditions." | 2.65 | Trial designs for multicentre clinical studies of investigational phases I B to III with praziquantel. ( Wegner, DH, 1981) |
| "Praziquantel seems to be a very promising drug against S." | 2.65 | Preliminary trials with praziquantel in human infections due to Schistosoma mansoni. ( Chaves, A; Katz, N; Rocha, RS, 1979) |
| " Thus the divided dosage gave a superior therapeutic result." | 2.65 | Preliminary clinical trials with praziquantel in Schistosoma japonicum infections in the Philippines. ( Blas, BL; Boehme, K; Hayashi, M; Noseñas, JS; Ortega, OM; Portillo, GP; Santos, AT, 1979) |
| "Schistosomiasis is a widespread public health concern in the poorest regions of the world." | 2.61 | Differential impact of mass and targeted praziquantel delivery on schistosomiasis control in school-aged children: A systematic review and meta-analysis. ( Clarke, NE; Cribb, DM; Doi, SAR; Vaz Nery, S, 2019) |
| "Schistosomiasis is a prevalent parasitic disease worldwide." | 2.61 | The role of microRNAs in the pathogenesis, grading and treatment of hepatic fibrosis in schistosomiasis. ( Chen, H; Chen, Q; Gong, Q; Nie, H; Zhang, J; Zheng, B; Zheng, T, 2019) |
| "Schistosomiasis affects more than 260 million people worldwide, mostly in sub-Saharan Africa, where more than 280 000 deaths per year are estimated." | 2.61 | High-dose or multi-day praziquantel for imported schistosomiasis? A systematic review. ( Bisoffi, Z; Bottieau, E; Buonfrate, D; Cucchetto, G; Ferrari, A; Gobbi, F; Marchese, V; Rodari, P; Silva, R; Zanotti, P, 2019) |
| "Chemotherapy for schistosomiasis has been around for 100 years." | 2.58 | Pharmacological and immunological effects of praziquantel against Schistosoma japonicum: a scoping review of experimental studies. ( Chen, MG; Sun, J; Xiao, SH, 2018) |
| "Schistosomiasis is a serious public health burden in sub-Saharan Africa." | 2.58 | Efficacy of praziquantel treatment regimens in pre-school and school aged children infected with schistosomiasis in sub-Saharan Africa: a systematic review. ( Chimbari, MJ; Kabuyaya, M; Mukaratirwa, S, 2018) |
| "Pyrimidine metabolism is an excellent target for such studies." | 2.55 | Pyrimidine metabolism in schistosomes: A comparison with other parasites and the search for potential chemotherapeutic targets. ( El Kouni, MH, 2017) |
| "Currently, the main forms of treatment used for schistosomiasis are praziquantel (PZQ) and oxaminiquine (OXA)." | 2.55 | Schistosomiasis: Drugs used and treatment strategies. ( Aguilera, CSB; Ângelos, MA; da Silva, RMF; de Melo, CG; Fontes, DAF; Neto, PJR; Rolim, LA; Silva, LCPBB; Siqueira, LDP; Timóteo, TRR, 2017) |
| "Control of schistosomiasis is by treatment of infected people with the antihelminthic drug praziquantel." | 2.55 | Getting a GRiPP on everyday schistosomiasis: experience from Zimbabwe. ( Mutapi, F, 2017) |
| "Praziquantel treatment not only cures infection but also frees the host from the powerful immunomodulatory action of the parasites." | 2.55 | Human schistosomiasis in the post mass drug administration era. ( Fenwick, A; Maizels, R; Mutapi, F; Woolhouse, M, 2017) |
| "PZQ is the drug of choice for the treatment of schistosomiasis; it is effective against all major forms of schistosomiasis, although it is less active against juvenile than mature parasites." | 2.55 | Praziquantel for Schistosomiasis: Single-Drug Metabolism Revisited, Mode of Action, and Resistance. ( Brindley, PJ; Correia da Costa, JM; Gärtner, F; Gouveia, MJ; Rinaldi, G; Vale, N, 2017) |
| "Schistosomiasis is a parasitic infection acquired through freshwater exposure in the tropics." | 2.53 | Schistosomiasis: Traverers in Africa. ( Locke, R; Matthews, I; Strohmayer, J, 2016) |
| "Schistosomiasis is a disease caused by infection with blood flukes of the genus Schistosoma." | 2.52 | The roles of water, sanitation and hygiene in reducing schistosomiasis: a review. ( Croll, D; Freeman, MC; Grimes, JE; Harrison, WE; Templeton, MR; Utzinger, J, 2015) |
| "Schistosomiasis has plagued the Egyptian population since the antiquity." | 2.52 | Schistosomiasis in Egypt: A never-ending story? ( Othman, AA; Soliman, RH, 2015) |
| "Schistosomiasis affects more than 200 million individuals, mostly in sub-Saharan Africa, but empirical estimates of the disease burden in this region are unavailable." | 2.52 | Spatial distribution of schistosomiasis and treatment needs in sub-Saharan Africa: a systematic review and geostatistical analysis. ( Assaré, RK; Biedermann, P; Ekpo, UF; Garba, A; Lai, YS; Mathieu, E; Midzi, N; Mwinzi, P; N'Goran, EK; Raso, G; Sacko, M; Schur, N; Talla, I; Tchuenté, LA; Touré, S; Utzinger, J; Vounatsou, P; Winkler, MS, 2015) |
| "Schistosomiasis is a devastating worldwide widespread tropical disease that currently affects more than 230 million people, making it an issue of great socioeconomic and public health importance." | 2.49 | The evolution of drugs on schistosoma treatment: looking to the past to improve the future. ( da Rocha Pitta, MG; de Melo Rêgo, MJ; Galdino, SL, 2013) |
| "Schistosomiasis is a tropical parasitic disease, caused by blood-dwelling worms of the genus Schistosoma." | 2.48 | Schistosomiasis. ( Gryseels, B, 2012) |
| "Schistosomiasis is a chronic and morbid disease that affects hundreds of millions of the poorest individuals in (sub)tropical regions, particularly sub-Saharan Africa." | 2.47 | Schistosomiasis: from drug deployment to drug development. ( Caffrey, CR; Secor, WE, 2011) |
| "Schistosomiasis is a wide-spread parasitic disease of many tropical and sub-tropical countries." | 2.46 | Better understanding of anti-schistosomal strategies through microarray analysis. ( Gobert, GN, 2010) |
| "Artemisinin treatment given early after exposure may decrease the risk of the syndrome." | 2.44 | Katayama syndrome. ( McManus, DP; Olds, GR; Ross, AG; Shah, SM; Vickers, D, 2007) |
| "Schistosomiasis is a chronic parasitic disease in tropical and subtropical regions and is associated with a variety of clinical syndromes that may lead to severe morbidity." | 2.44 | Chemotherapy of schistosomiasis: present and future. ( Caffrey, CR, 2007) |
| "Combination treatment for schistosomiasis, gastrointestinal helminths and filariasis reduces costs of control programmes." | 2.43 | Towards control of schistosomiasis in sub-Saharan Africa. ( Hagan, P; Rollinson, D; Southgate, VR; Tchuem Tchuenté, LA, 2005) |
| "Schistosomiasis affects 200 million individuals in underdeveloped and developing regions and is a growing concern for travelers worldwide." | 2.43 | Schistosomiasis--a century searching for chemotherapeutic drugs. ( Leite, LC; Ribeiro-dos-Santos, G; Verjovski-Almeida, S, 2006) |
| "Schistosomiasis is a major disease of public health importance in humans occurring in over 70 countries of the tropics and sub-tropics." | 2.43 | Implementation of human schistosomiasis control: Challenges and prospects. ( Fenwick, A; Rollinson, D; Southgate, V, 2006) |
| "Praziquantel is the drug treatment of choice." | 2.43 | Human schistosomiasis. ( Clerinx, J; Gryseels, B; Kestens, L; Polman, K, 2006) |
| "Treatment by praziquantel remains justified together with health education, improving living standard and hopes placed in the future vaccination campaigns associated with medical treatment in endemic areas." | 2.42 | [Portal hypertension and schistosomiasis: "an originally killing entity"]. ( Klotz, F, 2003) |
| "Diethylcarbamazine has been used in the treatment of onchocerciasis and human filariasis." | 2.41 | Drug treatment of tropical parasitic infections: recent achievements and developments. ( Stephenson, I; Wiselka, M, 2000) |
| "Praziquantel is a synthetic drug with a remarkable activity against parasites, particularly treamatodes and cestodes." | 2.40 | Genotoxic activity of praziquantel. ( Montero, R; Ostrosky, P, 1997) |
| "Spontaneous abortion has also been reported." | 2.40 | [Schistosoma intercalatum bilharziasis: clinical and epidemiological considerations]. ( De Muynck, A; Jusot, JF; Simarro, PP, 1997) |
| "Schistosomiasis is a curable parasitic infection that, if left untreated, can persist for 30 years even though the parasite cannot reproduce in its human host." | 2.38 | Schistosomiasis. ( Lucey, DR; Maguire, JH, 1993) |
| "Acute schistosomiasis is observed in subjects with primary infestation, Schistosoma mansoni and S." | 2.38 | [Acute form of primary bilharziasis]. ( Algayres, JP; Daly, JP; Laverdant, C, 1993) |
| "Schistosomiasis is a parasitic disease of the tropics which is estimated to affect up to 300 million people worldwide." | 2.37 | Schistosomiasis in childhood. ( Doehring, E, 1988) |
| "Schistosomiasis is a neglected tropical disease and a serious global-health problem with over 230 million people requiring treatment, of which the majority live in Africa." | 1.91 | Understanding perceptions of schistosomiasis and its control among highly endemic lakeshore communities in Mayuge, Uganda. ( Lamberton, PHL; Meginnis, K; Mujumbusi, L; Nalwadda, E; Pickering, L; Seeley, J; Ssali, A, 2023) |
| "Schistosomiasis is an important zoonotic disease affecting up to 40 kinds of animals and is responsible for ∼250 million human cases per year." | 1.91 | Functional characterization of differentially expressed proteins coming from unisexual and bisexual infected Schistosoma japonicum female worms. ( Gu, S; Hou, L; Jin, Y; Li, X; Qin, F; Ren, Y; Zhong, H, 2023) |
| "Schistosomiasis is one of the most prevalent helminthic infections worldwide." | 1.91 | Anti-angiogenic and anti-proliferative activity of ziziphus leaf extract as a novel potential therapeutic agent for reducing hepatic injury in experimental hamster schistosomiasis. ( Alghamdi, T; El-Refaei, MF; Salem, DA, 2023) |
| "Human schistosomiasis is a neglected tropical disease caused by Schistosoma mansoni, S." | 1.91 | Oxamniquine derivatives overcome Praziquantel treatment limitations for Schistosomiasis. ( Alwan, SN; LoVerde, PT; McHardy, SF; Rhodes, J; Taylor, AB; Tidwell, M, 2023) |
| "Malaria and schistosomiasis are two of the neglected tropical diseases that persistently wreak havoc worldwide." | 1.91 | Design, Synthesis and Evaluation of Praziquantel Analogues and New Molecular Hybrids as Potential Antimalarial and Anti-Schistosomal Agents. ( Häberli, C; Kasago, FM; Keiser, J; Masamba, W, 2023) |
| "Schistosomiasis is the second most prevailing parasitic disease worldwide." | 1.91 | In vitro and In silico assessment of antischistosomal activities of ethanolic extract of Cornulacamonacantha. ( Abdel-Malek, AR; Abdelrady, YA; Ali, MF; Anwar, FS; Farouk, M; Salem, SH; Sayed, AM, 2023) |
| "Schistosomiasis is a neglected tropical disease (NTD) that is endemic in Uganda, despite several interventions to eliminate it." | 1.91 | Gendered lives, gendered Vulnerabilities: An intersectional gender analysis of exposure to and treatment of schistosomiasis in Pakwach district, Uganda. ( Morgan, R; Nakiranda, S; Opio, CK; Otmani Del Barrio, M; Ssali, SN, 2023) |
| "The goal for schistosomiasis is to achieve elimination as a public health problem (EPHP) and elimination of transmission (EOT) in 78 and 25 countries (by 2030), respectively." | 1.72 | Determining the optimal strategies to achieve elimination of transmission for Schistosoma mansoni. ( Anderson, RM; Ayabina, D; Hollingsworth, TD; Kura, K, 2022) |
| "Schistosomiasis mansoni is considered a serious public health problem." | 1.72 | The prophylactic and anti-fibrotic activity of phthalimido-thiazole derivatives in schistosomiasis mansoni. ( Araújo, DL; de Araújo, RE; de Oliveira Barbosa, M; de Oliveira, SA; Ferreira Pinto, A; Laranjeira Miranda Filho, CA; Lima Leite, AC; Lucena, JP; Rodrigues Oliveira, A, 2022) |
| "Schistosomiasis is one of the most devastating tropical diseases in the world." | 1.72 | Use of wogonin as a cooperative drug with praziquantel to better combat schistosomiasis. ( Cheng, PC; Hung, MY; Pekkle Lam, HY; Peng, SY, 2022) |
| "Praziquantel treatment of infected mice fed with a standard diet (IN-PZQ) resulted in a significant reduction of worm and egg burdens and a normalization of iron and calcium levels." | 1.72 | Protein undernutrition reduces the efficacy of praziquantel in a murine model of Schistosoma mansoni infection. ( Abou-Bacar, A; Boukeng Jatsa, H; Brunet, J; Cannet, C; Gipwe Feussom, N; Greigert, V; Kadji Fassi, JB; Kamgang, R; Kamtchouing, P; Kenfack, CM; Membe Femoe, U; Pfaff, AW; Tchuem Tchuenté, LA; Tienga Nkondo, E, 2022) |
| "Schistosomiasis is a prevalent yet neglected tropical parasitic disease caused by the Schistosoma genus of blood flukes." | 1.72 | Phenotypic Screening of Histone Deacetylase (HDAC) Inhibitors against Schistosoma mansoni. ( de Araujo, ED; Gunning, PT; Häberli, C; Hassan, MM; Jung, M; Keiser, J; Merz, A; Olaoye, OO; Ramos-Morales, E; Romier, C; Sedighi, A, 2022) |
| "Schistosomiasis is a neglected tropical disease with more than 200 million new infections per year." | 1.72 | Disulfiram and dithiocarbamate analogues demonstrate promising antischistosomal effects. ( Gallinger, TL; Grevelding, CG; Grünweller, A; Haeberlein, S; Lange-Grünweller, K; Mäder, P; Rennar, GA; Schlitzer, M, 2022) |
| "Plumbagin treatment restored hepatic enzymes activity to nearly normal levels and induced an increase in catalase, SOD, GSH, total thiol and GST in liver tissue homogenate." | 1.72 | Anti-inflammatory, antioxidant, anti-fibrotic and schistosomicidal properties of plumbagin in murine schistosomiasis. ( Abdel-Latif, M; Abuelsaad, ASA; Allam, GA; Bakery, HH; Elkenawy, AE; Khalil, RG, 2022) |
| "Schistosomiasis is caused by parasitic blood flukes." | 1.72 | Colonic polyps: a rare clinical manifestation of schistosomiasis (a case report). ( Gatheru, J; Mohamed, A; Orare, K; Rajula, A; Thakkar, M, 2022) |
| "Schistosomiasis is an infectious tropical disease caused by parasitic flatworm of the genus Schistosoma." | 1.72 | ( Adekiya, TA; Aruleba, RT; Fadaka, AO; Klein, A, 2022) |
| "Neuroschistosomiasis is a severe complication of schistosomiasis, triggered by the local immune reaction to egg deposition, with spinal cord involvement the most well recognised form." | 1.62 | Delayed diagnosis of spinal cord schistosomiasis in a non-endemic country: A tertiary referral centre experience. ( Aggarwal, D; Chiodini, PL; de Wilton, A; Jäger, HR; Manji, H, 2021) |
| "Schistosomiasis was highly prevalent in China before the initiation of the national schistosomiasis control program in the mid-1950s, and, at that time, the country bore the world's highest burden of schistosomiasis." | 1.62 | Elimination of schistosomiasis in China: Current status and future prospects. ( Bergquist, R; King, CH; Wang, W; Yang, K, 2021) |
| "Praziquantel was the treatment of choice (70." | 1.56 | Delay in schistosomiasis diagnosis and treatment: a multicenter cohort study in Italy. ( Bartoloni, A; Caligaris, S; Canetti, D; Castelli, F; Cenderello, G; Comelli, A; Di Biagio, A; Gaiera, G; Magro, P; Marchese, V; Nicolini, LA; Riccardi, N; Spinicci, M; Zammarchi, L, 2020) |
| "Schistosomiasis is one of the neglected tropical diseases (NTDs) selected for worldwide elimination in the near future." | 1.56 | Elimination of schistosomiasis requires multifactorial diagnostics: evidence from high- and low-prevalence areas in the Nile Delta, Egypt. ( Abdel-Gawwad, E; Barakat, R; Bergquist, R; Eissa, S; Elmorshedy, H; Fayed, A; Guirguis, W, 2020) |
| "Tropical splenomegaly is often associated with malaria and schistosomiasis." | 1.56 | Clinical Sequelae Associated with Unresolved Tropical Splenomegaly in a Cohort of Recently Resettled Congolese Refugees in the United States-Multiple States, 2015-2018. ( Allkhenfr, H; Bakhsh, Y; Basnet, MS; Bezold, C; Davids, A; Goers, M; Horth, R; Iverson, SA; Jentes, E; Kachur, SP; Kacka, M; Klosovsky, A; Laws, R; Marano, N; McDonald, R; Miller, S; Morawski, B; Mortimer, M; Mwesigwa, M; Naoum, M; Njuguna, H; Nsobya, SL; Peak, C; Phares, C; Samson, O; Stauffer, W; Weinberg, M; Yang, J; Zambrano, LD, 2020) |
| "Schistosomiasis has continued to plague low-resource areas of the Nigerian population." | 1.56 | Schistosomiasis Control in Nigeria: Moving Round the Circle? ( Oyeyemi, OT, 2020) |
| "Schistosomiasis is traditionally classified into an acute and a chronic phase, although a precise temporal distinction between the two phases has not been established." | 1.51 | Restaging Pulmonary Schistosomiasis. ( Angheben, A; Bisoffi, Z; Buonfrate, D; Gobbi, F, 2019) |
| "Schistosomiasis is infrequently seen in the UK, but remains an important cause of haematuria in endemic areas." | 1.51 | ( Howling, S; Massie, J, 2019) |
| "When suspecting or treating schistosomiasis, a specialized center should always be consulted." | 1.51 | [Tropical Medicine in an Age of High Global Mobility - Schistosomiasis in a School Class after Travel to Rwanda]. ( Junghanss, T; Mickan, C; Stojkovic, M, 2019) |
| "Schistosomiasis is one of the neglected tropical diseases endemic to Mali." | 1.51 | The association between child Schistosoma spp. infections and morbidity in an irrigated rice region in Mali: A localized study. ( Dembélé, R; Fenwick, A; Keita, AD; Landouré, A; Man, WY; McLaws, ML; Mutombo, N; Sacko, M; Traoré, MS; Webster, JP, 2019) |
| "Schistosomiasis is considered a serious public health problem in 78 countries and territories located in Africa, Asia and America and it is estimated in more than 249 million people infected by any of the species of Schistosoma." | 1.48 | New 1,3-benzodioxole derivatives: Synthesis, evaluation of in vitro schistosomicidal activity and ultrastructural analysis. ( Aires, AL; Albuquerque, MCPA; Alves, LC; Barbosa Dos Santos, VH; Brayner Dos Santos, FA; Costa, VMA; da Silva, AL; de Almeida Junior, ASA; de Lima, MDCA; de Oliveira, JF; Mariz Gomes da Silva, LM; Silva, WL, 2018) |
| " CONCLUSIONS Our findings suggest that the treatment using APS-1 in combination with praziquantel attenuated S." | 1.48 | A Polysaccharide from Amusium Pleuronectes Combined with Praziquantel Treatment Ameliorates Hepatic Fibrosis in Schistosoma Japonicum-Infected Mice. ( Hu, W; Jiang, Y; Lv, Y; Sun, T; Tang, X; Zhan, X; Zhang, W; Zhou, S, 2018) |
| "Schistosomiasis is a parasitic disease caused by blood flukes." | 1.46 | Developing a comprehensive response for treatment of children under 6 years of age with schistosomiasis: research and development of a pediatric formulation of praziquantel. ( Klohe, K; Reinhard-Rupp, J, 2017) |
| "Schistosomiasis is a major and highly resilient disease of both humans and livestock." | 1.46 | Should we be treating animal schistosomiasis in Africa? The need for a One Health economic evaluation of schistosomiasis control in people and their livestock. ( Gower, CM; Vince, L; Webster, JP, 2017) |
| "Schistosomiasis has been of concern to local health authorities for most of the last century, and in spite of a lack of effective chemotherapy, the disease was dealt with quite effectively in many endemic countries by snail control and environmental management [1]." | 1.46 | Why reinvent the wheel? Lessons in schistosomiasis control from the past. ( Shiff, C, 2017) |
| "Schistosomiasis is a debilitating neglected tropical disease, caused by flatworms of Schistosoma genus." | 1.43 | Discovery of New Anti-Schistosomal Hits by Integration of QSAR-Based Virtual Screening and High Content Screening. ( Andrade, CH; Braga, RC; Carpenter, AE; Dantas, RF; de Almeida, AC; Furnham, N; Kamentsky, L; Lima, EF; Melo-Filho, CC; Muratov, E; Neves, BJ; Paveley, R; Rezende-Neto, JM; Senger, MR; Silva-Junior, FP; Valente, WC, 2016) |
| "Schistosomiasis is a debilitating neglected tropical disease caused by schistosome worms." | 1.43 | Schistosomiasis therapeutics: whats in the pipeline? ( Mutapi, F; Trainor-Moss, S, 2016) |
| "Schistosomiasis has been a public health burden in a number of countries across the globe for centuries and probably beyond." | 1.43 | Schistosomiasis elimination by 2020 or 2030? ( Fenwick, A; Jourdan, P, 2016) |
| "WHO guidelines recommend annual treatment for schistosomiasis or soil-transmitted helminthiasis when prevalence in school-aged children is at or above a threshold of 50% and 20%, respectively." | 1.43 | Assessment of global guidelines for preventive chemotherapy against schistosomiasis and soil-transmitted helminthiasis: a cost-effectiveness modelling study. ( Andrews, JR; Bendavid, E; Bogoch, II; Coulibaly, JT; Karagiannis-Voules, DA; Lai, YS; Lo, NC; Utzinger, J; Vounatsou, P, 2016) |
| "Schistosomiasis is the second most significant parasitic disease in children in several African countries." | 1.43 | Schistosomiasis Sustained Control Program in Ethnic Groups Around Ninefescha (Eastern Senegal). ( Barbier, D; Bessin, F; Dewavrin, P; Diawara, L; Diedhiou, K; Dioukhane, EM; Georges, P; Klotz, F; N'Diaye, M; Ndao, B; Talla, I; Vernet, C, 2016) |
| "Schistosomiasis is a known risk after exposure to freshwater in tropical parts of the world." | 1.43 | Clinical Report: Schistosomiasis Exposure in U.S. Service Personnel During Whitewater Rafting on the Nile River in Jinja, Uganda. ( Maluil, S; Stevens, RA, 2016) |
| "Methods: The present study was mainly designed to re-evaluate the prevalence of schistosomiasis after many years of mass drug administration with praziquantel 600 mg allowing analysis of the pertinence of World Health Organisation guidelines in terms of dosing frequency, particularly in the Senegal River Basin." | 1.43 | Assessment of schistosomiasis prevalence among children 5 to 14 years old after several years of mass drug administration in the Senegal River basin ( Abdellahi, M; Ndir, O; Niang, S, 2016) |
| "Schistosomiasis is one of the major parasitic diseases of the tropics, causing acute and long-term clinical syndromes." | 1.42 | Schistosomiasis in non-endemic countries. ( Coltart, C; Whitty, CJ, 2015) |
| "Schistosomiasis is an important communicable disease in the developing world." | 1.42 | Testicular Schistosomiasis Mimicking Malignancy in a Child: A Case Report. ( Ekenze, SO; Ekpemo, SC; Ezomike, UO; Modekwe, VO; Nzegwu, MA, 2015) |
| "Praziquantel (PZQ), an anthelmintic drug used in developing countries for the treatment of schistosome infections, was processed using the fluid bed wet granulation technology to prepare fast dispersible granules, as an appropriate and flexible dosage form for pre-school-aged children." | 1.42 | Development of flexible and dispersible oral formulations containing praziquantel for potential schistosomiasis treatment of pre-school age children. ( Albertini, B; Dolci, LS; Passerini, N; Trastullo, R, 2015) |
| " From the obtained results, PZQ-loaded SLN could be a new drug delivery system for the schistosomiasis treatment especially in marginalized communities, improving the therapeutic efficacy and reducing the toxic effects of PZQ." | 1.40 | In vitro evaluation of permeation, toxicity and effect of praziquantel-loaded solid lipid nanoparticles against Schistosoma mansoni as a strategy to improve efficacy of the schistosomiasis treatment. ( Allegretti, SM; Andreani, T; Chaud, MV; de Oliveira, RN; de Souza, AL; dos Santos, FK; Gremião, MP; Kiill, CP; Silva, AM; Souto, EB, 2014) |
| "Schistosomiasis is a parasitic flatworm disease that infects 200 million people worldwide." | 1.40 | 'Death and axes': unexpected Ca²⁺ entry phenologs predict new anti-schistosomal agents. ( Agbedanu, PN; Chan, JD; Day, TA; Gruba, SM; Haynes, CL; Marchant, JS; Zamanian, M, 2014) |
| "mansoni and malaria are highly prevalent may have indirect benefits on reducing malaria transmission as a result of disease interactions." | 1.40 | Impact of Schistosoma mansoni on malaria transmission in Sub-Saharan Africa. ( Galvani, AP; Greenhalgh, S; Hotez, P; Ndeffo Mbah, ML; Skrip, L, 2014) |
| " Proper dosage adjustment of praziquantel by bodyweight can be difficult to achieve if accurate weighing scales are unavailable." | 1.39 | Validating the WHO dose pole in the Philippines for school-based mass drug administration of praziquantel for morbidity control of schistosomiasis. ( Belizario, VY; Chua, PL; Erfe, JM; Naig, JR, 2013) |
| " Praziquantel treatment markedly alters polarization of schistosome-specific cytokine responses, and these changes, particularly in response to egg-stage parasites, may promote resistance to reinfection." | 1.39 | Integrated analysis of innate, Th1, Th2, Th17, and regulatory cytokines identifies changes in immune polarisation following treatment of human schistosomiasis. ( Appleby, LJ; Bourke, CD; Mduluza, T; Midzi, N; Mitchell, KM; Mutapi, F; Nausch, N; Rujeni, N, 2013) |
| "Hepatic schistosomiasis is a well recognized cause of chronic liver disease and portal hypertension." | 1.38 | Incidental hepatic schistosomiasis in a liver transplant recipient. ( Ariza-Heredia, E; Razonable, RR, 2012) |
| "Praziquantel treatment needs may be over- or underestimated depending on the level of spatial aggregation." | 1.38 | Determining treatment needs at different spatial scales using geostatistical model-based risk estimates of schistosomiasis. ( Schur, N; Utzinger, J; Vounatsou, P, 2012) |
| "Testicular schistosomiasis is extremely rare but the number of reported cases worldwide has doubled over the past decade." | 1.37 | An increasingly notorious mimicker of testicular tumours; crossing borders. ( Periyasamy, P; Rajalingham, S; Subramaniam, SR, 2011) |
| "The combined effect of the Lymphatic Filariasis Elimination Programme (LFEP) and the National Schistosomiasis and Soil-transmitted Helminthiasis Control Programme (NSSCP) on soil-transmitted helminthiasis (STH) was evaluated." | 1.35 | The combined effect of the Lymphatic Filariasis Elimination Programme and the Schistosomiasis and Soil-transmitted Helminthiasis Control Programme on soil-transmitted helminthiasis in schoolchildren in Tanzania. ( Magnussen, P; Massa, K; Ndawi, B; Ntakamulenga, R; Olsen, A; Sheshe, A, 2009) |
| "haematobium and hookworm infections were significantly lower in the ComDT approach villages compared to the school-based approach villages (10." | 1.35 | The effect of the community-directed treatment approach versus the school-based treatment approach on the prevalence and intensity of schistosomiasis and soil-transmitted helminthiasis among schoolchildren in Tanzania. ( Magnussen, P; Massa, K; Ndawi, B; Ntakamulenga, R; Olsen, A; Sheshe, A, 2009) |
| "Schistosomiasis is the second most common parasitic disease after malaria." | 1.35 | Intestinal schistosomiasis, importation of a neglected tropical disease in Romania. Case report of a traveler to endemic regions. ( Iacobiciu, I; Marincu, I; Merkler, C; Moldovan, R; Neghina, AM; Neghina, R, 2009) |
| "We clarify that schistosomiasis is only one of many neglected tropical diseases and that considerable uncertainties remain regarding global burden estimates." | 1.35 | Schistosomiasis and neglected tropical diseases: towards integrated and sustainable control and a word of caution. ( Brooker, S; De Savigny, D; N'goran, EK; Ornbjerg, N; Raso, G; Singer, BH; Tanner, M; Utzinger, J, 2009) |
| "Travellers with schistosomiasis are often asymptomatic or have unspecific symptoms, while immigrants may present with severe complications to the infection." | 1.35 | [Schistosomiasis in Danish travellers and immigrants]. ( Helleberg, M; Thybo, S, 2009) |
| "Schistosomiasis is a highly prevalent parasitic infection causing significant morbidity and mortality in sub-Saharan Africa." | 1.35 | Seroprevalence of schistosomiasis in African patients infected with HIV. ( Fox, R; Seaton, RA; Smith, C; Smith, H, 2008) |
| "In Cambodia, schistosomiasis is transmitted in the provinces of Kratie and Stung Treng where approximately 80000 individuals are estimated to be at risk of infection." | 1.34 | Control of Schistosoma mekongi in Cambodia: results of eight years of control activities in the two endemic provinces. ( Matsuda, H; Montresor, A; Odermatt, P; Ohmae, H; Palmer, K; Sinuon, M; Socheat, D; Tsuyuoka, R, 2007) |
| "Mass treatment with praziquantel and albendazole led to a significant decrease in the intensity of Schistosoma mansoni - 70% (95% confidence interval (CI): 66-73%) after one year and 82% (95% CI: 80-85%) after two years of treatment." | 1.34 | Impact of a national helminth control programme on infection and morbidity in Ugandan schoolchildren. ( Brooker, S; Fenwick, A; Fleming, FM; Kabatereine, NB; Kazibwe, F; Koukounari, A; Stothard, JR; Tukahebwa, EM; Webster, JP; Zhang, Y, 2007) |
| "Pentoxifylline (PTX) was proved to exert both anti-inflammatory and anti-fibrotic effects, and was used therapeutically in this experimental model to investigate its role alone or with praziquantel (PZQ) in Schistosoma mansoni-infected mice, and to explore its impact on the tissue expression of transforming growth factor-beta1 (TGF-beta1)." | 1.34 | Pharmacodynamics of pentoxifylline and/or praziquantel in murine schistosomiasis mansoni. ( El-Lakkany, N; Nosseir, M, 2007) |
| "Schistosomiasis is a parasitic disease that can cause significant illness in humans." | 1.34 | Urinary schistosomiasis: an uncommon cause of gross hematuria in the industrialized countries. ( Kosut, J; Moudgil, A, 2007) |
| "Schistosomiasis is one of the many illnesses endemic in Africa and approximately 40% of refugees have been found to be infected by this parasite." | 1.34 | Asymptomatic schistosomiasis in a young Sudanese refugee. ( Benson, J, 2007) |
| "Clinical hepatomegaly (25 vs." | 1.34 | Liver morbidity due to Schistosoma mekongi in Cambodia after seven rounds of mass drug administration. ( Cheam, S; Degrémont, A; Hatz, C; Keang, H; Odermatt, P; Odermatt-Biays, S, 2007) |
| "4) the pole estimated an acceptable dosage (30-60 mg/kg), a performance statistically similar to that observed in African populations." | 1.33 | The WHO dose pole for the administration of praziquantel is also accurate in non-African populations. ( Al-Awaidy, S; Allen, H; Assis, AM; Engels, D; Fenwick, A; Iwata, F; Kabatereine, NB; Montresor, A; Muth, S; Odermatt, P; Raja'a, YA; Savioli, L; Zulkifli, A, 2005) |
| "Praziquantel (PZQ) was given as soon as the diagnosis was probable, most of the time with steroids." | 1.33 | Imported Katayama fever: clinical and biological features at presentation and during treatment. ( Bottieau, E; Clerinx, J; Colebunders, R; de Vega, MR; Van den Ende, J; Van den Enden, E; Van Esbroeck, M; Van Gompel, A; Vervoort, T, 2006) |
| "Praziquantel treatment for Schistosoma mansoni infection enhances Th2 responsiveness against parasite Ags, but also increases the variance in Ab isotype levels." | 1.33 | Carriage of DRB1*13 is associated with increased posttreatment IgE levels against Schistosoma mansoni antigens and lower long-term reinfection levels. ( Booth, M; Carpenter, D; Dunne, DW; Jones, FM; Joseph, S; Kabatereine, NB; Kariuki, HC; Mwatha, JK; Ouma, JH; Shaw, MA; Vennervald, BJ, 2006) |
| "Schistosomiasis is highly endemic in Nigeria." | 1.33 | Willingness to pay for praziquantel treatment in a hyperendemic community of Ogun State, Nigeria. ( Adeneye, AK; Akande, DO; Appelt, B; Idowu, ET; Mafe, MA, 2006) |
| "Schistosomiasis is increasingly encountered among travelers returning from the tropics; signs and symptoms of travelers may differ from those of local populations." | 1.33 | Schistosomiasis among travelers: new aspects of an old disease. ( Artom, G; Assous, MV; Marva, E; Meltzer, E; Rahav, G; Schwartzt, E, 2006) |
| "Onchocerciasis is co-endemic with schistosomiasis and intestinal helminths infections, which are all diseases of the rural and the poorest communities in Africa." | 1.32 | Integrated community-directed treatment for the control of onchocerciasis, schistosomiasis and intestinal helminths infections in Uganda: advantages and disadvantages. ( Kabatereine, N; Ndyomugyenyi, R, 2003) |
| "Urogenital bilharziasis is a well-known disease that seldom is encountered in western countries." | 1.32 | [Urogenital bilharziasis: imaging diagnosis]. ( Delomez, J; Duchêne, F; Faucher, V; Khorgami, B; Lemaitre, L; Puech, P, 2004) |
| "Schistosomiasis is one of the main health problems hindering socio-economic development in Egypt." | 1.31 | Histological assessment of tissue repair after treatment of human schistosomiasis. ( Abdel-Hadi, AM; Talaat, M, 2000) |
| "Schistosomiasis is endemic in many parts of the tropics and subtropics with an estimated 200 million people, at least, infected worldwide." | 1.31 | Localized papular cutaneous schistosomiasis: two cases in travellers. ( Leman, JA; Small, G; Tidman, MJ; Wilks, D, 2001) |
| "Schistosomiasis is a major health problem in some areas of the world." | 1.31 | Impact of schistosomiasis on patient and graft outcome after renal transplantation: 10 years' follow-up. ( Baz, ME; El-Agroudy, AE; Ghoneim, MA; Mahmoud, KM; Mostafa, FE; Shokeir, AA; Sobh, MA, 2001) |
| "Schistosomiasis is a major public health problem in Africa, the Middle East, Asia and South America." | 1.31 | Heterogeneities in anti-schistosome humoral responses following chemotherapy. ( Mutapi, F, 2001) |
| "Praziquantel was administered to all bilharzial positive cases." | 1.29 | The effect of praziquantel administration on the course of hepatitis B among cases with concomitant schistosome infection. ( Barakat, RM; Farghaly, AG, 1993) |
| "Praziquantel was the most effective drug; a dose of 100 mg/kg given orally for 5 days resulted in a 95% reduction in worm burdens." | 1.28 | Experimental chemotherapy of Schistosoma curassoni in mice. ( Hilderson, H; Rollinson, D; Southgate, VR; Vercruysse, J, 1989) |
| "Treatment with praziquantel resulted in a remarkable decrease of the titers with cercaria antigen and in only a gradual decrease with egg, tegument and gut antigen." | 1.27 | Variations of titers of immunofluorescent antibody against cercaria, adult and egg antigens developed in rabbits infected with Schistosoma japonicum before and after treatment with praziquantel. ( Beisler, GK; Matsuda, H; Nakao, M; Tanaka, H, 1984) |
| "Urinary schistosomiasis is a common cause of hematuria in tropical regions, where it most often affects teenage boys." | 1.27 | Urinary schistosomiasis: a report of four cases and a review. ( Harding, GK; Sekla, L; Sheehan, GJ, 1984) |
| "Praziquantel seems to be an ideal drug against Schistosoma mansoni infection especially for mass treatment as it is given in a single oral dose." | 1.27 | Assessment of efficacy of praziquantel against Schistosoma mansoni infection. ( Anwar, WA; el Kholy, AM; Massoud, AA, 1984) |
| "Hepatomegaly was somewhat more frequent in moderate and heavy infections, but splenomegaly was rare and unrelated to intensity of infection." | 1.27 | Morbidity in schistosomiasis japonica in relation to intensity of infection. A study of two rural brigades in Anhui Province, China. ( Cook, JA; Houser, HB; Mott, KE; Peters, PA; Su, DL; Warren, KS; Xu, ZY; Yuan, HC, 1983) |
| "Praziquantel recently has been approved in the United States for use against a broad range of trematodes and cestodes." | 1.27 | Praziquantel: a major advance in anthelminthic therapy. ( Guerrant, RL; Pearson, RD, 1983) |
| "Mice treated with praziquantel showed a prompt decrease in S." | 1.27 | Reversal of hepatic fibrosis after praziquantel therapy of murine schistosomiasis. ( Dunn, MA; Girgis, NI; Ishak, EA; Khayyal, MT; Mansour, MM; Morcos, SH; Saleh, S, 1985) |
| "Although schistosomiasis is an important occupational hazard for irrigation workers in Central Sudan, few measures have been found to protect them, short of abandoning the work." | 1.27 | Protection of Sudanese irrigation workers from schistosome infections by a shift to earlier working hours. ( Abdu, KM; el Gaddal, AA; Jobin, WR; Tameim, O, 1985) |
| " japonicum were treated orally with different dosage regimens of 2-cyclohexylcarbonyl-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-on e(praziquantel, EMBAY 8440, Biltricide) and were autopsied and perfused 3--4 months after treatment." | 1.26 | The effect of praziquantel on Schistosoma haematobium, S. japonicum and S. mansoni in primates. ( James, C; Nelson, GS; Sturrock, RF; Webbe, G, 1981) |
| "Praziquantel appears to be an effective, well tolerated and easily administrable schistosomicide and thus a favourable contribution to the control of urinary schistosomiasis." | 1.26 | [Trial of praziquantel in the treatment of urinary schistosomiasis in Senegal]. ( Bah, IB; Diallo, S; Dieng, Y; Diouf, F; Ndir, O; Victorius, A, 1981) |
| "2." | 1.26 | Observations on praziquantel against Schistosoma haematobium. ( McMahon, JE, 1981) |
| "In Eseka and Edea bilharziasis caused by S." | 1.26 | [Epidemiological study of foci of S. intercalatum schistosomiasis in Eseka and Edea (Cameroon). Effects of treatment with praziquantel]. ( Carrié, J; Deniau, M; Pagbe, JJ; Ravinet, L; Ripert, C; Same Ekobo, A, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 156 (21.28) | 18.7374 |
| 1990's | 63 (8.59) | 18.2507 |
| 2000's | 136 (18.55) | 29.6817 |
| 2010's | 245 (33.42) | 24.3611 |
| 2020's | 133 (18.14) | 2.80 |
| Authors | Studies |
|---|---|
| Botros, SS | 2 |
| William, S | 2 |
| Beadle, JR | 1 |
| Valiaeva, N | 1 |
| Hostetler, KY | 1 |
| Sadhu, PS | 1 |
| Kumar, SN | 1 |
| Chandrasekharam, M | 1 |
| Pica-Mattoccia, L | 7 |
| Cioli, D | 8 |
| Rao, VJ | 1 |
| Neves, BJ | 1 |
| Dantas, RF | 1 |
| Senger, MR | 1 |
| Melo-Filho, CC | 1 |
| Valente, WC | 1 |
| de Almeida, AC | 1 |
| Rezende-Neto, JM | 1 |
| Lima, EF | 1 |
| Paveley, R | 1 |
| Furnham, N | 1 |
| Muratov, E | 1 |
| Kamentsky, L | 1 |
| Carpenter, AE | 1 |
| Braga, RC | 1 |
| Silva-Junior, FP | 1 |
| Andrade, CH | 1 |
| Wang, C | 1 |
| Zhao, Q | 1 |
| Vargas, M | 1 |
| Jones, JO | 1 |
| White, KL | 1 |
| Shackleford, DM | 1 |
| Chen, G | 1 |
| Saunders, J | 1 |
| Ng, AC | 1 |
| Chiu, FC | 1 |
| Dong, Y | 1 |
| Charman, SA | 1 |
| Keiser, J | 13 |
| Vennerstrom, JL | 1 |
| Ghazy, E | 1 |
| Heimburg, T | 1 |
| Lancelot, J | 1 |
| Zeyen, P | 1 |
| Schmidtkunz, K | 1 |
| Truhn, A | 1 |
| Darwish, S | 1 |
| Simoben, CV | 1 |
| Shaik, TB | 1 |
| Erdmann, F | 1 |
| Schmidt, M | 1 |
| Robaa, D | 1 |
| Romier, C | 2 |
| Jung, M | 2 |
| Pierce, R | 1 |
| Sippl, W | 1 |
| Chienwichai, P | 1 |
| Tipthara, P | 1 |
| Tarning, J | 1 |
| Limpanont, Y | 1 |
| Chusongsang, P | 1 |
| Chusongsang, Y | 1 |
| Adisakwattana, P | 1 |
| Reamtong, O | 1 |
| Ouattara, M | 5 |
| Bassa, FK | 2 |
| Diakité, NR | 3 |
| Hattendorf, J | 3 |
| Coulibaly, JT | 7 |
| Yao, PK | 2 |
| Tian-Bi, YT | 2 |
| Konan, CK | 2 |
| Assaré, RK | 4 |
| Koné, N | 2 |
| Guindo-Coulibaly, N | 2 |
| Utzinger, J | 28 |
| N'Goran, EK | 15 |
| De Boni, L | 1 |
| Msimang, V | 1 |
| De Voux, A | 1 |
| Frean, J | 1 |
| Cheuka, PM | 1 |
| Ferraz, LRM | 1 |
| Silva, LCPBB | 2 |
| Souza, ML | 1 |
| Alves, LP | 1 |
| Sales, VAW | 1 |
| Barbosa, IDNG | 1 |
| Andrade, MC | 1 |
| Santos, WMD | 1 |
| Rolim, LA | 2 |
| Rolim-Neto, PJ | 1 |
| Fusco, D | 2 |
| Rakotozandrindrainy, R | 2 |
| Rakotoarivelo, RA | 2 |
| Andrianarivelo, MR | 2 |
| Rakotozandrindrainy, N | 1 |
| Rasamoelina, T | 1 |
| Puradiredja, DI | 1 |
| Klein, P | 1 |
| Stahlberg, K | 1 |
| Dechenaud, M | 1 |
| Lorenz, E | 1 |
| Jaeger, A | 1 |
| Kreidenweiss, A | 2 |
| Hoekstra, PT | 3 |
| Adegnika, AA | 4 |
| Sicuri, E | 2 |
| Corstjens, PLAM | 3 |
| van Dam, GJ | 8 |
| May, J | 1 |
| Schwarz, NG | 2 |
| Kokaliaris, C | 1 |
| Garba, A | 8 |
| Matuska, M | 1 |
| Bronzan, RN | 1 |
| Colley, DG | 14 |
| Dorkenoo, AM | 1 |
| Ekpo, UF | 5 |
| Fleming, FM | 7 |
| French, MD | 2 |
| Kabore, A | 1 |
| Mbonigaba, JB | 1 |
| Midzi, N | 5 |
| Mwinzi, PNM | 4 |
| Polo, MR | 1 |
| Sacko, M | 8 |
| Tchuem Tchuenté, LA | 5 |
| Tukahebwa, EM | 6 |
| Uvon, PA | 1 |
| Yang, G | 1 |
| Wiesner, L | 1 |
| Zhang, Y | 4 |
| Vounatsou, P | 7 |
| Putri, ASD | 1 |
| Vera Diana, T | 1 |
| Daris, R | 1 |
| Afriana, F | 1 |
| Hidayat, SH | 1 |
| Liyew, EF | 1 |
| Chernet, M | 1 |
| Belay, H | 1 |
| Maddren, R | 1 |
| Landeryou, T | 1 |
| Kalahasti, S | 1 |
| Ower, AK | 1 |
| Mekete, K | 2 |
| Phillips, AE | 6 |
| Anjulo, U | 1 |
| Endrias, T | 1 |
| Tamiru, A | 1 |
| Gidey, B | 1 |
| Mehari, Z | 1 |
| Mengistu, B | 1 |
| Tollera, G | 1 |
| Tasew, G | 1 |
| Falcoz, C | 1 |
| Guzy, S | 1 |
| Kovač, J | 1 |
| Meister, I | 1 |
| Coulibaly, J | 1 |
| Sayasone, S | 3 |
| Wesche, D | 1 |
| Lin, YW | 1 |
| Dejon-Agobé, JC | 1 |
| Edoa, JR | 1 |
| Grobusch, MP | 2 |
| Atwa, MTM | 1 |
| Abd-Elrazek, AM | 1 |
| Salem, NIS | 1 |
| Kura, K | 1 |
| Ayabina, D | 1 |
| Hollingsworth, TD | 1 |
| Anderson, RM | 2 |
| Mielke, N | 1 |
| Johnson, S | 1 |
| Bahl, A | 1 |
| Fadladdin, YAJ | 1 |
| Xue, M | 1 |
| Zhang, X | 1 |
| Chen, J | 1 |
| Liu, F | 1 |
| Xu, J | 3 |
| Xie, J | 1 |
| Yang, Y | 1 |
| Yu, W | 1 |
| Qiu, H | 1 |
| Xue, J | 1 |
| Jiang, J | 2 |
| Liu, Y | 5 |
| Shallom, SJ | 1 |
| Zelazny, AM | 1 |
| Giri, AR | 1 |
| Kaur, N | 1 |
| Yarrarapu, SNS | 1 |
| Rottman Pietrzak, KA | 1 |
| Santos, C | 1 |
| Lowman, PE | 1 |
| Niaz, S | 1 |
| Franco, PM | 1 |
| Sanghavi, DK | 1 |
| Zhu, D | 1 |
| Liang, R | 1 |
| Li, Z | 2 |
| Cheng, L | 1 |
| Ren, J | 1 |
| Guo, Y | 2 |
| Wang, M | 1 |
| Chai, H | 1 |
| Niu, Q | 1 |
| Yang, S | 2 |
| Bai, J | 1 |
| Yu, H | 2 |
| Zhang, H | 1 |
| Qin, X | 1 |
| Sahrakorpi, N | 1 |
| Engberg, E | 1 |
| Stach-Lempinen, B | 1 |
| Tammelin, TH | 1 |
| Kulmala, J | 1 |
| Roine, RP | 1 |
| Koivusalo, SB | 1 |
| Cheng, W | 1 |
| Pang, H | 1 |
| Campen, MJ | 1 |
| Zhang, J | 6 |
| Li, Y | 8 |
| Gao, J | 1 |
| Ren, D | 1 |
| Ji, X | 1 |
| Rothman, N | 1 |
| Lan, Q | 1 |
| Zheng, Y | 2 |
| Leng, S | 1 |
| Hu, Z | 1 |
| Tang, J | 1 |
| Dong, Q | 1 |
| Song, N | 1 |
| Qin, N | 1 |
| Chen, C | 1 |
| Sun, X | 1 |
| Easton, J | 1 |
| Mulder, H | 1 |
| Plyler, E | 1 |
| Neale, G | 1 |
| Walker, E | 1 |
| Li, Q | 1 |
| Ma, X | 1 |
| Chen, X | 2 |
| Huang, IC | 1 |
| Yasui, Y | 1 |
| Ness, KK | 1 |
| Hudson, MM | 1 |
| Robison, LL | 1 |
| Wang, Z | 1 |
| Subota, A | 1 |
| Spotswood, N | 1 |
| Roach, M | 1 |
| Goodarzi, Z | 1 |
| Holroyd-Leduc, J | 1 |
| Park, EA | 1 |
| Graves, SA | 1 |
| Menda, Y | 1 |
| Ogongo, P | 1 |
| Nyakundi, RK | 1 |
| Chege, GK | 1 |
| Ochola, L | 1 |
| Lo, NC | 3 |
| Bezerra, FSM | 1 |
| Homeida, M | 2 |
| Kabatereine, N | 3 |
| Kabole, FM | 2 |
| King, CH | 19 |
| Mafe, MA | 5 |
| Mutapi, F | 13 |
| Mwanga, JR | 3 |
| Ramzy, RMR | 3 |
| Satrija, F | 1 |
| Stothard, JR | 11 |
| Traoré, MS | 2 |
| Webster, JP | 8 |
| Zhou, XN | 7 |
| Danso-Appiah, A | 2 |
| Eusebi, P | 1 |
| Loker, ES | 2 |
| Obonyo, CO | 2 |
| Quansah, R | 1 |
| Liang, S | 2 |
| Vaillant, M | 3 |
| Murad, MH | 1 |
| Hagan, P | 6 |
| Laranjeira Miranda Filho, CA | 1 |
| de Oliveira Barbosa, M | 1 |
| Rodrigues Oliveira, A | 1 |
| Ferreira Pinto, A | 1 |
| Araújo, DL | 1 |
| Lucena, JP | 1 |
| de Araújo, RE | 1 |
| de Oliveira, SA | 2 |
| Lima Leite, AC | 1 |
| Pekkle Lam, HY | 1 |
| Hung, MY | 1 |
| Cheng, PC | 1 |
| Peng, SY | 1 |
| Paulino, ÉT | 1 |
| Ribeiro de Lima, M | 1 |
| Viçosa, AL | 1 |
| da Silva, CH | 1 |
| Salomon, CJ | 1 |
| Real, DA | 1 |
| Leonardi, D | 1 |
| Mello Silva, CC | 1 |
| de Moraes Neto, AHA | 1 |
| Huseein, EAM | 1 |
| Samir, M | 1 |
| Al-Karmalawy, AA | 1 |
| Hassan, SS | 1 |
| Embarek Mohamed, M | 1 |
| Mostafa, FAAM | 1 |
| Moharram, AM | 1 |
| Alkhalil, SS | 1 |
| Farrag, HMM | 1 |
| Kabatende, J | 1 |
| Barry, A | 1 |
| Mugisha, M | 1 |
| Ntirenganya, L | 1 |
| Bergman, U | 1 |
| Bienvenu, E | 1 |
| Aklillu, E | 1 |
| Lacorcia, M | 1 |
| Kugyelka, R | 1 |
| Spechtenhauser, L | 1 |
| Prodjinotho, UF | 1 |
| Hamway, Y | 1 |
| Spangenberg, T | 4 |
| da Costa, CP | 1 |
| Kadji Fassi, JB | 1 |
| Boukeng Jatsa, H | 1 |
| Membe Femoe, U | 1 |
| Greigert, V | 1 |
| Brunet, J | 1 |
| Cannet, C | 1 |
| Kenfack, CM | 2 |
| Gipwe Feussom, N | 1 |
| Tienga Nkondo, E | 1 |
| Abou-Bacar, A | 1 |
| Pfaff, AW | 1 |
| Kamgang, R | 1 |
| Kamtchouing, P | 1 |
| Probst, A | 1 |
| Biendl, S | 1 |
| Hassan, MM | 2 |
| Sedighi, A | 1 |
| Olaoye, OO | 1 |
| Häberli, C | 2 |
| Merz, A | 1 |
| Ramos-Morales, E | 1 |
| de Araujo, ED | 1 |
| Gunning, PT | 1 |
| Rennar, GA | 1 |
| Gallinger, TL | 3 |
| Mäder, P | 1 |
| Lange-Grünweller, K | 3 |
| Haeberlein, S | 3 |
| Grünweller, A | 3 |
| Grevelding, CG | 4 |
| Schlitzer, M | 3 |
| Bakery, HH | 1 |
| Allam, GA | 1 |
| Abuelsaad, ASA | 1 |
| Abdel-Latif, M | 1 |
| Elkenawy, AE | 1 |
| Khalil, RG | 1 |
| Zhang, LJ | 2 |
| Xu, ZM | 2 |
| Yang, F | 1 |
| He, JY | 1 |
| Dang, H | 2 |
| Li, YL | 3 |
| Cao, CL | 3 |
| Li, SZ | 2 |
| Senkwe, MN | 1 |
| Berta, KK | 1 |
| Yibi, SM | 1 |
| Sube, J | 1 |
| Bidali, A | 1 |
| Abe, A | 1 |
| Onyeze, A | 1 |
| Ajo, JPH | 1 |
| Pascale, JR | 1 |
| Ndenzako, F | 1 |
| Olu, OO | 1 |
| Badoco, FR | 1 |
| Paula, LAL | 1 |
| Orenha, RP | 1 |
| Mendes, TMF | 1 |
| Squarisi, IS | 1 |
| El-Sakkary, N | 1 |
| Loiola, MC | 1 |
| Katz, N | 2 |
| Tavares, DC | 1 |
| Sairre, MI | 1 |
| Parreira, RLT | 1 |
| Janku Cabral, F | 1 |
| Alegretti, SM | 1 |
| Caffrey, CR | 6 |
| Magalhães, LG | 1 |
| Araújo Fiuza, J | 1 |
| Colt, S | 1 |
| Gambogi de Ornellas, L | 1 |
| Ferreira Matoso, L | 1 |
| Gazzinelli, A | 2 |
| Friedman, JF | 6 |
| Corrêa-Oliveira, R | 2 |
| Orare, K | 1 |
| Mohamed, A | 1 |
| Thakkar, M | 1 |
| Rajula, A | 1 |
| Gatheru, J | 1 |
| Mewamba, EM | 1 |
| Tiofack, AAZ | 1 |
| Kamdem, CN | 1 |
| Tchounkeu, EY | 1 |
| Tatang, RJA | 1 |
| Mengoue, LET | 1 |
| Mbagnia, MCT | 1 |
| Njiokou, F | 1 |
| Casacuberta-Partal, M | 1 |
| Womeni, HM | 1 |
| Simo, G | 1 |
| Ncube, MV | 1 |
| Kabuyaya, M | 2 |
| Chimbari, MJ | 2 |
| Xue, Q | 1 |
| Deng, Y | 1 |
| Wang, Y | 3 |
| Hu, W | 2 |
| Huang, Y | 1 |
| Yang, K | 2 |
| Nogueira, RA | 1 |
| Lira, MGS | 1 |
| Licá, ICL | 1 |
| Frazão, GCCG | 1 |
| Dos Santos, VAF | 1 |
| Filho, ACCM | 1 |
| Rodrigues, JGM | 1 |
| Miranda, GS | 1 |
| Carvalho, RC | 1 |
| Nascimento, FRF | 1 |
| Zammarchi, L | 6 |
| Botta, A | 3 |
| Tilli, M | 3 |
| Gobbi, F | 5 |
| Bartoloni, A | 5 |
| Boccalini, S | 3 |
| Obermann, W | 2 |
| Schmidt, N | 2 |
| Mujumbusi, L | 1 |
| Nalwadda, E | 1 |
| Ssali, A | 1 |
| Pickering, L | 1 |
| Seeley, J | 1 |
| Meginnis, K | 1 |
| Lamberton, PHL | 2 |
| Yang, GJ | 1 |
| Odiere, MR | 3 |
| Assandé Aka, R | 1 |
| Aka, NAD | 1 |
| Ogutu, B | 1 |
| Rawago, F | 2 |
| Bagchus, WM | 1 |
| Bödding, M | 1 |
| Kourany-Lefoll, E | 3 |
| Tappert, A | 1 |
| Yin, X | 1 |
| Bezuidenhout, D | 3 |
| Badenhorst, H | 1 |
| Huber, E | 3 |
| Dälken, B | 1 |
| Haj-Ali Saflo, O | 1 |
| Zhong, H | 2 |
| Qin, F | 1 |
| Ren, Y | 1 |
| Li, X | 1 |
| Hou, L | 1 |
| Gu, S | 1 |
| Jin, Y | 2 |
| Waechtler, A | 1 |
| Cezanne, B | 1 |
| Maillard, D | 1 |
| Sun, R | 1 |
| Wang, S | 1 |
| Wang, J | 2 |
| Harder, A | 1 |
| Ahamide, JO | 1 |
| Sossa, C | 1 |
| Sissinto, Y | 1 |
| Mongbo, V | 1 |
| Dougnon, V | 1 |
| Legba, B | 1 |
| Ouendo, EM | 1 |
| Caldwell, N | 1 |
| Afshar, R | 1 |
| Baragaña, B | 1 |
| Bustinduy, AL | 6 |
| Collins, JJ | 1 |
| Gardner, M | 1 |
| Gomes, M | 1 |
| Hoffmann, KF | 2 |
| Hsieh, M | 1 |
| McNamara, CW | 1 |
| Nono, JK | 3 |
| Padalino, G | 1 |
| Read, KD | 1 |
| Roestenberg, M | 4 |
| Specht, S | 1 |
| Gilbert, IH | 1 |
| Kangogo, G | 1 |
| Conserve, DF | 1 |
| Kayuni, S | 1 |
| Kumwenda, MK | 1 |
| Dovel, KL | 1 |
| Chirombo, J | 1 |
| MacPherson, P | 1 |
| Corbett, EL | 1 |
| Butterworth, A | 1 |
| Choko, AT | 1 |
| Maganga, JK | 1 |
| Campbell, CH | 10 |
| Angelo, T | 1 |
| Mosha, J | 1 |
| Kinung'hi, SM | 4 |
| Anyolitho, MK | 1 |
| Nyakato, VN | 1 |
| Huyse, T | 1 |
| Poels, K | 1 |
| Masquillier, C | 1 |
| Alghamdi, T | 1 |
| Salem, DA | 1 |
| El-Refaei, MF | 1 |
| Petukhova, VZ | 1 |
| Aboagye, SY | 1 |
| Ardini, M | 1 |
| Lullo, RP | 1 |
| Fata, F | 1 |
| Byrne, ME | 1 |
| Gabriele, F | 1 |
| Martin, LM | 1 |
| Harding, LNM | 1 |
| Gone, V | 1 |
| Dangi, B | 1 |
| Lantvit, DD | 1 |
| Nikolic, D | 1 |
| Ippoliti, R | 1 |
| Effantin, G | 1 |
| Ling, WL | 1 |
| Johnson, JJ | 1 |
| Thatcher, GRJ | 1 |
| Angelucci, F | 2 |
| Williams, DL | 1 |
| Petukhov, PA | 1 |
| Marangoni, D | 1 |
| Manciulli, T | 1 |
| Barbiero, A | 1 |
| Mantella, A | 1 |
| Spinicci, M | 2 |
| Alwan, SN | 2 |
| Taylor, AB | 3 |
| Rhodes, J | 2 |
| Tidwell, M | 1 |
| McHardy, SF | 3 |
| LoVerde, PT | 3 |
| Holtfreter, MC | 1 |
| Mischlinger, J | 1 |
| Davi, SD | 1 |
| Schleenvoigt, BT | 1 |
| Kasago, FM | 1 |
| Masamba, W | 1 |
| Emara, MH | 1 |
| Mahros, AM | 1 |
| Rasheda, AMA | 1 |
| Radwan, MI | 1 |
| Mohamed, B | 1 |
| Abdelrazik, O | 1 |
| Elazab, M | 1 |
| Elbatae, H | 1 |
| Zhu, P | 1 |
| Wu, K | 1 |
| Zhang, C | 1 |
| Batool, SS | 1 |
| Li, A | 1 |
| Yu, Z | 1 |
| Huang, J | 1 |
| Lim, RM | 1 |
| Arme, TM | 1 |
| Pedersen, AB | 1 |
| Li, J | 1 |
| Li, H | 1 |
| Guo, C | 1 |
| Zhou, Z | 2 |
| Luo, Y | 1 |
| Zhou, C | 1 |
| Ming, Y | 1 |
| Anwar, FS | 1 |
| Abdel-Malek, AR | 1 |
| Salem, SH | 1 |
| Farouk, M | 1 |
| Ali, MF | 1 |
| Abdelrady, YA | 1 |
| Sayed, AM | 1 |
| Azevedo, CM | 1 |
| Meira, CS | 1 |
| da Silva, JW | 1 |
| Moura, DMN | 1 |
| da Costa, CJ | 1 |
| Santos, ES | 1 |
| Soares, MBP | 1 |
| Ssali, SN | 1 |
| Morgan, R | 1 |
| Nakiranda, S | 1 |
| Opio, CK | 1 |
| Otmani Del Barrio, M | 1 |
| Diop, B | 2 |
| Sylla, K | 1 |
| Kane, NM | 1 |
| Boh, OK | 1 |
| Guèye, B | 1 |
| Ba, M | 1 |
| Talla, I | 5 |
| Mané, M | 1 |
| Monteil, R | 1 |
| Kinvi, B | 1 |
| Zoure, HGM | 1 |
| Ortega, JC | 1 |
| Mwinzi, P | 3 |
| Faye, B | 1 |
| Were, VO | 1 |
| Wamae, P | 1 |
| Muok, EMO | 1 |
| Alharbi, RA | 1 |
| Alwajeeh, TS | 1 |
| Assabri, AM | 1 |
| Almalki, SSR | 1 |
| Alruwetei, A | 1 |
| Azazy, AA | 1 |
| Cribb, DM | 1 |
| Clarke, NE | 1 |
| Doi, SAR | 1 |
| Vaz Nery, S | 1 |
| Comelli, A | 1 |
| Riccardi, N | 1 |
| Canetti, D | 1 |
| Cenderello, G | 1 |
| Magro, P | 1 |
| Nicolini, LA | 1 |
| Marchese, V | 2 |
| Castelli, F | 1 |
| Di Biagio, A | 1 |
| Caligaris, S | 1 |
| Gaiera, G | 1 |
| Gonzalez, MA | 1 |
| Ramírez Rigo, MV | 1 |
| Gonzalez Vidal, NL | 1 |
| Ower, A | 1 |
| Dunn, J | 1 |
| Sime, H | 1 |
| Tadesse, G | 1 |
| Abate, E | 1 |
| Nigussu, N | 1 |
| Seife, F | 1 |
| McNaughton, E | 1 |
| Fukuchi, T | 1 |
| Sugawara, H | 1 |
| Koizumi, Y | 1 |
| Hirooka, M | 1 |
| Tanaka, T | 1 |
| Sunago, K | 1 |
| Yukimoto, A | 1 |
| Imai, Y | 1 |
| Watanabe, T | 1 |
| Ishihara, T | 1 |
| Yoshida, O | 1 |
| Yamamoto, Y | 1 |
| Takeshita, E | 1 |
| Ikeda, Y | 1 |
| Abe, M | 1 |
| Hiasa, Y | 1 |
| Park, SK | 1 |
| Marchant, JS | 3 |
| Mendoza-Palomar, N | 1 |
| Sulleiro, E | 1 |
| Perez-Garcia, I | 1 |
| Espiau, M | 1 |
| Soriano-Arandes, A | 1 |
| Martín-Nalda, A | 1 |
| Espasa, M | 1 |
| Zarzuela, F | 1 |
| Soler-Palacin, P | 1 |
| Chen, Q | 2 |
| Zheng, T | 1 |
| Chen, H | 2 |
| Nie, H | 1 |
| Zheng, B | 1 |
| Gong, Q | 1 |
| Walker, JW | 2 |
| Kittur, N | 8 |
| Binder, S | 8 |
| Castleman, JD | 3 |
| Drake, JM | 1 |
| Ayé, P | 1 |
| Phongluxa, K | 3 |
| Vonghachack, Y | 2 |
| Oroth, R | 1 |
| Odermatt, P | 8 |
| Wilson, RA | 1 |
| Buonfrate, D | 3 |
| Tamarozzi, F | 1 |
| Gobbi, AF | 1 |
| Guzman, M | 1 |
| Rugel, A | 1 |
| Tarpley, RS | 1 |
| Cao, X | 1 |
| Vale, N | 3 |
| Gouveia, MJ | 3 |
| Gärtner, F | 3 |
| Melkus, MW | 1 |
| Le, L | 1 |
| Siddiqui, AJ | 1 |
| Molehin, AJ | 1 |
| Zhang, W | 3 |
| Lazarus, S | 1 |
| Siddiqui, AA | 2 |
| Wells, N | 1 |
| Chappuis, F | 1 |
| Beran, D | 1 |
| Salari, P | 1 |
| Fürst, T | 1 |
| Knopp, S | 7 |
| Tediosi, F | 1 |
| Elmorshedy, H | 1 |
| Bergquist, R | 6 |
| Fayed, A | 1 |
| Guirguis, W | 1 |
| Abdel-Gawwad, E | 1 |
| Eissa, S | 1 |
| Barakat, R | 1 |
| Bais, S | 2 |
| Greenberg, RM | 4 |
| Jimie, J | 1 |
| Lyttle, M | 1 |
| Bizimana, P | 1 |
| Polman, K | 3 |
| Ortu, G | 1 |
| Krit, M | 1 |
| Nsabiyumva, F | 1 |
| Nkeshimana, A | 1 |
| Bijabuka, U | 1 |
| Nibakire, M | 1 |
| Van Geertruyden, JP | 1 |
| Strahan, R | 2 |
| McAdam, D | 2 |
| Paul, E | 1 |
| Zambrano, LD | 1 |
| Jentes, E | 1 |
| Phares, C | 1 |
| Weinberg, M | 1 |
| Kachur, SP | 1 |
| Basnet, MS | 1 |
| Klosovsky, A | 1 |
| Mwesigwa, M | 1 |
| Naoum, M | 1 |
| Nsobya, SL | 1 |
| Samson, O | 1 |
| Goers, M | 1 |
| McDonald, R | 1 |
| Morawski, B | 1 |
| Njuguna, H | 1 |
| Peak, C | 1 |
| Laws, R | 1 |
| Bakhsh, Y | 1 |
| Iverson, SA | 1 |
| Bezold, C | 1 |
| Allkhenfr, H | 1 |
| Horth, R | 1 |
| Yang, J | 1 |
| Miller, S | 1 |
| Kacka, M | 1 |
| Davids, A | 1 |
| Mortimer, M | 1 |
| Stauffer, W | 1 |
| Marano, N | 2 |
| Wiegand, RE | 3 |
| Shen, Y | 3 |
| Ge, Y | 1 |
| Whalen, CC | 3 |
| Jacobson, JA | 1 |
| Matendechero, SH | 2 |
| Rollinson, D | 8 |
| Kinung'hi, S | 4 |
| Bergquist, NR | 2 |
| Olsen, A | 9 |
| Magnussen, P | 6 |
| Karanja, DMS | 3 |
| Montgomery, SP | 7 |
| Secor, WE | 10 |
| Dhanani, N | 2 |
| Gazzinelli-Guimaraes, PH | 3 |
| Clements, MN | 1 |
| Meite, A | 4 |
| Hamidou, AA | 1 |
| Musuva, RM | 1 |
| Timson, DJ | 1 |
| Maphumulo, A | 1 |
| Mahomed, O | 1 |
| Vennervald, B | 1 |
| Gundersen, SG | 4 |
| Taylor, M | 3 |
| Kjetland, EF | 3 |
| Crosnier, C | 1 |
| Hokke, CH | 1 |
| Protasio, AV | 1 |
| Brandt, C | 1 |
| Rinaldi, G | 2 |
| Langenberg, MCC | 1 |
| Clare, S | 1 |
| Janse, JJ | 1 |
| Wilson, S | 3 |
| Berriman, M | 1 |
| Wright, GJ | 1 |
| Fu, K | 1 |
| Mpotje, T | 1 |
| Varrone, G | 1 |
| Aziz, NA | 1 |
| Mosala, P | 1 |
| Hlaka, L | 1 |
| Kamdem, SD | 2 |
| Xu, D | 2 |
| Brombacher, F | 2 |
| Kolamunnage-Dona, R | 1 |
| Mirochnick, MH | 1 |
| Capparelli, EV | 1 |
| Tallo, V | 4 |
| Acosta, LP | 4 |
| Olveda, RM | 10 |
| Hope, WW | 1 |
| Rabiee, A | 1 |
| Abd Elaziz, KM | 1 |
| Haggag, AA | 1 |
| Oyeyemi, OT | 1 |
| Tagwireyi, P | 1 |
| Lim, R | 1 |
| Mangwanda, B | 1 |
| Fourier, C | 1 |
| Mduluza, T | 4 |
| Miranda, VHS | 1 |
| Gomes, TR | 1 |
| Eller, DE | 1 |
| Ferraz, LCN | 1 |
| Chaves, AT | 1 |
| Bicalho, KA | 1 |
| Silva, CEC | 1 |
| Birbrair, A | 1 |
| Pascoal Xavier, MA | 1 |
| de Goes, AM | 1 |
| Alves, ÉAR | 1 |
| Bozzi, A | 1 |
| Ejike, CU | 1 |
| Oluwole, AS | 3 |
| Omitola, OO | 1 |
| Bayegun, AA | 1 |
| Shoneye, IY | 1 |
| Akeredolu-Ale, BI | 1 |
| Idowu, OA | 1 |
| Mafiana, CF | 3 |
| Zdesenko, G | 1 |
| Engels, D | 8 |
| Hotez, PJ | 2 |
| Ducker, C | 1 |
| Gyapong, M | 1 |
| Harrison, W | 1 |
| Theobald, S | 1 |
| Thomson, R | 1 |
| Gamba, V | 1 |
| Masong, MC | 1 |
| Lammie, P | 1 |
| Govender, K | 1 |
| Mbabazi, PS | 1 |
| Malecela, MN | 1 |
| Akurut, H | 1 |
| Sanya, RE | 1 |
| Lubyayi, L | 1 |
| Nampijja, M | 1 |
| Kizza, M | 1 |
| Kaweesa, J | 1 |
| Kizindo, R | 1 |
| Sewankambo, M | 1 |
| Nsubuga, D | 1 |
| Tukahebwa, E | 2 |
| Kabatereine, NB | 10 |
| Elliott, AM | 3 |
| Webb, EL | 1 |
| Le Govic, Y | 2 |
| Gourbal, B | 1 |
| Boissier, J | 2 |
| Adekiya, TA | 3 |
| Aruleba, RT | 2 |
| Klein, A | 1 |
| Fadaka, AO | 1 |
| Zacharia, A | 1 |
| Mushi, V | 1 |
| Makene, T | 1 |
| Mantica, G | 1 |
| Terrone, C | 1 |
| Der Merwe, AV | 1 |
| Lü, S | 1 |
| Saric, J | 1 |
| Manjang, B | 1 |
| Ochola, EA | 1 |
| Elliott, SJ | 1 |
| Torres-Vitolas, CA | 1 |
| Seitzer, M | 1 |
| Klapper, S | 1 |
| Mazigo, HD | 2 |
| Holzgrabe, U | 1 |
| Mueller, A | 1 |
| de Wilton, A | 1 |
| Aggarwal, D | 1 |
| Jäger, HR | 1 |
| Manji, H | 1 |
| Chiodini, PL | 2 |
| Onasanya, A | 1 |
| Bengtson, M | 1 |
| Oladepo, O | 1 |
| Van Engelen, J | 1 |
| Diehl, JC | 1 |
| Fukushige, M | 2 |
| Chase-Topping, M | 1 |
| Woolhouse, MEJ | 2 |
| Driciru, E | 1 |
| Koopman, JPR | 1 |
| Cose, S | 1 |
| Yazdanbakhsh, M | 2 |
| Nigo, MM | 1 |
| Nigo, DW | 1 |
| Salieb-Beugelaar, GB | 1 |
| Battegay, M | 1 |
| Hunziker, PR | 1 |
| Kumar, P | 1 |
| Kondiah, PPD | 1 |
| Pillay, V | 1 |
| Choonara, YE | 1 |
| Cridge, H | 1 |
| Lupiano, H | 1 |
| Nipper, JD | 1 |
| Mackin, AJ | 1 |
| Steiner, JM | 1 |
| Ahmed, MMZ | 1 |
| Osman, HHM | 1 |
| Mohamed, AHA | 1 |
| Ginawi, A | 1 |
| Assefa, A | 1 |
| Erko, B | 1 |
| Medhin, G | 1 |
| Berhe, N | 1 |
| Mahende, MK | 1 |
| Ali, A | 1 |
| Hayward, B | 1 |
| Bagchus, W | 1 |
| Kabanywanyi, AM | 1 |
| Chevalier, FD | 1 |
| Anderson, TJ | 1 |
| N'Diaye, M | 2 |
| Keita, BF | 1 |
| Danfakha, F | 1 |
| Keita, F | 1 |
| Keita, G | 1 |
| Senghor, CS | 2 |
| Diawara, L | 2 |
| Bessin, F | 2 |
| Vernet, C | 2 |
| Barbier, D | 3 |
| Dewavrin, P | 3 |
| Klotz, F | 4 |
| Birhanu, Y | 1 |
| Asefa, M | 1 |
| Sultan, A | 1 |
| Lim, J | 1 |
| Sharma, S | 1 |
| Dowling, D | 1 |
| Ojo, JA | 1 |
| Adedokun, SA | 1 |
| Akindele, AA | 1 |
| Olorunfemi, AB | 1 |
| Otutu, OA | 1 |
| Ojurongbe, TA | 1 |
| Thomas, BN | 1 |
| Velavan, TP | 1 |
| Ojurongbe, O | 1 |
| Kwofie, SK | 1 |
| Agyenkwa-Mawuli, K | 1 |
| Broni, E | 1 |
| Miller Iii, WA | 1 |
| Wilson, MD | 1 |
| Wang, W | 5 |
| Musaigwa, F | 1 |
| Nnaji, CA | 1 |
| Knowles, SCL | 1 |
| Sturrock, HJW | 1 |
| Turner, H | 1 |
| Whitton, JM | 1 |
| Gower, CM | 2 |
| Jemu, S | 1 |
| Thomas, B | 1 |
| Kollie, K | 1 |
| Thomas, C | 1 |
| Rebollo, MP | 1 |
| Styles, B | 1 |
| Clements, M | 1 |
| Fenwick, A | 23 |
| Harrison, WE | 2 |
| Lingscheid, T | 1 |
| Kurth, F | 1 |
| Clerinx, J | 3 |
| Marocco, S | 1 |
| Trevino, B | 1 |
| Schunk, M | 1 |
| Muñoz, J | 3 |
| Gjørup, IE | 1 |
| Jelinek, T | 1 |
| Develoux, M | 1 |
| Fry, G | 1 |
| Jänisch, T | 1 |
| Schmid, ML | 1 |
| Bouchaud, O | 2 |
| Puente, S | 1 |
| Mørch, K | 1 |
| Björkman, A | 1 |
| Siikamäki, H | 1 |
| Neumayr, A | 1 |
| Nielsen, H | 1 |
| Hellgren, U | 1 |
| Paul, M | 1 |
| Calleri, G | 1 |
| Kosina, P | 1 |
| Myrvang, B | 1 |
| Ramos, JM | 1 |
| Just-Nübling, G | 1 |
| Beltrame, A | 1 |
| Saraiva da Cunha, J | 1 |
| Kern, P | 3 |
| Rochat, L | 1 |
| Stich, A | 1 |
| Pongratz, P | 1 |
| Suttorp, N | 1 |
| Witzenrath, M | 1 |
| Hatz, C | 3 |
| Zoller, T | 1 |
| El Kouni, MH | 1 |
| Leblanc, C | 1 |
| Pham, LL | 1 |
| Mariani, P | 1 |
| Titomanlio, L | 1 |
| El Ghoneimi, A | 1 |
| Paris, L | 3 |
| Escoda, S | 1 |
| Lottmann, H | 1 |
| Toubiana, J | 1 |
| Paugam, A | 1 |
| Ulinski, T | 1 |
| Brun, S | 1 |
| Izri, A | 1 |
| Faye, A | 1 |
| De Pontual, L | 1 |
| Reinhard-Rupp, J | 2 |
| Klohe, K | 1 |
| Siqueira, LDP | 1 |
| Fontes, DAF | 1 |
| Aguilera, CSB | 1 |
| Timóteo, TRR | 1 |
| Ângelos, MA | 1 |
| de Melo, CG | 1 |
| da Silva, RMF | 1 |
| Neto, PJR | 1 |
| Carvalho, GBF | 1 |
| Resende, DM | 1 |
| Siqueira, LMV | 1 |
| Lopes, MD | 1 |
| Lopes, DO | 1 |
| Coelho, PMZ | 1 |
| Teixeira-Carvalho, A | 1 |
| Ruiz, JC | 1 |
| Fonseca, CT | 1 |
| You, H | 1 |
| Liu, C | 1 |
| Du, X | 1 |
| McManus, DP | 10 |
| Chan, YL | 1 |
| Andiego, K | 1 |
| Omedo, M | 2 |
| Muchiri, G | 2 |
| Ogutu, MO | 1 |
| Vince, L | 1 |
| Shiff, C | 1 |
| Burnim, M | 1 |
| Ivy, JA | 1 |
| Li, YQ | 1 |
| Chen, YF | 1 |
| Dang, YP | 1 |
| Shang, ZZ | 1 |
| Ma, Q | 1 |
| Wang, YJ | 1 |
| Luo, L | 1 |
| Li, QQ | 1 |
| Zhao, L | 1 |
| Lago, EM | 1 |
| Xavier, RP | 1 |
| Teixeira, TR | 1 |
| Silva, LM | 1 |
| da Silva Filho, AA | 1 |
| de Moraes, J | 1 |
| Agrawal, MC | 1 |
| Rao, VG | 1 |
| Ezeamama, AE | 2 |
| Nkwata, AK | 1 |
| Martinez, L | 1 |
| Pabalan, N | 1 |
| Boivin, MJ | 1 |
| Mariz Gomes da Silva, LM | 1 |
| de Oliveira, JF | 1 |
| Silva, WL | 1 |
| da Silva, AL | 1 |
| de Almeida Junior, ASA | 1 |
| Barbosa Dos Santos, VH | 1 |
| Alves, LC | 1 |
| Brayner Dos Santos, FA | 1 |
| Costa, VMA | 1 |
| Aires, AL | 1 |
| de Lima, MDCA | 1 |
| Albuquerque, MCPA | 1 |
| Hürlimann, E | 2 |
| Webster, B | 1 |
| Allan, F | 2 |
| Xiao, SH | 5 |
| Sun, J | 1 |
| Chen, MG | 7 |
| Stingl, P | 1 |
| Stingl, T | 1 |
| Hong-Bao, L | 1 |
| Ming, S | 1 |
| Ru-Yi, L | 1 |
| Na, Z | 1 |
| Ni-Na, P | 1 |
| Li-le, L | 1 |
| Yan, M | 1 |
| Hong-Bo, W | 1 |
| Chang-E, D | 1 |
| Zhao-Jun, D | 1 |
| Gupta, RS | 1 |
| Wilke, K | 1 |
| Vieth, M | 1 |
| Tang, X | 1 |
| Lv, Y | 1 |
| Sun, T | 1 |
| Jiang, Y | 1 |
| Zhan, X | 1 |
| Zhou, S | 1 |
| Kang, N | 1 |
| Shen, W | 1 |
| Gao, H | 1 |
| Feng, Y | 1 |
| Zhu, W | 1 |
| Xu, Q | 1 |
| Yu, D | 1 |
| Majrashi, SA | 1 |
| Al Amoodi, OM | 1 |
| Mukaratirwa, S | 1 |
| Ai, X | 1 |
| Ya-Min, Z | 1 |
| Jun, J | 1 |
| Heng-Ye, T | 1 |
| Lin, W | 1 |
| Sha-Sha, L | 1 |
| Yi-Xin, H | 1 |
| Panic, G | 1 |
| Dunne, DW | 6 |
| Vennervald, BJ | 6 |
| Viana, AG | 1 |
| Coelho, ALG | 1 |
| Bartholomeu, DC | 1 |
| Bueno, LL | 1 |
| Fujiwara, RT | 1 |
| Saade, A | 1 |
| Carton, E | 1 |
| Mansuet-Lupo, A | 1 |
| Jouffroy, R | 1 |
| Damotte, D | 1 |
| Yera, H | 1 |
| Revel, MP | 1 |
| Goldwasser, F | 1 |
| Abe, EM | 3 |
| Casacuberta Partal, M | 1 |
| Amoah, AS | 1 |
| van Lieshout, L | 2 |
| Tsonaka, S | 1 |
| Silué, KD | 1 |
| N'Gbesso, YK | 1 |
| Oyinloye, BE | 1 |
| Masamba, P | 1 |
| Mbatha, LS | 1 |
| Pretorius, A | 1 |
| Kappo, AP | 1 |
| Angheben, A | 1 |
| Bisoffi, Z | 2 |
| Massie, J | 1 |
| Howling, S | 1 |
| Lechien, JR | 1 |
| Horoi, M | 1 |
| Kampouridis, S | 1 |
| N'Goran, E | 1 |
| David Aka, NA | 1 |
| Leir, SA | 1 |
| Foot, O | 1 |
| Jeyaratnam, D | 1 |
| Whyte, MB | 1 |
| Mickan, C | 1 |
| Junghanss, T | 1 |
| Stojkovic, M | 1 |
| Abioye, AI | 1 |
| McDonald, EA | 2 |
| Park, S | 1 |
| Ripp, K | 1 |
| Bennett, B | 1 |
| Wu, HW | 3 |
| Pond-Tor, S | 1 |
| Sagliba, MJ | 1 |
| Amoylen, AJ | 1 |
| Baltazar, PI | 2 |
| Kurtis, JD | 3 |
| Cavalcanti, MG | 1 |
| Cunha, AFA | 1 |
| Peralta, JM | 1 |
| Brindley, PJ | 2 |
| Azevedo, C | 1 |
| da Costa, JMC | 1 |
| Cucchetto, G | 1 |
| Rodari, P | 1 |
| Ferrari, A | 1 |
| Zanotti, P | 1 |
| Bottieau, E | 2 |
| Silva, R | 1 |
| Mutombo, N | 1 |
| Landouré, A | 6 |
| Man, WY | 1 |
| Dembélé, R | 3 |
| Keita, AD | 2 |
| McLaws, ML | 1 |
| Issa, YA | 1 |
| El Achy, SN | 1 |
| Mady, RF | 1 |
| Sousa-Figueiredo, JC | 6 |
| Betson, M | 4 |
| Bustinduy, A | 1 |
| Labuda, LA | 1 |
| Ateba-Ngoa, U | 1 |
| Feugap, EN | 1 |
| Heeringa, JJ | 1 |
| van der Vlugt, LE | 1 |
| Pires, RB | 1 |
| Mewono, L | 1 |
| Kremsner, PG | 1 |
| van Zelm, MC | 1 |
| Smits, HH | 1 |
| Logan, S | 1 |
| Armstrong, M | 1 |
| Moore, E | 1 |
| Nebbia, G | 1 |
| Jarvis, J | 1 |
| Suvari, M | 1 |
| Bligh, J | 1 |
| Brown, M | 2 |
| Doherty, T | 1 |
| Maraj, H | 1 |
| Chin, K | 1 |
| Bhattacharjee, D | 1 |
| Abdel-Rahman, M | 1 |
| El-Sayed, M | 1 |
| El Raziky, M | 1 |
| Elsharkawy, A | 1 |
| El-Akel, W | 1 |
| Ghoneim, H | 1 |
| Khattab, H | 1 |
| Esmat, G | 1 |
| Schur, N | 3 |
| Nebe, OJ | 1 |
| Isiyaku, S | 1 |
| Olamiju, F | 2 |
| Kadiri, M | 1 |
| Poopola, TO | 1 |
| Braide, EI | 1 |
| Saka, Y | 1 |
| Kristensen, TK | 1 |
| Aldasoro, E | 1 |
| Pinazo, MJ | 1 |
| Arguis, P | 2 |
| Gascon, J | 2 |
| Liang, XL | 1 |
| Yuan, JY | 1 |
| Schneider, ME | 1 |
| Thétiot-Laurent, SA | 1 |
| Robert, A | 1 |
| Meunier, B | 1 |
| Navaratnam, AM | 1 |
| Kato-Hayashi, N | 1 |
| Yasuda, M | 1 |
| Yuasa, J | 1 |
| Isaka, S | 1 |
| Haruki, K | 1 |
| Ohmae, H | 3 |
| Osada, Y | 1 |
| Kanazawa, T | 1 |
| Chigusa, Y | 3 |
| Wu, DZ | 1 |
| Ma, Z | 1 |
| Liu, YF | 1 |
| Zhu, WF | 1 |
| Ning, A | 2 |
| Wang, WL | 1 |
| Song, LJ | 1 |
| Yin, XR | 1 |
| Fan, WH | 1 |
| Wang, GP | 1 |
| Yu, CX | 1 |
| Feng, B | 1 |
| Ndeffo Mbah, ML | 2 |
| Poolman, EM | 1 |
| Atkins, KE | 1 |
| Orenstein, EW | 1 |
| Meyers, LA | 1 |
| Townsend, JP | 1 |
| Galvani, AP | 2 |
| Olliaro, PL | 3 |
| Hayes, DJ | 1 |
| Montresor, A | 4 |
| Chitsulo, L | 4 |
| Erfe, JM | 1 |
| Belizario, VY | 1 |
| Chua, PL | 1 |
| Naig, JR | 1 |
| Becker, SL | 1 |
| Ingram, KJ | 1 |
| Jarrell, A | 1 |
| Kawsky, J | 1 |
| Johnson, T | 1 |
| Voss, S | 1 |
| Madan, R | 1 |
| Weitkamp, T | 1 |
| Wigle, P | 1 |
| Rizk, M | 1 |
| Ibrahim, N | 1 |
| El-Rigal, N | 1 |
| Benito, N | 1 |
| Ehsani, L | 1 |
| Osunkoya, AO | 1 |
| Dongmo Noumedem, C | 1 |
| Ngassam, P | 1 |
| Gipwe, NF | 1 |
| Dankoni, E | 1 |
| Tarini, A | 1 |
| Koukounari, A | 3 |
| Donnelly, CA | 2 |
| Moustaki, I | 1 |
| Deelder, AM | 4 |
| de Souza, AL | 1 |
| Andreani, T | 1 |
| de Oliveira, RN | 1 |
| Kiill, CP | 1 |
| dos Santos, FK | 1 |
| Allegretti, SM | 1 |
| Chaud, MV | 1 |
| Souto, EB | 1 |
| Silva, AM | 1 |
| Gremião, MP | 1 |
| Olliaro, P | 4 |
| Delgado-Romero, P | 1 |
| Chan, JD | 2 |
| Agbedanu, PN | 1 |
| Zamanian, M | 1 |
| Gruba, SM | 1 |
| Haynes, CL | 1 |
| Day, TA | 2 |
| Palha De Sousa, CA | 1 |
| Brigham, T | 1 |
| Chasekwa, B | 1 |
| Mbuya, MN | 1 |
| Tielsch, JM | 1 |
| Humphrey, JH | 1 |
| Prendergast, AJ | 1 |
| Poole, H | 1 |
| Terlouw, DJ | 1 |
| Naunje, A | 1 |
| Mzembe, K | 1 |
| Stanton, M | 1 |
| Lalloo, DG | 1 |
| van Eeuwijk, P | 1 |
| Soukhathammavong, PA | 1 |
| Akkhavong, K | 2 |
| Muhumuza, S | 2 |
| Katahoire, A | 2 |
| Kiragga, AN | 1 |
| Nuwaha, F | 3 |
| Kleppa, E | 1 |
| Ramsuran, V | 1 |
| Zulu, S | 1 |
| Karlsen, GH | 1 |
| Bere, A | 1 |
| Passmore, JA | 1 |
| Ndhlovu, P | 1 |
| Lillebø, K | 1 |
| Holmen, SD | 1 |
| Onsrud, M | 1 |
| Ndung'u, T | 1 |
| MacDonald, K | 1 |
| Buxton, S | 1 |
| Kimber, MJ | 1 |
| Robertson, AP | 1 |
| Ribeiro, P | 1 |
| Ndao, B | 2 |
| Sy, I | 1 |
| Diedhiou, K | 2 |
| Georges, P | 2 |
| Basso, A | 2 |
| Guidi, A | 1 |
| Wang, CY | 1 |
| Zhang, F | 1 |
| Hou, M | 1 |
| Chen, L | 2 |
| Yang, BY | 1 |
| Ji, MJ | 1 |
| Cleland, CR | 1 |
| Blair, L | 1 |
| Ross, AG | 9 |
| Chy, D | 1 |
| Olveda, DU | 4 |
| Harn, DA | 4 |
| Gray, DJ | 2 |
| Chau, TN | 2 |
| Williams, GM | 3 |
| Stanton, MC | 1 |
| Waterhouse, D | 1 |
| Ward, S | 1 |
| Hassan, AA | 1 |
| Al-Helal, MA | 1 |
| Memish, ZA | 1 |
| Liang, Y | 1 |
| Ogutu, M | 1 |
| Awiti, A | 1 |
| Musuva, R | 1 |
| Skrip, L | 1 |
| Greenhalgh, S | 1 |
| Hotez, P | 1 |
| Kasinathan, RS | 1 |
| Sharma, LK | 1 |
| Cunningham, C | 3 |
| Webb, TR | 1 |
| Gurarie, D | 1 |
| Coltart, C | 1 |
| Whitty, CJ | 1 |
| Grimes, JE | 1 |
| Croll, D | 1 |
| Freeman, MC | 1 |
| Templeton, MR | 1 |
| Othman, AA | 1 |
| Soliman, RH | 1 |
| Todd, MH | 4 |
| Coaker, H | 1 |
| Cupit, PM | 2 |
| Hess, J | 1 |
| Gasser, G | 1 |
| Lai, YS | 2 |
| Biedermann, P | 1 |
| Mathieu, E | 1 |
| Raso, G | 4 |
| Tchuenté, LA | 1 |
| Touré, S | 1 |
| Winkler, MS | 1 |
| Diawara, A | 2 |
| Scherrer, AU | 2 |
| Stete, K | 2 |
| Sanches, BF | 1 |
| Morgado, J | 1 |
| Carvalho, N | 1 |
| Anjos, R | 1 |
| Ekenze, SO | 1 |
| Modekwe, VO | 1 |
| Nzegwu, MA | 1 |
| Ekpemo, SC | 1 |
| Ezomike, UO | 1 |
| Yepes, E | 1 |
| Varela-M, RE | 1 |
| López-Abán, J | 2 |
| Rojas-Caraballo, J | 1 |
| Muro, A | 2 |
| Mollinedo, F | 1 |
| de Campos, VE | 1 |
| Silva, JA | 1 |
| Ricci-Júnior, E | 1 |
| Mansur, CR | 1 |
| Conti, DS | 1 |
| da Rocha, SR | 1 |
| Savioli, L | 7 |
| Albonico, M | 1 |
| Ame, SM | 1 |
| Trastullo, R | 1 |
| Dolci, LS | 1 |
| Passerini, N | 1 |
| Albertini, B | 1 |
| Chami, GF | 1 |
| Kontoleon, AA | 1 |
| Bulte, E | 1 |
| Trainor-Moss, S | 1 |
| Luty, AJ | 1 |
| Lesiguez, JL | 1 |
| Estanislao, GG | 1 |
| Ayaso, EB | 1 |
| Monterde, DB | 1 |
| Ida, A | 1 |
| Watson, N | 1 |
| Siza, JE | 2 |
| Kaatano, GM | 2 |
| Chai, JY | 2 |
| Eom, KS | 2 |
| Rim, HJ | 2 |
| Yong, TS | 2 |
| Min, DY | 2 |
| Chang, SY | 2 |
| Ko, Y | 2 |
| Changalucha, JM | 2 |
| Budge, PJ | 1 |
| Sognikin, E | 1 |
| Akosa, A | 1 |
| Mathieu, EM | 1 |
| Deming, M | 1 |
| Coron, N | 1 |
| Kettani, S | 1 |
| Pihet, M | 1 |
| Hemery, S | 1 |
| de Gentile, L | 1 |
| Chabasse, D | 1 |
| Walker, M | 1 |
| Mabud, TS | 1 |
| Basáñez, MG | 1 |
| Namatame, I | 1 |
| Parikh, ND | 1 |
| Gurung, A | 1 |
| Chaptini, L | 1 |
| Jourdan, P | 1 |
| Zoni, AC | 1 |
| Catalá, L | 1 |
| Ault, SK | 1 |
| Azoulay, D | 1 |
| Djabbari, M | 1 |
| Calderaro, J | 1 |
| Laursen, L | 1 |
| He, CL | 1 |
| Yin, XP | 1 |
| Binder, SC | 1 |
| Rathbun, S | 1 |
| Phillips, A | 1 |
| Ferro, J | 1 |
| Karanja, DM | 2 |
| Mwinzi, PN | 2 |
| Montgomery, S | 1 |
| Hamidou, A | 1 |
| Karagiannis-Voules, DA | 1 |
| Bogoch, II | 1 |
| Bendavid, E | 1 |
| Andrews, JR | 1 |
| Dioukhane, EM | 1 |
| Sun, Q | 1 |
| Mao, R | 1 |
| Wang, D | 1 |
| Hu, C | 1 |
| Sun, D | 2 |
| Patel, TA | 1 |
| Lukawska, J | 1 |
| Rowe, J | 1 |
| Bailey, RL | 1 |
| Qian, C | 1 |
| Gong, F | 1 |
| Wami, WM | 1 |
| Nausch, N | 3 |
| Gwisai, R | 1 |
| Woolhouse, ME | 1 |
| Strohmayer, J | 1 |
| Matthews, I | 1 |
| Locke, R | 1 |
| Inobaya, MT | 2 |
| Vinluan, ML | 2 |
| Ng, SK | 2 |
| Guevarra, JR | 2 |
| Lam, AK | 2 |
| Inobaya, M | 1 |
| Weerakoon, K | 1 |
| Ramm, GA | 1 |
| Maluil, S | 1 |
| Stevens, RA | 1 |
| Maizels, R | 1 |
| Woolhouse, M | 1 |
| Zwang, J | 1 |
| Abdellahi, M | 1 |
| Ndir, O | 2 |
| Niang, S | 1 |
| Andrade, G | 1 |
| Bertsch, DJ | 1 |
| Zhang, D | 1 |
| Wang, H | 2 |
| Ji, J | 1 |
| Nie, L | 1 |
| Correia da Costa, JM | 1 |
| Tohon, ZB | 1 |
| Mainassara, HB | 1 |
| Mahamane, AE | 1 |
| Bosqué-Oliva, E | 2 |
| Ibrahim, ML | 1 |
| Duchemin, JB | 1 |
| Chanteau, S | 1 |
| Boisier, P | 1 |
| Gholam, P | 1 |
| Autschbach, F | 1 |
| Hartschuh, W | 1 |
| Massa, K | 2 |
| Sheshe, A | 2 |
| Ntakamulenga, R | 2 |
| Ndawi, B | 2 |
| Erikstrup, C | 3 |
| Kallestrup, P | 3 |
| Zinyama-Gutsire, RB | 1 |
| Gomo, E | 3 |
| Butterworth, AE | 3 |
| Pedersen, BK | 1 |
| Ostrowski, SR | 1 |
| Gerstoft, J | 3 |
| Ullum, H | 3 |
| Tallo, VL | 1 |
| Carabin, H | 1 |
| Alday, PP | 1 |
| Balolong, E | 1 |
| McGarvey, ST | 1 |
| Doenhoff, MJ | 3 |
| Bomers, MK | 1 |
| Veenstra, J | 1 |
| Sörén, K | 2 |
| Monrad, J | 5 |
| Johansen, MV | 6 |
| Lindberg, R | 3 |
| Kohno, M | 1 |
| Kuwatsuru, R | 1 |
| Suzuki, K | 1 |
| Nishii, N | 1 |
| Hayano, T | 1 |
| Mitsuhashi, N | 1 |
| Tanabe, K | 1 |
| Aragon, AD | 1 |
| Imani, RA | 1 |
| Blackburn, VR | 1 |
| Melman, SD | 1 |
| Goronga, T | 1 |
| Webb, T | 1 |
| Meyer, T | 1 |
| Sekljic, H | 1 |
| Fuchs, S | 1 |
| Bothe, H | 1 |
| Schollmeyer, D | 1 |
| Miculka, C | 1 |
| Neghina, R | 1 |
| Neghina, AM | 1 |
| Merkler, C | 1 |
| Marincu, I | 1 |
| Moldovan, R | 1 |
| Iacobiciu, I | 1 |
| Duus, LM | 1 |
| Christensen, AV | 1 |
| Navntoft, D | 1 |
| Tarp, B | 1 |
| Nielsen, HV | 1 |
| Petersen, E | 1 |
| Rascarachi, G | 1 |
| Linares Torres, P | 1 |
| Arias Rodríguez, L | 1 |
| Pérez Andrada, S | 1 |
| Sierra Ausin, M | 1 |
| Díez Rodríguez, R | 1 |
| Herrera Abián, A | 1 |
| Southgate, V | 2 |
| Botros, S | 2 |
| Coles, G | 1 |
| Mbaye, A | 2 |
| Jauréguiberry, S | 2 |
| Caumes, E | 2 |
| Lei, JH | 1 |
| Liu, WQ | 1 |
| Sun, CS | 1 |
| Tang, CL | 1 |
| Li, MJ | 1 |
| Chen, YL | 1 |
| Sangho, H | 1 |
| Dabo, A | 1 |
| Sidibé, A | 1 |
| Diallo, A | 1 |
| Konaté, S | 2 |
| Gutman, J | 1 |
| Richards, FO | 2 |
| Eigege, A | 3 |
| Umaru, J | 3 |
| Alphonsus, K | 1 |
| Miri, ES | 2 |
| Brooker, S | 3 |
| De Savigny, D | 1 |
| Tanner, M | 8 |
| Ornbjerg, N | 2 |
| Singer, BH | 2 |
| Helleberg, M | 1 |
| Thybo, S | 1 |
| de Jongste, AH | 1 |
| Tilanus, AM | 1 |
| Bax, H | 1 |
| Willems, MH | 1 |
| van der Feltz, M | 1 |
| van Hellemond, JJ | 1 |
| Li, T | 1 |
| Yang, Z | 1 |
| Cai, HJ | 1 |
| Song, LW | 1 |
| Lu, KY | 1 |
| Wu, ZD | 1 |
| Morgan, OW | 1 |
| Brunette, G | 1 |
| Kapella, BK | 1 |
| McAuliffe, I | 1 |
| Katongole-Mbidde, E | 1 |
| Li, W | 1 |
| Okware, S | 1 |
| Olsen, SJ | 1 |
| Tappero, JW | 1 |
| Wilkins, PP | 1 |
| Gobert, GN | 1 |
| Dial, C | 1 |
| Noël, LH | 1 |
| Singh, NG | 1 |
| Mannan, AA | 1 |
| Kahvic, M | 1 |
| Alanzi, FM | 1 |
| Lin, CT | 1 |
| Chen, CY | 1 |
| Jao, SW | 1 |
| Wu, CC | 1 |
| Muth, S | 2 |
| Odermatt-Biays, S | 2 |
| Phompida, S | 1 |
| Duong, S | 1 |
| Gabrielli, AF | 3 |
| Gouvras, A | 1 |
| Traoré, M | 4 |
| Dömling, A | 3 |
| Khoury, K | 1 |
| Hawary, A | 1 |
| Taylor, R | 1 |
| McEwans, A | 1 |
| Napier-Hemy, R | 1 |
| Balbaa, M | 2 |
| Abdel Moneam, NM | 1 |
| El-Kersh, M | 1 |
| Omran, H | 1 |
| Kandeel, K | 1 |
| Dennis, N | 1 |
| Wilkinson, J | 1 |
| Robboy, S | 1 |
| Idrissa, A | 1 |
| Chiyaka, ET | 1 |
| Magombedze, G | 1 |
| Mutimbu, L | 1 |
| Sandhu, G | 1 |
| Georgescu, A | 1 |
| Korniyenko, A | 1 |
| Florita, C | 1 |
| Iuga, A | 1 |
| Day, M | 1 |
| Cao, H | 1 |
| Liu, H | 2 |
| McCrann, CH | 1 |
| Boyer, JL | 1 |
| Dissous, C | 1 |
| Kanoksil, W | 1 |
| Larbcharoensub, N | 1 |
| Soontrapa, P | 1 |
| Phongkitkarun, S | 1 |
| Sriphojanart, S | 1 |
| Nitiyanant, P | 1 |
| Juraschek, SP | 1 |
| Bankova, L | 1 |
| Falade, O | 1 |
| Chow, G | 1 |
| McKenzie, R | 1 |
| Bhogal, HK | 1 |
| Kolosionek, E | 1 |
| Crosby, A | 1 |
| Harhay, MO | 1 |
| Morrell, N | 1 |
| Butrous, G | 1 |
| Vaid, A | 1 |
| Patalas, E | 1 |
| Tandon, M | 1 |
| Namwanje, H | 1 |
| Brodwall, K | 1 |
| Ariza-Heredia, E | 1 |
| Razonable, RR | 1 |
| Miele, AE | 1 |
| Boumis, G | 1 |
| Brunori, M | 1 |
| Dimastrogiovanni, D | 1 |
| Bellelli, A | 1 |
| Anto, F | 1 |
| Asoala, V | 1 |
| Anyorigiya, T | 1 |
| Oduro, A | 1 |
| Adjuik, M | 1 |
| Akweongo, P | 1 |
| Aborigo, R | 1 |
| Bimi, L | 1 |
| Amankwa, J | 1 |
| Hodgson, A | 1 |
| Seto, EY | 1 |
| Wong, BK | 1 |
| Lu, D | 1 |
| Zhong, B | 2 |
| Staines, HM | 1 |
| Croft, SL | 1 |
| Horrocks, PD | 1 |
| Oshish, A | 1 |
| AlKohlani, A | 1 |
| Hamed, A | 1 |
| Kamel, N | 1 |
| AlSoofi, A | 1 |
| Farouk, H | 1 |
| Ben-Ismail, R | 1 |
| Woelfle, M | 2 |
| Wu, L | 1 |
| Wu, M | 1 |
| Tian, D | 1 |
| Chen, S | 2 |
| Liu, B | 1 |
| Cai, Q | 1 |
| Ji, B | 1 |
| Wang, L | 3 |
| Zhang, S | 3 |
| Ruan, D | 1 |
| Zhu, X | 1 |
| Guo, Z | 1 |
| Seerden, JP | 1 |
| de Gooijer, J | 1 |
| Pouwer, K | 1 |
| Olbrych, SK | 1 |
| Soon, M | 1 |
| Singer, ME | 1 |
| Carter, J | 1 |
| Wu, W | 1 |
| Huang, YX | 1 |
| Liu, R | 1 |
| Dong, HF | 1 |
| Zhao, QP | 1 |
| Jiang, MS | 1 |
| Herdtweck, E | 1 |
| Qiu, SJ | 1 |
| Xia, CM | 1 |
| Chai, ZW | 1 |
| Xu, QC | 1 |
| Zhang, SX | 1 |
| Zhang, TY | 1 |
| Rivas, P | 1 |
| Aguilar-Durán, S | 1 |
| Lago, M | 1 |
| Musselwhite, LW | 1 |
| Maciag, K | 1 |
| Lankowski, A | 1 |
| Gretes, MC | 1 |
| Wellems, TE | 1 |
| Tavera, G | 1 |
| Goulding, RE | 1 |
| Guillen, E | 1 |
| Etta, HE | 1 |
| Lee, H | 1 |
| Moody-Davis, A | 1 |
| Saha, U | 1 |
| Suzuki, BM | 1 |
| Asarnow, D | 1 |
| Arkin, M | 1 |
| Singh, R | 1 |
| Bao, ZP | 1 |
| Wang, DH | 1 |
| Meng, XH | 1 |
| Zhang, YY | 1 |
| Zhao, GM | 1 |
| Guo, JG | 3 |
| Caserta, S | 1 |
| Sawtell, A | 1 |
| Drummond, R | 1 |
| Barr, T | 1 |
| Macdonald, AS | 1 |
| Zamoyska, R | 1 |
| Thrift, AP | 1 |
| Zheng, F | 1 |
| Li, YS | 1 |
| Guo, J | 2 |
| Wang, T | 1 |
| Xu, XJ | 1 |
| Zhu, R | 1 |
| Zhu, H | 1 |
| Lin, DD | 1 |
| Zhao, ZY | 1 |
| Li, RS | 1 |
| Davis, GM | 1 |
| Knapper, C | 1 |
| Morrell, K | 1 |
| Lomax, N | 1 |
| Gryseels, B | 7 |
| Periyasamy, P | 1 |
| Subramaniam, SR | 1 |
| Rajalingham, S | 1 |
| Neumayr, AL | 1 |
| Tschirky, B | 1 |
| Warren, A | 1 |
| Hatz, CF | 1 |
| Blum, JA | 1 |
| Lovis, L | 1 |
| Mak, TK | 1 |
| Ayé Soukhathammavong, P | 1 |
| Liang, YJ | 1 |
| Luo, J | 1 |
| Lu, Q | 1 |
| Zhou, Y | 2 |
| Zheng, D | 1 |
| Ren, YY | 1 |
| Sun, KY | 1 |
| Zhang, ZS | 1 |
| Richter, J | 3 |
| Quintanilla-Martinez, L | 1 |
| Bienemann, K | 1 |
| Zeus, T | 1 |
| Germing, U | 1 |
| Sander, O | 1 |
| Kandolf, R | 1 |
| Häussinger, D | 1 |
| Klingel, K | 1 |
| Owaga, CO | 1 |
| Mwanje, M | 1 |
| Muok, EM | 1 |
| Ayisi, JG | 1 |
| Laserson, KF | 1 |
| Muchiri, EM | 1 |
| Pavlin, BI | 1 |
| Kozarsky, P | 1 |
| Cetron, MS | 1 |
| Pérez del Villar, L | 1 |
| Burguillo, FJ | 1 |
| Valle, C | 1 |
| Bourke, CD | 1 |
| Rujeni, N | 1 |
| Appleby, LJ | 1 |
| Mitchell, KM | 1 |
| Liang, YS | 1 |
| Patel, SM | 1 |
| Rizza, SA | 1 |
| Morona, D | 1 |
| Pinot de Moira, A | 1 |
| Heukelbach, J | 1 |
| Zarowiecki, M | 1 |
| Kupferschmidt, K | 1 |
| da Rocha Pitta, MG | 2 |
| de Melo Rêgo, MJ | 1 |
| Galdino, SL | 1 |
| Schwartz, E | 2 |
| Rozenman, J | 1 |
| Bhigjee, A | 1 |
| Fraysse-Consigny, S | 1 |
| Chosidow, O | 1 |
| Becherel, PA | 1 |
| Datry, A | 2 |
| Frances, C | 1 |
| Hopkins, DR | 1 |
| Gontor, I | 1 |
| Ogah, G | 1 |
| Gwomkudu, CC | 1 |
| Mathai, W | 1 |
| Jinadu, M | 1 |
| Amadiegwu, S | 1 |
| Oyenekan, OK | 1 |
| Korve, K | 1 |
| Pick, N | 1 |
| Shazberg, G | 1 |
| Potasman, I | 1 |
| Stelma, FF | 1 |
| Le Cessie, S | 1 |
| De Vlas, SJ | 4 |
| Falcão Ferreira, ST | 1 |
| Chen, Y | 1 |
| Xie, M | 1 |
| Lin, D | 1 |
| Murakami, H | 1 |
| Wu, Z | 1 |
| Murakami, T | 1 |
| Totsuya, T | 1 |
| Gu, X | 1 |
| Hu, G | 1 |
| Gao, Z | 1 |
| Hu, F | 1 |
| Chen, T | 1 |
| Hu, GH | 1 |
| Xiong, YL | 1 |
| Zhang, YQ | 2 |
| Sun, WS | 1 |
| Wong, CM | 1 |
| Murdoch, DR | 1 |
| Shuhua, X | 1 |
| Olds, GR | 5 |
| Hoffmann, H | 1 |
| Bauerfeind, I | 1 |
| Montes de Oca, M | 1 |
| Sánchez, MA | 1 |
| Tálamo, C | 1 |
| de Noya, B | 1 |
| López, JM | 1 |
| Traore, HA | 1 |
| Maiga, MY | 1 |
| Sogodogo, S | 1 |
| Dembele, M | 1 |
| Sidibe, TA | 1 |
| Diallo, D | 1 |
| Diallo, AN | 1 |
| Guindo, A | 1 |
| Pichard, E | 1 |
| Doumbo, O | 2 |
| Robert Bergquist, N | 1 |
| van der Werf, MJ | 3 |
| Yan, SN | 1 |
| Fang, H | 1 |
| Xiang, LK | 1 |
| Ndyomugyenyi, R | 1 |
| Mwanakasale, V | 1 |
| Sukwa, TY | 1 |
| Ziba, M | 1 |
| Ernest, A | 1 |
| Sharaf, O | 1 |
| Houston, S | 1 |
| Kowalewska-Grochowska, K | 1 |
| Naik, S | 1 |
| McKean, J | 1 |
| Johnson, ES | 1 |
| Warren, K | 1 |
| Bosompem, KM | 2 |
| Habbema, JD | 2 |
| Appleton, CC | 2 |
| Coles, GC | 1 |
| Kusel, JR | 1 |
| Tchuem-Tchuenté, LA | 1 |
| Roungou, JB | 1 |
| Endo, H | 1 |
| Loverde, P | 1 |
| Spicher, VM | 1 |
| Genin, B | 1 |
| Jordan, AR | 1 |
| Rubbia-Brandt, L | 1 |
| Le Coultre, C | 1 |
| Evan Secor, W | 1 |
| Fitzsimmons, CM | 1 |
| Joseph, S | 3 |
| Jones, FM | 3 |
| Reimert, CM | 2 |
| Kazibwe, F | 3 |
| Kimani, G | 3 |
| Mwatha, JK | 3 |
| Ouma, JH | 3 |
| Kariuki, HC | 3 |
| Faucher, V | 1 |
| Delomez, J | 1 |
| Puech, P | 1 |
| Duchêne, F | 1 |
| Khorgami, B | 1 |
| Lemaitre, L | 1 |
| Adam, I | 1 |
| Elwasila, el T | 1 |
| Walter, K | 1 |
| Fulford, AJ | 1 |
| Kamau, T | 1 |
| Iwata, F | 1 |
| Raja'a, YA | 1 |
| Assis, AM | 1 |
| Zulkifli, A | 1 |
| Al-Awaidy, S | 1 |
| Allen, H | 1 |
| Kumari, SB | 1 |
| Allan, PS | 1 |
| Poggensee, G | 2 |
| Krantz, I | 2 |
| Nordin, P | 1 |
| Mtweve, S | 1 |
| Ahlberg, B | 1 |
| Mosha, G | 1 |
| Freudenthal, S | 1 |
| Jiraungkoorskul, W | 1 |
| Sahaphong, S | 1 |
| Sobhon, P | 1 |
| Riengrojpitak, S | 1 |
| Kangwanrangsan, N | 1 |
| van der Vliet, HJ | 1 |
| van Kemenade, FJ | 1 |
| Hekker, TA | 1 |
| Craanen, ME | 1 |
| Curtis, J | 1 |
| Feng, Z | 1 |
| Minchella, DJ | 1 |
| Zhang, R | 1 |
| Hu, H | 1 |
| Shu, R | 1 |
| Sun, W | 1 |
| He, Q | 1 |
| Liu, J | 1 |
| Sun, A | 1 |
| Mao, Z | 1 |
| Kamel, MH | 1 |
| Murphy, M | 1 |
| Kelleher, M | 1 |
| Aquilina, K | 1 |
| Lim, C | 1 |
| Marks, C | 1 |
| Southgate, VR | 4 |
| de Vega, MR | 1 |
| Van den Enden, E | 1 |
| Colebunders, R | 1 |
| Van Esbroeck, M | 1 |
| Vervoort, T | 1 |
| Van Gompel, A | 1 |
| Van den Ende, J | 1 |
| Zinyama, R | 2 |
| Mudenge, B | 1 |
| Bassiouny, K | 1 |
| Ribeiro-dos-Santos, G | 1 |
| Verjovski-Almeida, S | 1 |
| Leite, LC | 1 |
| Olson, BG | 1 |
| Domachowske, JB | 1 |
| Booth, M | 1 |
| Shaw, MA | 1 |
| Carpenter, D | 1 |
| Otake, H | 1 |
| Keang, H | 2 |
| Sinuon, M | 3 |
| Saem, C | 1 |
| Socheat, D | 3 |
| Matsuda, H | 7 |
| Ducarme, G | 1 |
| Seince, N | 1 |
| Poulet, B | 1 |
| Jeantils, V | 1 |
| Uzan, M | 1 |
| Thors, C | 1 |
| Holmblad, P | 1 |
| Maleki, M | 1 |
| Carlson, J | 1 |
| Linder, E | 1 |
| Kestens, L | 1 |
| Tsuyuoka, R | 1 |
| Palmer, K | 1 |
| Adeneye, AK | 3 |
| Appelt, B | 3 |
| Idowu, ET | 3 |
| Akande, DO | 3 |
| Meltzer, E | 1 |
| Artom, G | 1 |
| Marva, E | 1 |
| Assous, MV | 1 |
| Rahav, G | 1 |
| Schwartzt, E | 1 |
| Vickers, D | 1 |
| Shah, SM | 1 |
| Mital, P | 1 |
| Kanzaria, HK | 1 |
| El-Lakkany, N | 1 |
| Nosseir, M | 1 |
| Moudgil, A | 1 |
| Kosut, J | 1 |
| Benson, J | 1 |
| Haus-Cheymol, R | 1 |
| Burlation, G | 1 |
| Berger, F | 1 |
| Wendling, G | 1 |
| Schwartzbrod, PE | 1 |
| Cardona, F | 1 |
| Terrier, F | 1 |
| Spiegel, A | 1 |
| Akinwale, OP | 2 |
| Adewale, B | 2 |
| Manafa, OU | 2 |
| Sulyman, MA | 1 |
| Omotola, BD | 1 |
| Cheam, S | 1 |
| Degrémont, A | 1 |
| Parker, M | 1 |
| Allen, T | 1 |
| Hastings, J | 1 |
| van Delft, F | 1 |
| Visser, L | 1 |
| Polderman, A | 1 |
| Tallima, H | 1 |
| El Ridi, R | 1 |
| Pede, E | 1 |
| Miri, E | 1 |
| Ogbu Pearce, P | 1 |
| Jinadu, MY | 1 |
| Njepuome, AN | 1 |
| Shadan, S | 1 |
| Smith, C | 1 |
| Smith, H | 1 |
| Seaton, RA | 1 |
| Fox, R | 1 |
| Pistone, T | 1 |
| Ezzedine, K | 1 |
| Accoceberry, I | 1 |
| Receveur, MC | 1 |
| Juguet, F | 1 |
| Malvy, D | 1 |
| Hisakane, N | 1 |
| Kirinoki, M | 1 |
| Ishikawa, H | 1 |
| Hayashi, M | 3 |
| Tormis, LC | 3 |
| Nosenas, JS | 6 |
| Blas, BL | 7 |
| Coulaud, JP | 2 |
| Yang, YQ | 3 |
| Yang, HZ | 3 |
| Zhang, CW | 1 |
| Wittes, R | 1 |
| MacLean, JD | 1 |
| Law, C | 1 |
| Lough, JO | 1 |
| Polderman, AM | 2 |
| Gerold, JL | 2 |
| Mpamila, K | 2 |
| Manshande, JP | 2 |
| Shaw, MK | 1 |
| Erasmus, DA | 1 |
| Schutte, CH | 2 |
| Osman, Y | 1 |
| Van Deventer, JM | 1 |
| Mosese, G | 1 |
| De Cock, KM | 1 |
| Pugh, RN | 3 |
| Teesdale, CH | 3 |
| Beisler, GK | 1 |
| Nakao, M | 1 |
| Tanaka, H | 2 |
| Wegner, DH | 4 |
| Santos, AT | 5 |
| Portillo, G | 1 |
| Poliquit, O | 1 |
| Papasin, M | 1 |
| Rugemalila, JB | 1 |
| Asila, J | 1 |
| Chimbe, A | 1 |
| Portillo, GP | 2 |
| Poliquit, OS | 1 |
| Papasin, MC | 1 |
| Flores, GS | 1 |
| Lorette, G | 2 |
| Jaafar, MR | 1 |
| Grojean, MF | 1 |
| Duong, T | 1 |
| Fu, FY | 1 |
| Zheng, JS | 1 |
| Chen, WQ | 1 |
| Qin, KS | 1 |
| Jin, MY | 1 |
| Liu, X | 1 |
| Wang, QL | 1 |
| Lu, SC | 1 |
| Liu, YH | 1 |
| Yan, ZZ | 1 |
| Hu, YD | 1 |
| Lu, ZY | 1 |
| Yu, ZZ | 1 |
| Fu, S | 6 |
| Yang, JS | 2 |
| Wang, MJ | 2 |
| Zhu, PJ | 2 |
| Cheng, ZG | 1 |
| Wang, JP | 2 |
| Tao, CG | 2 |
| Liu, BL | 2 |
| Shen, SB | 1 |
| Chen, LD | 1 |
| Wen, ST | 1 |
| Zhu, XY | 1 |
| Le, WJ | 1 |
| Burchard, GD | 2 |
| Baltes, R | 1 |
| Dietrich, M | 3 |
| Farid, L | 1 |
| el-Masry, NA | 1 |
| Bassily, S | 1 |
| Trabolsi, B | 2 |
| Wallace, CK | 2 |
| Keittivuti, B | 1 |
| Keittivuti, A | 1 |
| O'Rourke, T | 1 |
| D'Agnes, T | 1 |
| Yogore, MG | 1 |
| Lewert, RM | 1 |
| Farid, Z | 2 |
| Stek, M | 1 |
| Sheehan, GJ | 1 |
| Sekla, L | 1 |
| Harding, GK | 1 |
| Metwally, AA | 1 |
| Khayyal, MT | 2 |
| Zhen, YL | 1 |
| Chen, GG | 1 |
| Liu, T | 1 |
| Massoud, A | 2 |
| Hafez, AS | 1 |
| Hussein, MM | 2 |
| Abdel Karim, AH | 1 |
| el Nahaal, A | 1 |
| Massoud, AA | 1 |
| el Kholy, AM | 1 |
| Anwar, WA | 2 |
| Webbe, G | 6 |
| Hayashi, Y | 1 |
| Southwood, T | 1 |
| Davidson, GP | 1 |
| Phillips, GE | 1 |
| Rice, M | 1 |
| Davidson, RA | 1 |
| Yue, WJ | 1 |
| Shao, BR | 3 |
| Pan, QR | 2 |
| Zhan, CQ | 2 |
| Xu, YQ | 2 |
| You, JQ | 1 |
| Guo, HF | 1 |
| Mei, JY | 1 |
| Pearson, RD | 2 |
| Guerrant, RL | 2 |
| Kardaman, MW | 2 |
| Amin, MA | 1 |
| Cheesmond, AK | 1 |
| Dixon, HG | 2 |
| Wang, XG | 1 |
| Madwar, MA | 1 |
| El-Fekhakh, EA | 1 |
| Montasser, MF | 1 |
| Ahmed, MS | 1 |
| Ahmed, SE | 1 |
| Bushara, HO | 2 |
| Majid, BY | 1 |
| Majid, AA | 1 |
| Khitma, I | 1 |
| Gameel, AA | 1 |
| Karib, EA | 1 |
| Hussein, MF | 2 |
| Taylor, MG | 2 |
| Warren, KS | 1 |
| Su, DL | 1 |
| Xu, ZY | 3 |
| Yuan, HC | 1 |
| Peters, PA | 1 |
| Cook, JA | 2 |
| Mott, KE | 1 |
| Houser, HB | 1 |
| Pehrson, PO | 1 |
| Bengtsson, E | 1 |
| Diekmann, HW | 1 |
| Groll, E | 1 |
| El-Hawey, A | 1 |
| Masoud, A | 1 |
| Metwally, A | 1 |
| El Badrawy, N | 1 |
| El Garam, A | 1 |
| Roushdi, M | 1 |
| Khalil, A | 1 |
| Ward, JM | 1 |
| Hua, XJ | 2 |
| Wu, HM | 3 |
| Lapierre, J | 1 |
| Keita, A | 1 |
| Faurant, C | 1 |
| Heyer, F | 1 |
| Tourte-Schaefer, C | 1 |
| Ancelle, T | 1 |
| Dupouy-Camet, J | 1 |
| Zhou, XZ | 1 |
| Fan, Y | 1 |
| Zhou, XL | 1 |
| Wang, DW | 1 |
| Shaw, JR | 1 |
| Brammer, KW | 1 |
| Nahmias, J | 1 |
| Aziz, E | 1 |
| Geraci, L | 1 |
| Coutinho, A | 1 |
| Domingues, AL | 1 |
| Neves, J | 1 |
| Almeida, ST | 1 |
| Papadopoulos, I | 1 |
| Ebert, W | 1 |
| Weniger, BG | 1 |
| Schantz, PM | 1 |
| Nash, TE | 1 |
| Hofstetter, M | 1 |
| Cheever, AW | 1 |
| Ottesen, EA | 1 |
| Weltman, JK | 1 |
| Cavier, R | 1 |
| Piekarski, G | 1 |
| Shen, GR | 1 |
| Mohr, W | 1 |
| McMahon, JE | 5 |
| Barsoum, IS | 1 |
| Gamil, FM | 1 |
| Al-Khafif, MA | 1 |
| Ramzy, RM | 1 |
| El Alamy, MA | 1 |
| Mehlhorn, H | 2 |
| Frenkel, JK | 2 |
| Andrews, P | 5 |
| Thomas, H | 2 |
| Oyediran, AB | 1 |
| Kofie, BA | 1 |
| Bammeke, AO | 1 |
| Bamgboye, EA | 1 |
| Mahmoud, AA | 3 |
| Disko, R | 1 |
| Peyer, P | 1 |
| Graber, P | 1 |
| Majid, MA | 1 |
| Gentilini, M | 1 |
| Brucker, G | 1 |
| Danis, M | 1 |
| Mogahed, A | 1 |
| de Souza Dias, LC | 1 |
| de Jesus Pedro, R | 1 |
| Deberaldini, ER | 1 |
| de Vries, H | 1 |
| Becker, B | 1 |
| James, C | 1 |
| Nelson, GS | 1 |
| Sturrock, RF | 2 |
| Davis, A | 4 |
| Biles, JE | 2 |
| Ulrich, AM | 2 |
| Dixon, H | 1 |
| Diallo, S | 1 |
| Victorius, A | 1 |
| Diouf, F | 1 |
| Dieng, Y | 1 |
| Bah, IB | 1 |
| Ripert, C | 3 |
| Carrié, J | 1 |
| Pagbe, JJ | 1 |
| Ravinet, L | 1 |
| Deniau, M | 2 |
| Same Ekobo, A | 1 |
| Eben-Moussi, E | 1 |
| Koki Ndombo, P | 1 |
| Same-Ekobo, A | 1 |
| Smith, DH | 1 |
| Highton, RB | 1 |
| Roberts, JM | 1 |
| Ranque, P | 1 |
| Karemberi, B | 1 |
| Kone, D | 1 |
| da Silva, LC | 1 |
| Sette, H | 1 |
| Christo, CH | 1 |
| Sáez-Alquezar, A | 1 |
| Carneiro, CR | 1 |
| Lacet, CM | 1 |
| Ohtsuki, N | 1 |
| Raia, S | 1 |
| Omer, AH | 1 |
| El-Alamy, MA | 1 |
| Habib, MA | 1 |
| McNeeley, DF | 1 |
| Cline, BL | 1 |
| Gilles, HM | 1 |
| Feldmeier, H | 2 |
| Zwingenberger, K | 1 |
| Steiner, A | 1 |
| Brunzema, F | 1 |
| Doenhoff, M | 2 |
| Bickle, Q | 1 |
| Bain, J | 1 |
| Nelson, G | 1 |
| Dycka, J | 1 |
| Frank, G | 1 |
| Rosin, MP | 1 |
| Saad el Din Zaki, S | 1 |
| Ward, AJ | 1 |
| Krolikowski, A | 1 |
| Janowski, K | 1 |
| Larsen, JV | 1 |
| Ali, AE | 1 |
| Shaheen, HI | 1 |
| Blanchard, TJ | 1 |
| Milne, LM | 1 |
| Pollok, R | 1 |
| Cook, GC | 1 |
| Morton, JR | 1 |
| Farghaly, AG | 1 |
| Barakat, RM | 1 |
| Lucey, DR | 1 |
| Maguire, JH | 1 |
| Katsivo, MN | 1 |
| Muthami, LN | 1 |
| Kimani, S | 1 |
| Karama, M | 1 |
| Kingori, F | 1 |
| Richard-Lenoble, D | 1 |
| Kombila, M | 1 |
| Duong, TH | 2 |
| Gendrel, D | 1 |
| Algayres, JP | 1 |
| Daly, JP | 1 |
| Laverdant, C | 1 |
| Charmot, G | 1 |
| Reimink, RL | 2 |
| DeGoede, JA | 1 |
| Blankespoor, HD | 1 |
| Christensen, NO | 3 |
| Madiba, TE | 1 |
| Dykhuis, RW | 1 |
| Ramdial, PK | 1 |
| Evans, AC | 1 |
| Pammenter, MD | 2 |
| Cooppan, RM | 1 |
| Pretorius, SJ | 1 |
| Joubert, PH | 1 |
| Gouws, E | 1 |
| Jooste, PL | 1 |
| Badenhorst, CJ | 1 |
| Joubert, JJ | 1 |
| Nagaty, IM | 1 |
| el Hayawan, IA | 1 |
| Nasr, ME | 1 |
| el Hamshery, AH | 1 |
| Fillié, Y | 1 |
| Deelder, A | 2 |
| Badawy, AA | 1 |
| el-Badrawy, NM | 1 |
| Mansy, SS | 1 |
| Akl, MM | 1 |
| Abdel Hady, AM | 1 |
| Ebeid, FA | 1 |
| Helling-Giese, G | 1 |
| Kumwenda, N | 1 |
| Haas, H | 1 |
| Mostafa, BB | 1 |
| Gad, HS | 1 |
| Jiang, Q | 1 |
| Yuan, H | 1 |
| Liu, Z | 1 |
| Zhao, G | 1 |
| Brinkmann, U | 1 |
| Morris, W | 1 |
| Knauer, CM | 1 |
| Hipgrave, DB | 1 |
| Prociv, P | 1 |
| Elsheikh, HA | 1 |
| Kheir, WM | 1 |
| Abdullah, AS | 1 |
| Bennett, JL | 2 |
| Day, T | 1 |
| Liang, FT | 1 |
| Ismail, M | 1 |
| Farghaly, A | 1 |
| Montero, R | 1 |
| Ostrosky, P | 1 |
| De Clercq, D | 1 |
| Vercruysse, J | 4 |
| vanden Bussche, V | 1 |
| Diarra, A | 1 |
| Jusot, JF | 1 |
| Simarro, PP | 2 |
| De Muynck, A | 1 |
| Rolland, Y | 1 |
| Moreau, J | 1 |
| Laroche, M | 1 |
| King, C | 1 |
| Hewlett, J | 1 |
| Olveda, R | 1 |
| Wu, G | 1 |
| Ouma, J | 1 |
| Peters, P | 1 |
| McGarvey, S | 1 |
| Odhiambo, O | 1 |
| Koech, D | 1 |
| Liu, CY | 1 |
| Aligui, G | 1 |
| Gachihi, G | 1 |
| Kombe, Y | 1 |
| Parraga, I | 1 |
| Ramirez, B | 1 |
| Whalen, C | 1 |
| Horton, RJ | 1 |
| Reeve, P | 1 |
| Kojima, S | 1 |
| Reich, MR | 1 |
| Govindaraj, R | 1 |
| Ohnishi, K | 1 |
| Fowler, R | 1 |
| Lee, C | 1 |
| Keystone, JS | 1 |
| Nessim, NG | 1 |
| Demerdash, Z | 1 |
| Abdel-Hadi, AM | 1 |
| Talaat, M | 1 |
| Stephenson, I | 1 |
| Wiselka, M | 1 |
| Leman, JA | 1 |
| Small, G | 1 |
| Wilks, D | 1 |
| Tidman, MJ | 1 |
| Blankespoor, CL | 1 |
| Blankespoort, HD | 1 |
| Shaw, DJ | 1 |
| De Bont, J | 2 |
| Eissa, MM | 1 |
| Baddour, NM | 1 |
| Guyatt, HL | 1 |
| Kihamia, CM | 1 |
| Hall, A | 1 |
| Bundy, DA | 1 |
| Nicodemus, P | 1 |
| Congdon, R | 1 |
| N'Guessan, AN | 1 |
| Müller, I | 1 |
| Zamblé, K | 1 |
| Lohourignon, KL | 1 |
| Sosthène, BA | 1 |
| Lengeler, C | 1 |
| Mahmoud, KM | 1 |
| Sobh, MA | 1 |
| El-Agroudy, AE | 1 |
| Mostafa, FE | 1 |
| Baz, ME | 1 |
| Shokeir, AA | 1 |
| Ghoneim, MA | 1 |
| Xiao, S | 2 |
| Roca, C | 1 |
| Balanzó, X | 1 |
| Fernández-Roure, JL | 1 |
| Vinuesa, T | 1 |
| Valls, ME | 1 |
| Sauca, G | 1 |
| Corachán, M | 2 |
| Bartley, PB | 1 |
| Sleigh, AC | 1 |
| Chollet, J | 1 |
| Chen, M | 1 |
| Zheng, J | 1 |
| Leonardo, LR | 1 |
| Aligui, GD | 1 |
| Tang, XM | 1 |
| Zhu, ZG | 1 |
| Zhang, HX | 1 |
| Rocha, RS | 1 |
| Chaves, A | 1 |
| Ishizaki, T | 1 |
| Kamo, E | 1 |
| Boehme, K | 2 |
| Ortega, OM | 1 |
| Kolstrup, N | 1 |
| Vlassoff, C | 1 |
| Capron, A | 1 |
| Dessaint, JP | 1 |
| Capron, M | 1 |
| Pierce, RJ | 1 |
| Zintzaras, E | 1 |
| Mecaskey, JW | 1 |
| Mathelier-Fusade, P | 1 |
| Beaulieu-Lacoste, I | 1 |
| Cailliez, D | 1 |
| Audebert, C | 1 |
| Klinkert, MQ | 1 |
| Bommert, K | 1 |
| Moser, D | 1 |
| Felleisen, R | 1 |
| Link, G | 1 |
| Beck, E | 1 |
| Ruppel, A | 1 |
| Xing, Y | 1 |
| Dell, R | 1 |
| Numrich, P | 1 |
| Shi, YE | 1 |
| Sima, FO | 1 |
| Mir, M | 1 |
| Ndong, P | 1 |
| el-Hawey, AM | 1 |
| Massoud, AM | 2 |
| el-Rakieby, A | 1 |
| Royzeik, MS | 1 |
| Nassar, MO | 1 |
| Haribhai, HC | 2 |
| Bhigjee, AI | 2 |
| Bill, PL | 2 |
| Modi, G | 1 |
| Hoffmann, M | 1 |
| Kelbe, C | 1 |
| Becker, P | 1 |
| Kotkat, A | 1 |
| el-Masry, S | 1 |
| Abdel-al Mahmoud, N | 1 |
| Boyce, TG | 1 |
| Azher, M | 1 |
| el-Kassimi, FA | 1 |
| Wright, SG | 1 |
| Mofti, A | 1 |
| Hamadto, HH | 1 |
| Rashed, SM | 1 |
| el Said, A | 1 |
| Elhayawan, IA | 1 |
| Ardal, O | 1 |
| Evengård, B | 1 |
| Boctor, FN | 1 |
| Peter, JB | 1 |
| Maunoury, V | 1 |
| Guillemot, F | 1 |
| Mathieu-Chandelier, C | 1 |
| Dutoit, E | 1 |
| Gower-Rousseau, C | 1 |
| Cortot, A | 1 |
| Paris, JC | 1 |
| Emonard, H | 1 |
| Grimaud, JA | 1 |
| Homeida, MM | 1 |
| Eltom, IA | 1 |
| Sulaiman, SM | 1 |
| Ali, HM | 1 |
| Van Aken, D | 1 |
| Fransen, J | 1 |
| Hilderson, H | 1 |
| Khalil, HM | 1 |
| Bebars, MA | 1 |
| el Okbi, LM | 1 |
| el Serougi, AO | 1 |
| Khalil, NM | 1 |
| el Tayeb, H | 1 |
| el Lamei, O | 1 |
| Tamara, F | 1 |
| Arbeille, B | 1 |
| Karagirwa, A | 1 |
| Combescot, C | 1 |
| el-Raghy, I | 1 |
| Back, DJ | 1 |
| Osman, F | 1 |
| Orme, ML | 1 |
| Fathalla, M | 1 |
| Shaker, ZA | 1 |
| Hassanein, HI | 1 |
| Kamel, MM | 1 |
| el-Bahairy, NM | 1 |
| el-Kalouby, AH | 1 |
| el-Raziky, EH | 1 |
| Ellner, JJ | 1 |
| Tweardy, DJ | 1 |
| Osman, GS | 1 |
| Wilson, C | 1 |
| El Kholy, A | 1 |
| Rocklin, RE | 1 |
| Doehring, E | 1 |
| Cosnett, JE | 1 |
| Rahman, SA | 1 |
| Sano, M | 1 |
| Jagannath, MS | 1 |
| Prabhakar, KS | 1 |
| D'Souza, PE | 1 |
| Prem, G | 1 |
| Romero, R | 1 |
| Mas, J | 1 |
| Palacin, A | 1 |
| Knowles, R | 1 |
| Johnson, RB | 1 |
| Ghoneem, M | 1 |
| Massoud, M | 1 |
| Xu, ML | 1 |
| Ma, DY | 1 |
| Wei, CC | 1 |
| Xu, PP | 1 |
| Ge, SD | 1 |
| Lu, ML | 1 |
| Conlon, CP | 1 |
| Ellis, CJ | 1 |
| Archer, S | 1 |
| el Igail, AB | 1 |
| el Tayeb, M | 1 |
| Daffalla, AA | 1 |
| el-Rooby, A | 1 |
| el-Hawy, AM | 1 |
| Anter, A | 1 |
| Hegazi, MM | 1 |
| Abou Tal, S | 1 |
| Morcos, SH | 1 |
| Mansour, MM | 1 |
| Saleh, S | 1 |
| Ishak, EA | 1 |
| Girgis, NI | 1 |
| Dunn, MA | 1 |
| Catto, BA | 1 |
| Webster, LT | 1 |
| Tuazon, CU | 1 |
| Nash, T | 1 |
| Cheever, A | 1 |
| Neva, F | 1 |
| Lininger, L | 1 |
| Rainsford, KD | 1 |
| Lüttges, J | 1 |
| Koransky, K | 1 |
| Watt, G | 1 |
| Long, G | 1 |
| Tameim, O | 1 |
| Abdu, KM | 1 |
| el Gaddal, AA | 1 |
| Jobin, WR | 1 |
| Hadidjaja, P | 1 |
| Syamsuddin, N | 1 |
| Ismid, IS | 1 |
| Sudomo, M | 1 |
| Campbell, J | 1 |
| Putrali, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Single Blind, Cross-over Study to Evaluate the Palatability of New Orally Disintegrating Tablets of PZQ and L-PZQ Versus Current PZQ Tablets in African Children Age 6-11 Years[NCT02315352] | Phase 1 | 48 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| Childhood Schistosomiasis: a Novel Strategy Extending the Benefits/Reach of Antihelminthic Treatment[NCT02495909] | 700 participants (Actual) | Observational | 2016-02-29 | Completed | |||
| Health Benefits of Repeated Treatment in Pediatric Schistosomiasis[NCT01424410] | 360 participants (Actual) | Observational | 2012-02-29 | Completed | |||
| Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST): An Open Label, Randomized Controlled Trial of Single vs. Multiple Treatments of Praziquantel in Intestinal African Schistosomiasis in Côte d'Ivoire[NCT02868385] | Phase 3 | 167 participants (Actual) | Interventional | 2018-10-01 | Completed | ||
| Sanitation, Hygiene, Infant Nutrition Efficacy Project[NCT01824940] | 5,280 participants (Actual) | Interventional | 2012-11-30 | Completed | |||
| Evaluation of Strategies for Improved Uptake of Preventive Treatment for Intestinal Schistosomiasis Among School Children in Jinja District, Uganda: a Stratified Cluster Randomized Controlled Trial[NCT01869465] | 1,277 participants (Actual) | Interventional | 2012-10-31 | Active, not recruiting | |||
| Prevention of HIV and Improved Diagnosis of Adolescent Genital Disease in Bilharzia Endemic KwaZulu-Natal, South Africa[NCT01154907] | 6,500 participants (Anticipated) | Observational | 2010-04-30 | Recruiting | |||
| S. Japonicum and Pregnancy Outcomes: A Randomized, Double Blind, Placebo Controlled Trial (RCT)[NCT00486863] | Phase 2 | 370 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| Gaps in Helminth Control: Safety and Efficacy of Drug Combinations Against Triple Infections[NCT01050517] | 250 participants (Anticipated) | Interventional | 2007-10-31 | Completed | |||
| Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in Subjects With Schistosomiasis: A Pilot Study[NCT02734186] | Phase 4 | 0 participants (Actual) | Interventional | 2016-04-06 | Withdrawn | ||
| Can Anthelminthic Treatment Delay the Progression of HIV? Randomised Open-label Trial Testing Presumptive Anthelminthic Treatment on Progression of HIV in ART-naïve HIV-positive Patients in a Rural African Setting With Presumed High Prevalence of Helminth[NCT00817713] | 295 participants (Actual) | Interventional | 2009-01-31 | Terminated (stopped due to Terminated prematurely due to recruitment difficulties. Expansion to more study sites not planned.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT02315352)
Timeframe: 2-5 minutes
| Intervention | Subjects (Number) |
|---|---|
| L-PZQ (Without Water) Day 1 | 0 |
| Rac-PZQ (Without Water) Day 1 | 0 |
| L-PZQ (With Water) Day 2 | 2 |
| Rac-PZQ (With Water) Day 2 | 0 |
| Cesol® (With Water) Day 2 | 0 |
Overall palatability was assessed on a 0 to 100 unit VAS scale, where higher scores indicate better palatability. (NCT02315352)
Timeframe: 2-5 minutes (After the IMP has been spat out)
| Intervention | units on a scale (Mean) |
|---|---|
| L-PZQ (Without Water) Day 1 | 50.7 |
| Rac-PZQ (Without Water) Day 1 | 45.1 |
| L-PZQ (With Water) Day 2 | 61.1 |
| Rac-PZQ (With Water) Day 2 | 50.2 |
| Cesol® (With Water) Day 2 | 33.5 |
Overall palatability was assessed on a 0 to 100 unit VAS scale, where higher scores indicate better palatability. (NCT02315352)
Timeframe: 0 minute (Right After the Spit-out of the IMP)
| Intervention | units on a scale (Mean) |
|---|---|
| L-PZQ (Without Water) Day 1 | 49.0 |
| Rac-PZQ (Without Water) Day 1 | 39.3 |
| L-PZQ (With Water) Day 2 | 67.5 |
| Rac-PZQ (With Water) Day 2 | 51.4 |
| Cesol® (With Water) Day 2 | 20.3 |
Hemoglobin concentration in a venous blood sample collected at 14 and 32 weeks gestation was measured using a multi-analyte analyzer. Each participant's change in hemoglobin concentration between the two timepoints was determined, and the mean and standard deviation for each group calculated. (NCT00486863)
Timeframe: 14 weeks and 32 weeks gestation
| Intervention | grams/deciliter (Mean) |
|---|---|
| Placebo Control at 12-16 Weeks Gestation | -0.42 |
| Praziquantel at 12-16 Weeks Gestation | -0.44 |
Maternal fat stores were measured by thigh skinfold thickness obtained using a Holtain skinfold caliper. The thickness increase from 14 to 32 weeks was determined for each participant, and the mean and standard deviation calculated. (NCT00486863)
Timeframe: 14 and 32 weeks gestation
| Intervention | millimeters (Mean) |
|---|---|
| Placebo Control at 12-16 Weeks Gestation | 0.08 |
| Praziquantel at 12-16 Weeks Gestation | 0.08 |
Maternal weight gain was assessed by measuring participants' weight in kilograms. The weight increase from 14 to 32 weeks was determined for each participant, and the mean and standard deviation calculated. (NCT00486863)
Timeframe: 14 and 32 weeks gestation
| Intervention | kilograms (Mean) |
|---|---|
| Placebo Control at 12-16 Weeks Gestation | 0.33 |
| Praziquantel at 12-16 Weeks Gestation | 0.32 |
Birth weight was collected for live infants at the time of delivery by a trained midwife, or within 24 hours of delivery for participants who chose to deliver at home with a helot, a birth attendant without formal training. (NCT00486863)
Timeframe: Within 24 hours of delivery.
| Intervention | kilograms (Mean) |
|---|---|
| Placebo Control at 12-16 Weeks Gestation | 2.85 |
| Praziquantel at 12-16 Weeks Gestation | 2.85 |
To assess total body iron, one needs to assess the storage compartment, which will contain sequestered iron, and the functional compartment, which represents bioavailable iron. Body iron status is defined by the two laboratory measurements that reflect these compartments, ferritin and serum transferrin receptor. The serum transferrin receptor:ferritin ratio has been shown in quantitative phlebotomy studies to provide an accurate assessment of total body iron over the entire range of status. At 14 and 32 weeks gestation, a blood sample was collected for assessment of total body iron by determination of the transferrin receptor:ferritin ratio. Each participant's change in ratio was calculated, and the median and interquartile range were determined for each group. (NCT00486863)
Timeframe: 14 weeks and 32 weeks gestation
| Intervention | ratio (Median) |
|---|---|
| Placebo Control at 12-16 Weeks Gestation | 0.0 |
| Praziquantel at 12-16 Weeks Gestation | 0.0 |
Anemia of inflammation was assessed via maternal urine hepcidin levels. In response to inflammation, elevated serum levels of hepcidin is synthesized. Hepcidin causes sequestration of iron from bio-available forms to storage forms such as ferritin and decreases intestinal absorption of iron. Hepcidin was measured in participants' urine at 32 weeks gestation. (NCT00486863)
Timeframe: 32 weeks gestation
| Intervention | nanograms/milliliter (Median) |
|---|---|
| Placebo Control at 12-16 Weeks Gestation | 2.58 |
| Praziquantel at 12-16 Weeks Gestation | 3.38 |
Abortion was defined by the protocol as bleeding followed by fetal loss as supported by ultrasound before 20 weeks gestation. Abortion was an important safety outcome measure due to the fact that abortion would occur closer to the time of dosing than miscarriage or stillbirth. Participants were observed in hospital for 24 hours after dosing and asked to return for any bleeding at any time. (NCT00486863)
Timeframe: After dosing and before 20 weeks gestation
| Intervention | participants (Number) |
|---|---|
| Placebo Control at 12-16 Weeks Gestation | 0 |
| Praziquantel at 12-16 Weeks Gestation | 0 |
Participants were observed in hospital for 24 hours after dosing for serious adverse events. Serious adverse events included any untoward medical occurrence that resulted in death; was life threatening; was a persistent/significant disability/incapacity; required in-patient hospitalization or prolongation thereof (for reasons other than the 24-hour observation period); resulted in a congenital anomaly/birth defect; or may have jeopardized the participant, or required intervention to prevent one of these outcomes. (NCT00486863)
Timeframe: Within 24 hours of dosing
| Intervention | participants (Number) |
|---|---|
| Placebo Control at 12-16 Weeks Gestation | 0 |
| Praziquantel at 12-16 Weeks Gestation | 0 |
The newborn was examined by the midwife at delivery and within 2-6 days of delivery to assess the presence of congenital anomalies and well-being. The newborn was also examined by study pediatrician at 28 days of life. (NCT00486863)
Timeframe: At delivery, within 2-6 days of delivery, and at 28 days
| Intervention | participants (Number) |
|---|---|
| Placebo Control at 12-16 Weeks Gestation | 1 |
| Praziquantel at 12-16 Weeks Gestation | 1 |
Each participant was followed until delivery to record if the outcome of the pregnancy was a live birth. Live births were defined as the complete expulsion or extraction from its mother of a product of conception, irrespective of the duration of the pregnancy, which, after such separation, breathes or shows any other evidence of life such as heartbeat, umbilical cord pulsation, or definite movement of voluntary muscles, whether the umbilical cord had been cut or the placenta was attached. (NCT00486863)
Timeframe: At delivery
| Intervention | participants (Number) |
|---|---|
| Placebo Control at 12-16 Weeks Gestation | 181 |
| Praziquantel at 12-16 Weeks Gestation | 181 |
Participants were assessed for the presence of pre-eclampsia at both the 22 and 32 week visits. Pre-eclampsia was defined by the presence of proteinurea (2+ protein on urine dipstick) and a single diastolic blood pressure reading of 100 millimiters of mercury (mm Hg) or above OR more than one reading, four hours apart, of 90 mm Hg or above. (NCT00486863)
Timeframe: 22 weeks and 32 weeks
| Intervention | participants (Number) |
|---|---|
| Placebo Control at 12-16 Weeks Gestation | 0 |
| Praziquantel at 12-16 Weeks Gestation | 0 |
Parasitologic response to treatment was evaluated by counting S. japonicum eggs per gram of stool at screening and again at 22 weeks gestation. Success of treatment was pre-specified as greater than 90 percent reduction in egg count from screening to 22 weeks gestation. (NCT00486863)
Timeframe: Screening and 22 weeks gestation
| Intervention | participants (Number) |
|---|---|
| Placebo Control at 12-16 Weeks Gestation | 92 |
| Praziquantel at 12-16 Weeks Gestation | 157 |
Since pregnancy is associated with increased cytochrome P450 activity and physiologic changes in the gastrointestinal tract that tend to reduce drug absorption, praziquantel pharmacokinetics may be affected by pregnancy. Thus, the metabolite-to-parent drug ratio may serve as a differential marker to help determine if variability in drug exposure following oral administration during pregnancy is due to altered metabolism or drug absorption. Samples that were collected from subjects who were randomized to receive praziquantel were analyzed for praziquantel and 4-hydroxy praziquantel concentrations. Assays were performed using high performance liquid chromatography-electrospray mass spectrometry in the University of California at San Diego Pediatric Clinical Pharmacology Laboratory. Descriptive statistics were obtained for concentrations at each of the four sparse sampling timepoints. (NCT00486863)
Timeframe: 4.5 and 8 hours after the first praziquantel dose (subjects assigned to an even study number) or 6 and 10 hours after the first praziquantel dose (subjects assigned to an odd study number).
| Intervention | ng/ml (Median) | |||
|---|---|---|---|---|
| 4.5 Hours, n=50 | 6 Hours, n=49 | 8 Hours, n=50 | 10 Hours, n=49 | |
| Praziquantel at 12-16 Weeks Gestation | 4020.1 | 4590.8 | 5373.7 | 4304.1 |
To assess total body iron, the serum transferrin receptor:ferritin ratio was assessed in the infant. At delivery, a heel stick blood sample and a cord blood sample were collected for assessment of total body iron by determination of the transferrin receptor:ferritin ratio. (NCT00486863)
Timeframe: 0-6 days after delivery.
| Intervention | ratio (Median) | |
|---|---|---|
| Cord Blood | Heel Stick | |
| Placebo Control at 12-16 Weeks Gestation | 1.76 | 0.00 |
| Praziquantel at 12-16 Weeks Gestation | 1.33 | 0.00 |
Toxicity to maternal kidney and liver was assessed by laboratory parameters collected just before and 24 hours after dosing. Specifically, blood was drawn just before the dose at 12-16 weeks gestation to determine baseline blood urea nitrogen (BUN), creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and bilirubin. Blood was then drawn 24 hours after the second part of the split dose and before discharge from the hospital to assess any changes in these parameters. Any values that were 1.1 times the upper limit of normal or greater for the parameter were considered abnormal. (NCT00486863)
Timeframe: Just before and 24 hours after dosing
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Blood Urea Nitrogen (BUN) Abnormal | Creatinine Abnormal | Aspartate Aminotransferase (AST) Abnormal | Alanine Aminotransferase (ALT) Abnormal | Bilirubin Abnormal | |
| Placebo Control at 12-16 Weeks Gestation | 127 | 23 | 8 | 13 | 127 |
| Praziquantel at 12-16 Weeks Gestation | 137 | 39 | 9 | 10 | 137 |
Toxicity to maternal bone marrow, kidney, and liver was assessed by laboratory parameters collected just before and 24 hours after dosing. Specifically, blood was drawn just before the dose at 12-16 weeks gestation to determine baseline complete blood count, including white blood count (WBC), platelets, and hemoglobin. Blood was then drawn 24 hours after the second part of the split dose and before discharge from the hospital to assess any changes in these parameters. White blood count was abnormal at or above 10,800 or at or below 3500 cells/square millimeter (sq mm), platelets were abnormal at or below 140,000 cells/sq mm, and hemoglobin was abnormal at or below 10.9 grams/deciliter (g/dL). (NCT00486863)
Timeframe: Just before and 24 hours after dosing
| Intervention | participants (Number) | ||
|---|---|---|---|
| White Blood Cell Abnormal | Platelets Abnormal | Hemoglobin Abnormal | |
| Placebo Control at 12-16 Weeks Gestation | 69 | 3 | 54 |
| Praziquantel at 12-16 Weeks Gestation | 60 | 0 | 56 |
Two plasma samples were collected during the overnight hospitalization from approximately 200 subjects that remained at the time of study modification to incorporate PK studies. Subjects had samples collected based on one of two sample collection strategies: 4.5 and 8 hr after the first praziquantel dose or 6 and 10 hr after the first praziquantel dose. Subjects randomized to an even study number were assigned to the 4.5 and 8 hour schedule. Subjects randomized to an odd study number were assigned to the 6 and 10 hour schedule. Samples only from subjects randomized to receive praziquantel were analyzed for praziquantel. Samples drawn from subjects randomized to the control group were not analyzed. Praziquantel concentrations (ng/ml) were assayed using high performance liquid chromatography-electrospray mass spectrometry in the University of California at San Diego Pediatric Clinical Pharmacology Laboratory. (NCT00486863)
Timeframe: 4.5 and 8 hours after the first praziquantel dose (subjects assigned to an even study number) or 6 and 10 hours after the first praziquantel dose (subjects assigned to an odd study number).
| Intervention | ng/mL (Median) | |||
|---|---|---|---|---|
| 4.5 Hours, n=50 | 6 Hours, n=49 | 8 Hours, n=50 | 10 Hours, n=49 | |
| Praziquantel at 12-16 Weeks Gestation | 814.7 | 945.2 | 687.8 | 422.2 |
158 reviews available for praziquantel and Bilharziasis
| Article | Year |
|---|---|
Drug associations as alternative and complementary therapy for neglected tropical diseases.
Topics: Complementary Therapies; Humans; Neglected Diseases; Pharmaceutical Preparations; Praziquantel; Schi | 2022 |
Schistosomiasis in Gabon from 2000 to 2021 - A review.
Topics: Coinfection; Gabon; Humans; Morbidity; Praziquantel; Schistosomiasis | 2022 |
Topics: Adult; Aging; Aluminum; Alzheimer Disease; Animals; Anti-Bacterial Agents; Artemisia annua; Body Mas | 2022 |
The Road to Elimination: Current State of Schistosomiasis Research and Progress Towards the End Game.
Topics: Animals; Neglected Diseases; Praziquantel; Schistosoma; Schistosomiasis; Vaccines | 2022 |
Review of 2022 WHO guidelines on the control and elimination of schistosomiasis.
Topics: Anthelmintics; Child; Child, Preschool; Helminthiasis; Humans; Mass Drug Administration; Praziquante | 2022 |
Improving translational power in antischistosomal drug discovery.
Topics: Animals; Drug Discovery; Mice; Praziquantel; Schistosoma mansoni; Schistosomiasis; Schistosomiasis m | 2022 |
Praziquantel: An update on the mechanism of its action against schistosomiasis and new therapeutic perspectives.
Topics: Adult; Animals; Anthelmintics; Humans; Praziquantel; Schistosoma; Schistosoma mansoni; Schistosomias | 2022 |
Praziquantel - 50 Years of Research.
Topics: Child; Humans; Praziquantel; Schistosomiasis; TRPM Cation Channels | 2023 |
Situation analysis of urogenital bilharzia in West Africa (2010-2021) and control strategies and prospects: systematic review and meta-analysis.
Topics: Africa, Western; Child; Humans; Praziquantel; Schistosomiasis | 2023 |
Perspective on Schistosomiasis Drug Discovery: Highlights from a Schistosomiasis Drug Discovery Workshop at Wellcome Collection, London, September 2022.
Topics: Animals; Anthelmintics; London; Praziquantel; Schistosoma; Schistosomiasis | 2023 |
Single-sex schistosomiasis: a mini review.
Topics: Animals; Female; Host-Parasite Interactions; Life Cycle Stages; Male; Mammals; Praziquantel; Schisto | 2023 |
Health-seeking behaviour regarding schistosomiasis treatment in the absence of a mass drug administration (MDA) program: the case of endemic communities along Lake Albert in Western Uganda.
Topics: Anthelmintics; Humans; Lakes; Mass Drug Administration; Patient Acceptance of Health Care; Praziquan | 2023 |
Schistosomal (bilharzial) polyps: Travel through the colon and beyond.
Topics: Colon; Humans; Polyps; Praziquantel; Schistosomiasis | 2023 |
Advances in new target molecules against schistosomiasis: A comprehensive discussion of physiological structure and nutrient intake.
Topics: Animals; Eating; Humans; Praziquantel; Schistosoma haematobium; Schistosoma japonicum; Schistosoma m | 2023 |
Defining schistosomiasis hotspots based on literature and shareholder interviews.
Topics: Animals; Anthelmintics; Praziquantel; Schistosoma haematobium; Schistosoma mansoni; Schistosomiasis | 2023 |
Therapeutic Potential of Natural Products in the Treatment of
Topics: Animals; Anthelmintics; Biological Products; Humans; Praziquantel; Schistosoma haematobium; Schistos | 2023 |
Differential impact of mass and targeted praziquantel delivery on schistosomiasis control in school-aged children: A systematic review and meta-analysis.
Topics: Animals; Child; Databases, Factual; Humans; Praziquantel; Prevalence; Schistosoma haematobium; Schis | 2019 |
The Journey to Discovering a Flatworm Target of Praziquantel: A Long TRP.
Topics: Animals; Anthelmintics; Ion Channels; Praziquantel; Schistosoma; Schistosomiasis | 2020 |
The role of microRNAs in the pathogenesis, grading and treatment of hepatic fibrosis in schistosomiasis.
Topics: Animals; Anthelmintics; Humans; Liver Cirrhosis; MicroRNAs; Praziquantel; Schistosoma; Schistosomias | 2019 |
Schistosomiasis then and now: what has changed in the last 100 years?
Topics: Animals; Carcinoma, Squamous Cell; Drug Resistance; History, 20th Century; History, 21st Century; Hu | 2020 |
Current and Novel Therapies Against Helminthic Infections: The Potential of Antioxidants Combined with Drugs.
Topics: Animals; Anthelmintics; Antioxidants; Drug Discovery; Drug Repositioning; Drug Therapy, Combination; | 2020 |
Spotlight on experiences of medicine unavailability: access to medicines challenges for NCDs and NTDs - the contrasting cases of insulin and praziquantel.
Topics: Anthelmintics; Diabetes Mellitus; Global Health; Health Services Accessibility; Humans; Hypoglycemic | 2020 |
Cost of interventions to control schistosomiasis: A systematic review of the literature.
Topics: Adolescent; Anthelmintics; Chemoprevention; Child; Communicable Disease Control; Cost-Benefit Analys | 2020 |
Schistosome TRP channels: An appraisal.
Topics: Animals; Anthelmintics; Genes, Helminth; Genome, Helminth; Humans; Ion Channels; Phylogeny; Praziqua | 2020 |
Schistosomiasis Consortium for Operational Research and Evaluation (SCORE): Its Foundations, Development, and Evolution.
Topics: Animals; Disease Reservoirs; Disease Vectors; History, 21st Century; Humans; Mass Drug Administratio | 2020 |
Contributions of the Schistosomiasis Consortium for Operational Research and Evaluation (SCORE) to Schistosomiasis Control and Elimination: Key Findings and Messages for Future Goals, Thresholds, and Operational Research.
Topics: Africa; Animals; Anthelmintics; Antigens, Helminth; Biomarkers; Child; Feces; Glycoproteins; Health | 2020 |
Lessons Learned in Conducting Mass Drug Administration for Schistosomiasis Control and Measuring Coverage in an Operational Research Setting.
Topics: Africa; Animals; Anthelmintics; Child; Child, Preschool; Female; Humans; Male; Mass Drug Administrat | 2020 |
Praziquantel: An Enigmatic, Yet Effective, Drug.
Topics: Animals; Humans; Models, Biological; Praziquantel; Schistosomiasis | 2020 |
Drug metabolism and pharmacokinetics of praziquantel: A review of variable drug exposure during schistosomiasis treatment in human hosts and experimental models.
Topics: Animals; Anthelmintics; Disease Models, Animal; Humans; Praziquantel; Schistosoma mansoni; Schistoso | 2020 |
A systematic review and meta-analysis on the rate of human schistosomiasis reinfection.
Topics: Animals; Biometry; Humans; Praziquantel; Reinfection; Schistosoma; Schistosomiasis | 2020 |
The use of non-pharmaceutical interventions for the prevention and control of schistosomiasis in sub-Saharan Africa: A systematic review.
Topics: Health Education; Humans; Pharmaceutical Preparations; Praziquantel; Sanitation; Schistosomiasis | 2022 |
Factors affecting the uptake of preventive chemotherapy treatment for schistosomiasis in Sub-Saharan Africa: A systematic review.
Topics: Africa South of the Sahara; Animals; Anthelmintics; Chemoprevention; Health Knowledge, Attitudes, Pr | 2021 |
Efficacy of praziquantel has been maintained over four decades (from 1977 to 2018): A systematic review and meta-analysis of factors influence its efficacy.
Topics: Animals; Anthelmintics; Humans; Parasite Egg Count; Praziquantel; Schistosoma; Schistosomiasis; Trea | 2021 |
Immunological Considerations for
Topics: Animals; Coinfection; Drug Design; Drug Development; Endemic Diseases; Host-Parasite Interactions; H | 2021 |
Synthesis and therapeutic delivery approaches for praziquantel: a patent review (2010-present).
Topics: Animals; Anthelmintics; Biological Availability; Drug Delivery Systems; Humans; Lipids; Medication A | 2021 |
Surgical management outcome of cerebral schistosomiasis: a case report and review of the literature.
Topics: Adult; Brain Diseases; Humans; Male; Praziquantel; Schistosomiasis; Schistosomiasis mansoni; Sudan; | 2021 |
Rational approach to drug discovery for human schistosomiasis.
Topics: Animals; Drug Discovery; Humans; Oxamniquine; Praziquantel; Schistosoma mansoni; Schistosomiasis | 2021 |
Prediction of antischistosomal small molecules using machine learning in the era of big data.
Topics: Artificial Intelligence; Bayes Theorem; Big Data; Humans; Machine Learning; Praziquantel; Schistosom | 2022 |
Influence of schistosomiasis on host vaccine responses.
Topics: Animals; Anthelmintics; Humans; Immunity; Praziquantel; Schistosoma; Schistosomiasis; Vaccines | 2022 |
Controlling schistosomiasis with praziquantel: How much longer without a viable alternative?
Topics: Animals; Anthelmintics; Antimalarials; Drug Repositioning; Drug Resistance; Drug Therapy, Combinatio | 2017 |
Putting the treatment of paediatric schistosomiasis into context.
Topics: Adolescent; Anthelmintics; Chemoprevention; Child; Child, Preschool; Drug Compounding; Humans; Pract | 2017 |
Putting the treatment of paediatric schistosomiasis into context.
Topics: Adolescent; Anthelmintics; Chemoprevention; Child; Child, Preschool; Drug Compounding; Humans; Pract | 2017 |
Putting the treatment of paediatric schistosomiasis into context.
Topics: Adolescent; Anthelmintics; Chemoprevention; Child; Child, Preschool; Drug Compounding; Humans; Pract | 2017 |
Putting the treatment of paediatric schistosomiasis into context.
Topics: Adolescent; Anthelmintics; Chemoprevention; Child; Child, Preschool; Drug Compounding; Humans; Pract | 2017 |
Pyrimidine metabolism in schistosomes: A comparison with other parasites and the search for potential chemotherapeutic targets.
Topics: Animals; Praziquantel; Pyrimidines; Schistosoma; Schistosomiasis; Schistosomicides | 2017 |
Schistosomiasis: Drugs used and treatment strategies.
Topics: Animals; Anthelmintics; Biomedical Research; Brazil; Child; Female; Humans; Neglected Diseases; Oxam | 2017 |
Acetylcholinesterase and Nicotinic Acetylcholine Receptors in Schistosomes and Other Parasitic Helminths.
Topics: Acetylcholinesterase; Animals; Anthelmintics; Drug Design; Drug Resistance; Helminths; Humans; Prazi | 2017 |
Paediatric and maternal schistosomiasis: shifting the paradigms.
Topics: Anthelmintics; Child; Communicable Diseases, Imported; Female; Humans; Praziquantel; Pregnancy; Preg | 2017 |
Systematic review of community-based, school-based, and combined delivery modes for reaching school-aged children in mass drug administration programs for schistosomiasis.
Topics: Chemoprevention; Child; Clinical Trials as Topic; Community Health Services; Delivery of Health Care | 2017 |
Antischistosomal agents: state of art and perspectives.
Topics: Animals; Anthelmintics; Humans; Parasitic Sensitivity Tests; Praziquantel; Schistosoma; Schistosomia | 2018 |
Some facts on south asian schistosomiasis and need for international collaboration.
Topics: Animals; Anthelmintics; Asia; Cattle; Communicable Disease Control; Female; Fresh Water; Humans; Ind | 2018 |
Cognitive deficits and educational loss in children with schistosome infection-A systematic review and meta-analysis.
Topics: Adolescent; Animals; Anthelmintics; Child; Child, Preschool; Cognition; Cognitive Dysfunction; Human | 2018 |
Pharmacological and immunological effects of praziquantel against Schistosoma japonicum: a scoping review of experimental studies.
Topics: Animals; Drug Resistance; Humans; Life Cycle Stages; Mice; Praziquantel; Schistosoma japonicum; Schi | 2018 |
[Schistosomiasis].
Topics: Cross-Sectional Studies; Diagnosis, Differential; Drug Administration Schedule; Eosinophilia; Humans | 2017 |
Efficacy of praziquantel treatment regimens in pre-school and school aged children infected with schistosomiasis in sub-Saharan Africa: a systematic review.
Topics: Africa South of the Sahara; Animals; Anthelmintics; Child; Child, Preschool; Humans; Praziquantel; S | 2018 |
Acting beyond 2020: better characterization of praziquantel and promising antischistosomal leads.
Topics: Drug Discovery; Female; Humans; Praziquantel; Pregnancy; Schistosomiasis; Schistosomicides | 2018 |
Schistosomiasis.
Topics: Animals; Anthelmintics; Enzyme-Linked Immunosorbent Assay; Humans; Praziquantel; Schistosoma haemato | 2018 |
TRP channels as potential targets for antischistosomals.
Topics: Animals; Anthelmintics; Drug Delivery Systems; Host-Parasite Interactions; Humans; Mice; Praziquante | 2018 |
Population level changes in schistosome-specific antibody levels following chemotherapy.
Topics: Animals; Anthelmintics; Antibodies, Helminth; Humans; Immunity, Humoral; Praziquantel; Schistosoma h | 2019 |
PZQ Therapy: How Close are we in the Development of Effective Alternative Anti-schistosomal Drugs?
Topics: Animals; Anthelmintics; Global Health; History, 20th Century; History, 21st Century; Humans; Praziqu | 2019 |
The Advances in Molecular and New Point-of-Care (POC) Diagnosis of Schistosomiasis Pre- and Post-praziquantel Use: In the Pursuit of More Reliable Approaches for Low Endemic and Non-endemic Areas.
Topics: Anthelmintics; Antigens, Helminth; Humans; Neglected Diseases; Point-of-Care Systems; Praziquantel; | 2019 |
High-dose or multi-day praziquantel for imported schistosomiasis? A systematic review.
Topics: Anthelmintics; Dose-Response Relationship, Drug; Global Health; Humans; Incidence; Praziquantel; Sch | 2019 |
Schistosomiasis in African infants and preschool children: let them now be treated!
Topics: Africa; Animals; Anthelmintics; Child, Preschool; Humans; Infant; Praziquantel; Prevalence; Public H | 2013 |
New approaches for understanding mechanisms of drug resistance in schistosomes.
Topics: Animals; ATP-Binding Cassette Transporters; Chromosome Mapping; Drug Resistance; Genomics; Helminth | 2013 |
Schistosomiasis chemotherapy.
Topics: Animals; Drug Resistance; Hemeproteins; Hemoglobins; Humans; Imidazoles; Lucanthone; Niacin; Oxadiaz | 2013 |
Advocacy, policies and practicalities of preventive chemotherapy campaigns for African children with schistosomiasis.
Topics: Africa; Anthelmintics; Child; Disease Eradication; Epidemiological Monitoring; Humans; Praziquantel; | 2013 |
[Progress of research on preparation and application of praziquantel].
Topics: Animals; Anthelmintics; Humans; Praziquantel; Schistosomiasis | 2013 |
Diagnosis and treatment of schistosomiasis in children in the era of intensified control.
Topics: Anthelmintics; Child; Child, Preschool; Disease Eradication; Humans; Praziquantel; Schistosomiasis | 2013 |
The little we know about the pharmacokinetics and pharmacodynamics of praziquantel (racemate and R-enantiomer).
Topics: Anthelmintics; Humans; Praziquantel; Schistosomiasis; Stereoisomerism | 2014 |
Schistosomiasis control: praziquantel forever?
Topics: Animals; Drug Discovery; Drug Resistance; Humans; Praziquantel; Schistosoma; Schistosomiasis; Schist | 2014 |
Diagnostics for schistosomiasis in Africa and Arabia: a review of present options in control and future needs for elimination.
Topics: Africa; Animals; Anthelmintics; Diagnostic Tests, Routine; Disease Eradication; Female; Humans; Male | 2014 |
The roles of water, sanitation and hygiene in reducing schistosomiasis: a review.
Topics: Animals; Child; Fresh Water; Global Health; Humans; Hygiene; Male; Praziquantel; Sanitation; Schisto | 2015 |
Schistosomiasis in Egypt: A never-ending story?
Topics: Animals; Anthelmintics; Antigens, Helminth; Egypt; Humans; Praziquantel; Public Health; Schistosoma; | 2015 |
Toward organometallic antischistosomal drug candidates.
Topics: Animals; Antifungal Agents; Antimalarials; Drug Discovery; Drug Repositioning; Humans; Organometalli | 2015 |
Spatial distribution of schistosomiasis and treatment needs in sub-Saharan Africa: a systematic review and geostatistical analysis.
Topics: Adolescent; Africa South of the Sahara; Animals; Bayes Theorem; Child; Child, Preschool; Health Serv | 2015 |
Toward Measuring Schistosoma Response to Praziquantel Treatment with Appropriate Descriptors of Egg Excretion.
Topics: Animals; Data Interpretation, Statistical; Feces; Linear Models; Outcome Assessment, Health Care; Ov | 2015 |
[Activity of NTDs Drug-discovery Research Consortium].
Topics: Antiprotozoal Agents; Drug Compounding; Drug Discovery; Health Services Accessibility; Humans; Negle | 2016 |
Schistosomiasis Prevalence and Intensity of Infection in Latin America and the Caribbean Countries, 1942-2014: A Systematic Review in the Context of a Regional Elimination Goal.
Topics: Anthelmintics; Disease Eradication; Humans; Latin America; Praziquantel; Schistosomiasis | 2016 |
Getting a GRiPP on everyday schistosomiasis: experience from Zimbabwe.
Topics: Child; Communicable Disease Control; Humans; Praziquantel; Schistosomiasis; Schistosomicides; School | 2017 |
Schistosomiasis: Traverers in Africa.
Topics: Africa; Animals; Anthelmintics; DEET; Humans; Insect Repellents; Life Cycle Stages; Military Personn | 2016 |
Human schistosomiasis in the post mass drug administration era.
Topics: Africa South of the Sahara; Animals; Anthelmintics; Humans; Praziquantel; Schistosoma; Schistosomias | 2017 |
Efficacy and safety of praziquantel 40 mg/kg in preschool-aged and school-aged children: a meta-analysis.
Topics: Anthelmintics; Child; Child, Preschool; Female; Humans; Male; Praziquantel; Schistosomiasis | 2017 |
Decline in infection-related morbidities following drug-mediated reductions in the intensity of Schistosoma infection: A systematic review and meta-analysis.
Topics: Animals; Anthelmintics; Humans; Praziquantel; Schistosoma; Schistosomiasis | 2017 |
Praziquantel for Schistosomiasis: Single-Drug Metabolism Revisited, Mode of Action, and Resistance.
Topics: Africa South of the Sahara; Animals; Drug Resistance; Humans; Praziquantel; Schistosoma; Schistosomi | 2017 |
Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis.
Topics: Africa; Animals; Anthelmintics; Artemisinins; Drug Resistance; Enzyme Inhibitors; Humans; Praziquant | 2008 |
Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs.
Topics: Africa South of the Sahara; Drug Resistance; Humans; Praziquantel; Schistosomiasis; Schistosomicides | 2009 |
Acute schistosomiasis, a diagnostic and therapeutic challenge.
Topics: Adrenal Cortex Hormones; Antibodies, Protozoan; Antiprotozoal Agents; Drug Interactions; Eosinophili | 2010 |
Better understanding of anti-schistosomal strategies through microarray analysis.
Topics: Animals; Drug Resistance; Humans; Microarray Analysis; Praziquantel; Schistosoma; Schistosomiasis; S | 2010 |
Controlling schistosomiasis in Southeast Asia: a tale of two countries.
Topics: Animals; Anthelmintics; China; Humans; Incidence; Medication Adherence; Philippines; Praziquantel; S | 2010 |
Schistosoma mekongi in Cambodia and Lao People's Democratic Republic.
Topics: Animals; Anthelmintics; Cambodia; Communicable Disease Control; Education; Humans; Incidence; Laos; | 2010 |
Praziquantel and schistosomiasis.
Topics: Animals; Anthelmintics; Glutathione Transferase; Praziquantel; Schistosomiasis; Stereoisomerism; Str | 2010 |
Eosinophilic appendicitis caused by Schistosoma japonicum: a case report and review of the literature.
Topics: Anthelmintics; Appendectomy; Appendicitis; Combined Modality Therapy; Eosinophilia; Female; Humans; | 2010 |
Pulmonary vascular disease associated with schistosomiasis.
Topics: Animals; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Portal; Hypertension | 2010 |
Macromolecular bases of antischistosomal therapy.
Topics: Acetylcholinesterase; Animals; Auranofin; Crystallography, X-Ray; Cyclophilins; Drug Design; Enzyme | 2011 |
Schistosomiasis: from drug deployment to drug development.
Topics: Anthelmintics; Drug Delivery Systems; Drug Design; Drug Resistance; Humans; Praziquantel; Schistosom | 2011 |
Utility of repeated praziquantel dosing in the treatment of schistosomiasis in high-risk communities in Africa: a systematic review.
Topics: Adolescent; Adult; Africa; Animals; Anthelmintics; Child; Child, Preschool; Humans; Middle Aged; Pra | 2011 |
New insight into praziquantel against various developmental stages of schistosomes.
Topics: Animals; Humans; Praziquantel; Schistosoma; Schistosomiasis; Schistosomicides | 2011 |
Efficacy of praziquantel and artemisinin derivatives for the treatment and prevention of human schistosomiasis: a systematic review and meta-analysis.
Topics: Animals; Artemisinins; Dose-Response Relationship, Drug; Humans; Praziquantel; Randomized Controlled | 2011 |
[Advances in research on antischistosomal drugs].
Topics: Animals; Biomedical Research; Drug Discovery; Humans; Praziquantel; Schistosoma; Schistosomiasis; Sc | 2011 |
Schistosomiasis in infants and pre-school-aged children in sub-Saharan Africa: implication for control.
Topics: Adult; Africa South of the Sahara; Animals; Anthelmintics; Child; Child, Preschool; Female; Health E | 2012 |
Schistosomiasis.
Topics: Acute Disease; Animals; Anthelmintics; Chronic Disease; Humans; Praziquantel; Sanitation; Schistosom | 2012 |
Acute pulmonary schistosomiasis in travelers: case report and review of the literature.
Topics: Acute Disease; Adult; Animals; Anthelmintics; Humans; Lung Diseases, Parasitic; Madagascar; Male; Pr | 2012 |
Systematic review and meta-analysis of artemisinin based therapies for the treatment and prevention of schistosomiasis.
Topics: Antiprotozoal Agents; Artemisinins; Clinical Trials as Topic; Drug Combinations; Drug Therapy, Combi | 2012 |
Susceptibility or resistance of praziquantel in human schistosomiasis: a review.
Topics: Animals; Anthelmintics; Disease Models, Animal; Drug Resistance; Humans; Mice; Praziquantel; Schisto | 2012 |
Epidemiology and control of human schistosomiasis in Tanzania.
Topics: Animals; Anthelmintics; Disease Vectors; Endemic Diseases; Humans; Morbidity; Praziquantel; Prevalen | 2012 |
Ca²⁺ channels and praziquantel: a view from the free world.
Topics: Animals; Anthelmintics; Calcium Channels; Calcium Signaling; Helminthiasis; Homeostasis; Planarians; | 2013 |
The evolution of drugs on schistosoma treatment: looking to the past to improve the future.
Topics: Animals; Anthelmintics; Antigens; Drug Design; Humans; Organophosphates; Peptide Hydrolases; Peroxir | 2013 |
Schistosomiasis: from risk assessment to control.
Topics: Adolescent; Adult; Animals; Anthelmintics; Endemic Diseases; Female; Genital Diseases, Female; Human | 2002 |
Combination chemotherapy of schistosomiasis in laboratory studies and clinical trials.
Topics: Animals; Artemisinins; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Oxamniquine; Pra | 2003 |
Administration of praziquantel to pregnant and lactating women.
Topics: Anthelmintics; Female; Humans; Lactation; Praziquantel; Pregnancy; Schistosomiasis | 2003 |
Praziquantel.
Topics: Animals; Drug Resistance; Humans; Praziquantel; Schistosoma; Schistosomiasis; Schistosomicides | 2003 |
Drugs for the control of parasitic diseases: current status and development in schistosomiasis.
Topics: Animals; Drug Resistance; Humans; Oxamniquine; Praziquantel; Public Health; Schistosoma; Schistosomi | 2003 |
[Portal hypertension and schistosomiasis: "an originally killing entity"].
Topics: Anthelmintics; Humans; Hypertension, Portal; Liver; Praziquantel; Prognosis; Schistosomiasis | 2003 |
Schistosomiasis vaccines.
Topics: Animals; Anthelmintics; Antigens, Helminth; Clinical Trials as Topic; Combined Modality Therapy; Hum | 2003 |
Schistosomiasis control: keep taking the tablets.
Topics: Administration, Oral; Animals; Drug Resistance; Humans; Parasitic Sensitivity Tests; Praziquantel; S | 2004 |
Immunoregulation and World Health Assembly resolution 54.19: why does treatment control morbidity?
Topics: Animals; Anthelmintics; Helminthiasis; Humans; Morbidity; Praziquantel; Schistosomiasis; Treatment O | 2004 |
Towards control of schistosomiasis in sub-Saharan Africa.
Topics: Africa South of the Sahara; Anthelmintics; Artemether; Artemisinins; Cameroon; Child; Endemic Diseas | 2005 |
[Research progress of the evaluation methods on the resistance of schistosome to praziquantel].
Topics: Animals; Anthelmintics; Drug Resistance; Humans; Praziquantel; Schistosoma; Schistosomiasis | 2005 |
Praziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance.
Topics: Animals; Anthelmintics; Drug Resistance; Endemic Diseases; Humans; Praziquantel; Schistosomiasis | 2006 |
Schistosomiasis--a century searching for chemotherapeutic drugs.
Topics: Animals; Drug Therapy, Combination; Humans; Praziquantel; Schistosoma; Schistosomiasis; Schistosomic | 2006 |
Implementation of human schistosomiasis control: Challenges and prospects.
Topics: Albendazole; Animals; Anthelmintics; Fresh Water; Global Health; Health Education; Humans; National | 2006 |
Human schistosomiasis.
Topics: Animals; Anthelmintics; Female; Humans; Male; Praziquantel; Schistosoma; Schistosomiasis | 2006 |
Schistosomiasis: challenges for control, treatment and drug resistance.
Topics: Adult; Animals; Child; Communicable Disease Control; Drug Resistance; Humans; Praziquantel; Quality | 2006 |
Katayama syndrome.
Topics: Animals; Artemisinins; Humans; Praziquantel; Schistosoma; Schistosomiasis; Schistosomicides; Sesquit | 2007 |
Schistosomiasis and pregnancy.
Topics: Animals; Female; Genitalia, Female; Humans; Mice; Morbidity; Placenta; Praziquantel; Pregnancy; Preg | 2007 |
Chemotherapy of schistosomiasis: present and future.
Topics: Animals; Antiparasitic Agents; Artemisinins; Humans; Praziquantel; Schistosomiasis; Thiosulfates | 2007 |
[Study progress on the mode of action of praziquantel against schistosomes].
Topics: Animals; Humans; Mice; Praziquantel; Schistosoma; Schistosomiasis; Schistosomicides | 2007 |
[Present status of the treatment of helminthiasis].
Topics: Albendazole; Anthelmintics; Benzimidazoles; Cestode Infections; Echinococcosis; Helminthiasis; Human | 1984 |
Schistosoma mansoni: the effects of a subcurative dose of praziquantel on the ultrastructure of worms in vivo.
Topics: Animals; Biomphalaria; Dose-Response Relationship, Drug; Isoquinolines; Mice; Mice, Inbred Strains; | 1983 |
Human schistosomiasis and its management.
Topics: Animals; Humans; Hycanthone; Oxamniquine; Praziquantel; Schistosoma; Schistosomiasis; Trichlorfon | 1984 |
A summary of the efficacy of praziquantel against schistosomes in animal experiments and notes on its mode of action.
Topics: Animals; Humans; Isoquinolines; Praziquantel; Schistosoma; Schistosoma mansoni; Schistosomiasis; Spe | 1981 |
Schistosomiasis: clinical features and relevance to hematology.
Topics: Anemia; Animals; Blood Coagulation Disorders; Eosinophilia; Humans; Mice; Niridazole; Oxamniquine; P | 1982 |
Involvement of inflammatory reactions and elevated cell proliferation in the development of bladder cancer in schistosomiasis patients.
Topics: Cell Division; DNA Damage; Humans; Inflammation; Micronucleus Tests; Praziquantel; Schistosomiasis; | 1994 |
Schistosomiasis research and the European Community.
Topics: Clinical Trials as Topic; Disease Models, Animal; European Union; Forecasting; Glutathione Transfera | 1994 |
Schistosomiasis.
Topics: Adult; Animals; Female; Hepatitis B; HIV Infections; Humans; Male; Neoplasms; Oxamniquine; Praziquan | 1993 |
[Bilharziasis caused by Schistosoma intercalatum, a recent and forgotten form of schistosomiasis].
Topics: Animals; Cameroon; Gabon; Humans; Praziquantel; Schistosoma; Schistosomiasis | 1993 |
[Acute form of primary bilharziasis].
Topics: Acute Disease; Humans; Praziquantel; Prognosis; Schistosomiasis | 1993 |
Cardiopulmonary manifestations of schistosomiasis.
Topics: Antiplatyhelmintic Agents; Heart Diseases; Humans; Hypertension, Portal; Liver Cirrhosis; Lung Disea | 1997 |
The development of resistance to anthelmintics: a perspective with an emphasis on the antischistosomal drug praziquantel.
Topics: Animals; Anthelmintics; Antiplatyhelmintic Agents; Drug Resistance; Humans; Mice; Praziquantel; Publ | 1997 |
Genotoxic activity of praziquantel.
Topics: Animals; Antiplatyhelmintic Agents; Carcinogenicity Tests; Carcinogens; Clinical Trials as Topic; Cr | 1997 |
[Schistosoma intercalatum bilharziasis: clinical and epidemiological considerations].
Topics: Abortion, Spontaneous; Africa South of the Sahara; Animals; Antiplatyhelmintic Agents; Female; Gastr | 1997 |
[Schistosomiasis].
Topics: Animals; Diagnosis, Differential; Humans; Praziquantel; Schistosoma; Schistosomiasis; Schistosomicid | 1999 |
[Schistosomiasis (intestinal, hepatic, urinary tract)].
Topics: Diagnosis, Differential; Humans; Intestinal Diseases, Parasitic; Liver Diseases, Parasitic; Praziqua | 1999 |
Community-wide treatment of schistosomiasis with praziquantel.
Topics: Developing Countries; Humans; Praziquantel; Schistosomiasis; Schistosomicides; United Kingdom | 1999 |
Evolution of schistosomiasis-induced pathology after therapy and interruption of exposure to schistosomes: a review of ultrasonographic studies.
Topics: Adolescent; Adult; Aged; Animals; Anthelmintics; Child; Female; Follow-Up Studies; Gallbladder; Huma | 2000 |
Drug treatment of tropical parasitic infections: recent achievements and developments.
Topics: Anthelmintics; Benzimidazoles; Diethylcarbamazine; Helminthiasis; Humans; Ivermectin; Malaria; Paras | 2000 |
Index of potential contamination for schistosomiasis.
Topics: Adolescent; Adult; Animals; Anthelmintics; Child; Child, Preschool; Environment; Female; Humans; Inf | 2001 |
Schistosomiasis epidemiology and control: how did we get here and where should we go?
Topics: Adolescent; Adult; Animals; Anthelmintics; Child; Child, Preschool; Humans; Infant; Infant, Newborn; | 2001 |
The potential of artemether for the control of schistosomiasis.
Topics: Animals; Artemether; Artemisinins; Cricetinae; Drugs, Chinese Herbal; Humans; Mice; Praziquantel; Ra | 2001 |
Schistosomiasis.
Topics: Animals; Artemether; Artemisinins; Drug Therapy, Combination; Feces; Humans; Life Cycle Stages; Ovum | 2002 |
Recent investigations of artemether, a novel agent for the prevention of schistosomiasis japonica, mansoni and haematobia.
Topics: Administration, Oral; Animals; Artemether; Artemisinins; Drug Resistance; Drug Therapy, Combination; | 2002 |
Vaccine strategies against schistosomiasis.
Topics: Animals; Antibodies, Helminth; Antibody-Dependent Cell Cytotoxicity; Antigens, Helminth; Disease Mod | 1992 |
Acute transverse myelitis in a 6-year-old girl with schistosomiasis.
Topics: Acute Disease; Child; Diagnosis, Differential; Female; Humans; Incidence; Myelitis; Myelitis, Transv | 1990 |
Exudative polyserositis and acute respiratory failure following praziquantel therapy.
Topics: Adult; Humans; Male; Praziquantel; Respiratory Insufficiency; Schistosomiasis; Serositis | 1990 |
Drugs five years later: praziquantel.
Topics: Animals; Brain Diseases; Costs and Cost Analysis; Cysticercosis; Echinococcosis; Humans; Praziquante | 1989 |
Schistosomiasis in childhood.
Topics: Child; Child, Preschool; Europe; Humans; Praziquantel; Schistosomiasis; Travel | 1988 |
Recent advances in schistosomiasis.
Topics: Adolescent; Child; Humans; Oxamniquine; Parasite Egg Count; Praziquantel; Schistosomiasis; Serologic | 1986 |
Praziquantel for the treatment of helminthic infections.
Topics: Animals; Cestode Infections; Helminthiasis; Humans; Kinetics; Praziquantel; Schistosomiasis; Tremato | 1987 |
The chemotherapy of schistosomiasis.
Topics: Animals; Chemical Phenomena; Chemistry; Diphenylamine; Humans; Hycanthone; Isothiocyanates; Niridazo | 1985 |
Management of hepatic schistosomiasis.
Topics: Acute Disease; Animals; Central Nervous System; Child; Chronic Disease; Colon; Diagnosis, Differenti | 1985 |
Praziquantel: mechanisms of anti-schistosomal activity.
Topics: Animals; Humans; Kinetics; Muscle Contraction; Praziquantel; Schistosoma; Schistosomiasis; Schistoso | 1985 |
56 trials available for praziquantel and Bilharziasis
| Article | Year |
|---|---|
Effectiveness of Four Different Interventions Against Schistosoma haematobium in a Seasonal Transmission Setting of Côte d'Ivoire: A Cluster Randomized Trial.
Topics: Animals; Child; Cote d'Ivoire; Humans; Praziquantel; Prevalence; Schistosoma haematobium; Schistosom | 2022 |
A cluster randomized controlled trial for assessing POC-CCA test based praziquantel treatment for schistosomiasis control in pregnant women and their young children: study protocol of the freeBILy clinical trial in Madagascar.
Topics: Anthelmintics; Antigens, Helminth; Child, Preschool; Clinical Trials, Phase III as Topic; Female; Hu | 2021 |
Efficacy, safety, and palatability of arpraziquantel (L-praziquantel) orodispersible tablets in children aged 3 months to 6 years infected with Schistosoma in Côte d'Ivoire and Kenya: an open-label, partly randomised, phase 3 trial.
Topics: Animals; Anthelmintics; Child, Preschool; Cote d'Ivoire; Female; Humans; Kenya; Male; Praziquantel; | 2023 |
Correlates of prior HIV testing and schistosomiasis treatment: Baseline survey findings from the "creating demand for fishermen's schistosomiasis HIV services" (FISH) cluster-randomized trial in Mangochi, Malawi.
Topics: HIV Infections; HIV Testing; Humans; Malawi; Praziquantel; Schistosomiasis; Surveys and Questionnair | 2023 |
SCHISTOACT: a protocol for an open-label, five-arm, non-inferiority, individually randomized controlled trial of the efficacy and safety of praziquantel plus artemisinin-based combinations in the treatment of Schistosoma mansoni infection.
Topics: Adult; Animals; Anthelmintics; Artemisinins; Artesunate; Child; Drug Therapy, Combination; Equivalen | 2023 |
Challenges in Protocol Development and Interpretation of the Schistosomiasis Consortium for Operational Research and Evaluation Intervention Studies.
Topics: Africa South of the Sahara; Animals; Anthelmintics; Drug Administration Schedule; Humans; Mass Drug | 2020 |
Population Pharmacokinetics of Praziquantel in Pregnant and Lactating Filipino Women Infected with Schistosoma japonicum.
Topics: Animals; Anthelmintics; Female; Humans; Lactation; Philippines; Praziquantel; Pregnancy; Schistosoma | 2020 |
Anthelminthic treatment receipt and its predictors in Lake Victoria fishing communities, Uganda: Intervention coverage results from the LaVIISWA cluster randomised trial.
Topics: Adolescent; Adult; Albendazole; Animals; Anthelmintics; Child; Child, Preschool; Female; Humans; Inf | 2020 |
Effectiveness of school-based preventive chemotherapy strategies for sustaining the control of schistosomiasis in Côte d'Ivoire: Results of a 5-year cluster randomized trial.
Topics: Animals; Chemoprevention; Child; Child, Preschool; Cote d'Ivoire; Cross-Sectional Studies; Feces; Fe | 2021 |
Comparative palatability of orally disintegrating tablets (ODTs) of Praziquantel (L-PZQ and Rac-PZQ) versus current PZQ tablet in African children: A randomized, single-blind, crossover study.
Topics: Administration, Oral; Anthelmintics; Child; Cross-Over Studies; Dosage Forms; Female; Humans; Male; | 2021 |
A Persistent Hotspot of Schistosoma mansoni Infection in a Five-Year Randomized Trial of Praziquantel Preventative Chemotherapy Strategies.
Topics: Adult; Animals; Child; Child, Preschool; Cross-Sectional Studies; Geographic Mapping; Humans; Kenya; | 2017 |
Interrupting seasonal transmission of Schistosoma haematobium and control of soil-transmitted helminthiasis in northern and central Côte d'Ivoire: a SCORE study protocol.
Topics: Adult; Albendazole; Animals; Anthelmintics; Child; Child, Preschool; Cluster Analysis; Cote d'Ivoire | 2018 |
[Efficacy of repeated application of praziquantel in treatment of hepatic fibrosis due to schistosomiasis].
Topics: Humans; Liver; Liver Cirrhosis; Praziquantel; Schistosomiasis | 2016 |
Repeated doses of Praziquantel in Schistosomiasis Treatment (RePST) - single versus multiple praziquantel treatments in school-aged children in Côte d'Ivoire: a study protocol for an open-label, randomised controlled trial.
Topics: Adolescent; Anthelmintics; Child; Child, Preschool; Cote d'Ivoire; Humans; Praziquantel; Schistosomi | 2018 |
Maternal anemia type during pregnancy is associated with anemia risk among offspring during infancy.
Topics: Anemia; Anthelmintics; Antigens, CD; C-Reactive Protein; Female; Ferritins; Hemoglobins; Hepcidins; | 2019 |
Persistent Hotspots in Schistosomiasis Consortium for Operational Research and Evaluation Studies for Gaining and Sustaining Control of Schistosomiasis after Four Years of Mass Drug Administration of Praziquantel.
Topics: Africa; Animals; Anthelmintics; Chemoprevention; Child; Cross-Sectional Studies; Humans; Mass Drug A | 2019 |
Effectiveness of a pre-treatment snack on the uptake of mass treatment for schistosomiasis in Uganda: a cluster randomized trial.
Topics: Adolescent; Child; Confidence Intervals; Female; Humans; Logistic Models; Male; Odds Ratio; Praziqua | 2014 |
Mass drug administration with praziquantel reduces the prevalence of Schistosoma mansoni and improves liver morbidity in untreated preschool children.
Topics: Administration, Oral; Animals; Anthelmintics; Chemoprevention; Child; Child, Preschool; Drug Adminis | 2014 |
Reduced uptake of mass treatment for schistosomiasis control in absence of food: beyond a randomized trial.
Topics: Abdominal Pain; Adolescent; Child; Cross-Sectional Studies; Demography; Diarrhea; Dizziness; Eating; | 2015 |
Efficacy and safety of praziquantel for the treatment of human schistosomiasis during pregnancy: a phase 2, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Anthelmintics; Birth Weight; Double-Blind Method; Female; Fetus; Gestational Age; Humans; Inf | 2016 |
Comparative Assessment of Health Benefits of Praziquantel Treatment of Urogenital Schistosomiasis in Preschool and Primary School-Aged Children.
Topics: Animals; Biomarkers; Child; Child, Preschool; Cohort Studies; Demography; Dose-Response Relationship | 2016 |
Controlling schistosomiasis: significant decrease of anaemia prevalence one year after a single dose of praziquantel in Nigerian schoolchildren.
Topics: Anemia; Anthelmintics; Child; Female; Humans; Male; Nigeria; Praziquantel; Schistosomiasis; Treatmen | 2008 |
Schistosomiasis and infection with human immunodeficiency virus 1 in rural Zimbabwe: systemic inflammation during co-infection and after treatment for schistosomiasis.
Topics: Adolescent; Adult; Cohort Studies; Cross-Sectional Studies; Cytokines; Female; HIV Infections; HIV-1 | 2008 |
A randomised controlled clinical trial on the safety of co-administration of albendazole, ivermectin and praziquantel in infected schoolchildren in Uganda.
Topics: Adolescent; Albendazole; Animals; Antiparasitic Agents; Child; Child, Preschool; Cost-Benefit Analys | 2011 |
Efficacy of praziquantel against Schistosoma mekongi and Opisthorchis viverrini: a randomized, single-blinded dose-comparison trial.
Topics: Adolescent; Animals; Anthelmintics; Child; Female; Humans; Laos; Male; Opisthorchiasis; Opisthorchis | 2012 |
Schistosomiasis and HIV-1 infection in rural Zimbabwe: effect of treatment of schistosomiasis on CD4 cell count and plasma HIV-1 RNA load.
Topics: Adult; Anthelmintics; CD4 Lymphocyte Count; Drug Administration Schedule; Female; HIV Infections; HI | 2005 |
Effectiveness of praziquantel against the South African strains of Schistosoma haematobium and S. mansoni.
Topics: Adolescent; Child; Clinical Trials as Topic; Feces; Female; Follow-Up Studies; Humans; Isoquinolines | 1983 |
Long-term efficacy of single-dose oral treatment in schistosomiasis haematobium.
Topics: Administration, Oral; Adolescent; Child; Child, Preschool; Clinical Trials as Topic; Double-Blind Me | 1984 |
The profile of the trematodicidal compound praziquantel.
Topics: Clinical Trials as Topic; Echinococcosis; Humans; Isoquinolines; Kinetics; Liver Diseases, Parasitic | 1984 |
Phase III clinical trials with praziquantel in S. japonicum infections in the Philippines.
Topics: Adolescent; Adult; Aged; Child; Clinical Trials as Topic; Female; Humans; Isoquinolines; Male; Middl | 1984 |
Randomized comparative trials of single doses of the newer antischistosomal drugs at Mwanza, Tanzania. I. Praziquantel and oxamniquine for the treatment of schistosomiasis mansoni.
Topics: Adolescent; Child; Clinical Trials as Topic; Feces; Female; Humans; Isoquinolines; Male; Nitroquinol | 1984 |
Experiences with praziquantel against Schistosoma japonicum infection in the Philippines.
Topics: Adolescent; Adult; Child; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Evaluatio | 1984 |
Single dose oral treatment in urinary schistosomiasis: a double blind trial.
Topics: Administration, Oral; Adolescent; Child; Clinical Trials as Topic; Double-Blind Method; Drug Combina | 1983 |
Further experience with praziquantel in schistosoma japonicum infections.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Drug Tolerance; Female; Humans; Isoquinolines; Ma | 1984 |
Comparative trial of oltipraz versus praziquantel in the treatment of urinary schistosomiasis in the Gabon.
Topics: Adolescent; Child; Female; Gabon; Humans; Isoquinolines; Male; Parasite Egg Count; Praziquantel; Pyr | 1984 |
Comparative study of oltipraz versus praziquantel for treatment of schistosomiasis with intestinal manifestation in the Gabon (Schistosoma intercalatum and S. haematobium).
Topics: Adolescent; Child; Child, Preschool; Feces; Female; Gabon; Humans; Intestinal Diseases, Parasitic; I | 1984 |
A field trial using praziquantel (BiltricideR) to treat Schistosoma mansoni and Schistosoma haematobium infection in Gezira, Sudan.
Topics: Adolescent; Adult; Child; Drug Administration Schedule; Female; Humans; Isoquinolines; Male; Middle | 1983 |
Treatment of Schistosoma mekongi with praziquantel: a double-blind study.
Topics: Adolescent; Adult; Child; Child, Preschool; Clinical Trials as Topic; Double-Blind Method; Female; H | 1982 |
Praziquantel--a new antiparasitic drug.
Topics: Cestode Infections; Clinical Trials as Topic; Humans; Isoquinolines; Praziquantel; Schistosomiasis; | 1982 |
A comparative trial of praziquantel, metrifonate and niridazole against Schistosoma haematobium.
Topics: Humans; Isoquinolines; Niridazole; Praziquantel; Random Allocation; Schistosoma haematobium; Schisto | 1983 |
Trial designs for multicentre clinical studies of investigational phases I B to III with praziquantel.
Topics: Clinical Trials as Topic; Drug Evaluation; Humans; Isoquinolines; Praziquantel; Research Design; Sch | 1981 |
Clinical experience with praziquantel in the treatment of Nigerian patients infected with S. haematobium.
Topics: Child; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Isoquinolines; Male; Nigeria; | 1981 |
Praziquantel in the treatment of mixed S. haematobium and S. mansoni infections.
Topics: Female; Humans; Isoquinolines; Male; Praziquantel; Schistosoma haematobium; Schistosoma mansoni; Sch | 1981 |
Praziquantel compared to niridazole in schistosomiasis intercalatum therapy.
Topics: Adolescent; Adult; Animals; Child; Feces; Female; Gabon; Humans; Isoquinolines; Male; Niridazole; Pa | 1981 |
Reversibility of lower reproductive tract abnormalities in women with Schistosoma haematobium infection after treatment with praziquantel--an interim report.
Topics: Adolescent; Adult; Animals; Antibodies, Helminth; Antigens, Helminth; Antiplatyhelmintic Agents; Bio | 1996 |
Double-blind placebo-controlled study of concurrent administration of albendazole and praziquantel in schoolchildren with schistosomiasis and geohelminths.
Topics: Adolescent; Albendazole; Child; Double-Blind Method; Drug Therapy, Combination; Female; Helminthiasi | 1999 |
Efficacy of praziquantel in treating natural schistosome infections in common mergansers.
Topics: Animals; Anthelmintics; Bird Diseases; Birds; Dose-Response Relationship, Drug; Michigan; Parasite E | 2001 |
Initial experiences with praziquantel in the treatment of human infections due to Schistosoma haematobium.
Topics: Adolescent; Adult; Child; Clinical Trials as Topic; Female; Humans; Isoquinolines; Male; Praziquante | 1979 |
Preliminary trials with praziquantel in human infections due to Schistosoma mansoni.
Topics: Adult; Brazil; Clinical Trials as Topic; Humans; Isoquinolines; Male; Middle Aged; Praziquantel; Sch | 1979 |
Double-blind studies of tolerance to praziquantel in Japanese patients with Schistosoma japonicum infections.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Drug Tolerance; Female; Humans; Isoquino | 1979 |
Preliminary clinical trials with praziquantel in Schistosoma japonicum infections in the Philippines.
Topics: Clinical Trials as Topic; Drug Tolerance; Female; Humans; Isoquinolines; Male; Philippines; Praziqua | 1979 |
Praziquantel: a new schistosomicide against Schistosoma haematobium.
Topics: Adolescent; Child; Humans; Isoquinolines; Parasite Egg Count; Praziquantel; Schistosoma haematobium; | 1979 |
Study of some aspects of cell mediated immune response in bilharzial children on a field level.
Topics: Adolescent; Child; Drug Therapy, Combination; Humans; Immunity, Cellular; Phagocytosis; Praziquantel | 1991 |
Tolerance of two brands of praziquantel.
Topics: Animals; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Male; Praziquantel; Random Alloc | 1989 |
Praziquantel.
Topics: Clinical Trials as Topic; Humans; Isoquinolines; Praziquantel; Schistosomiasis; Taeniasis | 1985 |
Treatment with praziquantel of schoolchildren with concurrent Schistosoma mansoni and S. haematobium infections in Gezira, Sudan.
Topics: Abdomen; Child; Clinical Trials as Topic; Diarrhea; Dose-Response Relationship, Drug; Humans; Isoqui | 1985 |
519 other studies available for praziquantel and Bilharziasis
| Article | Year |
|---|---|
Antischistosomal activity of hexadecyloxypropyl cyclic 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine and other alkoxyalkyl esters of acyclic nucleoside phosphonates assessed by schistosome worm killing in vitro.
Topics: Adenine; Animals; Cricetinae; Mesocricetus; Molecular Structure; Organophosphonates; Schistosoma; Sc | 2009 |
Synthesis of new praziquantel analogues: potential candidates for the treatment of schistosomiasis.
Topics: Animals; Dose-Response Relationship, Drug; Drug Design; Molecular Structure; Praziquantel; Schistoso | 2012 |
Discovery of New Anti-Schistosomal Hits by Integration of QSAR-Based Virtual Screening and High Content Screening.
Topics: Animals; Dose-Response Relationship, Drug; Drug Discovery; Drug Evaluation, Preclinical; Humans; Mod | 2016 |
Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).
Topics: Administration, Oral; Animals; Dose-Response Relationship, Drug; Humans; Hydantoins; Male; Mice; Mol | 2016 |
Synthesis, structure-activity relationships, cocrystallization and cellular characterization of novel smHDAC8 inhibitors for the treatment of schistosomiasis.
Topics: Animals; Crystallography, X-Ray; Dose-Response Relationship, Drug; HEK293 Cells; Histone Deacetylase | 2021 |
Metabolomics reveal alterations in arachidonic acid metabolism in Schistosoma mekongi after exposure to praziquantel.
Topics: Animals; Anthelmintics; Arachidonic Acid; Drug Resistance; Female; Humans; Life Cycle Stages; Mice; | 2021 |
Trends in the prevalence of microscopically-confirmed schistosomiasis in the South African public health sector, 2011-2018.
Topics: Adolescent; Adult; Anthelmintics; Child; Child, Preschool; Female; Humans; Infant; Male; Praziquante | 2021 |
Drug Discovery and Target Identification against Schistosomiasis: A Reality Check on Progress and Future Prospects.
Topics: Animals; Drug Discovery; Humans; Mice; Oxamniquine; Praziquantel; Schistosoma; Schistosomiasis | 2022 |
Effect of preventive chemotherapy with praziquantel on schistosomiasis among school-aged children in sub-Saharan Africa: a spatiotemporal modelling study.
Topics: Adolescent; Africa South of the Sahara; Animals; Anthelmintics; Chemoprevention; Child; Child, Presc | 2022 |
Does the presence of praziquantel-related adverse events affect the health community's perception toward the mass chemopreventive program in the highest prevalence area of Schistosomiasis in Indonesia? Study in Dodolo village, Napu Valley, Central Sulawes
Topics: Cross-Sectional Studies; Humans; Indonesia; Perception; Praziquantel; Prevalence; Schistosomiasis | 2021 |
Coverage evaluation surveys following soil-transmitted helminthiasis and schistosomiasis mass drug administration in Wolaita Zone of Ethiopia-The Geshiyaro project.
Topics: Adolescent; Adult; Albendazole; Animals; Anthelmintics; Chemoprevention; Child; Child, Preschool; Cr | 2021 |
R-praziquantel integrated population pharmacokinetics in preschool- and school-aged African children infected with Schistosoma mansoni and S. haematobium and Lao adults infected with Opisthorchis viverrini.
Topics: Adult; Animals; Anthelmintics; Child; Child, Preschool; Chromatography, Liquid; Humans; Laos; Opisth | 2022 |
Dandelion (Taraxacum officinale) Improves the Therapeutic Efficiency of Praziquantel in Experimental Schistosomiasis.
Topics: Animals; Anthelmintics; Granuloma; Liver; Liver Diseases; Mice; Plant Extracts; Praziquantel; Schist | 2022 |
Determining the optimal strategies to achieve elimination of transmission for Schistosoma mansoni.
Topics: Animals; Anthelmintics; Humans; Mass Drug Administration; Praziquantel; Prevalence; Schistosoma mans | 2022 |
The prophylactic and anti-fibrotic activity of phthalimido-thiazole derivatives in schistosomiasis mansoni.
Topics: Animals; Praziquantel; Schistosoma mansoni; Schistosomiasis; Schistosomiasis mansoni; Thiazoles | 2022 |
Use of wogonin as a cooperative drug with praziquantel to better combat schistosomiasis.
Topics: Animals; Anthelmintics; Flavanones; Liver; Mice; Praziquantel; Schistosoma mansoni; Schistosomiasis; | 2022 |
The Effect of Different Formulations of Praziquantel in Reducing Worms in the Prepatent Period of Schistosomiasis in Murine Models.
Topics: Animals; Disease Models, Animal; Mice; Praziquantel; Schistosoma mansoni; Schistosomiasis; Schistoso | 2022 |
Ganoderma lucidum extract inhibits Schistosoma mansoni survival in silico and in vitro study.
Topics: Animals; Larva; Molecular Docking Simulation; Praziquantel; Reishi; Schistosoma mansoni; Schistosomi | 2022 |
Safety of Praziquantel and Albendazole Coadministration for the Control and Elimination of Schistosomiasis and Soil-Transmitted Helminths Among Children in Rwanda: An Active Surveillance Study.
Topics: Albendazole; Animals; Anthelmintics; Child; Female; Helminths; Humans; Praziquantel; Rwanda; Schisto | 2022 |
Praziquantel Reduces Maternal Mortality and Offspring Morbidity by Enhancing Anti-Helminthic Immune Responses.
Topics: Animals; Anthelmintics; Antibody Formation; Cytokines; Female; Humans; Maternal Mortality; Mebendazo | 2022 |
Protein undernutrition reduces the efficacy of praziquantel in a murine model of Schistosoma mansoni infection.
Topics: Animals; Anthelmintics; Anti-Inflammatory Agents; Calcium; Disease Models, Animal; Iron; Liver; Maln | 2022 |
Phenotypic Screening of Histone Deacetylase (HDAC) Inhibitors against Schistosoma mansoni.
Topics: Animals; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Isoenzymes; Praziquantel; Rep | 2022 |
Disulfiram and dithiocarbamate analogues demonstrate promising antischistosomal effects.
Topics: Adult; Aldehyde Dehydrogenase; Animals; Disulfiram; Humans; Neglected Diseases; Nitrogen; Oxamniquin | 2022 |
Anti-inflammatory, antioxidant, anti-fibrotic and schistosomicidal properties of plumbagin in murine schistosomiasis.
Topics: Animals; Anthelmintics; Anti-Inflammatory Agents; Antioxidants; Catalase; Female; Granuloma; Immunog | 2022 |
[Progress of schistosomiasis control in People's Republic of China in 2021].
Topics: Animals; Cattle; China; Cities; Humans; Praziquantel; Schistosomiasis; Schistosomiasis japonica | 2022 |
Prevalence and factors associated with transmission of schistosomiasis in school-aged children in South Sudan: a cross-sectional study.
Topics: Adolescent; Animals; Child; Child, Preschool; Cross-Sectional Studies; Feces; Female; Humans; Male; | 2022 |
EF24, a schistosomicidal curcumin analog: Insights from its synthesis and phenotypic, biochemical and cytotoxic activities.
Topics: Animals; Antioxidants; Curcumin; Female; Glutathione Peroxidase; Glutathione Reductase; Glutathione | 2022 |
The role of environmental enteric dysfunction in the pathogenesis of Schistosoma mansoni-associated morbidity in school-aged children.
Topics: Animals; Anthelmintics; Child; Fatty Acids; Humans; Insulin-Like Growth Factor I; Insulins; Lipopoly | 2022 |
Colonic polyps: a rare clinical manifestation of schistosomiasis (a case report).
Topics: Animals; Colonic Polyps; Colonoscopy; Male; Neglected Diseases; Praziquantel; Schistosoma mansoni; S | 2022 |
Fine-scale mapping of Schistosoma mansoni infections and infection intensities in sub-districts of Makenene in the Centre region of Cameroon.
Topics: Animals; Antigens, Helminth; Cameroon; Child; Feces; Humans; Praziquantel; Prevalence; Schistosoma m | 2022 |
Patient journey and resources mapping to implement a praziquantel mass drug administration program for children aged 5 years and below in resource-limited settings.
Topics: Anthelmintics; Child; Child, Preschool; Drug-Related Side Effects and Adverse Reactions; Humans; Mas | 2022 |
A retrospective analysis of schistosomiasis related literature from 2011-2020: Focusing on the next decade.
Topics: Animals; Bibliometrics; Humans; Neglected Diseases; Praziquantel; Retrospective Studies; Schistosoma | 2023 |
Presumptive treatment or serological screening for schistosomiasis in migrants from Sub-Saharan Africa could save both lives and money for the Italian National Health System: results of an economic evaluation.
Topics: Cost-Benefit Analysis; Humans; Italy; Mass Screening; Praziquantel; Schistosomiasis; Transients and | 2023 |
Presumptive treatment or serological screening for schistosomiasis in migrants from Sub-Saharan Africa could save both lives and money for the Italian National Health System: results of an economic evaluation.
Topics: Cost-Benefit Analysis; Humans; Italy; Mass Screening; Praziquantel; Schistosomiasis; Transients and | 2023 |
Presumptive treatment or serological screening for schistosomiasis in migrants from Sub-Saharan Africa could save both lives and money for the Italian National Health System: results of an economic evaluation.
Topics: Cost-Benefit Analysis; Humans; Italy; Mass Screening; Praziquantel; Schistosomiasis; Transients and | 2023 |
Presumptive treatment or serological screening for schistosomiasis in migrants from Sub-Saharan Africa could save both lives and money for the Italian National Health System: results of an economic evaluation.
Topics: Cost-Benefit Analysis; Humans; Italy; Mass Screening; Praziquantel; Schistosomiasis; Transients and | 2023 |
Presumptive treatment or serological screening for schistosomiasis in migrants from Sub-Saharan Africa could save both lives and money for the Italian National Health System: results of an economic evaluation.
Topics: Cost-Benefit Analysis; Humans; Italy; Mass Screening; Praziquantel; Schistosomiasis; Transients and | 2023 |
Presumptive treatment or serological screening for schistosomiasis in migrants from Sub-Saharan Africa could save both lives and money for the Italian National Health System: results of an economic evaluation.
Topics: Cost-Benefit Analysis; Humans; Italy; Mass Screening; Praziquantel; Schistosomiasis; Transients and | 2023 |
Presumptive treatment or serological screening for schistosomiasis in migrants from Sub-Saharan Africa could save both lives and money for the Italian National Health System: results of an economic evaluation.
Topics: Cost-Benefit Analysis; Humans; Italy; Mass Screening; Praziquantel; Schistosomiasis; Transients and | 2023 |
Presumptive treatment or serological screening for schistosomiasis in migrants from Sub-Saharan Africa could save both lives and money for the Italian National Health System: results of an economic evaluation.
Topics: Cost-Benefit Analysis; Humans; Italy; Mass Screening; Praziquantel; Schistosomiasis; Transients and | 2023 |
Presumptive treatment or serological screening for schistosomiasis in migrants from Sub-Saharan Africa could save both lives and money for the Italian National Health System: results of an economic evaluation.
Topics: Cost-Benefit Analysis; Humans; Italy; Mass Screening; Praziquantel; Schistosomiasis; Transients and | 2023 |
From dithiocarbamates to branched dithiocarbazates: Compounds with potent antischistosomal activity.
Topics: Animals; Humans; Praziquantel; Schistosoma mansoni; Schistosomiasis; Schistosomicides; Structure-Act | 2023 |
From dithiocarbamates to branched dithiocarbazates: Compounds with potent antischistosomal activity.
Topics: Animals; Humans; Praziquantel; Schistosoma mansoni; Schistosomiasis; Schistosomicides; Structure-Act | 2023 |
From dithiocarbamates to branched dithiocarbazates: Compounds with potent antischistosomal activity.
Topics: Animals; Humans; Praziquantel; Schistosoma mansoni; Schistosomiasis; Schistosomicides; Structure-Act | 2023 |
From dithiocarbamates to branched dithiocarbazates: Compounds with potent antischistosomal activity.
Topics: Animals; Humans; Praziquantel; Schistosoma mansoni; Schistosomiasis; Schistosomicides; Structure-Act | 2023 |
Understanding perceptions of schistosomiasis and its control among highly endemic lakeshore communities in Mayuge, Uganda.
Topics: Drinking Water; Humans; Lakes; Praziquantel; Prevalence; Schistosomiasis; Schistosomiasis mansoni; U | 2023 |
A new formulation of praziquantel to achieve schistosomiasis elimination.
Topics: Anthelmintics; Humans; Praziquantel; Schistosomiasis | 2023 |
Functional characterization of differentially expressed proteins coming from unisexual and bisexual infected Schistosoma japonicum female worms.
Topics: Animals; Female; Humans; Mice; Praziquantel; Proteomics; Schistosoma japonicum; Schistosomiasis; Sch | 2023 |
Test-Treat-Track-Test-Treat Strategy for Control of Schistosomiasis in Two Low-Prevalence Villages in Northwestern Tanzania.
Topics: Animals; Anthelmintics; Child; Feces; Humans; Praziquantel; Prevalence; Schistosoma mansoni; Schisto | 2023 |
Anti-angiogenic and anti-proliferative activity of ziziphus leaf extract as a novel potential therapeutic agent for reducing hepatic injury in experimental hamster schistosomiasis.
Topics: Animals; Anthelmintics; Antioxidants; Cricetinae; Granuloma; Ki-67 Antigen; Liver; Plant Extracts; P | 2023 |
Non-covalent inhibitors of thioredoxin glutathione reductase with schistosomicidal activity in vivo.
Topics: Animals; Mice; NADH, NADPH Oxidoreductases; Praziquantel; Schistosoma; Schistosoma mansoni; Schistos | 2023 |
Seroconversion following empiric praziquantel treatment as confirmatory diagnostic tool for chronic schistosomiasis.
Topics: Humans; Praziquantel; Schistosomiasis; Seroconversion | 2023 |
Oxamniquine derivatives overcome Praziquantel treatment limitations for Schistosomiasis.
Topics: Animals; Anthelmintics; Combined Modality Therapy; Humans; Neglected Diseases; Oxamniquine; Praziqua | 2023 |
Investigation on birth weight outcomes in schistosomiasis and praziquantel research: a correspondence.
Topics: Birth Weight; Female; Fetus; Humans; Infant, Newborn; Praziquantel; Pregnancy; Schistosomiasis | 2023 |
Design, Synthesis and Evaluation of Praziquantel Analogues and New Molecular Hybrids as Potential Antimalarial and Anti-Schistosomal Agents.
Topics: Animals; Antimalarials; Praziquantel; Schistosoma mansoni; Schistosomiasis; Schistosomicides | 2023 |
Single-cell RNA sequencing reveals a peripheral landscape of immune cells in Schistosomiasis japonica.
Topics: Humans; Natural Killer T-Cells; Praziquantel; Schistosomiasis; Schistosomiasis japonica; Sequence An | 2023 |
In vitro and In silico assessment of antischistosomal activities of ethanolic extract of Cornulacamonacantha.
Topics: Animals; Microscopy, Electron, Scanning; Molecular Docking Simulation; Praziquantel; Schistosoma man | 2023 |
Gendered lives, gendered Vulnerabilities: An intersectional gender analysis of exposure to and treatment of schistosomiasis in Pakwach district, Uganda.
Topics: Child; Delivery of Health Care; Female; Humans; Intersectional Framework; Male; Praziquantel; Pregna | 2023 |
Schistosomiasis control in Senegal: results from community data analysis for optimizing preventive chemotherapy intervention with praziquantel.
Topics: Anthelmintics; Chemoprevention; Child; Humans; Praziquantel; Prevalence; Schistosomiasis; Senegal | 2023 |
Intestinal parasitoses and schistosome infections among students with special reference to praziquantel efficacy in patients with schistosomosis in Hajjah governorate, Yemen
Topics: Animals; Child; Feces; Humans; Intestinal Diseases, Parasitic; Praziquantel; Prevalence; Schistosoma | 2019 |
Delay in schistosomiasis diagnosis and treatment: a multicenter cohort study in Italy.
Topics: Adult; Anthelmintics; Delayed Diagnosis; Enzyme-Linked Immunosorbent Assay; Female; Humans; Italy; M | 2020 |
Orphan Formulations in Pediatric Schistosomiasis Treatment: Development and Characterization of Praziquantel Nanoparticle-Loaded Powders for Reconstitution.
Topics: Anthelmintics; Child; Drug Compounding; Humans; Nanoparticles; Particle Size; Powders; Praziquantel; | 2019 |
The Geshiyaro Project: a study protocol for developing a scalable model of interventions for moving towards the interruption of the transmission of soil-transmitted helminths and schistosome infections in the Wolaita zone of Ethiopia.
Topics: Adolescent; Albendazole; Anthelmintics; Child; Child, Preschool; Cost-Benefit Analysis; Cross-Sectio | 2019 |
Praziquantel Could Be the Appropriate Choice for the Diagnostic Treatment of Schistosomiasis.
Topics: Anthelmintics; Colonoscopy; Humans; Laparoscopy; Praziquantel; Schistosomiasis | 2020 |
Authors' Response to "Praziquantel Could Be the Appropriate Choice for the Diagnostic Treatment of Schistosomiasis".
Topics: Anthelmintics; Colonoscopy; Humans; Laparoscopy; Praziquantel; Schistosomiasis | 2020 |
Schistosomiasis in children: review of 51 imported cases in Spain.
Topics: Adolescent; Animals; Anthelmintics; Child; Emigrants and Immigrants; Female; Humans; Male; Praziquan | 2020 |
Environmental Predictors of Schistosomiasis Persistent Hotspots following Mass Treatment with Praziquantel.
Topics: Africa South of the Sahara; Anthelmintics; Child; Databases, Factual; Environment; Humans; Mass Drug | 2020 |
Patients with severe schistosomiasis mekongi morbidity demonstrating ongoing transmission in Southern Lao People's Democratic Republic.
Topics: Adolescent; Adult; Aged; Animals; Anthelmintics; Child; Feces; Female; Humans; Laos; Male; Middle Ag | 2020 |
Imported chronic schistosomiasis: screening and management issues.
Topics: Anthelmintics; Delayed Diagnosis; Disease Progression; Humans; Mass Screening; Praziquantel; Schisto | 2020 |
Molecular basis for hycanthone drug action in schistosome parasites.
Topics: Animals; Crystallization; Crystallography, X-Ray; Drug Design; Drug Resistance; Humans; Hycanthone; | 2020 |
Elucidation of Cellular Responses in Non-human Primates With Chronic Schistosomiasis Followed by Praziquantel Treatment.
Topics: Animals; Anthelmintics; Leukocytes, Mononuclear; Praziquantel; Primates; Schistosomiasis | 2020 |
Elimination of schistosomiasis requires multifactorial diagnostics: evidence from high- and low-prevalence areas in the Nile Delta, Egypt.
Topics: Adolescent; Adult; Animals; Anthelmintics; Child; Cross-Sectional Studies; Egypt; Feces; Female; Hea | 2020 |
Narrow band imaging in the diagnosis of bladder schistosomiasis.
Topics: Anthelmintics; Hematuria; Humans; Male; Narrow Band Imaging; Praziquantel; Schistosomiasis; Young Ad | 2020 |
Can direct smear results that are routinely collected at health centre level be used for monitoring the impact of mass drug administration with praziquantel on schistosomiasis in Burundi? A preliminary assessment.
Topics: Adolescent; Ambulatory Care Facilities; Anthelmintics; Burundi; Child; Child, Preschool; Feces; Huma | 2020 |
Change in schistosomiasis-related liver disease with repeated praziquantel treatment in school children in rural Zambia.
Topics: Adolescent; Animals; Anthelmintics; Child; Child, Preschool; Female; Humans; Liver Diseases, Parasit | 2020 |
Clinical Sequelae Associated with Unresolved Tropical Splenomegaly in a Cohort of Recently Resettled Congolese Refugees in the United States-Multiple States, 2015-2018.
Topics: Adolescent; Adult; Alkaline Phosphatase; Anemia; Anthelmintics; Antimalarials; Artemether, Lumefantr | 2020 |
Schistosomiasis Consortium for Operational Research and Evaluation: Mission Accomplished.
Topics: Africa South of the Sahara; Animals; Anthelmintics; Chemoprevention; Cost-Benefit Analysis; Disease | 2020 |
Discovering, Defining, and Summarizing Persistent Hotspots in SCORE Studies.
Topics: Africa; Animals; Anthelmintics; Female; Humans; Hygiene; Male; Mass Drug Administration; Praziquante | 2020 |
The cost of a school based mass treatment of schistosomiasis in Ugu District, KwaZulu Natal, South Africa in 2012.
Topics: Adolescent; Anthelmintics; Capital Expenditures; Child; Direct Service Costs; Drug Costs; Endemic Di | 2020 |
Screening of a Library of Recombinant Schistosoma mansoni Proteins With Sera From Murine and Human Controlled Infections Identifies Early Serological Markers.
Topics: Animals; Biomarkers; Humans; Male; Mammals; Mice; Praziquantel; Recombinant Proteins; Schistosoma ma | 2022 |
Investigating the antifibrotic effect of the antiparasitic drug Praziquantel in in vitro and in vivo preclinical models.
Topics: Animals; Antiparasitic Agents; Female; Hepatic Stellate Cells; Hepatocytes; Kupffer Cells; Liver Cir | 2020 |
Test, Treat, Track, Test, and Treat Active Surveillance toward Elimination of Schistosomiasis: A Feasibility Study.
Topics: Adolescent; Antigens, Helminth; Child; Disease Eradication; Egypt; Feasibility Studies; Female; Huma | 2020 |
Fast and reliable easy-to-use diagnostics for eliminating bilharzia in young children and mothers: An introduction to the freeBILy project.
Topics: Adult; Animals; Anthelmintics; Antigens, Helminth; Child; Child, Preschool; Female; Humans; Immunolo | 2020 |
Schistosomiasis Control in Nigeria: Moving Round the Circle?
Topics: Animals; Anthelmintics; Biomphalaria; Bulinus; Communicable Disease Control; Health Policy; Humans; | 2020 |
Alternatives to Praziquantel for the Prevention and Control of Schistosomiasis.
Topics: Anthelmintics; Humans; Neglected Diseases; Praziquantel; Schistosomiasis | 2021 |
Positive impact of preventative chemotherapy during a national helminth control program: Perception and KAP.
Topics: Albendazole; Anthelmintics; Child; Community Health Services; Female; Health Knowledge, Attitudes, P | 2020 |
Liver damage in schistosomiasis is reduced by adipose tissue-derived stem cell therapy after praziquantel treatment.
Topics: Adipose Tissue; Animals; Cell- and Tissue-Based Therapy; Cytokines; Disease Models, Animal; Granulom | 2020 |
Schisto and Ladders version 2: a health educational board game to support compliance with school-based mass drug administration with praziquantel - a pilot study.
Topics: Anthelmintics; Child; Humans; Mass Drug Administration; Pilot Projects; Praziquantel; Schistosomiasi | 2021 |
Integration of prevention and control measures for female genital schistosomiasis, HIV and cervical cancer.
Topics: Africa South of the Sahara; Anthelmintics; Anti-Retroviral Agents; Awareness; Female; Genital Diseas | 2020 |
Booming Omics in Schistosoma.
Topics: Animals; Praziquantel; RNA-Seq; Schistosoma mansoni; Schistosomiasis; Schistosomicides | 2021 |
Topics: Animals; Anthelmintics; Humans; Ligands; Praziquantel; Schistosoma; Schistosomiasis | 2022 |
Bladder Cancer and Associated Risk Factors: The African Panorama.
Topics: Animals; Anthelmintics; Humans; Praziquantel; Schistosoma haematobium; Schistosomiasis; Urinary Blad | 2021 |
[Endemic status of schistosomiasis in People's Republic of China in 2019].
Topics: Animals; Cattle; China; Cities; Endemic Diseases; Humans; Praziquantel; Schistosomiasis; Schistosomi | 2020 |
Quality and composition of Albendazole, Mebendazole and Praziquantel available in Burkina Faso, Côte d'Ivoire, Ghana and Tanzania.
Topics: Albendazole; Anthelmintics; Burkina Faso; Cote d'Ivoire; Ghana; Helminthiasis; Humans; Mebendazole; | 2021 |
Delayed diagnosis of spinal cord schistosomiasis in a non-endemic country: A tertiary referral centre experience.
Topics: Adult; Delayed Diagnosis; Female; Humans; Magnetic Resonance Imaging; Malawi; Male; Middle Aged; Mye | 2021 |
Rethinking the Top-Down Approach to Schistosomiasis Control and Elimination in Sub-Saharan Africa.
Topics: Africa South of the Sahara; Humans; Mass Drug Administration; Neglected Diseases; Praziquantel; Schi | 2021 |
Patients with severe schistosomiasis mansoni in Ituri Province, Democratic Republic of the Congo.
Topics: Adult; Animals; Democratic Republic of the Congo; Feces; Female; Humans; Middle Aged; Praziquantel; | 2021 |
Efficacy of a low-dose praziquantel and fenbendazole protocol in the treatment of asymptomatic schistosomiasis in dogs.
Topics: Animals; Dog Diseases; Dogs; Fenbendazole; Praziquantel; Schistosomatidae; Schistosomiasis | 2021 |
Low awareness and common misconceptions about schistosomiasis in endemic lowland areas in Western Ethiopia: a mixed-methods study.
Topics: Child; Cross-Sectional Studies; Ethiopia; Health Knowledge, Attitudes, Practice; Humans; Male; Mass | 2021 |
A 12-year follow-up of intestinal schistosomiasis in pre-school-aged children in Assoni Village, Eastern Senegal.
Topics: Child; Child, Preschool; Follow-Up Studies; Humans; Infant; Praziquantel; Prevalence; Schistosomiasi | 2021 |
Colonic Schistosomiasis Presenting with Findings of Inflammatory Bowel Disease.
Topics: Anthelmintics; Colonic Diseases; Humans; Male; Praziquantel; Schistosomiasis; Young Adult | 2021 |
Schistosomiasis: a rare cause of gastrointestinal bleeding.
Topics: Adult; Animals; Anthelmintics; Biopsy; Colonoscopy; Esophageal and Gastric Varices; Follow-Up Studie | 2021 |
Prevalence of urogenital and intestinal schistosomiasis among school children in South-west Nigeria.
Topics: Adolescent; Anthelmintics; Child; Feces; Female; Humans; Male; Nigeria; Praziquantel; Prevalence; Sc | 2021 |
Elimination of schistosomiasis in China: Current status and future prospects.
Topics: Animals; China; Disease Eradication; Humans; Mass Drug Administration; Praziquantel; Public Health; | 2021 |
The evolving schistosomiasis agenda 2007-2017-Why we are moving beyond morbidity control toward elimination of transmission.
Topics: Global Health; History, 21st Century; Humans; Mass Drug Administration; Praziquantel; Prevalence; Sa | 2017 |
Optimising cluster survey design for planning schistosomiasis preventive chemotherapy.
Topics: Adolescent; Chemoprevention; Child; Child, Preschool; Cote d'Ivoire; Female; Health Care Costs; Huma | 2017 |
Schistosomiasis in European Travelers and Migrants: Analysis of 14 Years TropNet Surveillance Data.
Topics: Adolescent; Adult; Africa South of the Sahara; Aged; Aged, 80 and over; Animals; Anthelmintics; Chil | 2017 |
Imported Schistosomiasis in Children: Clinical, Diagnostic Aspects And Outcome in 5 Tertiary Hospitals in France.
Topics: Adolescent; Anthelmintics; Child; Child, Preschool; Emigrants and Immigrants; Female; Hematuria; Hum | 2017 |
Developing a comprehensive response for treatment of children under 6 years of age with schistosomiasis: research and development of a pediatric formulation of praziquantel.
Topics: Child, Preschool; Drug Compounding; Humans; Infant; Praziquantel; Public-Private Sector Partnerships | 2017 |
Selecting targets for the diagnosis of Schistosoma mansoni infection: An integrative approach using multi-omic and immunoinformatics data.
Topics: Animals; Anthelmintics; Case-Control Studies; Computer Simulation; Epitopes; Helminth Proteins; Huma | 2017 |
Defining Persistent Hotspots: Areas That Fail to Decrease Meaningfully in Prevalence after Multiple Years of Mass Drug Administration with Praziquantel for Control of Schistosomiasis.
Topics: Anthelmintics; Child; Cross-Sectional Studies; Feces; Humans; Mass Drug Administration; Praziquantel | 2017 |
Should we be treating animal schistosomiasis in Africa? The need for a One Health economic evaluation of schistosomiasis control in people and their livestock.
Topics: Africa; Animal Diseases; Animals; Anthelmintics; Cost-Benefit Analysis; Humans; Income; Livestock; O | 2017 |
Why reinvent the wheel? Lessons in schistosomiasis control from the past.
Topics: Africa; Animals; Congresses as Topic; Disease Eradication; Disease Vectors; Humans; Molluscacides; N | 2017 |
Corilagin Counteracts IL-13Rα1 Signaling Pathway in Macrophages to Mitigate Schistosome Egg-Induced Hepatic Fibrosis.
Topics: Animals; Anthelmintics; Biomarkers; Cell Line; Glucosides; Hydrolyzable Tannins; Interleukin-13 Rece | 2017 |
Schistosomiasis and soil-transmitted helminthiases: number of people treated in 2016.
Topics: Adult; Africa; Albendazole; Americas; Anthelmintics; Asia; Child; Child, Preschool; Female; Helminth | 2017 |
New 1,3-benzodioxole derivatives: Synthesis, evaluation of in vitro schistosomicidal activity and ultrastructural analysis.
Topics: Animals; Cell Survival; Dioxoles; HeLa Cells; Humans; Microscopy, Electron, Scanning; Praziquantel; | 2018 |
[Therapeutic effect of BILT combined with praziquantel in treatment of chronic schistosomiasis].
Topics: Case-Control Studies; Humans; Infrared Rays; Liver Cirrhosis; Praziquantel; Schistosomiasis | 2017 |
[One case report of ectopic schistosomiasis in fallopian tube in Jingmen City].
Topics: Animals; Anthelmintics; China; Diagnosis, Differential; Fallopian Tubes; Female; Humans; Praziquante | 2017 |
An Exotic Visitor.
Topics: Abdominal Pain; Adult; Animals; Anthelmintics; Colonoscopy; Eosinophilia; Humans; Male; Praziquantel | 2018 |
A Polysaccharide from Amusium Pleuronectes Combined with Praziquantel Treatment Ameliorates Hepatic Fibrosis in Schistosoma Japonicum-Infected Mice.
Topics: Animals; Bivalvia; Cytokines; Hyaluronoglucosaminidase; Interleukin-13; Liver Cirrhosis; Male; Mice, | 2018 |
Antischistosomal Properties of Hederacolchiside A1 Isolated from
Topics: Animals; Artemisinins; Artesunate; Disease Models, Animal; Female; Mice; Plant Extracts; Praziquante | 2018 |
Schistosomiasis as a cause of acute cholecystitis.
Topics: Anthelmintics; Cholecystectomy, Laparoscopic; Cholecystitis, Acute; Humans; Male; Middle Aged; Prazi | 2018 |
[Strategy of transmission interruption of schistosomiasis and its effects in Runzhou District, Zhenjiang City, Jiangsu Province].
Topics: Animals; Antibodies, Helminth; China; Cities; Feces; Humans; Pest Control; Praziquantel; Rivers; Sch | 2018 |
Schistosomiasis.
Topics: Animals; Anthelmintics; Humans; Neglected Diseases; Praziquantel; Quality of Life; Schistosomiasis; | 2018 |
Development of the PraziCalc mobile device-app to calculate praziquantel dosage in the treatment of schistosomiasis.
Topics: Adult; Child; Drug Delivery Systems; Humans; Mobile Applications; Praziquantel; Schistosomiasis; Sch | 2018 |
Lung Involvement in Chronic Schistosomiasis with Bladder Squamous Cell Carcinoma.
Topics: Adult; Animals; Anthelmintics; Biopsy; Carcinoma, Squamous Cell; Chronic Disease; Humans; Lung Disea | 2018 |
Integrating ecological approaches to interrupt schistosomiasis transmission: opportunities and challenges.
Topics: Africa; China; Disease Eradication; Humans; Mass Drug Administration; Praziquantel; Schistosomiasis | 2018 |
Restaging Pulmonary Schistosomiasis.
Topics: Animals; Anthelmintics; Female; Humans; Lung; Lung Diseases, Parasitic; Male; Praziquantel; Schistos | 2019 |
Topics: Adult; Animals; Anthelmintics; Cystoscopy; Diagnosis, Differential; Hematuria; Humans; Lung Diseases | 2019 |
Central Vertigo and Hearing Loss in an African Swimmer.
Topics: Anthelmintics; Belgium; Black People; Diagnosis, Differential; Hearing Loss; Humans; Male; Middle Ag | 2019 |
Challenges and Lessons From Conducting A Paediatric Clinical Trial in Sub-Saharan Africa: The Case of the Praziquantel Oral Dispersible Tablets Phase II Study in Côte d'Ivoire.
Topics: Administration, Oral; Anthelmintics; Child, Preschool; Clinical Trials, Phase II as Topic; Cote d'Iv | 2019 |
Schistosomiasis and associated iron-deficiency anaemia presenting decades after immigration from sub-Saharan Africa.
Topics: Adenoma; Administration, Oral; Africa South of the Sahara; Aged; Anemia, Iron-Deficiency; Animals; A | 2019 |
[Tropical Medicine in an Age of High Global Mobility - Schistosomiasis in a School Class after Travel to Rwanda].
Topics: Adolescent; Animals; Eosinophilia; Female; Germany; Humans; Male; Praziquantel; Rwanda; Schistosoma | 2019 |
The antioxidants resveratrol and N-acetylcysteine enhance anthelmintic activity of praziquantel and artesunate against Schistosoma mansoni.
Topics: Acetylcysteine; Animals; Antioxidants; Antiprotozoal Agents; Artesunate; Biomphalaria; Drug Synergis | 2019 |
Egypt's schistosomiasis control programme in the 1980s prepared the ground for the global elimination of schistosomiasis by 2030.
Topics: Africa; Animals; Anthelmintics; Child; Disease Vectors; Egypt; Humans; International Cooperation; Mo | 2019 |
The association between child Schistosoma spp. infections and morbidity in an irrigated rice region in Mali: A localized study.
Topics: Adolescent; Agricultural Irrigation; Anemia; Animals; Child; Cross-Sectional Studies; Female; Humans | 2019 |
Cannabinoid receptor-1 antagonism: a new perspective on treating a murine schistosomal liver fibrosis model.
Topics: Actins; Animals; Anthelmintics; Cannabinoid Receptor Antagonists; Drug Therapy, Combination; Granulo | 2019 |
Alterations in peripheral blood B cell subsets and dynamics of B cell responses during human schistosomiasis.
Topics: Adolescent; Animals; Anthelmintics; Antibodies, Helminth; B-Lymphocyte Subsets; Child; Female; Gabon | 2013 |
Acute schistosomiasis in travelers: 14 years' experience at the Hospital for Tropical Diseases, London.
Topics: Acute Disease; Adolescent; Adult; Africa, Southern; Cough; Endemic Diseases; Female; Fever; Follow-U | 2013 |
Schistosomiasis: number of people treated in 2011.
Topics: Adult; Anthelmintics; Child; Child, Preschool; Endemic Diseases; Global Health; Humans; Praziquantel | 2013 |
Cervical schistosomiasis: an increasing presentation in the developed world.
Topics: Adult; Antiplatyhelmintic Agents; Female; Humans; Praziquantel; Schistosomiasis; Uterine Cervical Dy | 2013 |
Coinfection with hepatitis C virus and schistosomiasis: fibrosis and treatment response.
Topics: Adult; Antiviral Agents; Chi-Square Distribution; Coinfection; Drug Therapy, Combination; Egypt; Fem | 2013 |
Mapping and prediction of schistosomiasis in Nigeria using compiled survey data and Bayesian geospatial modelling.
Topics: Anthelmintics; Bayes Theorem; Geographic Information Systems; Humans; Models, Theoretical; Nigeria; | 2013 |
Pulmonary infiltrates and eosinophilia in a 25-year-old traveler.
Topics: Adult; Anthelmintics; Eosinophilia; Humans; Lung; Lung Diseases, Parasitic; Male; Praziquantel; Radi | 2013 |
Effect of Chinese herbal compound on liver fibrosis in rabbits with schistosomiasis by B-ultrasound.
Topics: Angelica sinensis; Animals; Anthelmintics; Disease Models, Animal; Herbal Medicine; Liver; Liver Cir | 2013 |
Sonographic response in the liver and urinary bladder of children 14 months after treatment for schistosomiasis.
Topics: Adolescent; Anthelmintics; Child; Child, Preschool; Humans; Liver; Liver Diseases, Parasitic; Praziq | 2013 |
Use of cell-free circulating schistosome DNA in serum, urine, semen, and saliva to monitor a case of refractory imported schistosomiasis hematobia.
Topics: Animals; Anthelmintics; Biopsy; DNA, Helminth; Drug Monitoring; Humans; Male; Parasitology; Praziqua | 2013 |
Synthesis and SAR studies of praziquantel derivatives with activity against Schistosoma japonicum.
Topics: Animals; Molecular Structure; Praziquantel; Schistosoma japonicum; Schistosomiasis; Schistosomicides | 2013 |
Potential cost-effectiveness of schistosomiasis treatment for reducing HIV transmission in Africa--the case of Zimbabwean women.
Topics: Adolescent; Adult; Africa; Animals; Anthelmintics; Cost-Benefit Analysis; Disease Transmission, Infe | 2013 |
Practical dosing of praziquantel for schistosomiasis in preschool-aged children.
Topics: Africa South of the Sahara; Anthelmintics; Body Weight; Brazil; Child; Child, Preschool; Dose-Respon | 2013 |
Validating the WHO dose pole in the Philippines for school-based mass drug administration of praziquantel for morbidity control of schistosomiasis.
Topics: Body Height; Body Weight; Child; Cross-Sectional Studies; Dose-Response Relationship, Drug; Drug Adm | 2013 |
An interdisciplinary approach to determine schistosomiasis prevalence and administer praziquantel to school-age children in Tanzania.
Topics: Anthelmintics; Child; Humans; Patient Care Team; Praziquantel; Prevalence; Risk Factors; Schistosomi | 2013 |
Comparative in vivo antioxidant levels in Schistosoma mansoni infected mice treated with praziquantel or the essential oil of Melaleuca armillaris leaves.
Topics: Animals; Anthelmintics; Antioxidants; Melaleuca; Mice; Oils, Volatile; Plant Extracts; Plant Leaves; | 2012 |
[A 24-year old man with fever and pulmonary infiltrates].
Topics: Anthelmintics; Antibodies, Helminth; Diagnosis, Differential; Endemic Diseases; Fever; Hemagglutinat | 2014 |
Schistosomiasis of the prostate: a case report.
Topics: Animals; Biopsy, Needle; Humans; Male; Middle Aged; Praziquantel; Prostate; Prostate-Specific Antige | 2013 |
Mapping of schistosomiasis and soil-transmitted helminthiasis in the regions of Littoral, North-West, South and South-West Cameroon and recommendations for treatment.
Topics: Adolescent; Cameroon; Child; Female; Helminthiasis; Humans; Male; Praziquantel; Schistosomiasis; Sch | 2013 |
A latent Markov modelling approach to the evaluation of circulating cathodic antigen strips for schistosomiasis diagnosis pre- and post-praziquantel treatment in Uganda.
Topics: Anthelmintics; Antigens, Protozoan; Humans; Markov Chains; Praziquantel; Schistosomiasis; Sensitivit | 2013 |
In vitro evaluation of permeation, toxicity and effect of praziquantel-loaded solid lipid nanoparticles against Schistosoma mansoni as a strategy to improve efficacy of the schistosomiasis treatment.
Topics: Animals; Anthelmintics; Cell Survival; Delayed-Action Preparations; Female; Hep G2 Cells; Humans; In | 2014 |
Schistosomiasis: number of people receiving preventive chemotherapy in 2012.
Topics: Adolescent; Adult; Africa; Anthelmintics; Child; Child, Preschool; Endemic Diseases; Global Health; | 2014 |
'Death and axes': unexpected Ca²⁺ entry phenologs predict new anti-schistosomal agents.
Topics: Animals; Body Patterning; Calcium Channels; Chromatography, High Pressure Liquid; Planarians; Praziq | 2014 |
Dosing of praziquantel by height in sub-Saharan African adults.
Topics: Adolescent; Adult; Anthelmintics; Body Height; Body Weight; Female; Humans; Male; Middle Aged; Prazi | 2014 |
Schistosomiasis in pre-school-age children and their mothers in Chikhwawa district, Malawi with notes on characterization of schistosomes and snails.
Topics: Adolescent; Adult; Aging; Animals; Anthelmintics; Child, Preschool; Female; Humans; Infant; Malawi; | 2014 |
Perceived illness drives participation in mass deworming campaigns in Laos.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albendazole; Animals; Anthelmintics; Cooking; Fasciolias | 2015 |
Effect of female genital schistosomiasis and anti-schistosomal treatment on monocytes, CD4+ T-cells and CCR5 expression in the female genital tract.
Topics: Adolescent; Adult; Animals; Case-Control Studies; CD4-Positive T-Lymphocytes; Coinfection; Female; G | 2014 |
Functional characterization of a novel family of acetylcholine-gated chloride channels in Schistosoma mansoni.
Topics: Acetylcholine; Animals; Anthelmintics; Cell Line; Chloride Channels; Cholinergic Agonists; HEK293 Ce | 2014 |
[Can we overcome schistosomiasis? A Senegalese example].
Topics: Adolescent; Anthelmintics; Child; Child, Preschool; Disease Eradication; Hand Hygiene; Health Educat | 2015 |
[Expression characteristics of microRNA in mice with schistosomiasis and praziquantel treatment].
Topics: Animals; Female; Gene Expression Regulation; Interleukin-1beta; Interleukin-6; Liver; Mice; MicroRNA | 2014 |
Can mass drug administration lead to the sustainable control of schistosomiasis?
Topics: Adolescent; Adult; Aged; Animals; Anthelmintics; Child; Child, Preschool; Cross-Sectional Studies; D | 2015 |
Mass drug administration (MDA) for schistosomiasis.
Topics: Animals; Anthelmintics; Female; Humans; Male; Praziquantel; Schistosomiasis | 2015 |
Reply to Wang and Liang.
Topics: Animals; Anthelmintics; Female; Humans; Male; Praziquantel; Schistosomiasis | 2015 |
The effect of a health communication campaign on compliance with mass drug administration for schistosomiasis control in western Kenya--the SCORE project.
Topics: Adult; Community Health Workers; Female; Health Behavior; Health Communication; Health Knowledge, At | 2014 |
Impact of Schistosoma mansoni on malaria transmission in Sub-Saharan Africa.
Topics: Africa South of the Sahara; Animals; Anthelmintics; Child; Child, Preschool; Coinfection; Humans; Im | 2014 |
Inhibition or knockdown of ABC transporters enhances susceptibility of adult and juvenile schistosomes to Praziquantel.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Disease Susceptibility; Drug Resis | 2014 |
An audacious goal: the elimination of schistosomiasis in our lifetime through mass drug administration.
Topics: Anthelmintics; Disease Eradication; Humans; Neglected Diseases; Practice Guidelines as Topic; Praziq | 2015 |
Population biology of Schistosoma mating, aggregation, and transmission breakpoints: more reliable model analysis for the end-game in communities at risk.
Topics: Animals; Anthelmintics; Behavior, Animal; Humans; Models, Biological; Population Density; Population | 2014 |
Schistosomiasis: number of people treated worldwide in 2013.
Topics: Adolescent; Adult; Africa; Anthelmintics; Cambodia; Child; Global Health; Humans; Indonesia; Laos; M | 2015 |
Schistosomiasis in non-endemic countries.
Topics: Animals; Anthelmintics; Disease Vectors; Humans; Praziquantel; Schistosoma; Schistosomiasis; Snails | 2015 |
Schistosomiasis and its treatment.
Topics: Animals; Anthelmintics; Drug Discovery; Drug Resistance; Humans; Praziquantel; Schistosoma; Schistos | 2015 |
Praziquantel: do we need another antischistosoma treatment?
Topics: Animals; Anthelmintics; Drug Resistance; Humans; Praziquantel; Schistosoma; Schistosomiasis | 2015 |
Something old, something new: is praziquantel enough for schistosomiasis control?
Topics: Animals; Anthelmintics; Communicable Disease Control; Humans; Praziquantel; Schistosoma; Schistosomi | 2015 |
Using an open source model to accelerate schistosomiasis drug research.
Topics: Animals; Anthelmintics; Drug Discovery; Humans; Internet; Praziquantel; Schistosoma; Schistosomiasis | 2015 |
What is the mechanism of action of praziquantel and how might resistance strike?
Topics: Animals; Anthelmintics; Drug Resistance; Humans; Praziquantel; Schistosoma; Schistosomiasis | 2015 |
Multiple parasitic infections in a cardiac transplant recipient.
Topics: Abdominal Pain; Adolescent; Albendazole; Animals; Anthelmintics; Diarrhea; Feces; Female; Heart Tran | 2015 |
Testicular Schistosomiasis Mimicking Malignancy in a Child: A Case Report.
Topics: Adolescent; Anthelmintics; Diagnosis, Differential; Humans; Male; Neoplasms, Germ Cell and Embryonal | 2015 |
Inhibition of Granulomatous Inflammation and Prophylactic Treatment of Schistosomiasis with a Combination of Edelfosine and Praziquantel.
Topics: Animals; Anthelmintics; Cytokines; Gene Expression Regulation; Granuloma; Inflammation; Mice; Phosph | 2015 |
Polymeric Nanostructured Systems for Liquid Formulation of Praziquan-tel: Development and in vitro Assessment.
Topics: Administration, Oral; Anthelmintics; Biological Availability; Caco-2 Cells; Chemistry, Pharmaceutica | 2016 |
An achievable goal: control and elimination of schistosomiasis.
Topics: Anthelmintics; Disease Eradication; Humans; Neglected Diseases; Praziquantel; Schistosomiasis | 2015 |
Development of flexible and dispersible oral formulations containing praziquantel for potential schistosomiasis treatment of pre-school age children.
Topics: Administration, Oral; Anthelmintics; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; | 2015 |
Profiling Nonrecipients of Mass Drug Administration for Schistosomiasis and Hookworm Infections: A Comprehensive Analysis of Praziquantel and Albendazole Coverage in Community-Directed Treatment in Uganda.
Topics: Adolescent; Adult; Albendazole; Animals; Anthelmintics; Chemoprevention; Child; Disease Transmission | 2016 |
Schistosomiasis therapeutics: whats in the pipeline?
Topics: Animals; Drug Design; Female; Humans; Neglected Diseases; Praziquantel; Schistosoma; Schistosomiasis | 2016 |
Tackling neglect: treating schistosomiasis in pregnancy.
Topics: Anthelmintics; Birth Weight; Female; Fetus; Humans; Praziquantel; Pregnancy; Schistosomiasis | 2016 |
Prevalence of Schistosomes and Soil-Transmitted Helminths among Schoolchildren in Lake Victoria Basin, Tanzania.
Topics: Adolescent; Albendazole; Animals; Anthelmintics; Child; Feces; Female; Helminthiasis; Helminths; Hum | 2015 |
Prevalence of Schistosomes and Soil-Transmitted Helminths and Morbidity Associated with Schistosomiasis among Adult Population in Lake Victoria Basin, Tanzania.
Topics: Adult; Albendazole; Animals; Anthelmintics; Feces; Female; Helminthiasis; Helminths; Humans; Intesti | 2015 |
Accuracy of Coverage Survey Recall following an Integrated Mass Drug Administration for Lymphatic Filariasis, Schistosomiasis, and Soil-Transmitted Helminthiasis.
Topics: Adolescent; Adult; Albendazole; Antiparasitic Agents; Child; Elephantiasis, Filarial; Female; Helmin | 2016 |
Early Detection of Schistosoma Egg-Induced Pulmonary Granulomas in a Returning Traveler.
Topics: Animals; Benin; France; Granuloma; Humans; Lung Diseases, Parasitic; Male; Ovum; Praziquantel; Schis | 2016 |
New approaches to measuring anthelminthic drug efficacy: parasitological responses of childhood schistosome infections to treatment with praziquantel.
Topics: Adolescent; Africa; Animals; Anthelmintics; Child; Child, Preschool; Drug Resistance; Feces; Female; | 2016 |
Schistosomiasis: number of people treated worldwide in 2014.
Topics: Adolescent; Adult; Africa; Age Distribution; Asia; Child; Child, Preschool; Endemic Diseases; Global | 2016 |
Images of the Month: Schistosomiasis as a Solitary Sigmoid Nodule.
Topics: Adult; Anthelmintics; Eggs; Granuloma; Humans; Male; Praziquantel; Schistosomiasis; Sigmoid Diseases | 2016 |
Schistosomiasis elimination by 2020 or 2030?
Topics: Anthelmintics; Disease Eradication; Global Health; Humans; Neglected Diseases; Praziquantel; Schisto | 2016 |
An Unusual Cause of Cholecystitis.
Topics: Animals; Biopsy; Cholecystectomy; Cholecystitis; Gallbladder; Humans; Male; Middle Aged; Praziquante | 2016 |
Tropical disease: A neglected cause.
Topics: Access to Information; Biomedical Research; Drug Discovery; Drug Industry; Humans; Information Disse | 2016 |
Gaining and sustaining schistosomiasis control: study protocol and baseline data prior to different treatment strategies in five African countries.
Topics: Africa; Animals; Anthelmintics; Child; Child, Preschool; Female; Humans; Male; Praziquantel; Prevale | 2016 |
Assessment of global guidelines for preventive chemotherapy against schistosomiasis and soil-transmitted helminthiasis: a cost-effectiveness modelling study.
Topics: Africa South of the Sahara; Albendazole; Anthelmintics; Chemoprevention; Cost-Benefit Analysis; Heal | 2016 |
Schistosomiasis Sustained Control Program in Ethnic Groups Around Ninefescha (Eastern Senegal).
Topics: Adolescent; Animals; Child; Child, Preschool; Ethnicity; Health Education; Health Promotion; Humans; | 2016 |
The cytotoxicity study of praziquantel enantiomers.
Topics: Cell Line, Tumor; Hep G2 Cells; Humans; L-Lactate Dehydrogenase; Praziquantel; Schistosomiasis; Ster | 2016 |
Treatment of Schistosomiasis in a Patient Allergic to Praziquantel: A Desensitization and Treatment Protocol.
Topics: Adult; Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Immunoglobulin E; Praziq | 2016 |
Mass drug administration and the global control of schistosomiasis: successes, limitations and clinical outcomes.
Topics: Anthelmintics; Disease Eradication; Global Health; Health Promotion; Humans; Praziquantel; Prevalenc | 2016 |
Praziquantel for schistosomiasis in pregnancy.
Topics: Anthelmintics; Female; Humans; Praziquantel; Pregnancy; Schistosomiasis | 2016 |
Biennial versus annual treatment for schistosomiasis and its impact on liver morbidity.
Topics: Adolescent; Adult; Aged; Animals; Child; Child, Preschool; Drug Administration Schedule; Female; Hum | 2017 |
Diagnosing schistosomiasis-induced liver morbidity: implications for global control.
Topics: Adolescent; Adult; Aged; Biomarkers; Child; Child, Preschool; Female; Humans; Hyaluronic Acid; Liver | 2017 |
Clinical Report: Schistosomiasis Exposure in U.S. Service Personnel During Whitewater Rafting on the Nile River in Jinja, Uganda.
Topics: Adult; Anthelmintics; Female; Fresh Water; Humans; Male; Military Personnel; Praziquantel; Rivers; S | 2016 |
A new global strategy for the elimination of schistosomiasis.
Topics: Anthelmintics; Global Health; Humans; Infection Control; Population Groups; Praziquantel; Rural Popu | 2017 |
Assessment of schistosomiasis prevalence among children 5 to 14 years old after several years of mass drug administration in the Senegal River basin
Topics: Adolescent; Animals; Child; Child, Preschool; Female; Humans; Male; Mauritania; Praziquantel; Preval | 2016 |
A quantification method for determination of racemate praziquantel and R-enantiomer in rat plasma for comparison of their pharmacokinetics.
Topics: Animals; Anthelmintics; Chromatography, High Pressure Liquid; Limit of Detection; Male; Praziquantel | 2017 |
Schistosomiasis in an HIV-positive patient presenting as an anal fissure and giant anal polyp.
Topics: Adult; Animals; Anthelmintics; Anus Diseases; Combined Modality Therapy; Diagnosis, Differential; Fe | 2008 |
The combined effect of the Lymphatic Filariasis Elimination Programme and the Schistosomiasis and Soil-transmitted Helminthiasis Control Programme on soil-transmitted helminthiasis in schoolchildren in Tanzania.
Topics: Albendazole; Animals; Anthelmintics; Child; Drug Therapy, Combination; Elephantiasis, Filarial; Fema | 2009 |
The effect of the community-directed treatment approach versus the school-based treatment approach on the prevalence and intensity of schistosomiasis and soil-transmitted helminthiasis among schoolchildren in Tanzania.
Topics: Adolescent; Albendazole; Anthelmintics; Child; Community Health Services; Female; Helminthiasis; Hoo | 2009 |
Global trends in schistosomiasis control.
Topics: Anthelmintics; Child; Global Health; Humans; Praziquantel; Schistosomiasis | 2008 |
Is mass treatment the appropriate schistosomiasis elimination strategy?
Topics: Adolescent; Adult; Anthelmintics; Child, Preschool; Endemic Diseases; Female; Humans; Male; Philippi | 2008 |
[Diagnostic image (391). A man with fever and urticaria after a trip to Uganda].
Topics: Adult; Animals; Fever; Humans; Male; Praziquantel; Schistosoma; Schistosomiasis; Schistosomicides; T | 2008 |
Persistent immune responses in late infection and after treatment in experimental Schistosoma bovis infections in goats.
Topics: Animals; Anthelmintics; Antibodies, Helminth; Enzyme-Linked Immunosorbent Assay; Female; Goat Diseas | 2009 |
Imaging findings from a case of bilharziasis in a patient with gross hematuria of several years' duration.
Topics: Adult; Animals; Anthelmintics; Diagnosis, Differential; Hematuria; Humans; Magnetic Resonance Imagin | 2008 |
Towards an understanding of the mechanism of action of praziquantel.
Topics: Animals; Anthelmintics; Gene Expression Profiling; Gene Expression Regulation; Genes, Helminth; Heat | 2009 |
Taste, a new incentive to switch to (R)-praziquantel in schistosomiasis treatment.
Topics: Child; Crystallography, X-Ray; Humans; Molecular Structure; Praziquantel; Schistosomiasis; Schistoso | 2009 |
Improving control of African schistosomiasis: towards effective use of rapid diagnostic tests within an appropriate disease surveillance model.
Topics: Adolescent; Africa South of the Sahara; Anthelmintics; Child; Child Health Services; Child, Preschoo | 2009 |
Intestinal schistosomiasis, importation of a neglected tropical disease in Romania. Case report of a traveler to endemic regions.
Topics: Adult; Anthelmintics; Diagnosis, Differential; Feces; Humans; Intestinal Diseases, Parasitic; Male; | 2009 |
The schistosoma-specific antibody response after treatment in non-immune travellers.
Topics: Adolescent; Adult; Animals; Anthelmintics; Antibodies, Helminth; Antibody Specificity; Antigens, Hel | 2009 |
[Intestinal schistosomiasis].
Topics: Animals; Colonic Diseases; Equatorial Guinea; Female; Humans; Middle Aged; Praziquantel; Schistosoma | 2009 |
Difficulties in the diagnosis and treatment of acute schistosomiasis.
Topics: Acute Disease; Adrenal Cortex Hormones; Animals; Anthelmintics; Humans; Praziquantel; Schistosomiasi | 2009 |
Detection of circulating antigen in serum of mice infected with Schistosoma japonicum by immunomagnetic bead ELISA based on IgY.
Topics: Animals; Anthelmintics; Antibodies, Helminth; Antibodies, Monoclonal; Antigens, Helminth; Chickens; | 2009 |
[Coverage rate and satisfaction of populations after mass treatment with praziquantel and albendazole in Mali].
Topics: Albendazole; Anthelmintics; Cross-Sectional Studies; Drug Therapy; Health Promotion; Humans; Lot Qua | 2009 |
The presumptive treatment of all school-aged children is the least costly strategy for schistosomiasis control in Plateau and Nasarawa states, Nigeria.
Topics: Adolescent; Anthelmintics; Child; Child, Preschool; Cost-Benefit Analysis; Drug Administration Sched | 2009 |
Schistosomiasis and neglected tropical diseases: towards integrated and sustainable control and a word of caution.
Topics: Anthelmintics; Communicable Disease Control; Global Health; Helminthiasis; Humans; National Health P | 2009 |
[Schistosomiasis in Danish travellers and immigrants].
Topics: Adolescent; Adult; Anthelmintics; Child; Child, Preschool; Denmark; Emigrants and Immigrants; Humans | 2009 |
New insights in diagnosing Schistosoma myelopathy.
Topics: Adult; Animals; Antibodies, Protozoan; Antiprotozoal Agents; Enzyme-Linked Immunosorbent Assay; Fece | 2010 |
Effects of in vitro cultivated Calculus Bovis compound on pulmonary lesions in rabbits with schistosomiasis.
Topics: Animals; Anthelmintics; Bilirubin; Disease Models, Animal; Drugs, Chinese Herbal; Fibronectins; Hype | 2010 |
Schistosomiasis among recreational users of Upper Nile River, Uganda, 2007.
Topics: Adolescent; Adult; Aged; Animals; Anthelmintics; Antibodies, Helminth; Female; Humans; Male; Middle | 2010 |
Eggs in the kidney.
Topics: Animals; Anthelmintics; Child; Glomerulonephritis, Membranoproliferative; Humans; Kidney; Male; Neph | 2010 |
Jejunal perforation caused by schistosomiasis.
Topics: Abdomen, Acute; Adult; Anastomosis, Surgical; Animals; Anthelmintics; Humans; Intestinal Perforation | 2010 |
An unusual pedunculated polyp of the transverse colon associated with schistosomiasis.
Topics: Anthelmintics; Colonic Polyps; Colonoscopy; Combined Modality Therapy; Diagnosis, Differential; Fema | 2010 |
The impact of single versus mixed schistosome species infections on liver, spleen and bladder morbidity within Malian children pre- and post-praziquantel treatment.
Topics: Adolescent; Animals; Anthelmintics; Child; Comorbidity; Female; Humans; Liver; Male; Mali; Praziquan | 2010 |
Change of semen quality after foreign travel: a rare presentation of genital schistosomiasis.
Topics: Adult; Animals; Anthelmintics; Humans; Male; Praziquantel; Reproductive Tract Infections; Schistosom | 2012 |
Succinate cytochrome c reductase in schistosomiasis: in vitro inhibition by some schistosomicidal drugs.
Topics: 2,6-Dichloroindophenol; Animals; Hot Temperature; In Vitro Techniques; Kinetics; Male; Mice; Mitocho | 2010 |
Schistosomiasis and vesicovaginal fistula.
Topics: Animals; Anthelmintics; Female; Humans; Praziquantel; Schistosoma haematobium; Schistosomiasis; Vesi | 2009 |
Africa is desperate for praziquantel.
Topics: Africa South of the Sahara; Child; Drug Costs; Humans; Praziquantel; Schistosomiasis; Schistosomicid | 2010 |
Modelling within host parasite dynamics of schistosomiasis.
Topics: Adult; Animals; Cercaria; Child; Computer Simulation; Eosinophils; Host-Parasite Interactions; Human | 2010 |
Recurrent perirectal abscess.
Topics: Abscess; Animals; Anthelmintics; Anus Diseases; Chronic Disease; Drainage; Endemic Diseases; Humans; | 2010 |
An inclusive dose pole for treatment of schistosomiasis in infants and preschool children with praziquantel.
Topics: Africa South of the Sahara; Anthelmintics; Body Height; Child, Preschool; Clinical Protocols; Cost-B | 2010 |
Efficient multicomponent reaction synthesis of the schistosomiasis drug praziquantel.
Topics: Magnetic Resonance Spectroscopy; Molecular Structure; Praziquantel; Schistosomiasis; Schistosomicide | 2010 |
Small-duct sclerosing cholangitis associated with Schistosoma mansoni.
Topics: Adolescent; Animals; Anthelmintics; Biopsy; Cholangitis, Sclerosing; Female; Humans; Liver; Praziqua | 2011 |
Piggy-backing the concept of cancer drugs for schistosomiasis treatment: a tangible perspective?
Topics: Animals; Drug Resistance; Humans; Praziquantel; Protein Kinase Inhibitors; Protein Kinases; Schistos | 2011 |
An uncommon cause of portal hypertension: schistosomiasis.
Topics: Adult; Animals; Anthelmintics; Antihypertensive Agents; Hepatomegaly; Humans; Hypertension, Portal; | 2011 |
An unusual case of hematochezia: a rectal Bilharzioma.
Topics: Biopsy, Needle; Brazil; Colonoscopy; Combined Modality Therapy; Emigration and Immigration; Follow-U | 2011 |
[Population targeted treatment against schistosomiasis].
Topics: Anthelmintics; Global Health; Humans; Praziquantel; Schistosomiasis | 2011 |
Incidental hepatic schistosomiasis in a liver transplant recipient.
Topics: Animals; Anthelmintics; Humans; Hypertension, Portal; Liver; Liver Cirrhosis; Liver Diseases, Parasi | 2012 |
Schistosomiasis elimination.
Topics: Africa South of the Sahara; Animals; Environmental Pollutants; Humans; Molluscacides; Praziquantel; | 2011 |
Simultaneous administration of praziquantel, ivermectin and albendazole, in a community in rural northern Ghana endemic for schistosomiasis, onchocerciasis and lymphatic filariasis.
Topics: Adolescent; Albendazole; Child; Drug Therapy, Combination; Elephantiasis, Filarial; Endemic Diseases | 2011 |
Human schistosomiasis resistance to praziquantel in China: should we be worried?
Topics: Adolescent; Adult; Child; Child, Preschool; China; Drug Resistance; Humans; Middle Aged; Praziquante | 2011 |
Developing novel strategies to prevent parasitic infections.
Topics: Animals; Anthelmintics; Antimalarials; Artemisinins; Carrier Proteins; Clinical Protocols; Drug Desi | 2011 |
Towards nationwide control of schistosomiasis in Yemen: a pilot project to expand treatment to the whole community.
Topics: Adolescent; Albendazole; Anthelmintics; Child; Community Health Services; Female; Humans; Male; Pilo | 2011 |
Open science is a research accelerator.
Topics: Anthelmintics; Chemistry, Pharmaceutical; Humans; Praziquantel; Research; Schistosomiasis; Software; | 2011 |
Clinical and imaging characteristics of cerebral schistosomiasis.
Topics: Adult; Anthelmintics; Diagnosis, Differential; Diagnostic Errors; Female; Humans; Magnetic Resonance | 2012 |
Resolution of praziquantel.
Topics: Anthelmintics; Chemistry, Pharmaceutical; Humans; International Cooperation; Praziquantel; Schistoso | 2011 |
Schistosomiasis.
Topics: Animals; Anthelmintics; Endemic Diseases; Humans; Life Cycle Stages; Praziquantel; Schistosoma; Schi | 2011 |
MCR synthesis of praziquantel derivatives.
Topics: Animals; Anthelmintics; Chemistry Techniques, Synthetic; Cricetinae; Crystallography, X-Ray; Humans; | 2012 |
[One case of acute kidney injury caused by praziquantel].
Topics: Acute Kidney Injury; Adult; Anthelmintics; Humans; Male; Praziquantel; Schistosomiasis | 2011 |
[Temperature recrudescence caused by praziquantel treatment after falling to normal automatically in acute schistosomiasis patients: a report of 19 cases].
Topics: Adolescent; Adult; Body Temperature; Female; Fever; Humans; Male; Praziquantel; Recurrence; Schistos | 2011 |
Lung nodules, fever, and eosinophilia in a traveler returning from Madagascar.
Topics: Adult; Animals; Anthelmintics; Eosinophilia; Fever; Humans; Lung; Madagascar; Male; Praziquantel; Ra | 2012 |
First Universities Allied for Essential Medicines (UAEM) Neglected Diseases and Innovation Symposium.
Topics: Access to Information; Animals; Anthelmintics; Biomedical Research; Developing Countries; Drug Indus | 2012 |
Quantification and clustering of phenotypic screening data using time-series analysis for chemotherapy of schistosomiasis.
Topics: Algorithms; Computational Biology; Drug Evaluation, Preclinical; Humans; Lovastatin; Phenotype; Praz | 2012 |
[Compliance of film-coated praziquantel tablets in schistosomiasis transmission-controlled areas].
Topics: Adolescent; Adult; Aged; China; Female; Humans; Male; Medication Adherence; Middle Aged; Praziquante | 2011 |
Chronic infection drives expression of the inhibitory receptor CD200R, and its ligand CD200, by mouse and human CD4 T cells.
Topics: Adolescent; Animals; Anthelmintics; Antigens, CD; Antigens, Surface; CD4-Positive T-Lymphocytes; Cel | 2012 |
Five-year longitudinal assessment of the downstream impact on schistosomiasis transmission following closure of the Three Gorges Dam.
Topics: Adolescent; Adult; Aged; Animals; Anthelmintics; Cattle; Child; Child, Preschool; China; Cohort Stud | 2012 |
Do not forget schistosomiasis: a rare cause of changes in ejaculate.
Topics: Adult; Animals; Anthelmintics; Humans; Male; Praziquantel; Schistosoma; Schistosomiasis; Spermatozoa | 2012 |
An increasingly notorious mimicker of testicular tumours; crossing borders.
Topics: Adult; Anthelmintics; Diagnosis, Differential; Emigration and Immigration; Humans; Malaysia; Male; O | 2011 |
Acute febrile respiratory reaction after praziquantel treatment during asymptomatic late form of acute schistosomiasis.
Topics: Acute Disease; Adolescent; Cough; Diagnosis, Differential; Dyspnea; Fever; Humans; Male; Praziquante | 2012 |
Gene profile of chemokines on hepatic stellate cells of schistosome-infected mice and antifibrotic roles of CXCL9/10 on liver non-parenchymal cells.
Topics: Animals; Chemokine CXCL10; Chemokine CXCL11; Chemokine CXCL9; Chemokines; Female; Gene Expression Pr | 2012 |
Meeting of the International Task Force for Disease Eradication, April 2012.
Topics: Anthelmintics; Disease Eradication; Endemic Diseases; Global Health; Health Education; Humans; Prazi | 2012 |
An unusual presentation of a common infection.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Blood Sedimentation; CD8-Positive T-Lymphocytes; Epst | 2013 |
Integrated community-directed intervention for schistosomiasis and soil transmitted helminths in western Kenya - a pilot study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albendazole; Animals; Anthelmintics; Child; Child, Presc | 2012 |
Determining treatment needs at different spatial scales using geostatistical model-based risk estimates of schistosomiasis.
Topics: Adolescent; Africa; Anthelmintics; Chemoprevention; Child; Child, Preschool; Female; Humans; Male; P | 2012 |
Decades down the line: the viability of praziquantel for future schistosomiasis treatment.
Topics: Animals; Anthelmintics; Drug Resistance; Humans; Parasite Load; Praziquantel; Schistosoma; Schistoso | 2012 |
Integrated analysis of innate, Th1, Th2, Th17, and regulatory cytokines identifies changes in immune polarisation following treatment of human schistosomiasis.
Topics: Adolescent; Animals; Anthelmintics; Child; Child, Preschool; Cytokines; Female; Humans; Immunity, In | 2013 |
The porcelain bladder: schistosomiasis.
Topics: Adult; Anthelmintics; Calcinosis; Chronic Disease; Contrast Media; Cystitis; Dysuria; Emigrants and | 2012 |
Schistosomiasis in 2012: current status and key research priorities required for control leading to elimination.
Topics: Anthelmintics; Biomedical Research; Humans; Neglected Diseases; Praziquantel; Schistosomiasis | 2012 |
A worm vaccine, coming at a snail's pace.
Topics: Animals; Anthelmintics; Biomedical Research; Brazil; Drug Resistance; Female; Humans; Male; Praziqua | 2013 |
Schistosomiasis.
Topics: Acute Disease; Artemether; Artemisinins; Humans; Praziquantel; Schistosomiasis; Schistosomicides; Se | 2002 |
Schistosomiasis.
Topics: Humans; Praziquantel; Schistosomiasis; Schistosomicides; Spinal Cord Diseases | 2002 |
Vulvar lesion in a 45-year-old woman.
Topics: Anthelmintics; Biopsy, Needle; Female; Follow-Up Studies; Humans; Immunohistochemistry; Middle Aged; | 2002 |
Lymphatic filariasis elimination and schistosomiasis control in combination with onchocerciasis control in Nigeria.
Topics: Anthelmintics; Elephantiasis, Filarial; Health Education; Health Knowledge, Attitudes, Practice; Hum | 2002 |
Hematospermia due to schistosome infection in travelers: diagnostic and treatment challenges.
Topics: Adult; Animals; Anthelmintics; Blood; Hematuria; Humans; Male; Praziquantel; Schistosoma haematobium | 2002 |
Evaluation of the patterns of Schistosoma mansoni infection and re-infection in Senegal, from faecal egg counts and serum concentrations of circulating anodic antigen.
Topics: Adolescent; Adult; Age Factors; Animals; Anthelmintics; Antigens, Helminth; Child; Child, Preschool; | 2002 |
[The role of chemotherapy in reducing the schistosom infection rate of livestock and schistosomiasis transmission in Dongting lake area].
Topics: Animals; Animals, Domestic; Cattle; Longitudinal Studies; Praziquantel; Schistosomiasis; Schistosomi | 1999 |
Pilot study of schistosomiasis control in Poyang lake region.
Topics: Adolescent; Adult; Antiplatyhelmintic Agents; Child; China; Health Education; Humans; Middle Aged; P | 1999 |
[Compliance analysis of the residents with mass medical treatment in areas highly endemic for schistosomiasis].
Topics: Adolescent; Adult; Female; Health Knowledge, Attitudes, Practice; Humans; Male; Middle Aged; Patient | 2000 |
[Observation on the effect of irrigation ditch reform and chemotherapy of humans and animals in the control of schistosomiasis].
Topics: Animals; Anthelmintics; Cattle; Communicable Disease Control; Disease Reservoirs; Humans; Praziquant | 2000 |
Evaluation of the 1992-1999 World Bank Schistosomiasis Control Project in China.
Topics: Adolescent; Animals; Anthelmintics; Buffaloes; Cattle; Child; China; Endemic Diseases; Humans; Prazi | 2003 |
Hematospermia due to schistosome infection in travelers.
Topics: Anthelmintics; Humans; Male; Praziquantel; Schistosomiasis; Spermatozoa; Travel | 2003 |
High tissue egg burden mechanically impairing the tubal motility in genital schistosomiasis of the female.
Topics: Adult; Animals; Diagnosis, Differential; Fallopian Tubes; Female; Genital Diseases, Female; Humans; | 2003 |
[Evaluation of exercise tolerance in patients treated with praziquantel for chronic schistosomiasis with no signs of cardiopulmonary impairment].
Topics: Adult; Anthelmintics; Chronic Disease; Exercise Test; Exercise Tolerance; Female; Humans; Lung Disea | 2003 |
[Importance of hepatic bilharziasis in liver pathologies in the internal medicine department of the National Hospital of Point "G", Bamako-Mali].
Topics: Adolescent; Adult; Aged; Anthelmintics; Biopsy; Child; Female; Granuloma; Hepatomegaly; Hospital Dep | 1996 |
Evaluation of case management in the integrated schistosomiasis-control programme in Mali.
Topics: Case Management; Costs and Cost Analysis; Endemic Diseases; Hematuria; Humans; Mali; Praziquantel; P | 2003 |
[Detection of serum transforming growth factor beta 1 in diagnosis of hepatic fibrosis in schistosomiasis and evaluation of treatment efficacy].
Topics: Anthelmintics; Humans; Liver Cirrhosis; Praziquantel; Schistosomiasis; Transforming Growth Factor be | 2003 |
Integrated community-directed treatment for the control of onchocerciasis, schistosomiasis and intestinal helminths infections in Uganda: advantages and disadvantages.
Topics: Adolescent; Anthelmintics; Child; Child, Preschool; Community Health Services; Decision Making; Feas | 2003 |
Interactions between Schistosoma haematobium and human immunodeficiency virus type 1: the effects of coinfection on treatment outcomes in rural Zambia.
Topics: Adolescent; Adult; Animals; Anthelmintics; Child; Cohort Studies; Drug Administration Schedule; Fema | 2003 |
First report of Schistosoma mekongi infection with brain involvement.
Topics: Adrenal Cortex Hormones; Adult; Animals; Anthelmintics; Brain; Cambodia; Humans; Laos; Male; Praziqu | 2004 |
Measuring schistosomiasis case management of the health services in Ghana and Mali.
Topics: Adult; Analysis of Variance; Anthelmintics; Anti-Bacterial Agents; Case Management; Child; Delivery | 2004 |
Schistosomiasis control.
Topics: Africa; Anthelmintics; Communicable Disease Control; Financing, Organized; Humans; Praziquantel; Sch | 2004 |
Sex- and stage-related sensitivity of Schistosoma mansoni to in vivo and in vitro praziquantel treatment.
Topics: Animals; Anthelmintics; Biomphalaria; Female; Gender Identity; Life Cycle Stages; Male; Mice; Mice, | 2004 |
Schistosomiasis.
Topics: Animals; Anthelmintics; Female; Genome; Humans; Praziquantel; Pregnancy; Pregnancy Complications, Pa | 2004 |
Peritoneal schistosomiasis: an unusual laparoscopic finding.
Topics: Adolescent; Appendicitis; Diagnosis, Differential; Granuloma; Humans; Incidental Findings; Laparosco | 2004 |
Quantitative evaluation of integrated schistosomiasis control: the example of passive case finding in Ghana.
Topics: Adolescent; Adult; Child; Delivery of Health Care, Integrated; Endemic Diseases; Ghana; Hematuria; H | 2004 |
Chemotherapy for schistosomiasis in Ugandan fishermen: treatment can cause a rapid increase in interleukin-5 levels in plasma but decreased levels of eosinophilia and worm-specific immunoglobulin E.
Topics: Adolescent; Adult; Animals; Anthelmintics; Eosinophils; Humans; Immunoglobulin E; Interleukin-5; Mal | 2004 |
[Urogenital bilharziasis: imaging diagnosis].
Topics: Adult; Biopsy; Chronic Disease; Cystitis; Diagnosis, Differential; France; Hematuria; Humans; Male; | 2004 |
Is praziquantel therapy safe during pregnancy?
Topics: Abnormalities, Drug-Induced; Adult; Anthelmintics; Child, Preschool; Endemic Diseases; Female; Human | 2004 |
Increases in human T helper 2 cytokine responses to Schistosoma mansoni worm and worm-tegument antigens are induced by treatment with praziquantel.
Topics: Adolescent; Adult; Animals; Anthelmintics; Antigens, Helminth; Cells, Cultured; Child; Cohort Studie | 2004 |
The WHO dose pole for the administration of praziquantel is also accurate in non-African populations.
Topics: Adolescent; Adult; Anthelmintics; Body Height; Body Weight; Child; Child, Preschool; Drug Administra | 2005 |
Trematodes in two travellers.
Topics: Adult; Animals; Anthelmintics; Diagnosis, Differential; Female; Hematuria; Humans; Male; Praziquante | 2005 |
A six-year follow-up of schoolchildren for urinary and intestinal schistosomiasis and soil-transmitted helminthiasis in Northern Tanzania.
Topics: Adolescent; Animals; Anthelmintics; Child; Cross-Sectional Studies; Feces; Female; Follow-Up Studies | 2005 |
Effects of praziquantel and artesunate on the tegument of adult Schistosoma mekongi harboured in mice.
Topics: Animals; Anthelmintics; Artemisinins; Artesunate; Female; Male; Mice; Mice, Inbred ICR; Microscopy, | 2005 |
Schistosomiasis.
Topics: Adult; Animals; Anthelmintics; Biopsy; Colon; Diagnosis, Differential; Female; Humans; Praziquantel; | 2005 |
On the role of schistosome mating structure in the maintenance of drug resistant strains.
Topics: Animals; Anthelmintics; Drug Resistance; Female; Humans; Male; Models, Biological; Praziquantel; Sch | 2005 |
[Effect of feces management and chemotherapy in the control of cattle schistosomiasis in lake region].
Topics: Animals; Anthelmintics; Cattle; Cattle Diseases; Feces; Praziquantel; Schistosomiasis | 2005 |
Schistosomiasis of the spinal cord presenting as progressive myelopathy. Case report.
Topics: Anthelmintics; Humans; Male; Middle Aged; Myelitis; Praziquantel; Schistosomiasis | 2005 |
Imported Katayama fever: clinical and biological features at presentation and during treatment.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Africa South of the Sahara; Anthelmintics; Anti-Inflamma | 2006 |
New initiatives against Africa's worms.
Topics: Africa; Anthelmintics; Child; Helminthiasis; Humans; Infectious Disease Transmission, Vertical; Praz | 2006 |
In vitro effect of schistosomicidal drugs on hepatic arylsulfatase B from the schistosoma-infected mouse.
Topics: Animals; Anthelmintics; Catalysis; Commiphora; Immunization; Immunoprecipitation; In Vitro Technique | 2006 |
Treatment efficacy and regulatory host responses in chronic experimental Schistosoma bovis infections in goats.
Topics: Animals; Anthelmintics; Chronic Disease; Feces; Goat Diseases; Goats; Hemoglobins; Liver; Male; Para | 2006 |
Mazzotti reaction after presumptive treatment for schistosomiasis and strongyloidiasis in a Liberian refugee.
Topics: Adolescent; Albendazole; Animals; Anthelmintics; Humans; Ivermectin; Liberia; Male; Praziquantel; Re | 2006 |
Schistosomiasis and HIV in rural Zimbabwe: efficacy of treatment of schistosomiasis in individuals with HIV coinfection.
Topics: Adult; Anthelmintics; Antigens, Helminth; CD4 Lymphocyte Count; Feces; Female; HIV Infections; Human | 2006 |
Carriage of DRB1*13 is associated with increased posttreatment IgE levels against Schistosoma mansoni antigens and lower long-term reinfection levels.
Topics: Adolescent; Adult; Amino Acid Sequence; Analysis of Variance; Animals; Anthelmintics; Antibodies, He | 2006 |
Effects of repeated praziquantel treatment on schistosomiasis mekongi morbidity as detected by ultrasonography.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Anthelmintics; Cambodia; Child; Female; Humans; | 2006 |
Breast: a rare localization of schistosomiasis.
Topics: Adult; Anthelmintics; Breast Diseases; Female; Humans; Praziquantel; Schistosomiasis; Treatment Outc | 2007 |
Schistosomiasis in Swedish travellers to sub-Saharan Africa: Can we rely on serology?
Topics: Adolescent; Adult; Africa South of the Sahara; Aged; Animals; Antibodies, Helminth; Drug Monitoring; | 2006 |
Control of Schistosoma mekongi in Cambodia: results of eight years of control activities in the two endemic provinces.
Topics: Adolescent; Adult; Aged; Cambodia; Child; Child, Preschool; Endemic Diseases; Humans; Middle Aged; P | 2007 |
Willingness to pay for praziquantel treatment in a hyperendemic community of Ogun State, Nigeria.
Topics: Adolescent; Adult; Anthelmintics; Endemic Diseases; Feasibility Studies; Fees, Pharmaceutical; Femal | 2006 |
Schistosomiasis in African infants and preschool children: to treat or not to treat?
Topics: Africa; Age Factors; Animals; Anthelmintics; Child, Preschool; Female; Humans; Hygiene; Infant; Male | 2007 |
Schistosomiasis among travelers: new aspects of an old disease.
Topics: Acute Disease; Adult; Chronic Disease; Female; Humans; Male; Praziquantel; Schistosomiasis; Travel | 2006 |
Impact of a national helminth control programme on infection and morbidity in Ugandan schoolchildren.
Topics: Adolescent; Albendazole; Ancylostoma; Animals; Anthelmintics; Child; Female; Health Promotion; Helmi | 2007 |
Pharmacodynamics of pentoxifylline and/or praziquantel in murine schistosomiasis mansoni.
Topics: Animals; Anthelmintics; Disease Models, Animal; Granuloma; Male; Mice; Pentoxifylline; Praziquantel; | 2007 |
Urinary schistosomiasis: an uncommon cause of gross hematuria in the industrialized countries.
Topics: Animals; Anthelmintics; Black or African American; Black People; Child; Developed Countries; Follow- | 2007 |
Asymptomatic schistosomiasis in a young Sudanese refugee.
Topics: Adolescent; Animals; Anthelmintics; Australia; Fibrosis; Humans; Male; Praziquantel; Refugees; Schis | 2007 |
[Clustered cases of urinary and intestinal bilharziasis in French military personnel].
Topics: Anthelmintics; France; Humans; Intestinal Diseases, Parasitic; Military Personnel; Praziquantel; Sch | 2007 |
Sociocultural aspects of mass delivery of praziquantel in schistosomiasis control: the Abeokuta experience.
Topics: Adolescent; Adult; Anthelmintics; Attitude to Health; Child; Child, Preschool; Culture; Female; Focu | 2007 |
Liver morbidity due to Schistosoma mekongi in Cambodia after seven rounds of mass drug administration.
Topics: Adolescent; Adult; Aged; Animals; Cambodia; Cross-Sectional Studies; Female; Hepatomegaly; Humans; L | 2007 |
Resisting control of neglected tropical diseases: dilemmas in the mass treatment of schistosomiasis and soil-transmitted helminths in north-west Uganda.
Topics: Adult; Albendazole; Animals; Anthelmintics; Female; Geography; Health Education; Helminthiasis; Helm | 2008 |
Cough and alterations in semen after a tropical swim.
Topics: Adult; Animals; Antiparasitic Agents; Cough; Genital Diseases, Male; Hemospermia; Humans; Malawi; Ma | 2007 |
Re: is actin the praziquantel receptor?
Topics: Actins; Animals; Anthelmintics; Humans; Praziquantel; Receptors, Drug; Schistosoma; Schistosomiasis | 2007 |
Leave children untreated and sustain inequity!
Topics: Age Factors; Animals; Anthelmintics; Child, Preschool; Dose-Response Relationship, Drug; Ethics, Med | 2007 |
Height as a substitute for weight for estimating praziquantel dosage.
Topics: Adolescent; Adult; Anthelmintics; Body Height; Body Weight; Child; Child, Preschool; Dose-Response R | 2007 |
Triple drug administration (TDA), with praziquantel, ivermectin and albendazole, for the prevention of three neglected tropical diseases in Nigeria.
Topics: Albendazole; Anthelmintics; Antiparasitic Agents; Cost-Benefit Analysis; Drug Interactions; Drug The | 2008 |
Drug discovery: schistosome treatment.
Topics: Animals; Anthelmintics; Antioxidants; Cell Line; Drug Evaluation, Preclinical; Drug Resistance; Huma | 2008 |
Seroprevalence of schistosomiasis in African patients infected with HIV.
Topics: Adult; Africa South of the Sahara; Animals; Enzyme-Linked Immunosorbent Assay; Feces; Female; HIV In | 2008 |
Ectopic cutaneous schistosomiasis-perigenital infiltrative granulomata in a 34-year-old French pregnant woman.
Topics: Administration, Oral; Adult; Anal Canal; Anthelmintics; Diagnosis, Differential; Female; France; Gra | 2008 |
The evaluation of control measures against Schistosoma mekongi in Cambodia by a mathematical model.
Topics: Animals; Anthelmintics; Cambodia; Dog Diseases; Dogs; Humans; Models, Biological; Praziquantel; Prev | 2008 |
Clinical study on cerebral schistosomiasis japonica on Leyte Island, Philippines: follow-up study 6 years after treatment with antischistosomal drugs.
Topics: Adult; Anticonvulsants; Benzenesulfonates; Brain Diseases; Drug Therapy, Combination; Female; Humans | 1984 |
Praziquantel: a new hope for schistosomiasis.
Topics: Dose-Response Relationship, Drug; Humans; Isoquinolines; Praziquantel; Schistosoma haematobium; Schi | 1980 |
[Effects of pyquiton on pulmonary S. japonicum egg granulomas in sensitized mice].
Topics: Animals; Female; Granuloma; Isoquinolines; Levamisole; Lung Diseases, Parasitic; Mice; Ovum; Praziqu | 1984 |
Three cases of schistosomiasis mekongi from northern Laos.
Topics: Adult; Asia, Southeastern; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Huma | 1984 |
Side effects of praziquantel in the treatment of Schistosoma mansoni in Maniema, Zaire.
Topics: Adolescent; Adult; Child; Child, Preschool; Democratic Republic of the Congo; Diarrhea; Feces; Femal | 1984 |
Variations of titers of immunofluorescent antibody against cercaria, adult and egg antigens developed in rabbits infected with Schistosoma japonicum before and after treatment with praziquantel.
Topics: Animals; Antibodies; Antigen-Antibody Reactions; Female; Fluorescent Antibody Technique; Male; Ovum; | 1984 |
Schistosomiasis mekongi diagnosed by rectal biopsy.
Topics: Adult; Biopsy; Humans; Intestinal Mucosa; Male; Praziquantel; Rectum; Schistosoma; Schistosomiasis | 1983 |
Synergy of concurrent low dose oxamniquine and praziquantel in schistosomiasis.
Topics: Adolescent; Adult; Child; Drug Synergism; Drug Therapy, Combination; Female; Humans; Isoquinolines; | 1983 |
[Profile of the new antihelminthic drug praziquantel for the therapy of tropical worm infections].
Topics: Cestode Infections; Drug Administration Schedule; Humans; Isoquinolines; Praziquantel; Schistosomias | 1983 |
[Praziquantel in the treatment of helminthiasis].
Topics: Animals; Cysticercosis; Echinococcosis; Helminthiasis; Humans; Isoquinolines; Praziquantel; Schistos | 1984 |
[Studies on the enzyme linked immunosorbent assay (ELISA) for evaluation of cure in schistosomiasis (author's transl)].
Topics: Adolescent; Adult; Aged; Child; Enzyme-Linked Immunosorbent Assay; Female; Humans; Immunoenzyme Tech | 1980 |
[Comparative study on pyquiton and nithiocyamin in treating Schistosomiasis japonica (author's transl)].
Topics: Adolescent; Adult; Aniline Compounds; Child; Diphenylamine; Female; Follow-Up Studies; Humans; Isoqu | 1981 |
[Analysis of 62 cases of acute schistosomiasis japonica treated with pyquiton or nithiocyamine].
Topics: Acute Disease; Adolescent; Adult; Aniline Compounds; Child; Child, Preschool; Diphenylamine; Female; | 1981 |
[Clinical studies on treatment of schistosomiasis japonica with a combination of pyquiton and furapromide].
Topics: Adolescent; Adult; Child; Drug Therapy, Combination; Female; Humans; Isoquinolines; Male; Middle Age | 1981 |
[Evaluation of praziquantel on rabbit liver cirrhosis due to schistosomiasis according to pathological changes (author's transl)].
Topics: Animals; Hepatic Artery; Isoquinolines; Liver Cirrhosis; Praziquantel; Rabbits; Radiography; Schisto | 1982 |
Treatment of bilharzial obstructive uropathy with praziquantel.
Topics: Adolescent; Child; Humans; Isoquinolines; Male; Praziquantel; Schistosoma haematobium; Schistosomias | 1984 |
Treatment of Schistosoma mekongi with praziquantel in Cambodian refugees in holding centres in Prachinburi Province, Thailand.
Topics: Adolescent; Adult; Aged; Cambodia; Child; Female; Humans; Isoquinolines; Male; Middle Aged; Praziqua | 1984 |
Seroepidemiology of schistosomiasis japonica by ELISA in the Philippines. III. Selective mass chemotherapy with praziquantel in a control program.
Topics: Antibodies; Child; Feces; Female; Humans; Isoquinolines; Male; Philippines; Praziquantel; Schistosom | 1984 |
Schistosomiasis and praziquantel.
Topics: Adolescent; Child; Drug Administration Schedule; Humans; Isoquinolines; Praziquantel; Schistosoma ha | 1984 |
Urinary schistosomiasis: a report of four cases and a review.
Topics: Child; Female; Humans; Male; Praziquantel; Schistosoma haematobium; Schistosomiasis; Urinary Tract I | 1984 |
The immunological aspects of praziquantel in unsensitized mice with experimentally induced schistosome pulmonary granuloma.
Topics: Animals; Antibody Formation; Antimony Potassium Tartrate; Cell Migration Inhibition; Granuloma; Hype | 1984 |
[Severe side effects of pyquiton in the treatment of 9 cases of schistosomiasis].
Topics: Adult; Drug Hypersensitivity; Female; Fever; Humans; Isoquinolines; Male; Middle Aged; Praziquantel; | 1984 |
[Clinical observation on 121 cases of acute schistosomiasis treated with pyquiton].
Topics: Acute Disease; Adolescent; Adult; Child; Humans; Isoquinolines; Male; Middle Aged; Praziquantel; Sch | 1984 |
[Allergic manifestation after pyquiton treatment of schistosomiasis].
Topics: Drug Hypersensitivity; Female; Humans; Isoquinolines; Middle Aged; Praziquantel; Schistosomiasis | 1984 |
[New developments in the clinical study of praziquantel].
Topics: Clonorchiasis; Cysticercosis; Humans; Intestinal Diseases, Parasitic; Isoquinolines; Paragonimiasis; | 1984 |
Pharmacokinetic studies on praziquantel and oxamniquine in intestinal schistosomiasis.
Topics: Adolescent; Humans; Intestinal Diseases, Parasitic; Isoquinolines; Kinetics; Male; Nitroquinolines; | 1984 |
Assessment of efficacy of praziquantel against Schistosoma mansoni infection.
Topics: Child; Humans; Isoquinolines; Praziquantel; Recurrence; Schistosoma mansoni; Schistosomiasis | 1984 |
Human trematode infections.
Topics: Anthelmintics; Asia, Southeastern; Bithionol; Clonorchiasis; Hexylresorcinol; Humans; Opisthorchiasi | 1984 |
Epidemiology and transmission dynamics; evaluation of control measures by means of annual incidence of infection with Schistosoma japonicum among school children at Dagami, Leyte, Philippines.
Topics: Child; Humans; Isoquinolines; Philippines; Praziquantel; Schistosoma japonicum; Schistosomiasis; Sch | 1984 |
Clinical study on hepatosplenomegalic schistosomiasis japonica on Leyte Island: follow-up study 4 years after treatment with praziquantel.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Drug Evaluation; Female; Follow-Up Studies; Hepato | 1984 |
The present status of schistosomiasis in the Philippines.
Topics: Animals; Disease Vectors; Health Education; Humans; Pest Control; Philippines; Praziquantel; Regiona | 1984 |
Hepatosplenic schistosomiasis in a South-East Asian refugee child in South Australia.
Topics: Australia; Child; Humans; Laos; Liver Diseases, Parasitic; Male; Praziquantel; Refugees; Schistosomi | 1983 |
An uncommon cause of hematuria: the patient's story.
Topics: Hematuria; Humans; Male; Middle Aged; Praziquantel; Schistosoma haematobium; Schistosomiasis | 1984 |
[Effect of pyquiton derivatives in experimental schistosomiasis japonica].
Topics: Animals; Dogs; Isoquinolines; Mice; Praziquantel; Rabbits; Schistosoma japonicum; Schistosomiasis; S | 1983 |
Correction: praziquantel and schistosomiasis treatment.
Topics: Humans; Isoquinolines; Praziquantel; Schistosomiasis | 1983 |
[One-dose regimen of praziquantel in the treatment of chronic schistosomiasis japonica].
Topics: Adult; Child; Electrocardiography; Humans; Isoquinolines; Liver; Praziquantel; Schistosoma japonicum | 1983 |
Effect of oxamniquine and praziquantel on cell mediated immunity in intestinal bilharziasis.
Topics: Humans; Immunity, Cellular; Isoquinolines; Nitroquinolines; Oxamniquine; Praziquantel; Schistosoma m | 1983 |
Observations on cattle schistosomiasis in the Sudan, a study in comparative medicine. V. The effect of praziquantel therapy on naturally acquired resistance to Schistosoma bovis.
Topics: Animals; Cattle; Cattle Diseases; Immunity, Active; Isoquinolines; Parasite Egg Count; Praziquantel; | 1983 |
Schistosomiasis and praziquantel.
Topics: Adolescent; Child; Humans; Isoquinolines; Praziquantel; Schistosomiasis | 1983 |
Morbidity in schistosomiasis japonica in relation to intensity of infection. A study of two rural brigades in Anhui Province, China.
Topics: Adolescent; Adult; Child; Child, Preschool; China; Feces; Female; Hepatomegaly; Humans; Male; Medica | 1983 |
Treatment with praziquantel in a patient with schistosomiasis and chronic renal failure.
Topics: Adult; Humans; Isoquinolines; Kidney Failure, Chronic; Kinetics; Male; Praziquantel; Renal Dialysis; | 1983 |
The effect of praziquantel therapy on the histopathological and parasitological aspects of experimental schistosomiasis mansoni.
Topics: Animals; Cricetinae; Isoquinolines; Liver; Praziquantel; Schistosoma mansoni; Schistosomiasis | 1983 |
Praziquantel in the treatment of bilharzia.
Topics: Costs and Cost Analysis; Humans; Isoquinolines; Praziquantel; Schistosomiasis; Zimbabwe | 1983 |
A retrospective survey on side effects of praziquantel among 25,693 cases of schistosomiasis japonica.
Topics: Adolescent; Adult; Aged; Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Child; Chi | 1983 |
[Treatment of 700 cases of bilharziasis with the new drugs oxamniquine, oltipraz, praziquantel].
Topics: Adolescent; Adult; Child; Child, Preschool; Humans; Isoquinolines; Middle Aged; Nitroquinolines; Oxa | 1983 |
[Comparative study on various dose schedules of praziquantel in the treatment of schistosomiasis japonica].
Topics: Adolescent; Adult; Aged; Child; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Iso | 1983 |
[Clinical observation on pyquiton treatment of 20 cases of schistosomiasis complicated with cardiovascular diseases].
Topics: Adult; Aged; Cardiovascular Diseases; Electrocardiography; Female; Humans; Isoquinolines; Male; Midd | 1983 |
[A retrospective survey on serious side-effects of pyquiton among 25,693 cases of schistosomiasis japonica].
Topics: Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Female; Humans; Isoquinolines; Male | 1983 |
The treatment of experimental schistosomiasis with a combination of oxamniquine and praziquantel.
Topics: Animals; Drug Combinations; Drug Synergism; Female; Isoquinolines; Mice; Mice, Inbred Strains; Nitro | 1983 |
[Praziquantel in the treatment of schistosomiasis].
Topics: Adult; Child; Feces; Female; Humans; Isoquinolines; Male; Parasite Egg Count; Praziquantel; Schistos | 1983 |
Treatment of hepatosplenic Schistosomiasis mansoni with praziquantel. Preliminary report on tolerance and efficacy.
Topics: Adolescent; Adult; Child; Electrocardiography; Electroencephalography; Female; Humans; Isoquinolines | 1983 |
[Urogenital bilharziasis in Germany].
Topics: Administration, Oral; Adult; Germany, West; Humans; Kidney Diseases; Male; Praziquantel; Prognosis; | 1984 |
Praziquantel and refugee health.
Topics: Asia, Southeastern; Cestode Infections; Clonorchiasis; Humans; Isoquinolines; Praziquantel; Refugees | 1984 |
Effect of praziquantel on antigenemia in murine schistosomiasis.
Topics: Animals; Antigens; Female; Guinea Pigs; Immunoenzyme Techniques; Isoquinolines; Mice; Praziquantel; | 1982 |
[Praziquantel and oltipraz, 2 new polyvalent anthelmintics].
Topics: Animals; Anthelmintics; Humans; Isoquinolines; Mice; Praziquantel; Pyrazines; Rats; Schistosomiasis; | 1982 |
[Medical parasitology and development aid (author's transl)].
Topics: Animals; Chagas Disease; Developing Countries; Humans; Parasitic Diseases; Parasitic Diseases, Anima | 1981 |
The six diseases of WHO. Schistosomiasis: some advances.
Topics: Humans; Molluscacides; Oxamniquine; Praziquantel; Schistosomiasis; Snails; Trichlorfon | 1981 |
[The value of praziquantel in treating schistosomiasis complicated by cardiac diseases (author's transl)].
Topics: Adolescent; Adult; Female; Heart Diseases; Humans; Isoquinolines; Male; Middle Aged; Praziquantel; S | 1982 |
[Bilharziasis. Initial results with biltricide].
Topics: Humans; Isoquinolines; Praziquantel; Schistosomiasis; Schistosomicides | 1982 |
[Long-term follow-up observations on 502 cases of schistosomiasis japonica treated by praziquantel].
Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Isoquinolines; Male; Middle Aged; Parasite Egg Count | 1982 |
Praziquantel: a major advance in anthelminthic therapy.
Topics: Animals; Cestode Infections; Cysticercosis; Dogs; Echinococcosis; Helminthiasis; Humans; Isoquinolin | 1983 |
Immune responses and immunoregulation in relation to human schistosomiasis in Egypt. I. Effect of treatment on in vitro cellular responsiveness.
Topics: Adolescent; Adult; Aged; Animals; Antigens; Child; Egypt; Female; Humans; Immunity, Cellular; Isoqui | 1982 |
Light and electron microscopic studies on Schistosoma mansoni Granulomas of mouse livers following treatment with praziquantel.
Topics: Animals; Female; Granuloma; Isoquinolines; Liver; Liver Diseases; Mice; Ovum; Praziquantel; Schistos | 1982 |
[Schistosomiasis. Problems and successes].
Topics: Communicable Disease Control; Egypt; Humans; Molluscacides; Oxamniquine; Praziquantel; Schistosomias | 1982 |
[Urogenital bilharziasis--apropos of several cases].
Topics: Humans; Male; Niridazole; Praziquantel; Schistosomiasis; Switzerland; Urinary Tract Infections | 1982 |
Effects of praziquantel and metrifonate on Schistosoma bovis infections in Sudanese cattle.
Topics: Animals; Cattle; Cattle Diseases; Feces; Isoquinolines; Parasite Egg Count; Praziquantel; Schistosom | 1982 |
[Treatment of urinary and intestinal bilharziosis with praziquantel. Apropos of 182 cases].
Topics: Adolescent; Adult; Child; Child, Preschool; Feces; Female; Humans; Infant; Intestinal Diseases, Para | 1982 |
Use of praziquantel in patients with schistosomiasis mansoni previously treated with oxamniquine and/or hycanthone: resistance of Schistosoma mansoni to schistosomicidal agents.
Topics: Adolescent; Adult; Animals; Child; Drug Resistance; Female; Humans; Hycanthone; Isoquinolines; Mice; | 1982 |
On the distribution and control of schistosomiasis mansoni in Maniema, Zaire.
Topics: Adolescent; Adult; Child; Democratic Republic of the Congo; Humans; Middle Aged; Oxamniquine; Parasi | 1982 |
Biltricide symposium on African schistosomiasis. Nairobi, 24--26 February, 1980.
Topics: Africa; Animals; Humans; Isoquinolines; Praziquantel; Schistosomiasis | 1981 |
In vivo and in vitro experiments on the effects of praziquantel on Schistosoma mansoni. A light and electron microscopic study.
Topics: Animals; Isoquinolines; Mice; Praziquantel; Schistosoma mansoni; Schistosomiasis | 1981 |
The effect of praziquantel on Schistosoma haematobium, S. japonicum and S. mansoni in primates.
Topics: Animals; Cebus; Cercopithecus; Isoquinolines; Papio; Praziquantel; Schistosoma haematobium; Schistos | 1981 |
Tolerance and efficacy of praziquantel in phase II A and II B therapeutic trials in Zambian patients.
Topics: Double-Blind Method; Drug Evaluation; Humans; Isoquinolines; Praziquantel; Schistosoma haematobium; | 1981 |
[Trial of praziquantel in the treatment of urinary schistosomiasis in Senegal].
Topics: Adolescent; Child; Drug Evaluation; Female; Humans; Isoquinolines; Male; Praziquantel; Schistosomias | 1981 |
Observations on praziquantel against Schistosoma haematobium.
Topics: Adult; Child; Humans; Isoquinolines; Praziquantel; Schistosoma haematobium; Schistosomiasis | 1981 |
[Epidemiological study of foci of S. intercalatum schistosomiasis in Eseka and Edea (Cameroon). Effects of treatment with praziquantel].
Topics: Cameroon; Helminthiasis; Humans; Isoquinolines; Praziquantel; Schistosomiasis | 1981 |
[Sensitivity of a strain of Schistosoma intercalatum from Loum (Cameroon) and is natural hybrid to treatment with praziquantel. Preliminary results].
Topics: Adolescent; Cameroon; Child; Child, Preschool; Female; Humans; Isoquinolines; Male; Praziquantel; Sc | 1981 |
Preliminary observations on the treatment of Schistosomiasis mansoni with praziquantel in Kenya.
Topics: Humans; Isoquinolines; Kenya; Praziquantel; Schistosoma mansoni; Schistosomiasis | 1981 |
Praziquantel: a new schistosomicide against Schistosoma mansoni.
Topics: Humans; Isoquinolines; Praziquantel; Schistosoma mansoni; Schistosomiasis; Time Factors | 1981 |
[Therapeutic field trial with praziquantel in a rural population in Mali infected with Schistosoma mansoni (author's transl)].
Topics: Adolescent; Adult; Child; Humans; Isoquinolines; Mali; Middle Aged; Praziquantel; Schistosoma manson | 1981 |
Praziquantel in the treatment of the hepatosplenic form of Schistosomiasis mansoni.
Topics: Adolescent; Adult; Child; Electrocardiography; Electroencephalography; Humans; Isoquinolines; Liver | 1981 |
Preliminary results of chemotherapy using praziquantel on a large scale in Qalyub Bilharziasis Project where simultaneous infection with S. mansoni and S. haematobium exists.
Topics: Egypt; Humans; Isoquinolines; Praziquantel; Schistosoma haematobium; Schistosoma mansoni; Schistosom | 1981 |
The treatment of schistosomiasis.
Topics: Humans; Hycanthone; Niridazole; Oxamniquine; Praziquantel; Schistosomiasis; Trichlorfon | 1981 |
[Coadministration of pyquiton and furapromidum in the treatment of experimental schistosomiasis japonica (author's transl)].
Topics: Acrylamides; Animals; Drug Synergism; Drug Therapy, Combination; Female; Isoquinolines; Male; Mice; | 1981 |
A note on drug trials in schistosomiasis.
Topics: Drug Evaluation; Humans; Hycanthone; Isoquinolines; Praziquantel; Schistosoma haematobium; Schistoso | 1981 |
[The modern treatment of bladder bilharziasis].
Topics: Drug Administration Schedule; Humans; Niridazole; Praziquantel; Schistosomiasis; Schistosomicides; T | 1981 |
[A clinical study of treating schistosomiasis and cysticercosis with praziquantel (author's transl)].
Topics: Adolescent; Adult; Aged; Cysticercosis; Female; Humans; Isoquinolines; Male; Middle Aged; Praziquant | 1981 |
[Clinical observation of treating late and complicating cases of schistosomiasis japonica with praziquantel (author's transl)].
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Female; Follow-Up Studies; Humans; Isoquinolines; Mal | 1981 |
Factors affecting the acquisition of resistance against Schistosoma mansoni in the mouse. V. Reduction in the degree of resistance to reinfection after chemotherapeutic elimination of recently patent primary infections.
Topics: Animals; Antimony Potassium Tartrate; Hycanthone; Immunity, Active; Mice; Mice, Inbred CBA; Niridazo | 1980 |
Effect of praziquantel on clinical-chemical parameters in healthy and schistosome-infected mice.
Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Aspartate Aminotransferases; Blood Cell Count; | 1980 |
Asherman syndrome caused by schistosomiasis.
Topics: Adult; Amenorrhea; Cesarean Section; Fallopian Tubes; Female; Humans; Ovarian Diseases; Postoperativ | 1995 |
Human resistance to reinfection with schistosomes. II. Specific IgA titres before & 3 months after praziquantel treatment.
Topics: Adolescent; Enzyme-Linked Immunosorbent Assay; Eosinophilia; Female; Humans; Immunoglobulin A; Immun | 1994 |
Early chemotherapy of imported neuroschistosomiasis.
Topics: Adult; Central Nervous System Diseases; Female; Humans; Magnetic Resonance Imaging; Praziquantel; Sc | 1993 |
Cost of bilharzia treatment.
Topics: Drug Costs; Humans; Praziquantel; Schistosomiasis | 1993 |
The effect of praziquantel administration on the course of hepatitis B among cases with concomitant schistosome infection.
Topics: Adult; Carrier State; Hepatitis B; Hepatitis B Surface Antigens; Humans; Liver Function Tests; Male; | 1993 |
Involvement of a community in schistosomiasis control: a Kenyan experience.
Topics: Adult; Agricultural Workers' Diseases; Agriculture; Child; Community Participation; Female; Health B | 1993 |
[Treatment of bilharziasis].
Topics: Humans; Mass Screening; Niridazole; Oxamniquine; Praziquantel; Schistosomiasis; Trichlorfon | 1993 |
Efficacy of praziquantel in natural populations of mallards infected with avian schistosomes.
Topics: Animals; Animals, Wild; Bird Diseases; Dermatitis; Ducks; Fresh Water; Humans; Praziquantel; Schisto | 1995 |
Effects of praziquantel on experimental Schistosoma bovis infection in goats.
Topics: Animals; Antiplatyhelmintic Agents; Feces; Female; Goats; Male; Orchiectomy; Parasite Egg Count; Pra | 1996 |
Schistosomiasis of the gallbladder.
Topics: Adult; Antiplatyhelmintic Agents; Cholecystectomy; Cholecystitis; Gallbladder Diseases; Humans; Male | 1995 |
Epidemiology and control of schistosomiasis mansoni in communities living on the Cuando River floodplain of East Caprivi, Namibia.
Topics: Adolescent; Adult; Age Distribution; Animals; Antiplatyhelmintic Agents; Case-Control Studies; Cattl | 1995 |
Observations on possible immunity to reinfection among school children after schistosomiasis treatment.
Topics: Animals; Antibodies, Helminth; Antibody Specificity; Antigens, Helminth; Antiplatyhelmintic Agents; | 1996 |
Experimental Schistosoma bovis infection in goats. Circulating antigen and antibody responses to egg and adult worm antigens during infection and following treatment with praziquantel.
Topics: Animals; Antibodies, Helminth; Antigens, Helminth; Antiplatyhelmintic Agents; Disease Models, Animal | 1996 |
Experimental Schistosoma bovis infection in goats: pathological consequences of praziquantel treatment.
Topics: Animals; Antiplatyhelmintic Agents; Female; Goats; Granuloma; Intestines; Liver; Liver Diseases; Lym | 1996 |
Requirements for sustainable schistosomiasis control.
Topics: Adolescent; Adult; Antiplatyhelmintic Agents; Child; Humans; Mali; Praziquantel; Prevalence; Sanitar | 1996 |
Evaluation of colchicine with or without praziquantel therapy in the control of hepatic fibrosis in murine schistosomiasis.
Topics: Animals; Body Weight; Colchicine; Collagen; Connective Tissue; Female; Liver Cirrhosis, Experimental | 1996 |
Effect of UV-irradiation, gamma irradiation and praziquantel on infected Biomphalaria alexandrina snails.
Topics: Animals; Antiplatyhelmintic Agents; Biomphalaria; Disease Vectors; Female; Gamma Rays; Mice; Praziqu | 1997 |
The effect of a combined approach to schistosomiasis control on the transmission of Schistosoma japonicum in Xingzi of Poyang Lake area, China.
Topics: Animals; Arthropod Vectors; Buffaloes; Cattle; China; Communicable Disease Control; Disease Reservoi | 1996 |
Schistosomiasis in the Senegal River Basin: before and after the construction of the dams at Diama, Senegal and Manantali, Mali and future prospects.
Topics: Animals; Antiplatyhelmintic Agents; Environment; Forecasting; Humans; Mali; Praziquantel; Prevalence | 1997 |
A case of refractory schistosomiasis.
Topics: Animals; Antiplatyhelmintic Agents; Drug Resistance; Humans; Praziquantel; Recurrence; Schistosoma; | 1997 |
A case of refractory schistosomiasis.
Topics: Africa; Animals; Antiplatyhelmintic Agents; Humans; Praziquantel; Schistosoma haematobium; Schistoso | 1997 |
The effect of praziquantel on the hepatic activities of some drug-metabolizing enzymes in rabbits experimentally infected with Schistosoma bovis.
Topics: Administration, Oral; Aminopyrine N-Demethylase; Aniline Hydroxylase; Animals; Antiplatyhelmintic Ag | 1997 |
Assessment of cure by detection of circulating antigens in serum and urine, following schistosomiasis mass treatment in two villages of the Office du Niger, Mali.
Topics: Animals; Antigens, Helminth; Antiplatyhelmintic Agents; Mali; Praziquantel; Schistosoma haematobium; | 1997 |
Schistosomial arthritis. A case-report.
Topics: Adult; Arthritis, Infectious; Humans; Male; Praziquantel; Schistosomiasis; Schistosomicides | 1998 |
Dilemmas in drug development for tropical diseases. Experiences with praziquantel.
Topics: Anthelmintics; Developing Countries; Drug Costs; Drug Industry; Health Policy; Health Services Acces | 1998 |
Cost of school-based drug treatment in Tanzania. The Partnership for Child Development.
Topics: Albendazole; Anthelmintics; Child; Cost Savings; Developing Countries; Drug Costs; Health Care Costs | 1998 |
The role of corticosteroids in the treatment of cerebral schistosomiasis caused by Schistosoma mansoni: case report and discussion.
Topics: Adult; Animals; Anti-Inflammatory Agents; Biopsy; Brain Diseases; Brazil; Dexamethasone; Headache; H | 1999 |
The cost of large-scale school health programmes which deliver anthelmintics to children in Ghana and Tanzania. The Partnership for Child Development.
Topics: Albendazole; Anthelmintics; Child; Costs and Cost Analysis; Ghana; Humans; Intestinal Diseases, Para | 1999 |
Correlation between infection intensity, serum immunoglobulin profile, cellular immunity and the efficacy of treatment with praziquantel in murine schistosomiasis mansoni.
Topics: Animals; Body Burden; Enzyme-Linked Immunosorbent Assay; Granuloma; Immunity, Cellular; Immunoglobul | 2000 |
Praziquantel and the control of schistosomiasis.
Topics: Anthelmintics; Drug Resistance; Praziquantel; Schistosomiasis | 2000 |
Histological assessment of tissue repair after treatment of human schistosomiasis.
Topics: Adult; Animals; Anthelmintics; Cricetinae; Dogs; Egypt; Fibrosis; Humans; Kidney Glomerulus; Liver; | 2000 |
[Schistosomiasis: diagnosis and treatment].
Topics: Animals; Anthelmintics; Humans; Oxamniquine; Praziquantel; Prognosis; Schistosomiasis; Schistosomici | 2000 |
Localized papular cutaneous schistosomiasis: two cases in travellers.
Topics: Adult; Antiparasitic Agents; Enzyme-Linked Immunosorbent Assay; Female; Humans; Praziquantel; Pregna | 2001 |
Parasitological, pathological and functional studies on the effects of IFN alpha 2b in murine hepatic schistosomiasis.
Topics: Animals; Anthelmintics; Drug Therapy, Combination; Interferon alpha-2; Interferon-alpha; Liver Disea | 2000 |
Evaluation of efficacy of school-based anthelmintic treatments against anaemia in children in the United Republic of Tanzania.
Topics: Albendazole; Anemia; Anthelmintics; Child; Cost-Benefit Analysis; Cross-Sectional Studies; Health Pr | 2001 |
Acute colonic obstruction due to schistosomiasis in conjunction with ingestion of mangos.
Topics: Abdominal Pain; Acute Disease; Adult; Animals; Colonic Diseases; Diagnosis, Differential; Eating; Fr | 2001 |
Reinfection with Schistosoma haematobium following school-based chemotherapy with praziquantel in four highly endemic villages in Côte d'Ivoire.
Topics: Adolescent; Animals; Anthelmintics; Child; Child, Preschool; Cote d'Ivoire; Disease-Free Survival; F | 2001 |
Impact of schistosomiasis on patient and graft outcome after renal transplantation: 10 years' follow-up.
Topics: Adult; Anthelmintics; Female; Follow-Up Studies; Humans; Kidney Failure, Chronic; Kidney Transplanta | 2001 |
Praziquantel--quality, dosages and markers of resistance.
Topics: Africa; Animals; Anthelmintics; Drug Resistance; Drugs, Generic; Humans; Praziquantel; Quality Contr | 2001 |
Heterogeneities in anti-schistosome humoral responses following chemotherapy.
Topics: Adolescent; Adult; Age Factors; Aged; Animals; Anthelmintics; Antigens, Helminth; Child; Child, Pres | 2001 |
Comparative, clinico-epidemiologic study of Schistosoma mansoni infections in travellers and immigrants in Spain.
Topics: Adult; Animals; Anthelmintics; Emigration and Immigration; Humans; Praziquantel; Schistosoma mansoni | 2002 |
The global epidemiological situation of schistosomiasis and new approaches to control and research.
Topics: Africa; Anthelmintics; Global Health; Humans; Praziquantel; Prevalence; Research Design; Schistosomi | 2002 |
Difficulties and strategies in the control of schistosomiasis in the Philippines.
Topics: Anthelmintics; Attitude to Health; Humans; Philippines; Population Surveillance; Praziquantel; Preva | 2002 |
[Observations on the histopathological changes of Schistosoma japonicum and host liver caused by pyquiton in experimental chemotherapy (author's transl)].
Topics: Animals; Isoquinolines; Liver; Mice; Praziquantel; Rabbits; Schistosoma japonicum; Schistosomiasis; | 1979 |
Multicentre trials of praziquantel in human schistosomiasis: design and techniques.
Topics: Clinical Trials as Topic; Double-Blind Method; Female; Humans; Isoquinolines; Male; Praziquantel; Sc | 1979 |
New approaches to social and economic research on schistosomiasis in TDR (Special Programme for Research and Training in Tropical Diseases).
Topics: Child; Costs and Cost Analysis; Developing Countries; Egypt; Engineering; Humans; Parasitology; Praz | 1992 |
Statistical assessment of the synergistic effect between a vaccine and a drug.
Topics: Animals; Drug Synergism; Injections, Intradermal; Mice; Praziquantel; Schistosomiasis; Statistics as | 1992 |
A look ahead in research and control of schistosomiasis.
Topics: Animals; Antigens, Helminth; Host-Parasite Interactions; Humans; Praziquantel; Schistosoma; Schistos | 1992 |
[Cutaneous schistosomiasis. Apropos of a case].
Topics: Adult; Antiparasitic Agents; Humans; Male; Praziquantel; Schistosomiasis; Skin Diseases, Parasitic | 1991 |
Immunological analysis of cloned Schistosoma mansoni antigens Sm31 and Sm32 with sera of schistosomiasis patients.
Topics: Adolescent; Adult; Animals; Antibodies, Helminth; Antigens, Helminth; Blotting, Western; Child; Clon | 1991 |
Schistosoma mansoni and S. japonicum: decline of antibodies against diagnostic adult worm antigens (Sm31/32) following praziquantel treatment of mice.
Topics: Animals; Antibodies, Helminth; Antigens, Helminth; Blotting, Western; Cysteine Endopeptidases; Enzym | 1991 |
Effect of repeated targeted mass treatment with praziquantel on the prevalence, intensity of infection and morbidity due to Schistosoma intercalatum in an urban community in equatorial Guinea.
Topics: Adolescent; Adult; Age Factors; Animals; Child; Child, Preschool; Drug Therapy, Combination; Equator | 1991 |
Acute and chronic schistosomiasis.
Topics: Acute Disease; Administration, Oral; Adult; Animals; Chronic Disease; Feces; Female; Humans; Praziqu | 1991 |
Spinal cord schistosomiasis. A clinical, laboratory and radiological study, with a note on therapeutic aspects.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Animals; Child; Female; Humans; Immunoglobulin G; Male; | 1991 |
Chronic hepatitis B antigenaemia in bilharzial patients treated with Praziquantel.
Topics: Chronic Disease; Comorbidity; Egypt; Hepatitis B; Hepatitis B Surface Antigens; Humans; Military Per | 1990 |
Humoral and cellular immune response in schistosomiasis pre and post praziquantel therapy.
Topics: Adolescent; Animals; Antibodies, Helminth; Humans; Immunity, Cellular; Immunoglobulins; Leukocyte Co | 1990 |
[Acute schistosomiasis can be diagnosed by early serology].
Topics: Acute Disease; Adult; Diagnosis, Differential; Female; Humans; Praziquantel; Schistosomiasis; Serolo | 1990 |
IgG subclasses in human chronic schistosomiasis: over-production of schistosome-specific and non-specific IgG4.
Topics: Adolescent; Adult; Animals; Antibodies, Helminth; Child; Chromatography, Affinity; Chronic Disease; | 1990 |
[Bilharziosis caused by Schistosoma mekongi: diagnosis by rectal biopsy and treatment with praziquantel: report of 5 cases].
Topics: Adult; Aged; Biopsy; Humans; Male; Praziquantel; Rectum; Schistosomiasis | 1990 |
Active and latent collagenase activity during reversal of hepatic fibrosis in murine schistosomiasis.
Topics: Animals; Female; Hydroxyproline; Liver; Liver Cirrhosis, Experimental; Mice; Microbial Collagenase; | 1989 |
The effect of praziquantel on Schistosoma nasale infections in cattle.
Topics: Animals; Cattle; Cattle Diseases; Female; Praziquantel; Schistosomiasis; Sri Lanka | 1989 |
Experimental chemotherapy of Schistosoma curassoni in mice.
Topics: Animals; Disease Models, Animal; Female; Hycanthone; Male; Mice; Nitroquinolines; Oxamniquine; Prazi | 1989 |
Relationship between schistosomiasis and arthropathy.
Topics: Arthritis, Infectious; Egypt; Humans; Praziquantel; Schistosomiasis | 1989 |
[Bilharziasis caused by Schistosoma mekongi along the Mekong and its affluents Mun and Tonle Sap. Apropos of 2 cases observed at the University Hospital Center of Tours].
Topics: Adult; Diagnosis, Differential; France; Humans; Laos; Male; Praziquantel; Schistosoma; Schistosomias | 1986 |
Contraceptive steroid concentrations in women with early active schistosomiasis: lack of effect of antischistosomal drugs.
Topics: Adolescent; Adult; Drug Interactions; Ethinyl Estradiol; Female; Humans; Levonorgestrel; Norgestrel; | 1986 |
Effect of praziquantel on certain immune responses of schistosomal Egyptian patients. I. Changes of specific immunoglobulins.
Topics: Adolescent; Child; Enzyme-Linked Immunosorbent Assay; Humans; Immunoglobulin E; Immunoglobulin G; Im | 1987 |
Report of an independent evaluation mission on the National Bilharzia Control Program, Egypt, 1985 (abridged version).
Topics: Animals; Costs and Cost Analysis; Disease Vectors; Egypt; Government Agencies; Humans; Molluscacides | 1987 |
Increased blastogenic responses to worm antigen and loss of adherent suppressor cell activity after treatment for human infection with Schistosoma mansoni.
Topics: Adolescent; Adult; Antigens, Helminth; Female; Humans; Isoquinolines; Lymphocyte Activation; Male; P | 1985 |
Schistosoma in the spinal cord.
Topics: Humans; Laminectomy; Praziquantel; Schistosomiasis; Spinal Cord; Spinal Cord Diseases; Spinal Nerve | 1988 |
Efficacy of praziquantel against Schistosoma nasale infection in cattle.
Topics: Animals; Cattle; Cattle Diseases; Female; Granuloma; Male; Nose Diseases; Parasite Egg Count; Praziq | 1988 |
A case of Schistosoma intercalatum infection from Sao Tomé.
Topics: Anemia; Atlantic Islands; Child; Feces; Female; Humans; Parasite Egg Count; Praziquantel; Schistosom | 1988 |
Treatment of schistosomiasis.
Topics: Humans; Nitroquinolines; Oxamniquine; Praziquantel; Schistosomiasis; Trichlorfon | 1987 |
Potential hazard of mass praziquantel use.
Topics: Cysticercosis; Humans; Praziquantel; Schistosomiasis | 1986 |
The chemotherapy of schistosomiasis control.
Topics: Child; Humans; Oxamniquine; Praziquantel; Schistosomiasis; Schistosomicides; Trichlorfon | 1986 |
Effect of oxamniquine and praziquantel on intrasplenic pressure and portal vein diameter in hepatosplenic schistosomiasis.
Topics: Adult; Blood Pressure; Humans; Liver Diseases, Parasitic; Male; Nitroquinolines; Oxamniquine; Portal | 1986 |
[Significance of determination of some biochemical indices in hepatic fibrosis of animal schistosomiasis japonica].
Topics: Animals; Hydroxyproline; Liver Cirrhosis, Experimental; Monoamine Oxidase; Mucoproteins; Praziquante | 1985 |
Polymorphonuclear leucocyte phagocytosis in bilharzial and non bilharzial patients with enteric fevers.
Topics: Adolescent; Adult; Ampicillin; Chloramphenicol; Female; Humans; Liver Cirrhosis; Male; Middle Aged; | 1985 |
Reversal of hepatic fibrosis after praziquantel therapy of murine schistosomiasis.
Topics: Animals; Collagen; Granuloma; Hydroxyproline; Isoquinolines; Liver; Liver Diseases; Male; Mice; Orga | 1985 |
Effects of praziquantel on different developmental stages of Schistosoma mansoni in vitro and in vivo.
Topics: Animals; Biotransformation; Dose-Response Relationship, Drug; Female; Isoquinolines; Metabolic Clear | 1985 |
Influence of salmonella bacteremia on the survival of mice infected with Schistosoma mansoni.
Topics: Animals; Mice; Praziquantel; Salmonella Infections; Schistosoma mansoni; Schistosomiasis; Sepsis | 1985 |
Pharmacological manipulation of the chronic granulomatous reactions in the livers of mice infected with schistosomiasis.
Topics: Animals; Granuloma; Indomethacin; Liver Diseases, Parasitic; Mice; Praziquantel; Schistosoma mansoni | 1985 |
[Vaginal involvement in a case of bilharziasis].
Topics: Adult; Female; Granuloma; Humans; Praziquantel; Schistosoma haematobium; Schistosomiasis; Vagina; Va | 1985 |
Case report of a patient having Schistosoma japonicum cerebritis and resolution of CAT brain scan abnormalities without specific antiparasitic therapy.
Topics: Brain Diseases; Humans; Praziquantel; Remission, Spontaneous; Schistosoma japonicum; Schistosomiasis | 1985 |
Protection of Sudanese irrigation workers from schistosome infections by a shift to earlier working hours.
Topics: Adult; Agriculture; Feces; Humans; Male; Middle Aged; Occupational Diseases; Parasite Egg Count; Per | 1985 |
The impact of schistosomiasis mass treatment on hepato-splenomegaly in Napu Valley, Central Sulawesi, Indonesia.
Topics: Adolescent; Adult; Child; Child, Preschool; Female; Hepatomegaly; Humans; Indonesia; Infant; Infant, | 1985 |